

16.2.1 Discontinued Participants

Listing 16.2.1.1 Subject Disposition for Subjects Who Discontinued from Participation in
the Study or Discontinued from Study Vaccine Randomization Set

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012033	2020-07-30	AMENDMENT 1	No/ 2020-07-30 (1)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO WAIT FOR VACCINATION. LEFT SITE PRIOR TO BEING VACCINATED.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032022	2020-07-28	AMENDMENT 1	No/ 2020-12-16 (142)	Withdrawal of Consent by Participant/ SUBJECT WORKS IN HEALTHCARE AND WANTED TO GET THE EUA VACCINE TODAY. SUBJECT WAS UNBLINDED AND DROPPED FROM THE STUDY AT THIS TIME.		Yes/ 2020-08-31 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042228	2020-08-18	AMENDMENT 2	No/ 2020-08-18 (1)	Other/ SUBJECT WAS RANDOMIZED INTO THE WRONG COHORT. DCF WAS SENT IN, NO RESPONSE WAS RECEIVED. SUBJECT WAS NOT VACCINATED.			
US3052296	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Other/ PT WAS UNABLE TO RESCHEDULE FOR VISIT 2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052314	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Other/ SUBJECT HAD INSUFFICIENT NASAL SWAB. PATIENT WAS OUT OF WINDOW BUT WANTED TO STAY IN STUDY.
US3052340	2020-09-01	AMENDMENT 3	No/ 2020-09-01 (1)	Other/ SUBJECT DID NOT MEET EXCL. #7			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082013	2020-08-10	AMENDMENT 1	No/ 2020-08-10 (1)	Physician Decision/ PI WANTED SUBJECT TO FOLLOW UP WITH PCP FOR MEDICAL HISTORY OF MALARIA. PI DID NOT WANT THE SUBJECT TO RECEIVE FIRST INJECTION WITHOUT APPROVAL FROM PCP.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102050	2020-07-29	AMENDMENT 1	No/ 2020-07-29 (1)	Withdrawal of Consent by Participant/ PARTICIPANT DECIDED NOT TO RECEIVE TREATMENT DESPITE ALREADY BEING RANDOMIZED.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112118	2020-08-05	AMENDMENT 1	No/ 2020-08-05 (1)	Withdrawal of Consent by Participant/ SUBJECT DECIDED AFTER BEING RANDOMIZED NOT TO PARTICIPATE DUE TO LENGTH OF TRIAL. COULD NOT COMMIT TO 2 YEARS. SUBJECT DID NOT RECEIVE IP DRUG DOSING			
US3132097	2020-10-01	AMENDMENT 3	No/ 2020-10-01 (1)	Other/ SUBJECT WAS NEVER DOSED. UNABLE TO GET BLOOD.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132125	2020-10-15	AMENDMENT 4	No/ 2020-10-15 (1)	Withdrawal of Consent by Participant			
US3132140	2020-10-20	AMENDMENT 4	No/ 2020-11-11 (23)	Other/ SUBJECT WAS RANDOMIZED PRIOR TO OBTAINING IMMUNOGENICITY SAMPLE. SUBJECT WAS SCHEDULED TO RETURN FOR BLOOD DRAW BUT STUDY CLOSED. SUBJECT WAS NEVER DOSED.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172054	2020-08-11	AMENDMENT 1	No/ 2020-08-12 (1)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT			
US3172068	2020-08-12	AMENDMENT 1	No/ 2020-08-12 (1)	Withdrawal of Consent by Participant/ NO LONGER INTERESTED			
US3172449	2020-10-21	AMENDMENT 2	No/ 2020-10-21 (1)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192773	2020-10-09	AMENDMENT 4	No/ 2020-10-09 (1)	Withdrawal of Consent by Participant/ PATIENT DECIDED TRIAL NOT FOR THEM.			
US3202340	2020-08-26	AMENDMENT 3	No/ 2020-08-26 (1)	Other/ SUBJECT RANDOMIZED IN ERROR, DIDNâ€™T MEET I/E CRITERIA, NEVER DOSED			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212036	2020-08-04	AMENDMENT 1	No/ 2020-08-14 (8)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT ON 14AUG2020 - ALL ATTEMPTS WERE MADE BY SITE STAFF TO KEEP SUBJECT IN THE STUDY HOWEVER SHE WISHED TO DISCONTINUE DUE TO PERSONAL REASONS.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212343	2020-09-02	AMENDMENT 3	No/ 2020-09-03 (2)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT ON 03SEP2020 DUE TO UNFORESEEN PERSONAL CIRCUMSTANCES, EVERY ATTEMPT WAS MADE BY SITE STAFF TO KEEP THE SUBJECT IN THE STUDY HOWEVER SHE DOES NOT WISH TO CONTINUE FURTHER.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222129	2020-08-13	AMENDMENT 2	No/ 2020-08-13 (1)	Withdrawal of Consent by Participant/ NO DIARY AVAILABLE DAY OF SCREEN WAS HELD ON VACCINATION BUT NEVER RETURNED FOR CONTINUATION IN TRIAL.'			
US3222524	2020-09-05	AMENDMENT 3	No/ 2021-03-12 (189)	Death	2021-03-12/ N	Yes/ 2020-10-09 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252148	2020-08-12	AMENDMENT 2	No/ 2020-08-12 (1)	Withdrawal of Consent by Participant/ PATIENT JUST DID NOT WANT TO BE IN THE STUDY ANYMORE			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252359	2020-08-28	AMENDMENT 3	No/ 2020-08-28 (1)	Physician Decision/ AS PER PI PATIENTS BLOOD PRESSURE WAS TOO HIGH AFTER RANDOMIZATION TOOK PLACE. AS PER PI THE PATIENT DID NOT CONTINUE TO DOSING.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272156	2020-08-14	AMENDMENT 2	No/ 2020-08-25 (1)	Withdrawal of Consent by Participant/ SUBJECT WALKED OUT OF CLINIC BEFORE VACCINATION			
US3322268	2020-09-08	AMENDMENT 3	No/ 2020-09-11 (1)	Withdrawal of Consent by Participant/ PATIENT NO LONGER INTERESTED IN PARTICIPATING			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322391	2020-09-23	AMENDMENT 3	No/ 2020-09-24 (1)	Withdrawal of Consent by Participant/ IP HELD PER PATIENT'S REQUEST; CONSENT WITHDRAWN			
US3322423	2020-10-12	AMENDMENT 4	No/ 2020-10-23 (12)	Other/ SUBJECT RANDOMIZED IN ERROR, ENROLLMENT HAD CLOSED, NEVER DOSED			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352007	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Other/ SUBJECT REFUSED TO GET 2ND VACCINATION. SUBJECT STATED SHE DID NOT WANT IT.
US3372223	2020-08-24	AMENDMENT 2	No/ 2020-08-26 (3)	Withdrawal of Consent by Participant/ PATIENT SAID THAT THEY COULD NO LONGER COMMIT TO THE STUDY TIMELINES			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382065	2020-08-18	AMENDMENT 2	No/ 2020-08-18 (1)	Physician Decision/ SUBJECT WAS RANDOMIZED BASED ON HER HEALTH STATUS AND PHYSICAL EXAM BEING UNREMARKABLE; HOWEVER LABS COULD NOT BE DRAWN AND HENCE HAD TO NOT VACCINATE AND TO EARLY TERMINATE THE SUBJECT.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382084	2020-08-20	AMENDMENT 2	No/ 2020-08-20 (1)	Withdrawal of Consent by Participant/ SUBJECT SIGNED CONSENT AND WAS RANDOMIZED; HOWEVER, SHE REFUSED TO COMPLETE THE NP SWAB COLLECTION.			
US3392277	2020-09-14	AMENDMENT 3	No/ 2020-12-21 (99)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412093	2020-08-01	AMENDMENT 1	No/ 2020-10-23 (79)	Other/ SUBJECT WAS RANDOMIZED AND NOT DOSED. SUBJECT LEFT THE SITE PRIOR TO THE DOSE AND NEVER RETURNED FOR IT.			
US3482115	2020-08-24	AMENDMENT 2	No/ 2020-08-24 (1)	Other/ SUBJECT DISCLOSED EXCLUSIONARY MEDICAL HISTORY AFTER RANDOMIZATION BUT BEFORE DOSING			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482315	2020-10-21	AMENDMENT 4	No/ 2020-10-21 (1)	Other/ PT WITHDRAWN BEFORE TREATMENT AFTER DISCUSSIONS WITH PPD ABOUT SUBJECT'S RACE (b) (6) ENT RESTRICTED TO MINORITIES			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512243	2020-09-09	AMENDMENT 3	No/ 2020-09-09 (1)	Withdrawal of Consent by Participant/ PT DECLINED TO GET VACCINE			
US3522153	2020-08-17	AMENDMENT 1	No/ 2020-08-27 (11)	Physician Decision/ SUBJECT WAS RANDOMIZED BEFORE BEING GIVEN IP. BLOOD PRESSURE WAS TOO LOW TO GIVE IP. SUBJECT WILL COME IN AT ANOTHER TIME AND WILL BE GIVEN NEW SUBJECT ID.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522586	2020-09-04	AMENDMENT 3	No/ 2020-09-04 (1)	Withdrawal of Consent by Participant/ PT CONSENTED AT 11:06 WITHDREW BEFORE BLOOD DRAW. PT PASSED OUT BEFORE BLOOD DRAW, AND WISHED TO BE REMOVED FROM THE STUDY.			
US3562206	2020-10-01	AMENDMENT 3	No/ 2020-10-01 (1)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT , DECLINED FOR BLOOD DRAW			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592169	2020-08-14	AMENDMENT 2	No/ 2020-12-30 (139)	Other/ UNBLINDED UNDER AMENDMENT 5 ASSIGNED PLACEBO		Yes/ 2020-09-14 (32)	
US3632148	2020-10-21	AMENDMENT 4	No/ 2020-10-21 (1)	Lost to Follow-Up			
US3702035	2020-09-15	AMENDMENT 3	No/ 2020-09-17 (1)	Withdrawal of Consent by Participant/ PARTICIPANT FELT TOO ANXIOUS TO CONTINUE WITH STUDY AND RECEIVE VACCINE ADMINISTRATION.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732345	2020-09-15	AMENDMENT 3	No/ 2020-09-15 (1)	Lost to Follow-Up			
US3802086	2020-09-01	AMENDMENT 3	No/ 2020-09-01 (1)	Other/ FOUND TO BE INELIGIBLE AFTER RANDOMIZATION			
US3802101	2020-09-02	AMENDMENT 3	No/ 2020-09-02 (1)	Withdrawal of Consent by Participant/ SUBJECT RANDOMIZED IN ERROR, DIDNâ€™T MEET I/E CRITERIA, NEVER DOSED			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802222	2020-09-11	AMENDMENT 3	No/ 2020-09-11 (1)	Other/ SUBJECT DID NOT MEET INCLUSION 3			
US3822099	2020-08-12	AMENDMENT 2	No/ 2021-03-03 (204)	Other/ SUBJECT IS MOVING OUT OF THE COUNTRY		Yes/ 2020-09-17 (37)	
US3872340	2020-08-28	AMENDMENT 2	ONGOING			No/ 2020-09-24 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872355	2020-08-28	AMENDMENT 3	No/ 2020-09-24 (28)	Protocol Deviation/ WANTED TO END THIS STUDY BECAUSE HE WAS IN ANOTHER STUDY		No/ 2020-09-23 (27)	Protocol Deviation/ PT SAID HE WANTED TO END , THAT HE WAS IN ANOTHER STUDY
US3902112	2020-09-24	AMENDMENT 3	No/ 2020-09-24 (1)	Other/ COHORT FULL			
US3932056	2020-09-01	AMENDMENT 3	No/ 2021-03-26 (207)	Lost to Follow-Up		Yes/ 2020-10-06 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042027	2020-07-29	AMENDMENT 1	No/ 2021-03-12 (227)	Withdrawal of Consent by Participant/ PATIENT MOVED TO PHASE 2 CROSSOVER		Yes/ 2020-08-26 (29)	
US3042084	2020-08-06	AMENDMENT 1	No/ 2020-08-21 (1)	Other/ SUBJECT WAS A SCREEN FAIL AND WAS INADVERTENTLY RANDOMIZED IN IRT.			
US3042198	2020-08-14	AMENDMENT 2	No/ 2020-10-15 (63)	Lost to Follow-Up		No/ 2020-09-10 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052184	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Lost to Follow-Up
US3102403	2020-09-30	AMENDMENT 3	No/ 2020-09-30 (1)	Withdrawal of Consent by Participant			
US3142173	2020-08-08	AMENDMENT 2	No/ 2020-10-30 (84)	Protocol Deviation/ PATIENT HAS BEEN NON COMPLIANT WITH VISITS AND INSTRUCTIONS. PATIENT HAS BEEN DISRUPTIVE AND VERBALLY ABUSIVE WITH STAFF MEMBERS.		Yes/ 2020-09-09 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152002	2020-07-27	AMENDMENT 1	No/ 2020-07-27 (1)	Other/ PATIENT HAD STRATIFICATION ERROR AFTER RANDOMIZATION AND HAD TO COME BACK TO BE RESCREENED UNDER US3152062.			
US3162241	2020-09-16	AMENDMENT 3	No/ 2020-09-16 (1)	Other/ UNABLE TO COLLECT PROPER AMOUNT OF BLOOD FROM PATIENT.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172125	2020-08-14	AMENDMENT 2	No/ 2020-08-14 (1)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT			
US3172214	2020-08-19	AMENDMENT 2	No/ 2020-08-19 (1)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT			
US3172235	2020-08-20	AMENDMENT 1	No/ 2020-08-20 (1)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172415	2020-10-19	AMENDMENT 2	No/ 2020-10-19 (1)	Withdrawal of Consent by Participant/ SUBJECT MENTIONED NOT HAVING ENOUGH TIME TO STAY AND COMPLETE STUDY VISIT. SUBJECT STATED HE WILL NOT BE ABLE TO COMPLY WITH STUDY SCHEDULE AND WITHDREW CONSENT.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192922	2020-10-23	AMENDMENT 4	No/ 2020-10-23 (1)	Withdrawal of Consent by Participant/ PATIENT DECIDED TRIAL NOT FOR THEM.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202365	2020-08-31	AMENDMENT 3	No/ 2020-08-31 (1)	Physician Decision/ RANDOMIZED IN ERROR -DID NOT RECEIVE ANY DOSES OF IP--NOT APPROPRIATE FOR PARTICIPATION PER INVESTIGATOR DURING EXAM--WAS INCOHERENT AND APPEARED TO BE UNDER INFLUENCE DEMONSTRATED INABILITY TO COMPLY			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212254	2020-08-19	AMENDMENT 2	No/ 2020-09-05 (18)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT ON 05SEP2020 DUE TO UNFORESEEN PERSONAL CIRCUMSTANCES, EVERY ATTEMPT WAS MADE BY SITE STAFF TO KEEP THE SUBJECT IN THE STUDY HOWEVER SHE DOES NOT WISH TO CONTINUE FURTHER.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252144	2020-08-12	AMENDMENT 2	No/ 2020-08-12 (1)	Other/ SUBJECT IS HIV POSITIVE AND SPONSOR DECIDED TO HOLD OFF SCREENING/DOSING HIV POSITIVE PATIENTS DESPITE AMD 3 APPROVAL.			
US3262247	2020-08-26	AMENDMENT 2	No/ 2020-10-02 (38)	Lost to Follow-Up		Yes/ 2020-10-02 (38)	
US3262248	2020-08-26	AMENDMENT 2	No/ 2020-10-05 (41)	Lost to Follow-Up		Yes/ 2020-09-28 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272011	2020-07-29	AMENDMENT 1	No/ 2020-07-29 (1)	Other/ SUBJECT DID NOT MEET ELIGIBILITY CRITERIA.			
US3292081	2020-08-08	AMENDMENT 1	No/ 2021-03-01 (206)	Withdrawal of Consent by Participant/ SUBJECT BECAME OVERWHELMED WITH THE DEMANDS OF THE STUDY, SUCH AS PHONE CALLS AND EDIARY.		Yes/ 2020-09-03 (27)	
US3342332	2020-10-05	AMENDMENT 3	No/ 2020-11-16 (32)	Lost to Follow-Up		No/ 2020-11-12 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372432	2020-09-17	AMENDMENT 3	No/ 2020-09-17 (1)	Withdrawal of Consent by Participant/ SUBJECT LEFT SITE PRIOR TO VACCINATION			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382008	2020-08-10	AMENDMENT 2	No/ 2020-08-10 (1)	Physician Decision/ SUBJECT WAS RANDOMIZED BUT THEN PI DEEMED HE DOES NOT HAVE A REASONABLE RISK TO CONTRACT COVID-19; HENCE WAS NOT DOSED. AT THAT TIME THE STUDY WAS LOOKING FOR SUBJECT WITH INCREASED OF EXPOSURE ONLY.			
US3402300	2020-08-08	AMENDMENT 2	ONGOING		No/ 2020-09-04 (28)		Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562234	2020-10-19	AMENDMENT 4	No/ 2020-10-19 (1)	Withdrawal of Consent by Participant/ DECLINED FOR BLOOD DRAW AND WITHDREW CONSENT			
US3602037	2020-09-14	AMENDMENT 3	No/ 2020-09-25 (12)	Adverse Event/ AE #1			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642173	2020-09-11	AMENDMENT 3	No/ 2020-09-11 (1)	Other/ PARTICIPANT DID NOT MEET STUDY ELIGIBILITY CRITERIA, WHICH WAS OBSERVED AFTER RANDOMIZATION. NO STUDY PRODUCT WAS GIVEN.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692054	2020-09-03	AMENDMENT 3	No/ 2020-09-14 (1)	Other/ PARTICIPANT WAS SUPPOSED TO BE A SCREEN FAIL AND WAS RANDOMIZED IN ERROR. THEREFORE IS AN EARLY TERMINATION PER SPONSOR.			
US3772024	2020-08-06	AMENDMENT 1	No/ 2020-08-06 (1)	Withdrawal of Consent by Participant/ SUBJECT W/C PRIOR TO IP ADMINISTRATION.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772237	2020-09-10	AMENDMENT 3	No/ 2020-09-10 (1)	Other/ SUBJECT WITHDRAWN DUE TO INABILITY TO DRAW BLOOD			
US3802176	2020-09-08	AMENDMENT 3	No/ 2020-09-08 (1)	Other/ SUBJECT COULD NOT STAY FOR DOSING			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872177	2020-08-13	AMENDMENT 2	No/ 2020-08-13 (1)	Withdrawal of Consent by Participant/ SUBJECT DID NOT HAVE THE TIME TO WAIT TO BE SEEN AT THE VISIT AS THE CLINIC WAS BUSY. SUBJECT WITHDREW CONSENT AND DID NOT WISH TO PARTICIPATE.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872296	2020-08-25	AMENDMENT 2	ONGOING			No/ 2020-09-21 (28)	Protocol Deviation/ VISIT 2 WAS TOO FAR OOV DUE TO NO SWAB RESULT BACK AND PER EPIP THAT WAS SENT IT WAS RECOMMENDED TO SKIP V2 AND CONDUCT V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872379	2020-08-31	AMENDMENT 3	No/ 2020-10-29 (58)	Withdrawal of Consent by Participant/ SWAB RESULTS WAS NOT BACK AT V2 WAS GOING TO HAVE TO BE RESCHEDULED AND FOR V3 AND SKIP V2 VACCINE , SUBJECT DECIDED TO WITHDRAW CONSENT		No/ 2020-09-29 (28)	Withdrawal of Consent by Participant/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3902076	2020-09-11	AMENDMENT 3	No/ 2020-09-11 (1)	Other/ SUBJECT COULD NOT GET BLOOD DRAWN			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3902113	2020-09-25	AMENDMENT 3	No/ 2020-09-25 (1)	Protocol Deviation/ UNABLE TO COMPLETE BLOOD DRAW			
US3902114	2020-09-25	AMENDMENT 3	No/ 2020-09-25 (1)	Withdrawal of Consent by Participant/ NO LONGER WANTED TO PARTICIPATE			
US3902131	2020-10-16	AMENDMENT 3	No/ 2020-10-16 (1)	Other/ UNABLE TO DRAW BLOOD			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Missing; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942107	2020-09-15	AMENDMENT 3	No/ 2020-09-23 (1)	Other/ UNABLE TO PERFORM VENIPUNCTURE			
US3982070	2020-09-01	AMENDMENT 3	No/ 2020-09-01 (1)	Withdrawal of Consent by Participant/ SUBJECT WAS RANDOMIZED 01 SEP 2020 BUT IP WAS NOT DISPENSED.			

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002001	2020-07-27	AMENDMENT	1 No/ 2021-02-15 (204)	Lost to Follow-Up		Yes/ 2020-08-25 (30)	
US3002012	2020-07-27	AMENDMENT	1 No/ 2021-01-13 (171)	Other/ GETTING PFIZER VACCINE THROUGH WORK		Yes/ 2020-08-27 (32)	
US3002016	2020-07-28	AMENDMENT	1 No/ 2021-02-19 (207)	Protocol Deviation/ GOT PFIZER VACCINE AT WORK		Yes/ 2020-08-27 (31)	
US3002020	2020-07-28	AMENDMENT	1 No/ 2021-03-18 (234)	Protocol Deviation/ PATIENT GOT HIS 2ND VACCINE THROUGH WORK		Yes/ 2020-08-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002031	2020-07-28	AMENDMENT	1 No/ 2021-02-26 (214)	Lost to Follow-Up		No/ 2020-08-24 (28)	Due to SARS-CoV-2
US3002046	2020-07-29	AMENDMENT	1 No/ 2020-11-06 (101)	Serious Adverse Event/ AE # 1		No/ 2020-08-25 (28)	Serious Adverse Event/ AE #1
US3002094	2020-08-04	AMENDMENT	1 No/ 2021-01-06 (156)	Withdrawal of Consent by Participant/ GETTING EUA		Yes/ 2020-09-17 (45)	
US3002099	2020-08-05	AMENDMENT	1 No/ 2021-03-22 (230)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF CLINIC.		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002102	2020-08-05	AMENDMENT	1 No/ 2021-02-12 (192)	Protocol Deviation/ PT RECEIVED OUTSIDE EUA		Yes/ 2020-09-02 (29)	
US3002117	2020-08-06	AMENDMENT	1 No/ 2021-01-11 (159)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-03 (29)	
US3002130	2020-08-07	AMENDMENT	1 No/ 2020-12-17 (133)	Other/ UNBLINDED PATIENT, RECEIVING VACCINE AT WORK		Yes/ 2020-09-04 (29)	
US3002133	2020-08-07	AMENDMENT	1 No/ 2021-01-04 (151)	Lost to Follow-Up		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002136	2020-08-10	AMENDMENT 2	No/ 2021-01-18 (162)	Withdrawal of Consent by Participant/ SUBJECT RECEIVED COVID-19 VACCINE NOT AT STUDY SITE		Yes/ 2020-09-15 (37)	
US3002162	2020-08-14	AMENDMENT 2	No/ 2020-12-17 (126)	Other/ PT UNBLINDED TO RECEIVE OUTSIDE COVID VACCINE		Yes/ 2020-09-15 (33)	
US3002204	2020-08-28	AMENDMENT 3	No/ 2020-10-27 (61)	Lost to Follow-Up		No/ 2020-09-24 (28)	Lost to Follow-Up
US3002224	2020-09-01	AMENDMENT 3	No/ 2021-02-05 (158)	Protocol Deviation/ PT GOT EUA		Yes/ 2020-10-05 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002231	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Physician Decision/ PATIENT CAME IN FOR 2ND VACCINATION BUT HAD COVID LIKE ILLNESS AND COMPLETED ILLNESS VISIT INSTEAD. PATIENT POSITIVE FOR RHINOVIRUS AND STILL HAVING SYMPTOMS ON LAST DAY OF VISIT 2 WINDOW.
US3002235	2020-09-02	AMENDMENT 3	No/ 2020-10-07 (36)	Lost to Follow-Up		No/ 2020-09-29 (28)	Lost to Follow-Up
US3002244	2020-09-03	AMENDMENT 3	No/ 2020-12-12 (101)	Lost to Follow-Up		Yes/ 2020-10-06 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002279	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Other/ DID NOT COMPLETE VISIT 2 VACCINATION DUE TO ILLNESS VISIT
US3002302	2020-09-15	AMENDMENT 3	ONGOING			No/ 2020-10-12 (28)	Due to SARS-CoV-2
US3002319	2020-09-24	AMENDMENT 3	No/ 2020-10-22 (29)	Lost to Follow-Up		No/ 2020-10-21 (28)	Lost to Follow-Up
US3002322	2020-09-24	AMENDMENT 3	No/ 2021-03-25 (183)	Lost to Follow-Up		No/ 2020-10-21 (28)	Physician Decision/ COULD NOT GET PATIENT IN FOR V2 WITHIN WINDOW.
US3002325	2020-09-24	AMENDMENT 3	No/ 2020-10-15 (22)	Lost to Follow-Up		No/ 2020-10-14 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002350	2020-10-08	AMENDMENT 4	No/ 2020-10-29 (22)	Lost to Follow-Up		No/ 2020-10-28 (21)	Lost to Follow-Up
US3012002	2020-07-27	AMENDMENT 1	No/ 2021-01-06 (164)	Protocol Deviation/ SUBJECT RECEIVED EUA COVID-19 VACCINE ON 05-JAN-2021 OUTSIDE OF STUDY AND HAS BEEN WITHDRAWN PER SPONSOR INSTRUCTION.		Yes/ 2020-08-21 (26)	
US3012008	2020-07-27	AMENDMENT 1	No/ 2020-12-29 (156)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-08-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012029	2020-07-29	AMENDMENT 1	No/ 2020-12-21 (146)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE UNDER EUA APPROVAL. WITHDRAWN, PER SPONSOR INSTRUCTION.		Yes/ 2020-08-26 (29)	
US3012041	2020-07-31	AMENDMENT 1	ONGOING			No/ 2020-08-27 (28)	Physician Decision/ SUBJECT HAD ELECTIVE SURGERY. PER PI DECISION, DOSE #2 WAS SKIPPED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012065	2020-08-06	AMENDMENT 1	No/ 2021-01-11 (159)	Protocol Deviation/ RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY , WITHDRAWN PER SPONSOR INSTRUCTIONS		Yes/ 2020-09-03 (29)	
US3012072	2020-08-06	AMENDMENT 1	No/ 2021-01-04 (152)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID-19 VACCINE UNDER EUA ON 20-DEC-2020 AND WAS WITHDRAWN PER SPONSOR INSTRUCTIONS.		Yes/ 2020-09-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012073	2020-08-06	AMENDMENT 1	No/ 2021-03-05 (212)	Serious Adverse Event/ #1		Yes/ 2020-09-03 (29)	
US3012078	2020-08-07	AMENDMENT 1	No/ 2020-12-21 (137)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE UNDER EUA APPROVAL. WITHDRAWN PER SPONSOR INSTRUCTION.		Yes/ 2020-09-04 (29)	
US3012088	2020-08-10	AMENDMENT 2	No/ 2021-03-12 (215)	Lost to Follow-Up		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012092	2020-08-10	AMENDMENT 2	No/ 2020-12-28 (141)	Other/ PATIENT REQUESTED UNBLINDING DUE TO MEETING CDC CRITERIA/ACCESS TO EUA VACCINE. RECEIVED PLACEBO DURING STUDY AND WAS WITHDRAWN, PER SPONSOR INSTRUCTIONS.		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012105	2020-08-11	AMENDMENT 2	No/ 2021-01-15 (158)	Other/ SUBJECT REQUESTED UNBLINDING DUE TO APPOINTMENT TO RECEIVE EUA VACCINE. PT DOES NOT CURRENTLY MEET EUA CRITERIA/LOCAL GUIDELINES TO BE UNBLINDED AT SITE. WITHDRAWN FROM STUDY PER SPONSOR INSTRUCTION.		Yes/ 2020-09-08 (29)	
US3012137	2020-08-14	AMENDMENT 2	No/ 2020-11-16 (95)	Lost to Follow-Up		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012181	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Protocol Deviation/ RECEIVED A NON TRIAL VACCINE
US3012188	2020-08-19	AMENDMENT 2	No/ 2020-09-18 (31)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO EXPERIENCE SIDE EFFECTS AGAIN AND IS DISCONTINUING PARTICIPATION FROM STUDY PRIOR TO SECOND VACCINE.		No/ 2020-09-15 (28)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO EXPERIENCE SIDE EFFECTS AGAIN AND IS DISCONTINUING PARTICIPATION FROM STUDY PRIOR TO SECOND VACCINE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012194	2020-08-20	AMENDMENT 2	No/ 2021-01-04 (138)	Protocol Deviation/ PT RECEIVED COVID-19 VACCINE UNDER EUA OUTSIDE OF STUDY. WITHDRAWN FROM STUDY PER SPONSOR INSTRUCTIONS.		No/ 2020-09-16 (28)	Protocol Deviation/ SUBJECT RECEIVED INFLUENZA VACCINE IN BETWEEN DOSES AND SECOND DOSE COULD NOT BE ACCOMMODATED IN WINDOW.
US3012198	2020-08-20	AMENDMENT 2	No/ 2020-12-23 (126)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012203	2020-08-21	AMENDMENT 2	No/ 2020-12-28 (130)	Protocol Deviation/ SUBJECT RECEIVED EUA COVID-19 VACCINE AND WAS WITHDRAWN.		Yes/ 2020-09-18 (29)	
US3012213	2020-08-25	AMENDMENT 2	No/ 2021-03-01 (189)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT TO BE VACCINATED OUTSIDE OF STUDY.		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012230	2020-08-26	AMENDMENT 2	No/ 2020-12-30 (127)	Protocol Deviation/ SUBJECT RECEIVED EUA-APPROVED PFIZER VACCINE AT PLACE OF WORK ON 30-DEC-2020 AND WAS WITHDRAWN, PER SPONSOR INSTRUCTIONS.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012237	2020-08-27	AMENDMENT 2	No/ 2021-01-07 (134)	Other/ SUBJECT REQUESTED UNBLINDING DUE TO ACCESS TO EUA COVID-19 VACCINE AT WORK. PI UNBLINDED SUBJECT FOR SAFETY AND SUBJECT HAS BEEN WITHDRAWN, PER SPONSOR INSTRUCTIONS.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012241	2020-08-28	AMENDMENT 2	No/ 2020-12-28 (123)	Other/ PATIENT REQUESTED UNBLINDING DUE TO MEETING CDC CRITERIA/ACCESS TO EUA VACCINE. RECEIVED PLACEBO DURING STUDY AND WAS WITHDRAWN, PER SPONSOR INSTRUCTIONS.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012275	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Protocol Deviation/ SUBJECT RECEIVED PROHIBITED MEDICATION (COVID-19 VACCINE) / MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-10-02 (29)	
US3012285	2020-09-10	AMENDMENT 3	No/ 2021-02-03 (147)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT, NO LONGER WANTS TO PARTICIPATE.		Yes/ 2020-10-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012318	2020-09-15	AMENDMENT 3	No/ 2021-03-12 (179)	Lost to Follow-Up		Yes/ 2020-10-13 (29)	
US3012322	2020-09-15	AMENDMENT 3	No/ 2020-12-28 (99)	Other/ PATIENT REQUESTED UNBLINDING DUE TO MEETING CDC CRITERIA/ACCESS TO EUA VACCINE. RECEIVED PLACEBO DURING STUDY AND WAS WITHDRAWN, PER SPONSOR INSTRUCTIONS.		Yes/ 2020-10-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012327	2020-09-15	AMENDMENT 3	No/ 2020-12-29 (106)	Other/ REQUESTED UNBLINDING / MEETS CDC REQUIREMENTS TO RECEIVE EUA COVID-19 VACCINE		Yes/ 2020-10-14 (30)	
US3022034	2020-07-27	AMENDMENT 1	No/ 2021-01-06 (164)	Other/ REQUEST TO UNBLIND/ EUA COVID-19		Yes/ 2020-08-25 (30)	
US3022060	2020-07-28	AMENDMENT 1	No/ 2020-12-28 (154)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE!		Yes/ 2020-08-31 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022066	2020-07-29	AMENDMENT 1	No/ 2021-01-06 (162)	Protocol Deviation/ SUBJECT REPORTS THAT HE RECEIVED PFIZER COVID-19 VACCINE ON 23DEC2020		Yes/ 2020-09-02 (36)	
US3022093	2020-07-31	AMENDMENT 1	No/ 2020-12-31 (154)	Other/ SUBJECT UNBLINDED FOR SAFETY. NOT WILLING TO COME IN AND SIGN UPDATED ICF.		Yes/ 2020-09-04 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022097	2020-07-31	AMENDMENT 1	No/ 2020-12-17 (140)	Physician Decision/ DUE TO UNBLINDING FOR COVID-19 VACCINE		Yes/ 2020-10-07 (69)	
US3022179	2020-08-19	AMENDMENT 2	No/ 2020-12-03 (107)	Lost to Follow-Up		No/ 2020-09-15 (28)	Lost to Follow-Up
US3022180	2020-08-20	AMENDMENT 2	No/ 2020-12-22 (125)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022215	2020-08-20	AMENDMENT 2	No/ 2020-09-30 (42)	Withdrawal of Consent by Participant/ SUBJECT STATES THAT SHE DOESN'T WANT TO PARTICIPATE ANYMORE.		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ SUBJECT STATES THAT SHE DOESN'T WANT TO PARTICIPATE IN STUDY ANYMORE.
US3022226	2020-08-20	AMENDMENT 2	No/ 2021-01-19 (153)	Protocol Deviation/ EUA (SAFETY UNBLINDING) SUBJECT RECEIVED PFIZER VACCINE ON 19JAN2021		Yes/ 2020-09-22 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022243	2020-08-21	AMENDMENT 2	No/ 2020-12-30 (132)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-29 (40)	
US3022284	2020-08-21	AMENDMENT 2	No/ 2021-01-15 (148)	Withdrawal of Consent by Participant/ SUBJECT STATED SHE DID NOT WANT TO CONTINUE IN STUDY ANYMORE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032009	2020-07-28	AMENDMENT 1	No/ 2021-01-11 (168)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT TO BE VACCINATED AT THEIR EMPLOYER INSTEAD OF THROUGH THE STUDY.		Yes/ 2020-08-25 (29)	
US3032027	2020-07-28	AMENDMENT 1	No/ 2020-10-11 (76)	Lost to Follow-Up		Yes/ 2020-08-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032029	2020-07-28	AMENDMENT 1	No/ 2020-12-17 (143)	Other/ SUBJECT WAS UNBLINDED AND IS GOING TO RECEIVE EUA DRUG FROM EMPLOYER.		Yes/ 2020-08-28 (32)	
US3032034	2020-07-29	AMENDMENT 1	No/ 2020-08-26 (29)	Withdrawal of Consent by Participant/ UNABLE TO COMPLY WITH STUDY PROCEDURES		No/ 2020-08-25 (28)	Withdrawal of Consent by Participant/ UNABLE TO COMPLY WITH STUDY PROCEDURES
US3032048	2020-07-30	AMENDMENT 1	No/ 2020-12-09 (133)	Lost to Follow-Up		Yes/ 2020-09-03 (36)	
US3032065	2020-08-03	AMENDMENT 1	No/ 2020-12-10 (130)	Lost to Follow-Up		Yes/ 2020-09-04 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032141	2020-08-07	AMENDMENT 1	No/ 2021-03-11 (217)	Lost to Follow-Up		Yes/ 2020-09-08 (33)	
US3032153	2020-08-08	AMENDMENT 1	No/ 2020-12-18 (133)	Other/ SUBJECT MEETS CDC GUIDELINES FOR EUA VACCINE AND SUBJECT WISHED TO BE UNBLINDED, SUBJECT IS WITHDRAWN FROM THE STUDY.		Yes/ 2020-09-09 (33)	
US3032171	2020-08-10	AMENDMENT 2	ONGOING			No/ 2020-09-06 (28)	Due to SARS-CoV-2
US3032172	2020-08-10	AMENDMENT 2	ONGOING			No/ 2020-09-06 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032181	2020-08-10	AMENDMENT 2	No/ 2021-01-20 (164)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WISH TO CONTINUE WITH THE STUDY		Yes/ 2020-09-09 (31)	
US3032204	2020-08-14	AMENDMENT 2	No/ 2020-11-16 (95)	Death	2020-11-16/ N	Yes/ 2020-09-14 (32)	
US3032240	2020-08-19	AMENDMENT 2	No/ 2020-10-20 (63)	Lost to Follow-Up		No/ 2020-09-15 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032257	2020-08-19	AMENDMENT 2	No/ 2020-12-21 (125)	Withdrawal of Consent by Participant/ CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-21 (34)	
US3032262	2020-08-20	AMENDMENT 2	No/ 2020-12-28 (131)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO GET VACCINE AT WORK.		Yes/ 2020-09-21 (33)	
US3032277	2020-08-20	AMENDMENT 2	No/ 2020-10-01 (43)	Serious Adverse Event/ SAE #1		No/ 2020-09-16 (28)	Serious Adverse Event/ #1 FOR ROW 1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032329	2020-08-22	AMENDMENT 2	No/ 2021-03-10 (201)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO BE IN THE STUDY.		Yes/ 2020-09-25 (35)	
US3032339	2020-08-25	AMENDMENT 3	No/ 2021-03-15 (203)	Lost to Follow-Up		Yes/ 2020-09-23 (30)	
US3042041	2020-07-30	AMENDMENT 1	No/ 2020-09-17 (50)	Lost to Follow-Up		No/ 2020-08-26 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042043	2020-07-30	AMENDMENT 1	No/ 2020-12-22 (146)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY COVID VACCINATION THROUGH EMPLOYER ON 21DEC2020; PATIENT DID NOT CONSULT STUDY TEAM PRIOR TO RECEIVING VACCINE.		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042045	2020-07-31	AMENDMENT 1	No/ 2021-01-14 (168)	Protocol Deviation/ PARTICIPANT RECEIVED COVID VACCINE THROUGH EMPLOYER ON 30DEC2020. PATIENT DID NOT CONTACT STUDY TEAM PRIOR TO RECEIVING VACCINE. PATIENT WITHDREW CONSENT WHEN HE NOTIFIED STUDY TEAM OF VACCINE.		Yes/ 2020-09-02 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042051	2020-08-03	AMENDMENT 1	No/ 2021-02-12 (194)	Protocol Deviation/ PATIENT RECEIVED COVID VACCINE OUTSIDE OF STUDY		No/ 2020-08-30 (28)	Due to SARS-CoV-2
US3042052	2020-08-03	AMENDMENT 1	No/ 2021-01-21 (172)	Withdrawal of Consent by Participant/ PATIENT IS OUT OF STATE AND NOT PLANNING ON RETURNING; PATIENT WITHDREW CONSENT.		Yes/ 2020-09-08 (37)	
US3042078	2020-08-05	AMENDMENT 1	No/ 2021-01-05 (154)	Lost to Follow-Up		Yes/ 2020-09-09 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042083	2020-08-06	AMENDMENT 1	No/ 2021-01-22 (170)	Protocol Deviation/ PATIENT RECEIVED VACCINE THROUGH EMPLOYER		Yes/ 2020-09-16 (42)	
US3042102	2020-08-06	AMENDMENT 1	No/ 2021-01-11 (159)	Protocol Deviation/ PATIENT RECEIVED COVID VACCINE OUTSIDE OF STUDY; PATIENT WITHDREW CONSENT WHEN CALLED TO NOTIFY STUDY TEAM.		Yes/ 2020-09-10 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042106	2020-08-07	AMENDMENT 1	No/ 2020-12-30 (146)	Protocol Deviation/ PATIENT WAS ADMINISTERED COVID VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-04 (29)	
US3042113	2020-08-07	AMENDMENT 1	No/ 2021-01-05 (152)	Protocol Deviation/ PATIENT WITHDREW CONSENT AND WAS ADMINISTERED COVID VACCINE AT EMPLOYER		Yes/ 2020-09-09 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042152	2020-08-12	AMENDMENT 2	No/ 2021-01-14 (156)	Withdrawal of Consent by Participant/ WHEN DOING CONVALESCENT PHONE CALL; PATIENT STATED NO LONGER WANTED TO BE A PART OF THE STUDY AND PARTICIPANT WITHDREW CONSENT.		Yes/ 2020-09-16 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042158	2020-08-12	AMENDMENT 2	No/ 2020-11-05 (86)	Withdrawal of Consent by Participant/ SUBJECT BELIEVES A VACCINE WILL BE AVAILABLE TO THE PUBLIC NEXT MONTH; SUBJECT WITHDREW CONSENT.		Yes/ 2020-09-09 (29)	
US3042171	2020-08-13	AMENDMENT 2	No/ 2020-11-05 (85)	Lost to Follow-Up		No/ 2020-09-09 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042187	2020-08-13	AMENDMENT 2	No/ 2021-01-13 (154)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT TO RECEIVE COVID VACCINE VIA EMPLOYER.		Yes/ 2020-09-10 (29)	
US3042197	2020-08-14	AMENDMENT 2	No/ 2021-01-11 (151)	Protocol Deviation/ PATIENT RECEIVED COVID VACCINE OUTSIDE OF STUDY THEN WITHDREW CONSENT WHEN CALLED TO NOTIFY STUDY STAFF		Yes/ 2020-09-14 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042209	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3042220	2020-08-17	AMENDMENT 2	No/ 2021-01-11 (148)	Protocol Deviation/ PATIENT WAS ADMINISTERED COVID VACCINE AT EMPLOYER WITHOUT NOTIFYING STUDY TEAM; PATIENT WITHDREW CONSENT.		Yes/ 2020-09-14 (29)	
US3042295	2020-08-21	AMENDMENT 2	No/ 2020-09-21 (32)	Adverse Event/ AE #1		No/ 2020-09-17 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052004	2020-07-30	AMENDMENT 1	No/ 2020-12-15 (139)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-08-26 (28)	
US3052012	2020-07-30	AMENDMENT 1	ONGOING			No/ 2020-08-26 (28)	Due to SARS-CoV-2
US3052022	2020-07-30	AMENDMENT 1	No/ 2021-01-28 (183)	Other/ SUBJECT DID NOT MEET EXCLUSION CRITERIA #13 HAVING RECEIVED A BLOOD TRANSFUSION 30 DEC 2021		Yes/ 2020-08-25 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052037	2020-07-31	AMENDMENT 1	No/ 2020-12-15 (138)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-08-26 (27)	
US3052051	2020-07-31	AMENDMENT 1	No/ 2020-11-25 (118)	Lost to Follow-Up		No/ 2020-08-27 (28)	Lost to Follow-Up
US3052062	2020-07-31	AMENDMENT 1	No/ 2020-12-15 (138)	Other/ SUBJECT REQUESTED UNBLINDING TO RECEIVE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-08-26 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052069	2020-08-03	AMENDMENT 1	ONGOING			No/ 2020-08-30 (28)	Withdrawal of Consent by Participant/ THE PATIENT LEFT HER APPOINTMENT AND WHEN CONTACTED TO RESCHEDULE SHE WITHDREW HER CONSENT.
US3052103	2020-08-04	AMENDMENT 1	No/ 2021-01-05 (155)	Protocol Deviation/ EUA VACCINE		Yes/ 2020-09-04 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052109	2020-08-06	AMENDMENT 1	No/ 2020-12-15 (132)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-09-10 (36)	
US3052112	2020-08-06	AMENDMENT 1	No/ 2020-12-16 (133)	Other/ SUBJECT UNBLINDED DUE TO COVID-19 VACCINE BEING AVAILABLE.		Yes/ 2020-09-11 (37)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052133	2020-08-07	AMENDMENT 1	No/ 2020-12-23 (139)	Withdrawal of Consent by Participant/ PT WAS UNBLINDED 23 DEC 2020 AND WITHDREW FROM STUDY AT THAT TIME.		Yes/ 2020-09-11 (36)	
US3052134	2020-08-07	AMENDMENT 1	No/ 2021-01-14 (161)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FROM STUDY		Yes/ 2020-09-11 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052187	2020-08-12	AMENDMENT 2	No/ 2020-12-28 (139)	Withdrawal of Consent by Participant/ PT WITHDRAW FROM STUDY		Yes/ 2020-09-10 (30)	
US3052226	2020-08-14	AMENDMENT 2	No/ 2020-12-17 (126)	Other/ SUBJECT REQUESTED UNBLINDING TO RECEIVE THE COVID-19 VACCINE AVAILABLE		Yes/ 2020-09-11 (29)	
US3052251	2020-08-18	AMENDMENT 2	No/ 2021-01-18 (154)	Withdrawal of Consent by Participant/ SUBJECT'S DISCRETION		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052270	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Lost to Follow-Up
US3052329	2020-08-31	AMENDMENT 2	No/ 2020-12-16 (108)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-09-29 (30)	
US3052334	2020-09-01	AMENDMENT 3	No/ 2020-12-16 (107)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-10-06 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052338	2020-09-01	AMENDMENT 3	No/ 2020-12-15 (106)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-10-06 (36)	
US3052349	2020-09-02	AMENDMENT 3	No/ 2021-01-16 (137)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE AT JOB WITHOUT BEING UNBLINDED FIRST ON 12/30/2020		Yes/ 2020-10-07 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052358	2020-09-02	AMENDMENT 3	No/ 2020-12-22 (112)	Other/ UNBLINDED FOR ADMINISTRATION OF ALTERNATE VACCINE, PLACEBO GROUP, WITHDRAWN FROM TRIAL.		Yes/ 2020-10-06 (35)	
US3052362	2020-09-03	AMENDMENT 3	No/ 2020-12-15 (104)	Other/ SUBJECT ASKED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-10-05 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052363	2020-09-03	AMENDMENT 3	No/ 2020-12-15 (104)	Other/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE THE COVID-19 VACCINE AVAILABLE.		Yes/ 2020-10-05 (33)	
US3062172	2020-08-08	AMENDMENT 1	No/ 2021-02-16 (193)	Withdrawal of Consent by Participant		Yes/ 2020-09-05 (29)	
US3062185	2020-08-08	AMENDMENT 1	No/ 2020-12-23 (138)	Other/ UN-BLINDED/RANDOMIZED TO PLACEBO GROUP PRIOR TO AMENDMENT 6 APPROVAL		Yes/ 2020-09-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3062232	2020-08-14	AMENDMENT 2	No/ 2021-02-09 (180)	Withdrawal of Consent by Participant/ SUBJECT JOINED ARMY		Yes/ 2020-09-11 (29)	
US3062245	2020-08-14	AMENDMENT 2	No/ 2021-03-03 (202)	Lost to Follow-Up		Yes/ 2020-09-11 (29)	
US3062311	2020-09-11	AMENDMENT 3	No/ 2021-03-17 (188)	Physician Decision/ EPIP 440811- POOR DATA		Yes/ 2020-10-06 (26)	
US3082004	2020-08-06	AMENDMENT 2	No/ 2021-01-13 (161)	Other/ REQUESTED TO BE UNBLINDED DUE TO EUA		Yes/ 2020-09-10 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082015	2020-08-11	AMENDMENT 2	No/ 2021-01-20 (163)	Protocol Deviation/ REQUEST TO UNBLIND POST EUA/ RECEIVED PFIZER VACCINE		Yes/ 2020-09-09 (30)	
US3082019	2020-08-12	AMENDMENT 2	No/ 2020-12-29 (140)	Other/ REQUEST TO UNBLIND EUA COVID-19 VACCINE		Yes/ 2020-09-09 (29)	
US3082025	2020-08-13	AMENDMENT 2	No/ 2021-02-18 (190)	Lost to Follow-Up		Yes/ 2020-09-10 (29)	
US3082029	2020-08-14	AMENDMENT 2	No/ 2021-01-04 (144)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082033	2020-08-14	AMENDMENT 2	No/ 2020-12-21 (130)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-11 (29)	
US3082043	2020-08-17	AMENDMENT 2	No/ 2021-01-11 (148)	Protocol Deviation/ POST-EUA APPROVAL/ RECEIVED APPROVED COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-14 (29)	
US3082076	2020-08-20	AMENDMENT 3	No/ 2020-12-21 (124)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-23 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082083	2020-08-21	AMENDMENT 3	No/ 2021-01-20 (153)	Protocol Deviation/ REQUEST TO UNBLIND POST-EUA/RECEIVED PFIZER		Yes/ 2020-09-25 (36)	
US3082102	2020-08-25	AMENDMENT 3	No/ 2021-01-08 (137)	Protocol Deviation/ RECEIVED MRNA-1273 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-23 (30)	
US3082107	2020-08-25	AMENDMENT 3	No/ 2020-12-21 (119)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082111	2020-08-26	AMENDMENT 3	No/ 2021-01-25 (153)	Other/ REQUEST TO UNBLIND POST-EUA/RECEIVING PFIZER THROUGH WORK		Yes/ 2020-09-24 (30)	
US3082116	2020-08-26	AMENDMENT 3	No/ 2021-01-25 (153)	Protocol Deviation/ REQUEST TO UNBLIND POST-EUA/PATIENT RECEIVED PFIZER VACCINE		Yes/ 2020-09-23 (29)	
US3082128	2020-08-27	AMENDMENT 3	No/ 2021-01-29 (156)	Other/ EUA DISCONTINUATION		Yes/ 2020-09-29 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082131	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-28 (32)	
US3082133	2020-08-28	AMENDMENT 3	No/ 2021-01-04 (130)	Other/ REQUEST TO UNBLIND POST COVID-19 VACCINE EUA		Yes/ 2020-10-01 (35)	
US3082136	2020-08-28	AMENDMENT 3	No/ 2021-01-07 (133)	Other/ REQUEST TO UNBLIND POST EUA COVID-19 VACCINE		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082141	2020-08-28	AMENDMENT 3	No/ 2020-12-28 (120)	Protocol Deviation/ POST EUA UNBLINDING/ PARTICIPANT RECEIVED PIFZER		Yes/ 2020-09-29 (30)	
US3082152	2020-08-29	AMENDMENT 3	No/ 2020-12-21 (115)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-01 (34)	
US3082154	2020-08-31	AMENDMENT 3	No/ 2021-02-22 (176)	Protocol Deviation/ POST-EUA UNBLINDING/ SUBJECT RECEIVED PFIZER		Yes/ 2020-10-01 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082167	2020-09-01	AMENDMENT 3	No/ 2021-01-05 (119)	Other/ REQUEST TO UNBLIND POST-EUA		Yes/ 2020-10-12 (34)	
US3082179	2020-09-02	AMENDMENT 3	No/ 2021-01-04 (125)	Other/ REQUEST TO UNBLIND POST EUA COVID-19 VACCINE		Yes/ 2020-10-01 (30)	
US3082198	2020-09-04	AMENDMENT 3	No/ 2020-12-21 (109)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-08 (35)	
US3082201	2020-09-04	AMENDMENT 3	No/ 2020-12-21 (109)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082247	2020-09-16	AMENDMENT 3	No/ 2021-03-15 (181)	Lost to Follow-Up		No/ 2020-10-13 (28)	Due to SARS-CoV-2
US3082249	2020-09-16	AMENDMENT 3	No/ 2021-01-28 (135)	Protocol Deviation/ REQUEST TO UNBLIND POST-EUA/ PATIENT RECEIVED PFIZER		Yes/ 2020-10-15 (30)	
US3082269	2020-09-21	AMENDMENT 3	No/ 2020-10-03 (13)	Death	2020-10-03/ UNK	No/ 2020-10-03 (13)	Death

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092001	2020-08-04	AMENDMENT 1	No/ 2020-12-16 (135)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY PROTOCOL. SUBJECT RECEIVED A NON_STUDY COVID VACCINE PRIOR TO WITHDRAWAL.		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092003	2020-08-04	AMENDMENT 1	No/ 2020-10-09 (67)	Protocol Deviation/ PHYSICIAN DECISION PER NON COMPLIANCE AFTER SEVERAL FAILED CALL ATTEMPTS TO SUBJECT.		No/ 2020-08-31 (28)	Physician Decision/ SUBJECT WITHDREW DUE TO ONLINE SCHOOLING.LATER CALLED SITE TO SCHEDULE NEXT VISIT. AFTER EPIP WAS SUBMITTED SUBJECT NEVER RESPONDED TO SITE CALLS. PHYSICIAN DECISION PER SUBJECT NON COMPLIANCE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092018	2020-08-05	AMENDMENT 1	No/ 2020-09-24 (51)	Withdrawal of Consent by Participant/ SUBJECT DID NOT PROVIDE REASON FOR WITHDRAWAL OF CONSENT.		No/ 2020-09-01 (28)	Withdrawal of Consent by Participant/ SUBJECT RETURNED TO SITE TO RETURN E-DIARY DEVICE AND WITHDREW CONSENT. SITE ATTEMPTED TO CONTACT SUBJECT AS NO REASON AS TO WHY SUBJECT WAS WITHDRAWING FROM STUDY WAS GIVEN.
US3092034	2020-08-06	AMENDMENT 1	No/ 2020-11-20 (107)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-25 (51)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092041	2020-08-06	AMENDMENT 1	No/ 2020-12-28 (145)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY> SUBJECT RECEIVED A NON_STUDY COVID VACCINE PRIOR TO WITHDRAWAL FROM STUDY.		Yes/ 2020-09-08 (34)	
US3092051	2020-08-07	AMENDMENT 1	No/ 2020-09-28 (53)	Withdrawal of Consent by Participant/ SUBJECT DECISION, WITHDREW CONSENT		Yes/ 2020-09-16 (41)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092059	2020-08-07	AMENDMENT 1	No/ 2020-10-23 (78)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE		No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE
US3092062	2020-08-07	AMENDMENT 1	No/ 2021-03-01 (207)	Other/ SUBJECT DISCONTINUED. UNBLINDED- IN PERU AND HAS ACCESS TO RECEIVE EUA		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092085	2020-08-08	AMENDMENT 1	No/ 2021-03-04 (209)	Protocol Deviation/ DISCONTINUED DUE TO RECEIVING VACCINE OUTSIDE OF PROTOCOL. SUBJECT RECEIVED A NON-STUDY COVID VACCINE PRIOR TO WITHDRAWAL FROM THE STUDY.		Yes/ 2020-09-12 (36)	
US3092104	2020-08-11	AMENDMENT 2	No/ 2021-01-04 (147)	Other/ SUBJECT UNBLINDED UNDER A5 AND PRIOR TO PDV		Yes/ 2020-09-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092109	2020-08-11	AMENDMENT 2	No/ 2020-10-30 (81)	Withdrawal of Consent by Participant/ SUBJECT DISCONTINUED FROM STUDY TREATMENT AND DID NOT WANT TO CONTINUE IN ANY SAFETY FOLLOW UP PROCEDURES.		No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ SUBJECT DISCONTINUED FROM STUDY TREATMENT AND DID NOT WANT TO CONTINUE IN ANY SAFETY FOLLOW UP PROCEDURES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092123	2020-08-12	AMENDMENT 2	No/ 2020-11-20 (101)	Withdrawal of Consent by Participant/ SUBJECT DIDN'T FEEL LIKE HE RECEIVED THE VACCINE AND WANTS TO WAIT FOR APPROVED VACCINE.		No/ 2020-09-08 (28)	Withdrawal of Consent by Participant/ SUBJECT DIDN'T FEEL LIKE HE RECEIVED THE VACCINE AND WANTS TO WAIT FOR APPROVED VACCINE.
US3092138	2020-08-15	AMENDMENT 2	No/ 2021-01-13 (152)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-18 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092162	2020-08-19	AMENDMENT 2	No/ 2021-03-02 (196)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-21 (34)	
US3092164	2020-08-19	AMENDMENT 2	No/ 2021-02-10 (176)	Protocol Deviation/ DISCONTINUED- UNBLINDED PRIOR TO PROTOCOL AMENDMENT 6, RECEIVED EUA.		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092165	2020-08-19	AMENDMENT 2	No/ 2020-12-24 (128)	Protocol Deviation/ SUBJECT MEETS CDC ELIGIBILITY CRITERIA AND HAS ACCESS TO RECEIVE NON-STUDY COVID-19 VACCINE UNDER EUA. SUBJECT UNBLINDED PRIOR TO AMENDMENT 6.		Yes/ 2020-09-21 (34)	
US3092188	2020-08-21	AMENDMENT 2	No/ 2021-03-01 (193)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-25 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092198	2020-08-24	AMENDMENT 2	No/ 2020-12-09 (108)	Lost to Follow-Up		No/ 2020-09-20 (28)	Lost to Follow-Up
US3092233	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Other/ SUBJECT DID NOT RECEIVE DOSE 2 DUE TO ILLNESSNESS VISIT. SUBJECT AGREES TO CONTINUE IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092277	2020-08-29	AMENDMENT 3	No/ 2021-01-12 (137)	Protocol Deviation/ PROTOCOL DEVIATION: SUBJECT TOOK A VACCINE OUTSIDE OF THE STUDY. SUBJECT TOOK NON-STUDY VACCINE PRIOR TO WITHDRAWAL FROM THE SYUDY.		Yes/ 2020-10-02 (35)	
US3092283	2020-09-01	AMENDMENT 3	No/ 2020-12-24 (115)	Other/ SUBJECT UNBLINDED UNDER ADMENMENT 5 AND PRIOR TO PDV.		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092287	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Other/ SUBJECT REQUIRED TO RECEIVE FLU VACCINE FOR MEDICAL SCHOOL WITHIN 14 DAYS OF DOSE 2. (THIS WAS UNKNOWN AT SCREENING) SUBJECT D/C DOSING AND DID NOT RECEIVE DOSE 2, BUT WILL CONTINUE IN THE STUDY.
US3092290	2020-09-02	AMENDMENT 3	No/ 2021-03-25 (205)	Withdrawal of Consent by Participant/ SUBJECT DECISION/ WITHDREW		Yes/ 2020-09-29 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092306	2020-09-11	AMENDMENT 3	No/ 2020-12-24 (105)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE AT WORK (SUBJECT RECEIVED A NON-STUDY COVID VACCINE PRIOR TO WITHDRAWAL FROM STUDY.)		Yes/ 2020-10-09 (29)	
US3102012	2020-07-28	AMENDMENT 1	No/ 2021-01-16 (173)	Other/ SUBJECT INFORMED SITE THAT SHE HAS MOVED OUT OF STATE. WISHED TO WITHDRAW FROM STUDY AND BE UNBLINDED.		Yes/ 2020-08-24 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102026	2020-07-28	AMENDMENT 1	No/ 2020-12-23 (149)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-08-25 (29)	
US3102031	2020-07-29	AMENDMENT 1	No/ 2020-10-19 (83)	Lost to Follow-Up		Yes/ 2020-08-25 (28)	
US3102041	2020-07-29	AMENDMENT 1	No/ 2021-01-16 (172)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE OF PFIZER RECEIVED 18DEC2020		Yes/ 2020-08-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102065	2020-07-30	AMENDMENT 1	No/ 2021-01-20 (175)	Protocol Deviation/ RECEIVED MODERNA COVID-19 VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-08-26 (28)	
US3102071	2020-07-30	AMENDMENT 1	No/ 2020-08-31 (33)	Withdrawal of Consent by Participant/ SUBJECT WANTS TO BE UNBLINDED SINCE HE CAN RECEIVE COVID-19 AT WORK.		No/ 2020-08-26 (28)	Withdrawal of Consent by Participant/ PARTICIPANT DOES NOT WANT TO DO ANOTHER NP SWAB AT VISIT 2.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102077	2020-08-03	AMENDMENT 1	No/ 2021-01-16 (167)	Protocol Deviation/ SUBJECT WAS CONTACTED TO SCHEDULE UNBLINDING VISIT AND INFORMED SITE THEY HAD A NON-STUDY EUA VACCINE ADMINISTERED OUTSIDE OF STUDY.		Yes/ 2020-08-28 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102090	2020-08-03	AMENDMENT 1	No/ 2021-01-07 (158)	Protocol Deviation/ NON-STUDY EUA-VACCINE ADMINISTERED OUTSIDE OF STUDY		Yes/ 2020-09-01 (30)	
US3102151	2020-08-10	AMENDMENT 2	No/ 2021-01-21 (165)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE, RECEIVED PFIZER VACCINE.		Yes/ 2020-09-04 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102158	2020-08-10	AMENDMENT 2	No/ 2021-02-01 (176)	Protocol Deviation/ REQUEST TO UNBLINDED, RECEIVED PFIZER COVID-19 VACCINE		Yes/ 2020-09-04 (26)	
US3102161	2020-08-10	AMENDMENT 2	No/ 2021-02-22 (197)	Lost to Follow-Up		Yes/ 2020-09-08 (30)	
US3102162	2020-08-10	AMENDMENT 2	No/ 2021-02-22 (197)	Lost to Follow-Up		Yes/ 2020-09-11 (33)	
US3102167	2020-08-11	AMENDMENT 2	No/ 2021-01-16 (159)	Protocol Deviation/ RECEIVED MODERNA VACCINE OUTSIDE OF STUDY, BEFORE UNBLINDING		Yes/ 2020-09-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102172	2020-08-11	AMENDMENT 2	No/ 2021-02-19 (193)	Protocol Deviation/ RECEIVED THE PFIZER COVID-19 VACCINE VIA WORK.		Yes/ 2020-09-08 (29)	
US3102180	2020-08-11	AMENDMENT 2	No/ 2020-12-28 (140)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA COVID-19 VACCINE AND THEN REQUESTED TO BE UNBLINDED FROM STUDY		Yes/ 2020-09-11 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102181	2020-08-11	AMENDMENT 2	No/ 2021-01-05 (148)	Withdrawal of Consent by Participant/ SUBJECT WAS CALLED 05JAN2021 TO SCHEDULE UNBLINDING VISIT. THEY STATED THEY WANTED TO BE UNBLINDED IN ORDER TO RECEIVE THE PFIZER VACCINE. SUBJECT WITHDREW FROM STUDY COMPLETELY.		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102182	2020-08-11	AMENDMENT 2	No/ 2021-02-18 (192)	Protocol Deviation/ RECEIVED MODERNA COVID-19 VACCINE THROUGH WORK		Yes/ 2020-09-08 (29)	
US3102193	2020-08-12	AMENDMENT 2	No/ 2021-01-21 (163)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE. RECEIVED THE PFIZER VACCINE.		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102198	2020-08-14	AMENDMENT 2	No/ 2021-01-05 (145)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-10 (28)	
US3102201	2020-08-14	AMENDMENT 2	No/ 2020-12-29 (138)	Withdrawal of Consent by Participant/ REQUEST FOR UNBLINDING, PLANS TO RECEIVE EUA COVID-19 VACCINE		Yes/ 2020-09-10 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102209	2020-08-18	AMENDMENT 2	No/ 2021-01-18 (154)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-14 (28)	
US3102212	2020-08-18	AMENDMENT 2	No/ 2021-02-11 (178)	Protocol Deviation/ RECEIVED MODERNA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-14 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102225	2020-08-19	AMENDMENT 2	No/ 2020-12-23 (127)	Withdrawal of Consent by Participant/ REQUEST TO WITHDRAW FROM STUDY IN ORDER TO RECEIVE EUA COVID-19 VACCINE		Yes/ 2020-09-15 (28)	
US3102231	2020-08-19	AMENDMENT 2	No/ 2021-01-09 (144)	Withdrawal of Consent by Participant/ PER SUBJECTS REQUEST TO WITHDRAW FROM STUDY.		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102285	2020-08-28	AMENDMENT 3	No/ 2021-03-02 (187)	Protocol Deviation/ REQUEST TO UNBLIND- RECEIVED VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-24 (28)	
US3102307	2020-09-01	AMENDMENT 3	No/ 2020-12-29 (120)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-02 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102310	2020-09-01	AMENDMENT 3	No/ 2020-12-23 (114)	Protocol Deviation/ REQUEST TO UNBLIND-/ EUA COVID-19 VACCINE. SCHEDULED TO RECEIVE THE PFIZER VACCINE.		Yes/ 2020-09-29 (29)	
US3102315	2020-09-02	AMENDMENT 3	No/ 2021-03-03 (183)	Protocol Deviation/ RECEIVED MODERNA VACCINE UNDER EUA		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102353	2020-09-14	AMENDMENT 3	No/ 2021-01-16 (125)	Protocol Deviation/ PROTOCOL DEVIATION RECEIVED MODERNA VACCINE OUT SIDE OF STUDY ON 07JAN2021		Yes/ 2020-10-09 (26)	
US3102354	2020-09-14	AMENDMENT 3	No/ 2020-10-05 (22)	Withdrawal of Consent by Participant/ STATED SHE WANTED TO WITHDRAW FROM THE STUDY AND SITED FAMILY COMMITMENTS AND ISSUES.		No/ 2020-10-04 (21)	Withdrawal of Consent by Participant/ STATED SHE WANTED TO WITHDRAW FROM THE STUDY AND SITED FAMILY COMMITMENTS AND ISSUES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102388	2020-09-18	AMENDMENT 3	No/ 2021-03-04 (168)	Protocol Deviation/ SUBJECT RECEIVED A COVID-19 VACCINATION AT WORK.		Yes/ 2020-10-16 (29)	
US3102395	2020-09-24	AMENDMENT 3	No/ 2021-02-22 (152)	Lost to Follow-Up		Yes/ 2020-10-19 (26)	
US3102401	2020-09-28	AMENDMENT 3	No/ 2021-02-02 (128)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE. SUBJECT RECEIVED PFIZER VACCINE WHILE ON-STUDY.		Yes/ 2020-10-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102404	2020-09-30	AMENDMENT 3	No/ 2020-10-27 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED HE WISHED TO WITHDRAW CONSENT DUE TO LENGTH IT TOOK TO TRAVEL TO THE SITE		No/ 2020-10-26 (27)	Withdrawal of Consent by Participant/ SUBJECT STATED HE WISHED TO WITHDRAW CONSENT DUE TO LENGTH IT TOOK TO TRAVEL TO THE SITE
US3102416	2020-10-08	AMENDMENT 4	No/ 2020-12-23 (77)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT FROM STUDY, STATED PERSONAL REASONS		Yes/ 2020-11-09 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112034	2020-07-30	AMENDMENT 1	No/ 2020-12-28 (152)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-08-27 (29)	
US3112035	2020-07-30	AMENDMENT 1	No/ 2020-10-09 (72)	Lost to Follow-Up		Yes/ 2020-08-26 (28)	
US3112051	2020-07-31	AMENDMENT 1	No/ 2021-01-27 (181)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT AS THEY PREFERRED TO RECEIVE THE PFIZER VACCINE.		Yes/ 2020-08-26 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112054	2020-07-31	AMENDMENT 1	No/ 2020-12-16 (139)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-08-28 (29)	
US3112069	2020-08-03	AMENDMENT 1	No/ 2020-12-23 (143)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-01 (30)	
US3112092	2020-08-04	AMENDMENT 1	No/ 2020-12-30 (149)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-04 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112096	2020-08-04	AMENDMENT 1	No/ 2020-12-28 (147)	Protocol Deviation/ REQUEST OT UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3112098*	2020-07-30	AMENDMENT 1	No/ 2020-12-17 (136)	Protocol Deviation/ REQUEST TO UNBLIND/EAU COVID-19 VACCINE		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112221	2020-08-12	AMENDMENT 2	No/ 2021-02-09 (182)	Withdrawal of Consent by Participant/ PATIENT DECISION TO WITHDRAW CONSENT AS CONTINUED PARTICIPATION/VACCINATION WILL BE COMPLICATED WITH UPCOMING MOVE TO RECEIVE TREATMENT OF RECENT COLORECTAL CANCER DIAGNOSIS.		Yes/ 2020-09-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112223	2020-08-13	AMENDMENT 2	No/ 2021-01-14 (155)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-23 (42)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112252	2020-08-14	AMENDMENT 2	No/ 2020-09-30 (48)	Withdrawal of Consent by Participant/ PT HAS AGREED TO WITHDRAW CONSENT DUE TO UPCOMING TOTAL KNEE REPLACEMENT CITING POTENTIAL INABILITY TO COMPLY FULLY WITH STUDY PROCEDURES. PT HAS ALSO DEMONSTRATED TENDENCY OF NON-COMPLIANCE.		No/ 2020-09-10 (28)	Withdrawal of Consent by Participant/ PT RESPONDED TO MISSED APPTS THROUGH CALL, AGREED TO WITHDRAW CONSENT DUE TO UPCOMING TOTAL KNEE REPLACEMENT SURGERY CITING POTENTIAL INABILITY TO COMPLY FULLY WITH STUDY PROCEDURES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112258	2020-08-14	AMENDMENT 2	No/ 2021-01-14 (154)	Other/ REQUEST TO UNBLIND/EUA COVID -19 VACCINE		Yes/ 2020-09-15 (33)	
US3112266	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3112267	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3112268	2020-08-14	AMENDMENT 2	No/ 2020-09-04 (22)	Lost to Follow-Up		No/ 2020-09-03 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112284	2020-08-17	AMENDMENT 2	No/ 2021-01-13 (150)	Withdrawal of Consent by Participant/ REQUEST TO UNBLIND/ EVA COVID-19 VACCINE		Yes/ 2020-09-14 (29)	
US3112292	2020-08-18	AMENDMENT 2	No/ 2020-12-21 (126)	Other/ REQUEST TO UNBLIND / EVA COVID-19 VACCINE		Yes/ 2020-09-15 (29)	
US3112304	2020-08-18	AMENDMENT 2	No/ 2021-03-02 (197)	Lost to Follow-Up		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112413	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Physician Decision/ 2ND DOSE NOT ADVISED PER PI DISCRETION DUE TO SYNCOPAL EPISODE AFTER BLOOD DRAW.
US3112423	2020-08-28	AMENDMENT 3	No/ 2021-01-22 (148)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID 19 VACCINE		Yes/ 2020-09-28 (32)	
US3112424	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112429	2020-08-31	AMENDMENT 3	No/ 2021-01-13 (136)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-29 (30)	
US3112450	2020-09-04	AMENDMENT 3	No/ 2020-12-22 (110)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	
US3122012	2020-07-27	AMENDMENT 1	No/ 2021-02-09 (198)	Lost to Follow-Up		Yes/ 2020-08-26 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122055	2020-07-28	AMENDMENT 1	No/ 2020-12-18 (144)	Other/ UNBLINDED: PLACEBO- AUTOMATICALLY WITHDRAW FROM STUDY		Yes/ 2020-08-25 (29)	
US3122069	2020-07-28	AMENDMENT 1	No/ 2021-01-14 (171)	Other/ UNBLINDED: STUDY OUTCOME WAS PLACEBO- AUTOMATICALLY WITHDRAW FROM STUDY.		Yes/ 2020-09-16 (51)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122088	2020-07-28	AMENDMENT 1	No/ 2020-12-16 (142)	Other/ UNBLINDED: PLACEBO- AUTOMATICALLY WITHDRAW FROM STUDY		Yes/ 2020-08-26 (30)	
US3122105	2020-07-29	AMENDMENT 1	No/ 2021-01-13 (169)	Other/ UNBLINDED: STUDY OUTCOME WAS PLACEBO- AUTOMATICALLY WITHDRAW FROM STUDY.		Yes/ 2020-08-25 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122106	2020-07-29	AMENDMENT 1	No/ 2021-01-13 (169)	Other/ UNBLINDED: STUDY OUTCOME WAS PLACEBO-AUTOMATICALLY WITHDRAW FROM STUDY.		Yes/ 2020-08-25 (28)	
US3122110	2020-07-29	AMENDMENT 1	No/ 2020-12-21 (146)	Other/ UNBLINDED: STUDY OUTCOME WAS PLACEBO-AUTOMATICALLY WITHDRAW FROM STUDY.		Yes/ 2020-08-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122116	2020-07-29	AMENDMENT 1	No/ 2020-11-24 (119)	Other/ SUBJECT LEFT COUNTRY AND WILL NOT RETURN UNTIL SUMMER 2021		Yes/ 2020-08-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122127	2020-07-29	AMENDMENT 1	No/ 2020-09-14 (48)	Withdrawal of Consent by Participant/ PATIENT LEFT SITE AT DAY 29 PRIOR TO IP ADMINISTRATION. CALLED SITE ON 14-SEP-2020 TO SAY THEY NO LONGER WISHED TO PARTICIPATE IN THE STUDY AND WITHDREW CONSENT.		No/ 2020-08-25 (28)	Withdrawal of Consent by Participant/ PATIENT LEFT SITE AT DAY 29 PRIOR TO IP ADMINISTRATION. CALLED SITE ON 14-SEP-2020 TO SAY THEY NO LONGER WISHED TO PARTICIPATE IN THE STUDY AND WITHDREW CONSENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122143	2020-09-01	AMENDMENT 3	No/ 2021-01-19 (141)	Withdrawal of Consent by Participant/ SCHEDULED FOR UNBLINDING ON 12JAN BUT WAS NO SHOW. CONTACT ATTEMPTED 18JAN & 19JAN. CONTACT WAS ESTABLISHED PARTICIPANT WITHDREW CONSENT DUE TO NEWS REPORT THEY SAW FROM DAILY MAIL.		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132005	2020-08-07	AMENDMENT 1	No/ 2020-12-22 (138)	Other/ SUBJECT IS A PHYSICIAN SCHEDULED FOR VACCINE 12/26/2020 UNWILLING TO WAIT UNTIL AMENDMENT IS APPROVED		Yes/ 2020-09-08 (33)	
US3132017	2020-08-14	AMENDMENT 2	No/ 2021-01-15 (155)	Protocol Deviation/ PROTOCOL DEVIATION, RECEIVED EUA PFIZER VAX		Yes/ 2020-09-18 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132018	2020-08-14	AMENDMENT 2	No/ 2021-01-13 (153)	Protocol Deviation/ PROTOCOL DEVIATION RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-14 (32)	
US3132030	2020-08-27	AMENDMENT 3	No/ 2020-12-29 (125)	Other/ EUA SCHEDULED FOR PFIZER VACCINE		Yes/ 2020-09-25 (30)	
US3132039	2020-09-03	AMENDMENT 3	No/ 2020-12-24 (113)	Protocol Deviation/ EUA VACCINE RECEIVED (PFIZER)		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132043	2020-09-10	AMENDMENT 3	No/ 2021-02-18 (162)	Protocol Deviation/ RECEIVED PFIZER VACCINE EUA		Yes/ 2020-10-14 (35)	
US3132046	2020-09-14	AMENDMENT 2	No/ 2021-01-28 (137)	Physician Decision/ PI NOT COMFORTABLE WITH CONTINUING PATIENT IN STUDY DUE TO MENTAL INSTABILITY.		Yes/ 2020-10-12 (29)	
US3132047	2020-09-14	AMENDMENT 3	No/ 2020-12-30 (108)	Other/ PT UNBLINDED PRIOR TO AMENDMENT 6.		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132049	2020-09-14	AMENDMENT 3	No/ 2020-12-23 (101)	Other/ UNWILLINGLY TO WAIT FOR AMENDMENT WAS UNBLINDED		Yes/ 2020-10-12 (29)	
US3132053	2020-09-15	AMENDMENT 3	No/ 2021-01-04 (112)	Other/ UNBLINDED PLACEBO GROUP. PT IS GETTING EAU VACCINE		Yes/ 2020-10-16 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132057	2020-09-16	AMENDMENT 3	No/ 2020-12-22 (98)	Other/ SUBJECT IS A PHYSICIAN AND SCHEDULED FOR VACCINE TODAY. UNWILLING TO WAIT FOR AMENDMENT APPROVAL		Yes/ 2020-10-14 (29)	
US3132058	2020-09-16	AMENDMENT 3	No/ 2021-01-22 (129)	Lost to Follow-Up		Yes/ 2020-10-21 (36)	
US3132059	2020-09-16	AMENDMENT 3	No/ 2020-12-18 (94)	Other/ RECEIVING EUA AND WAS UNBLINDED		Yes/ 2020-10-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132061	2020-09-16	AMENDMENT 3	No/ 2020-12-21 (97)	Other/ MEET CDC GUIDELINES FROM TIER 1		Yes/ 2020-10-13 (28)	
US3132071	2020-09-17	AMENDMENT 3	No/ 2021-01-26 (132)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE THE STUDY		Yes/ 2020-10-15 (29)	
US3132090	2020-09-25	AMENDMENT 3	No/ 2021-01-05 (103)	Other/ OFFERED EUA VACCINE. REQUESTED TO UNBLIND. RECEIVED PLACEBO IN THE STUDY		Yes/ 2020-10-26 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132134	2020-10-19	AMENDMENT 4	No/ 2020-12-29 (72)	Protocol Deviation/ PROTOCOL DEVIATION RECEIVED PFIZER EUA		Yes/ 2020-11-20 (33)	
US3132142	2020-10-20	AMENDMENT 4	No/ 2021-01-12 (85)	Protocol Deviation/ PROTOCOL DEVIATION SCHEDULED TO RECEIVED EUA PFIZER VACCINE 12/23/2020		Yes/ 2020-11-17 (29)	
US3142013	2020-07-30	AMENDMENT 1	No/ 2021-02-26 (212)	Lost to Follow-Up		Yes/ 2020-09-29 (62)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3142104	2020-08-05	AMENDMENT 2	ONGOING			No/ 2020-09-01 (28)	Due to SARS-CoV-2
US3142127	2020-08-06	AMENDMENT 2	No/ 2021-01-07 (155)	Withdrawal of Consent by Participant/ PATIENT SEEKING VACCINATION THROUGH EMPLOYER		Yes/ 2020-09-04 (30)	
US3142128	2020-08-06	AMENDMENT 2	No/ 2021-01-14 (162)	Protocol Deviation/ PATIENT RECEIVED EAU APPROVED PFIZER VACCINE IN EARLY JANUARY, PROTOCOL DEVIATION		Yes/ 2020-09-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3142161	2020-08-08	AMENDMENT 1	No/ 2021-02-24 (201)	Withdrawal of Consent by Participant/ SUBJECT RECEIVED OUTSIDE MODERNA VACCINE AND WITHDREW CONSENT AT UNBLINDING VISIT.		Yes/ 2020-09-09 (33)	
US3142218	2020-08-13	AMENDMENT 2	No/ 2021-02-01 (173)	Protocol Deviation/ PATIENT RECEIVED EAU APPROVED VACCINE PRIOR TO DECISION VISIT		Yes/ 2020-09-15 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3142219	2020-08-13	AMENDMENT 2	No/ 2021-02-01 (173)	Protocol Deviation/ PATIENT RECEIVE EAU APPROVED VACCINE 04JAN2020 PRIOR TO STUDY DISCONTINUATION		Yes/ 2020-09-15 (34)	
US3142234	2020-08-18	AMENDMENT 2	No/ 2021-03-08 (203)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY PRIOR TO UNBLINDING		Yes/ 2020-09-14 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3142238	2020-08-19	AMENDMENT 2	No/ 2021-01-07 (142)	Withdrawal of Consent by Participant/ WISHED TO SEEK VACCINATION OUTSIDE OF THE TRIAL		Yes/ 2020-09-17 (30)	
US3142267	2020-09-04	AMENDMENT 3	No/ 2021-03-17 (195)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE COVID VACCINES X 2		Yes/ 2020-09-30 (27)	
US3142274	2020-09-21	AMENDMENT 3	No/ 2021-01-12 (114)	Protocol Deviation		Yes/ 2020-10-20 (30)	
US3152011	2020-07-28	AMENDMENT 1	No/ 2021-02-10 (198)	Lost to Follow-Up		Yes/ 2020-08-26 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152012	2020-07-28	AMENDMENT 1	No/ 2020-12-22 (148)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF THE STUDY WITHOUT NOTIFYING THE SITE.		Yes/ 2020-08-25 (29)	
US3152025	2020-07-29	AMENDMENT 1	ONGOING			No/ 2020-08-25 (28)	Due to SARS-CoV-2
US3152054	2020-07-30	AMENDMENT 1	No/ 2020-12-30 (154)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-02 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152079	2020-08-04	AMENDMENT 1	No/ 2020-12-21 (140)	Protocol Deviation/ REQUESTED UNBLINDING/ EUA COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3152116	2020-08-07	AMENDMENT 1	No/ 2020-12-17 (133)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-09 (34)	
US3152117	2020-08-07	AMENDMENT 1	No/ 2021-03-25 (231)	Lost to Follow-Up		Yes/ 2020-09-10 (35)	
US3152124	2020-08-10	AMENDMENT 2	No/ 2020-09-08 (30)	Lost to Follow-Up		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152132	2020-08-10	AMENDMENT 2	No/ 2021-01-29 (173)	Protocol Deviation/ SUBJECT RECEIVED EUA COVID-19 VACCINE OUTSIDE OF THE STUDY PRIOR TO UNBLINDING.		Yes/ 2020-09-09 (31)	
US3152156	2020-08-13	AMENDMENT 2	No/ 2020-12-22 (132)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-11 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152188	2020-08-14	AMENDMENT 2	No/ 2021-01-11 (151)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-16 (34)	
US3152194	2020-08-14	AMENDMENT 2	No/ 2021-01-15 (155)	Protocol Deviation/ SUBJECT RECEIVED AN EUA OUTSIDE OF STUDY ON 16DEC2020.		Yes/ 2020-09-11 (29)	
US3152217	2020-08-14	AMENDMENT 2	No/ 2020-09-29 (47)	Other/ SUBJECT MOVING TO CA UNEXPECTEDLY		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152223	2020-08-14	AMENDMENT 2	No/ 2021-01-07 (147)	Protocol Deviation/ SUBJECT CHOSE TO DISCONTINUE PARTICIPATION ON EUA CONSENT ADDENDUM 24DEC2020 DUE TO RECEIPT OF PFIZER COVID-19 VACCINE		Yes/ 2020-09-18 (36)	
US3152271	2020-08-15	AMENDMENT 2	No/ 2021-01-20 (159)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-15 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152283	2020-08-17	AMENDMENT 2	No/ 2020-11-05 (81)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO BELIEVING HE HAD RECEIVED PLACEBO.		Yes/ 2020-09-16 (31)	
US3152293	2020-08-18	AMENDMENT 2	No/ 2020-12-21 (126)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-22 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152297	2020-08-18	AMENDMENT 2	No/ 2021-02-17 (184)	Protocol Deviation/ SUBJECT RECEIVED EUA- COVID VACCINE OUTSIDE STUDY		Yes/ 2020-09-16 (30)	
US3152319	2020-08-20	AMENDMENT 2	No/ 2020-09-22 (34)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO REFUSAL TO DO NASAL COVID TESTING		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ WITHDREW DUE TO REFUSAL TO DO NASAL COVID TESTING

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152334	2020-08-20	AMENDMENT 2	No/ 2020-12-21 (124)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	
US3152362	2020-08-21	AMENDMENT 3	No/ 2020-12-22 (124)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-24 (35)	
US3152389	2020-08-27	AMENDMENT 2	No/ 2020-12-17 (113)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-30 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152402	2020-09-09	AMENDMENT 3	No/ 2020-12-23 (106)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-08 (30)	
US3152410	2020-09-28	AMENDMENT 3	No/ 2020-10-05 (8)	Withdrawal of Consent by Participant/ SUBJECT BELIEVED HE RECEIVED PLACEBO AND DID NOT WANT TO CONTINUE		No/ 2020-10-04 (7)	Withdrawal of Consent by Participant/ SUBJECT THINKS HE RECEIVED PLACEBO

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152412	2020-09-28	AMENDMENT 3	No/ 2021-01-15 (110)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY AND UNBLINDING, CONSENT PROCESS		Yes/ 2020-10-26 (29)	
US3152414	2020-09-29	AMENDMENT 3	No/ 2020-12-18 (81)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-29 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152452	2020-10-07	AMENDMENT 4	No/ 2021-01-11 (97)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY.		Yes/ 2020-11-04 (29)	
US3152471	2020-10-13	AMENDMENT 4	No/ 2020-12-22 (71)	Protocol Deviation/ REQUEST FOR UNBLINDING/ EUA COVID-19 VACCINE		Yes/ 2020-11-10 (29)	
US3152489	2020-10-15	AMENDMENT 4	No/ 2020-12-23 (70)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-11-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152512	2020-10-20	AMENDMENT 4	No/ 2021-02-10 (114)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-11-20 (32)	
US3152516	2020-10-21	AMENDMENT 4	No/ 2020-11-25 (36)	Protocol Deviation/ SUBJECT NON-COMPLIANT WITH STUDY PROCEDURES. ASSESSED BY PI TO BE UNABLE TO COMPLY WITH STUDY PROCEDURES .		No/ 2020-11-17 (28)	Physician Decision/ SUBJECT NON-COMPLIANT WITH STUDY PROCEDURES. ASSESSED BY PI TO BE UNABLE TO COMPLY WITH STUDY PROCEDURES .

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152544	2020-10-22	AMENDMENT 4	No/ 2020-10-29 (8)	Withdrawal of Consent by Participant/ PARTICIPANT IS MOVING OUT OF THE AREA AND UNABLE TO COMPLETE FOLLOW UP CALLS OR VISITS. SUBJECT DID NOT WANT TO CONTACTED AFTER THE 29OCT2020 SO CONSENT WITHDRAWN.		No/ 2020-10-28 (7)	Withdrawal of Consent by Participant/ PARTICIPANT WAS RELOCATING AND WANTED TO WITHDREW CONSENT AND ASKED NOT TO BE CONTACTED FOR ANY FURTHER SAFETY CALLS AND WILL NOT BE SHOWING UP FOR ANY OTHER IN OFFICE VISITS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162001	2020-07-27	AMENDMENT 1	No/ 2021-02-01 (190)	Protocol Deviation/ SUBJECT REVEALED ON 01FEB2021 THAT HE HAD ENROLLED IN THE ASTRA ZENECA STUDY ON 04SEP2020 AND WAS STILL ENROLLED IN THAT STUDY		Yes/ 2020-08-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162035	2020-07-31	AMENDMENT 1	No/ 2021-01-25 (179)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE. SUBJECT RECEIVED MODERNA VACCINE OUTSIDE STUDY ON 07JAN2021		Yes/ 2020-08-28 (29)	
US3162065	2020-08-06	AMENDMENT 1	No/ 2021-03-02 (209)	Withdrawal of Consent by Participant/ SUBJECT VERBALLY COMMUNICATED NOT TO CONTACT HER AGAIN.		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162120	2020-08-13	AMENDMENT 2	No/ 2021-01-21 (162)	Protocol Deviation/ REQUEST TO BE UNBLINDED/ PFIZER EUA COVID-19 VACCINE		Yes/ 2020-09-14 (33)	
US3162165	2020-08-20	AMENDMENT 2	No/ 2020-12-30 (133)	Protocol Deviation/ REQUEST TO BE UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-16 (28)	
US3162185	2020-08-25	AMENDMENT 3	No/ 2020-12-25 (123)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID 19 VACCINE.		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162195	2020-08-27	AMENDMENT 3	No/ 2020-12-31 (127)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 AND RECEIVED EUA VACCINE		Yes/ 2020-09-21 (26)	
US3162235	2020-09-11	AMENDMENT 3	No/ 2020-12-21 (98)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE RECEIVED BEFORE STUDY DISCONTINUATION		Yes/ 2020-10-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162243	2020-09-16	AMENDMENT 3	No/ 2020-10-14 (29)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO PARTICIPATE IN THE STUDY. THEY STATED THEY DID NOT HAVE TIME TO DEVOTE TO STUDY PARTICIPATION AND MAKING IT TO THE VISITS. AND THAT THEY LIVED A DISTANCE AWAY.		No/ 2020-10-13 (28)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO PARTICIPATE IN THE STUDY. THEY STATED THEY DID NOT HAVE TIME TO DEVOTE TO STUDY PARTICIPATION AND MAKING IT TO THE VISITS. AND THAT THEY LIVED A DISTANCE AWAY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162255	2020-09-25	AMENDMENT 3	No/ 2021-03-01 (158)	Protocol Deviation/ RECEIVED OUTSIDE VACCINE		Yes/ 2020-10-23 (29)	
US3162262	2020-10-05	AMENDMENT 3	No/ 2020-12-17 (74)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE		Yes/ 2020-11-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162269	2020-10-09	AMENDMENT 3	No/ 2021-02-04 (119)	Withdrawal of Consent by Participant/ THE SUBJECT STATED THE (b) (6) HOUR LONG DRIVE WAS TOO FAR AND DIDN'T WANT TO MAKE THE DRIVE ANY LONGER. ALSO WANTED TO GET THE VACCINE OUTSIDE THE STUDY		Yes/ 2020-11-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162304	2020-10-23	AMENDMENT 4	No/ 2021-01-16 (86)	Protocol Deviation/ SUBJECT TOOK MODERNA VACCINE AT WORK		Yes/ 2020-11-20 (29)	
US3172002	2020-08-07	AMENDMENT 1	No/ 2020-09-24 (49)	Lost to Follow-Up		No/ 2020-09-03 (28)	Lost to Follow-Up
US3172009	2020-08-07	AMENDMENT 1	No/ 2020-10-23 (78)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT IN PERSON		No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT IN PERSON

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172015	2020-08-10	AMENDMENT 1	No/ 2020-09-15 (37)	Withdrawal of Consent by Participant/ SUBJECT NOT BEING COMPLIANT WITH INCLUSION #3		Yes/ 2020-09-04 (26)	
US3172022	2020-08-10	AMENDMENT 1	ONGOING			No/ 2020-09-06 (28)	Other/ MISSED VISIT
US3172027	2020-08-11	AMENDMENT 1	No/ 2020-09-08 (29)	Withdrawal of Consent by Participant/ NO LONGER INTERESTED IN STUDY PARTICIPATION.		No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ NO LONGER INTERESTED IN STUDY PARTICIPATION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172033	2020-08-11	AMENDMENT	1 No/ 2021-02-11 (185)	Withdrawal of Consent by Participant		Yes/ 2020-09-08 (29)	
US3172052	2020-08-11	AMENDMENT	1 No/ 2020-09-08 (29)	Other/ SUBJECT MOVING TO CALIFORNIA		No/ 2020-09-07 (28)	Other/ SUBJECT MOVING TO CALIFORNIA.
US3172053	2020-08-11	AMENDMENT	1 No/ 2020-09-08 (29)	Other/ SUBJECT MOVING TO CALIFORNIA		No/ 2020-09-07 (28)	Other/ SUBJECT MOVING TO CALIFORNIA
US3172069	2020-08-12	AMENDMENT	1 ONGOING			No/ 2020-09-08 (28)	Serious Adverse Event/ SAE #1
US3172093	2020-08-13	AMENDMENT	1 No/ 2021-02-24 (196)	Withdrawal of Consent by Participant		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172150	2020-08-17	AMENDMENT 1	ONGOING			No/ 2020-09-13 (28)	Other/ SUBJECT RECEIVED 2ND DOSE ON 09MAR2021 DURING OPEN LABEL DAY29
US3172165	2020-08-18	AMENDMENT 1	No/ 2020-09-15 (29)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAW CONSENT		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAW CONSENT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172177	2020-08-18	AMENDMENT 1	No/ 2020-11-30 (105)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO BUSY WORK SCHEDULE IN TEXAS		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ SUBJECT CANNOT CONTINUE IN TRIAL. SUBJECT DECIDED TO WITHDRAW CONSENT DUE TO BUSY SCHEDULE AT WORK IN TEXAS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172178	2020-08-18	AMENDMENT 1	No/ 2020-10-01 (45)	Withdrawal of Consent by Participant/ SPOKE TO DOCTOR ABOUT HEART CONDITION AND DOES NOT WANT TO CONTINUE IN STUDY.		No/ 2020-09-14 (28)	Other/ MISSED VISIT.
US3172184	2020-08-18	AMENDMENT 1	ONGOING			No/ 2020-09-14 (28)	Other/ SUBJECT DECLINED 2ND DOSE, SUBJECT AGREED TO CONTINUE IN TRIAL BUT DOES NOT WANT THE VACCINE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172193	2020-08-18	AMENDMENT 2	No/ 2021-01-21 (157)	Protocol Deviation/ SUBJECT DISCONTINUED FROM STUDY DUE TO RECEIVING VACCINE IN A DIFFERENT SITE.		Yes/ 2020-09-15 (29)	
US3172199	2020-08-19	AMENDMENT 1	No/ 2021-03-11 (205)	Protocol Deviation/ SUBJECT HAD RECEIVED VACCINE FROM PRIMARY DOCTOR. WITHDREW CONSENT		Yes/ 2020-09-16 (29)	
US3172203	2020-08-19	AMENDMENT 1	No/ 2021-01-26 (161)	Lost to Follow-Up		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172205	2020-08-19	AMENDMENT 1	No/ 2021-01-08 (143)	Withdrawal of Consent by Participant/ NO SPECIFIC REASON GIVEN BY SUBJECT, JUST WANTED TO BE REMOVED FROM STUDY		Yes/ 2020-09-16 (29)	
US3172215	2020-08-19	AMENDMENT 2	No/ 2020-11-25 (99)	Lost to Follow-Up		No/ 2020-09-15 (28)	Other/ MISSED VISIT DAY 29
US3172218	2020-08-19	AMENDMENT 1	No/ 2020-10-08 (51)	Lost to Follow-Up		No/ 2020-09-15 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172222	2020-08-19	AMENDMENT 1	No/ 2021-03-09 (203)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE IN STUDY, ASKED TO BE REMOVED.		No/ 2020-09-15 (28)	Adverse Event/ SUBJECT WITH ONGOING AE OF LEFT FOREARM / HAND PARESTHESIAS AND NEW AE OF LEFT ARM PAIN IS DECLINING VACCINATION DESPITE EXPLANATION GIVEN OF NO RELATIONSHIP WITH IP.
US3172240	2020-08-20	AMENDMENT 1	No/ 2021-02-25 (190)	Withdrawal of Consent by Participant		Yes/ 2020-09-18 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172241	2020-08-20	AMENDMENT 1	No/ 2020-09-28 (40)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WANT TO CONTINUE WITH STUDY DUE TO SO MANY BLOOD VIALS BEING DRAWN.		No/ 2020-09-16 (28)	Other/ SKIPPED VISIT
US3172247	2020-08-20	AMENDMENT 1	No/ 2020-10-20 (62)	Lost to Follow-Up		No/ 2020-09-16 (28)	Other/ MISSED VISIT.
US3172255	2020-08-20	AMENDMENT 1	ONGOING			No/ 2020-09-16 (28)	Other/ MISSED VISIT
US3172260	2020-08-21	AMENDMENT 1	ONGOING			No/ 2020-09-17 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172273	2020-08-21	AMENDMENT 2	No/ 2020-09-30 (41)	Other/ MOVED TO TEXAS (b) (6)		No/ 2020-09-17 (28)	Other/ MOVED TO TEXAS (b) (6)
US3172279	2020-08-21	AMENDMENT 2	No/ 2020-10-21 (62)	Other/ LEAVING OUT OF TOWN AND NO LONGER INTERESTED IN PARTICIPATING.		No/ 2020-09-17 (28)	Other/ PENDING SUBJECT COVID SWAB TEST RESULTS FROM SCREENING VISIT. TEST LAB RESULTS FROM COVID TEST WAS NOT RECEIVED.
US3172294	2020-08-24	AMENDMENT 2	No/ 2020-10-13 (51)	Lost to Follow-Up		No/ 2020-09-20 (28)	Other/ MISSED VISIT
US3172308	2020-08-25	AMENDMENT 3	No/ 2020-09-30 (37)	Lost to Follow-Up		Yes/ 2020-09-21 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172319	2020-08-25	AMENDMENT 3	ONGOING			No/ 2020-09-21 (28)	Other/ SUBJECT DECLINED 2ND DOSE, SUBJECT AGREED TO CONTINUE IN TRIAL BUT DOES NOT WANT THE VACCINE DUE TO SYMPTOMS REPORTED AFTER 1ST DOSE.
US3172320	2020-08-25	AMENDMENT 3	No/ 2021-03-15 (203)	Other/ MOVED OUT OF TOWN, WITHDREW CONSENT.		No/ 2020-09-21 (28)	Other/ SUBJECT DECLINED SECOND DOSE DUE TO SOLICITED ADVERSE REACTION SYMPTOMS PRESENTED AT DAY 1 DOSE VACCINATION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172335	2020-08-25	AMENDMENT 2	No/ 2020-10-02 (39)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAW CONSENT		No/ 2020-09-21 (28)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAW CONSENT
US3172349	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Pregnancy
US3172372	2020-08-27	AMENDMENT 3	No/ 2020-09-24 (29)	Lost to Follow-Up		No/ 2020-09-23 (28)	Other/ SUBJECT DID NOT COME TO THE VISIT.
US3172376	2020-10-16	AMENDMENT 2	No/ 2021-03-16 (152)	Withdrawal of Consent by Participant		Yes/ 2020-11-16 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172384	2020-10-16	AMENDMENT 2	No/ 2020-10-20 (5)	Protocol Deviation/ EXCLUSION # 10		No/ 2020-10-19 (4)	Other/ EXCLUSION # 10
US3172397	2020-10-19	AMENDMENT 3	No/ 2021-01-25 (99)	Withdrawal of Consent by Participant		Yes/ 2020-11-17 (30)	
US3172403	2020-10-19	AMENDMENT 2	No/ 2020-11-16 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED DID NOT WANT TO BE IN THE STUDY		No/ 2020-11-15 (27)	Other/ INCLUSION #3
US3172409	2020-10-19	AMENDMENT 2	No/ 2020-11-24 (37)	Withdrawal of Consent by Participant/ DOES NOT WANT TO CONTINUE.		No/ 2020-11-15 (28)	Withdrawal of Consent by Participant/ DOES NOT WANT TO CONTINUE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172439	2020-10-20	AMENDMENT 2	No/ 2020-11-24 (36)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE DUE TO WORK		No/ 2020-11-16 (28)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE DUE TO WORK
US3172460	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Other/ MISSED VISIT
US3172468	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Other/ MISSED VISIT
US3172482	2020-10-22	AMENDMENT 3	ONGOING			No/ 2020-11-18 (28)	Other/ SUBJECT MISSED VISIT
US3172486	2020-10-23	AMENDMENT 2	ONGOING			No/ 2020-11-19 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172497	2020-10-23	AMENDMENT 3	ONGOING			No/ 2020-11-19 (28)	Other/ MISSED VISIT
US3172498	2020-10-23	AMENDMENT 3	ONGOING			No/ 2020-11-19 (28)	Other/ MISSED VISIT
US3182060	2020-07-29	AMENDMENT 1	No/ 2021-01-19 (175)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE		Yes/ 2020-08-25 (28)	
US3182081	2020-07-30	AMENDMENT 1	No/ 2021-03-15 (229)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO TRANSPORTATION CHALLENGES		Yes/ 2020-09-01 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3182127	2020-08-03	AMENDMENT	1 No/ 2020-10-26 (85)	Lost to Follow-Up		Yes/ 2020-08-31 (29)	
US3182151	2020-08-04	AMENDMENT	1 No/ 2021-03-24 (233)	Pregnancy		Yes/ 2020-09-01 (29)	
US3182188	2020-08-06	AMENDMENT	1 No/ 2021-01-07 (155)	Protocol Deviation/ RECEIPT OF PFIZER COVID VACCINE		Yes/ 2020-09-03 (29)	
US3182210	2020-08-06	AMENDMENT	1 No/ 2021-01-07 (155)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID VACCINE		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3182227	2020-08-07	AMENDMENT 1	No/ 2021-03-02 (208)	Withdrawal of Consent by Participant/ SUBJECT CHOICE TO WITHDRAWAL		Yes/ 2020-09-08 (33)	
US3182230	2020-08-07	AMENDMENT 1	No/ 2021-02-11 (189)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE		Yes/ 2020-09-14 (39)	
US3182243	2020-08-10	AMENDMENT 2	No/ 2021-01-19 (163)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-11 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3182292	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3182322	2020-08-13	AMENDMENT 2	No/ 2021-02-18 (190)	Lost to Follow-Up		Yes/ 2020-09-14 (33)	
US3192008	2020-08-01	AMENDMENT 1	No/ 2020-12-19 (141)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-08-29 (29)	
US3192019	2020-08-02	AMENDMENT 1	No/ 2021-02-06 (189)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-08-29 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192039	2020-08-03	AMENDMENT 1	No/ 2021-02-20 (202)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-08-31 (29)	
US3192078	2020-08-06	AMENDMENT 1	No/ 2020-09-16 (42)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO DISCONTINUE TRIAL		No/ 2020-09-02 (28)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAWAL PARTICIPATION, STATED SHE DOESNT THINK THIS TRIAL IS FOR HER.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192090	2020-08-06	AMENDMENT 1	No/ 2020-08-31 (26)	Withdrawal of Consent by Participant/ PATIENT DECIDED SITE AND TRIAL NOT FOR HER		No/ 2020-08-30 (25)	Withdrawal of Consent by Participant/ PATIENT DECIDED SITE AND TRIAL NOT FOR HER
US3192094	2020-08-07	AMENDMENT 1	No/ 2021-02-20 (198)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-04 (29)	
US3192106	2020-08-07	AMENDMENT 1	No/ 2020-12-18 (134)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192109	2020-08-07	AMENDMENT 1	No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAWAL ICF, STATED HE FELT HE RECEIVED PLACEBO AND THERE'S NO NEED FOR HIM TO CONTINUE.		No/ 2020-09-02 (27)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAWAL ICF, STATED HE FELT HE RECEIVED PLACEBO AND THERE'S NO NEED FOR HIM TO CONTINUE.
US3192117	2020-08-08	AMENDMENT 1	No/ 2020-12-18 (133)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-19 (43)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192129	2020-08-08	AMENDMENT 1	No/ 2021-01-03 (149)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-05 (29)	
US3192153	2020-08-10	AMENDMENT 1	No/ 2021-01-31 (175)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-10 (32)	
US3192169	2020-08-10	AMENDMENT 1	No/ 2021-01-03 (147)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-04 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192172	2020-08-10	AMENDMENT 1	No/ 2021-01-06 (150)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-15 (37)	
US3192202	2020-08-12	AMENDMENT 1	No/ 2020-12-18 (129)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-10 (30)	
US3192225	2020-08-13	AMENDMENT 1	No/ 2021-02-20 (192)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-15 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192228	2020-08-13	AMENDMENT 1	No/ 2021-01-13 (154)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-15 (34)	
US3192235	2020-08-14	AMENDMENT 1	No/ 2021-01-05 (145)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-24 (42)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192249	2020-08-14	AMENDMENT 1	No/ 2021-02-20 (191)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-11 (29)	
US3192256	2020-08-14	AMENDMENT 1	No/ 2020-12-18 (127)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-11 (29)	
US3192263	2020-08-15	AMENDMENT 1	No/ 2021-02-20 (190)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-11 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192268	2020-08-15	AMENDMENT 1	No/ 2021-01-10 (149)	Protocol Deviation/ RECEIVED PFIZER EUA COVID-19 VACCINE.		Yes/ 2020-09-12 (29)	
US3192272	2020-08-15	AMENDMENT 1	No/ 2020-12-22 (130)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-12 (29)	
US3192273	2020-08-15	AMENDMENT 1	No/ 2020-12-19 (127)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-16 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192275	2020-08-15	AMENDMENT 1	No/ 2021-02-26 (196)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-12 (29)	
US3192284	2020-08-15	AMENDMENT 1	No/ 2020-12-22 (130)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-25 (42)	
US3192294	2020-08-16	AMENDMENT 1	No/ 2021-03-08 (205)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-12 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192308	2020-08-16	AMENDMENT 1	No/ 2021-01-05 (133)	Protocol Deviation/ RECEIVED MODERNA EUA COVID-19 VACCINE OUTSIDE OF TRIAL		Yes/ 2020-09-20 (26)	
US3192314	2020-08-17	AMENDMENT 1	No/ 2020-10-19 (55)	Withdrawal of Consent by Participant/ PATIENT WITHDREW FROM THE STUDY		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ PATIENT WANTED TO BE WITHDRAWN FROM THE STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192316	2020-08-17	AMENDMENT 1	No/ 2021-02-06 (169)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW CONSENT AFTER UNBLINDING		Yes/ 2020-09-18 (28)	
US3192321	2020-08-17	AMENDMENT 1	No/ 2021-02-20 (184)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192331	2020-08-18	AMENDMENT 1	No/ 2021-02-20 (182)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-24 (33)	
US3192344	2020-08-18	AMENDMENT 1	No/ 2021-01-31 (163)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-19 (29)	
US3192347	2020-08-19	AMENDMENT 1	No/ 2021-02-23 (182)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192364	2020-08-19	AMENDMENT 2	No/ 2021-01-29 (162)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-18 (29)	
US3192370	2020-08-20	AMENDMENT 2	No/ 2020-12-16 (119)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-20 (32)	
US3192372	2020-08-20	AMENDMENT 1	No/ 2020-12-16 (119)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-20 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192384	2020-08-20	AMENDMENT 2	No/ 2020-12-17 (120)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-21 (33)	
US3192406	2020-08-22	AMENDMENT 2	No/ 2020-12-16 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-16 (26)	
US3192435	2020-08-23	AMENDMENT 2	No/ 2020-12-23 (123)	Other/ REQUEST TO UNBLIND-EUA COVID-19 VACCINE.		Yes/ 2020-09-19 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192442	2020-08-23	AMENDMENT 2	No/ 2020-12-17 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-20 (29)	
US3192449	2020-08-24	AMENDMENT 2	No/ 2020-12-16 (115)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192461	2020-08-24	AMENDMENT 2	No/ 2020-10-22 (60)	Withdrawal of Consent by Participant/ PATIENT DID NOT WANT TO PARTICIPATE ANY LONG IN THE TRIAL		No/ 2020-09-20 (28)	Withdrawal of Consent by Participant/ PATIENT STATED THAT HE DID NOT WANT TO PARTICIPATE WITH THE TRIAL ANY LONGER
US3192487	2020-08-26	AMENDMENT 2	No/ 2021-03-15 (202)	Withdrawal of Consent by Participant/ PATIENT STATED HE NO LONGER WANTED TO BE A PART OF THE TRIAL.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192488	2020-08-26	AMENDMENT 2	No/ 2020-12-16 (113)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-23 (29)	
US3192492	2020-08-26	AMENDMENT 2	No/ 2021-02-01 (160)	Protocol Deviation/ SUBJECT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-24 (30)	
US3192509	2020-08-26	AMENDMENT 3	No/ 2021-01-29 (157)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192522	2020-08-27	AMENDMENT 2	No/ 2020-12-18 (114)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-24 (29)	
US3192531	2020-08-27	AMENDMENT 2	No/ 2020-12-19 (115)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE DUE TO BEING A HEALTHCARE WORKER AND WAS EARLY TERMED.		Yes/ 2020-09-26 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192554	2020-08-28	AMENDMENT 3	No/ 2020-10-06 (40)	Withdrawal of Consent by Participant/ PATIENT STATED SHE HAS MOVED AWAY AND NO LONGER WILL BE ABLE TO ME APPTS.		No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ PT HAS MOVED AWAY
US3192555	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Protocol Deviation/ PATENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192562	2020-08-28	AMENDMENT 3	No/ 2020-12-22 (117)	Protocol Deviation/ PATIENT DUE TO RECEIVE EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192569	2020-08-29	AMENDMENT 3	No/ 2021-02-10 (166)	Adverse Event/ SUBJECT HAS PANCREATIC AND LIVER CANCER. HE STATED THAT HE WOULD LIKE TO WITHDRAW FROM THE STUDY BECAUSE HE IS UNABLE TO MAKE IT TO APPOINTMENTS GOING FORWARD DUE TO NOT FEELING WELL.#3 ROW 3 AND 4	2021-02-17/	Yes/ 2020-09-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192591	2020-08-29	AMENDMENT 3	No/ 2021-02-02 (158)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-26 (29)	
US3192603	2020-08-31	AMENDMENT 3	No/ 2020-09-30 (31)	Adverse Event/ PATIENT HAD AE OF WORSENING OF HYPERTENSION AND DECIDED TO WITHDRAWAL FROM STUDY AE#1		No/ 2020-09-27 (28)	Adverse Event/ PATIENT HAD AE OF WORSENING OF HYPERTENSION AND DECIDED TO WITHDRAWAL FROM STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192651	2020-09-02	AMENDMENT 3	No/ 2020-12-02 (92)	Other/ UNABLE TO REACH SUBJECT AFTER MULTIPLE ATTEMPTS OVER 3 MONTHS. AFTER FINALLY REACHING HIM, SUBJECT STATES HE MOVED AND CAN'T MAKE THE APPOINTMENTS AND WOULD LIKE TO WITHDRAW		No/ 2020-09-29 (28)	Other/ MULTIPLE ATTEMPTS TO REACH SUBJECT OVER THE COURSE OF 3 MONTHS. AFTER FINALLY REACHING SUBJECT, HE STATES HE HAS MOVED OUT OF TOWN AND WONT MAKE IT TO ANY APPOINTMENTS AND WOULD LIKE TO WITHDRAW.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192656	2020-09-03	AMENDMENT 3	No/ 2021-02-20 (171)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-10-01 (29)	
US3192660	2020-09-03	AMENDMENT 3	No/ 2021-02-20 (171)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192664	2020-09-03	AMENDMENT 3	No/ 2021-02-20 (171)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF THE TRIAL.		Yes/ 2020-10-02 (30)	
US3192666	2020-09-03	AMENDMENT 3	No/ 2020-12-22 (111)	Protocol Deviation/ PATIENT REQUESTED UNBLINDING AND WILL RECEIVE PFIZER VACCINE OUTSIDE OF TRIAL		Yes/ 2020-10-02 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192693	2020-09-05	AMENDMENT 3	No/ 2020-12-17 (104)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-10-03 (29)	
US3192706	2020-09-05	AMENDMENT 3	No/ 2021-02-12 (161)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF, NON COMPLIANT WITH E-DIARY ENTRIES AND CHOSE NOT TO CONTINUE		Yes/ 2020-10-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192723	2020-10-02	AMENDMENT 4	No/ 2021-03-02 (152)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-10-30 (29)	
US3192726	2020-10-03	AMENDMENT 4	No/ 2020-12-23 (82)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-10-30 (28)	
US3192730	2020-10-04	AMENDMENT 4	ONGOING			No/ 2020-10-31 (28)	Adverse Event/ PATIENT DECLINED DOSE 2 DUE TO WORSENING OF TACHYCARDIA.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192733	2020-10-04	AMENDMENT 4	No/ 2021-02-06 (126)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		No/ 2020-10-31 (28)	Other/ PATIENT DECLINED 2ND INJECTION
US3192744	2020-10-05	AMENDMENT 4	No/ 2021-03-17 (164)	Protocol Deviation/ PATIENT RECEIVED 2ND DOSE OUTSIDE OF TRIAL.		Yes/ 2020-11-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192749	2020-10-07	AMENDMENT 4	No/ 2021-01-18 (104)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF, STATED SHE IS POSITIVE IP ALLOCATED TO HER WAS PLACEBO. DECIDED THIS STUDY ISN'T FOR HER, AND SHE NO LONGER WOULD LIKE TO BE PART OF IT. ALSO STATED ITS DIFFICULT TO DO EDIARY.		No/ 2020-11-03 (28)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF, STATED SHE IS POSITIVE IP ALLOCATED TO HER WAS PLACEBO. DECIDED THIS STUDY ISN'T FOR HER, AND SHE NO LONGER WOULD LIKE TO BE PART OF IT. ALSO STATED ITS DIFFICULT TO DO EDIARY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192758	2020-10-08	AMENDMENT 4	No/ 2021-02-20 (136)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-12 (36)	
US3192772*	2020-10-09	AMENDMENT 4	No/ 2021-01-25 (109)	Other/ PATIENT RECEIVED EUA ANTIBODY INFUSION OUTSIDE OF TRIAL.		Yes/ 2020-12-01 (54)	
US3192807	2020-10-14	AMENDMENT 4	No/ 2021-01-31 (110)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192815	2020-10-14	AMENDMENT 4	No/ 2021-02-20 (130)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-11 (29)	
US3192818	2020-10-14	AMENDMENT 4	No/ 2020-12-17 (65)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-11-11 (29)	
US3192834	2020-10-16	AMENDMENT 4	No/ 2021-02-20 (128)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192835	2020-10-16	AMENDMENT 4	No/ 2021-02-20 (128)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-13 (29)	
US3192845	2020-10-16	AMENDMENT 4	No/ 2021-03-11 (147)	Other/ PATIENT IS CONSTANTLY NON-COMPLIANT WITH E-DIARIES AND VISIT SCHEDULE.		Yes/ 2020-11-16 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192847	2020-10-18	AMENDMENT 4	No/ 2021-02-20 (126)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF THE TRIAL.		Yes/ 2020-11-18 (32)	
US3192852	2020-10-18	AMENDMENT 4	No/ 2020-12-18 (62)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-16 (30)	
US3192861	2020-10-19	AMENDMENT 4	ONGOING			No/ 2020-11-15 (28)	Other/ PATIENT WAS A CONTINUOUS NO SHOW FOR D29 VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192898	2020-10-22	AMENDMENT 4	No/ 2021-02-04 (106)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF, STATED WITH FAMILY PROBLEMS SHE JUST CANNOT COMMIT TO THE STUDY.		Yes/ 2020-11-20 (30)	
US3202002	2020-08-04	AMENDMENT 1	No/ 2020-12-18 (137)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-02 (30)	
US3202008	2020-08-05	AMENDMENT 1	No/ 2020-12-21 (139)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-01 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202021	2020-08-05	AMENDMENT 1	No/ 2021-02-03 (183)	Protocol Deviation/ SUBJECT DISCLOSED RECEIPT OF NON-STUDY EUA VACCINE PRIOR TO DECISION VISIT. SUBJECT SIGNED ICF INDICATING UNBLINDING REQUEST BUT WITHDRAWAL FROM STUDY		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202064	2020-08-07	AMENDMENT 1	No/ 2021-01-05 (152)	Protocol Deviation/ SUBJECT REFUSED TO COMPLY WITH STUDY PROCEDURES INCLUDING LAB SAMPLE COLLECTIONS		Yes/ 2020-09-10 (35)	
US3202071	2020-08-08	AMENDMENT 1	No/ 2020-12-21 (136)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-14 (38)	
US3202113	2020-08-10	AMENDMENT 2	No/ 2020-12-21 (127)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202116	2020-08-10	AMENDMENT 1	No/ 2020-12-16 (129)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-22 (44)	
US3202134	2020-08-11	AMENDMENT 2	No/ 2021-01-11 (154)	Other/ SUBJECT WITHDREW TO RECEIVE NON-STUDY VACCINE		Yes/ 2020-09-11 (32)	
US3202148	2020-08-12	AMENDMENT 2	No/ 2020-10-01 (51)	Withdrawal of Consent by Participant/ SUBJECT CONVINCED HE GOT PLACEBO SO HE REFUSED TO COME BACK		No/ 2020-09-08 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT FROM STUDY AND REFUSED TO CONTINUE W/ FOLLOWUP.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202152	2020-08-12	AMENDMENT 2	No/ 2020-12-17 (128)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-09 (29)	
US3202164	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Other/ SUBJECT'S INCREASED WORKLOAD AND SCHEDULE PREVENTED HER FROM KEEPING APPOINTMENTS-DECLINED ANY FUTURE SITE VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202193	2020-08-14	AMENDMENT 2	No/ 2021-02-01 (172)	Other/ SUBJECT UNBLINDED UNDER AMENDMENT 5 AND DROPPED BECAUSE HE WISHED TO RECEIVE THE PFIZER EUA COVID-19 VACCINE THROUGH EMPLOYER		Yes/ 2020-09-11 (29)	
US3202219	2020-08-17	AMENDMENT 2	No/ 2021-02-18 (186)	Lost to Follow-Up		Yes/ 2020-09-18 (33)	
US3202228	2020-08-17	AMENDMENT 2	No/ 2020-12-21 (127)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-24 (39)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202234	2020-08-18	AMENDMENT 2	No/ 2020-12-17 (122)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (31)	
US3202240	2020-08-18	AMENDMENT 2	No/ 2020-12-28 (133)	Other/ WISH TO RECEIVE VACCINE THROUGH EMPLOYER		Yes/ 2020-09-15 (29)	
US3202245	2020-08-18	AMENDMENT 2	No/ 2020-10-01 (45)	Lost to Follow-Up		No/ 2020-09-14 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202267	2020-08-20	AMENDMENT 2	No/ 2021-02-22 (187)	Protocol Deviation/ CHOSE TO GET DOSED WITH PFIZER COVID-19 VACCINE ON 25JAN2021, WHICH SITE LEARNED OF DURING SAFETY CALL DAY 179 ON 22FEB2021		Yes/ 2020-09-17 (29)	
US3202275	2020-08-20	AMENDMENT 2	No/ 2020-12-18 (121)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-22 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202292	2020-08-21	AMENDMENT 2	No/ 2020-12-18 (120)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-22 (33)	
US3202311	2020-08-25	AMENDMENT 3	No/ 2020-12-23 (121)	Other/ UNBLINDED TO RECEIVE NON-STUDY EUA VACCINE		Yes/ 2020-09-24 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202314	2020-08-25	AMENDMENT 3	No/ 2021-01-19 (148)	Protocol Deviation/ NONCOMPLIANT W PROTOCOL RESTRICTION SUBJECT IN SCREENING PERIOD FOR ANOTHER CLINICAL TRIAL AT ANOTHER FACILITY IN ANOTHER STATE. HAS NOT YET RECEIVED THE IP FOR THE OTHER STUDY BUT WAS SCHEDULED		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202317	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (116)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-21 (28)	
US3202325	2020-08-26	AMENDMENT 3	No/ 2020-12-17 (114)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-25 (31)	
US3202356	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Other/ WISHED TO RECEIVE NON-STUDY EUA VACCINE		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202361	2020-08-28	AMENDMENT 3	No/ 2020-12-17 (112)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-16 (50)	
US3202362	2020-08-28	AMENDMENT 3	No/ 2020-12-30 (125)	Other/ WISHED TO BE UNBLINDED AND RECEIVE NON-MODERNA EUA VACCINE		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202364	2020-08-31	AMENDMENT 3	No/ 2020-09-30 (31)	Withdrawal of Consent by Participant/ SUBJECT REPORTS THAT HE KNOWS HE GOT PLACEBO SO HE DOESN'T WANT TO TO CONTINUE IN STUDY. HE GOT AN ANTIBODY TEST LAST WEEK THAT WAS NEGATIVE AND DID NOT WISH TO DISCUSS CONTINUING		No/ 2020-09-27 (28)	Withdrawal of Consent by Participant/ SUBJECT REPORTS THAT HE KNOWS HE GOT PLACEBO SO HE DOESN'T WANT TO TO CONTINUE IN STUDY. HE GOT AN ANTIBODY TEST LAST WEEK THAT WAS NEGATIVE AND DID NOT WISH TO DISCUSS CONTINUING

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202381	2020-09-02	AMENDMENT 3	No/ 2020-12-16 (106)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212071	2020-08-06	AMENDMENT 1	No/ 2021-03-17 (224)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE TO INFORM THAT THEY ARE NO LONGER INTERESTED IN CONTINUING WITH THE STUDY DUE TO NOT ABLE TO OBTAIN THE ANTIBODY TEST RESULTS FROM THE SPONSOR/SITE.		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212097	2020-08-10	AMENDMENT 1	No/ 2021-01-06 (150)	Protocol Deviation/ SUBJECT RECEIVED COVID VACCINE FROM OUTSIDE THE STUDY		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212112	2020-08-10	AMENDMENT 2	ONGOING			No/ 2020-09-06 (28)	Other/ PARTICIPANT MISSED VACCINE 2 WINDOW DUE TO TRANSFER TO US363. VACCINE WINDOW CLOSED ON SEPT 14. PARTICIPANT STARTED WITH COVID SYMPTOMS ON 14OCT2020 AND TESTED POSITIVE OUTSIDE OF STUDY ON 16OCT2020.
US3212120	2020-08-11	AMENDMENT 2	No/ 2020-11-18 (100)	Lost to Follow-Up		No/ 2020-09-07 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212150	2020-08-12	AMENDMENT 2	No/ 2021-03-16 (217)	Withdrawal of Consent by Participant/ SUBJECT WILL BE RECEIVING OUTSIDE VACCINATION DUE TO SPONSOR NO LONGER PROVIDING OPEN LABEL VACCINATIONS, AS IT IS PAST THE DEADLINE PROVIDED.		Yes/ 2020-09-15 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212167	2020-08-13	AMENDMENT 2	No/ 2021-01-14 (155)	Protocol Deviation/ SUBJECT NOTED SHE RECEIVED VACCINE IN COMMUNITY ON 05JAN2021 THROUGH HER PLACE OF EMPLOYMENT.		Yes/ 2020-09-10 (29)	
US3212169	2020-08-13	AMENDMENT 2	No/ 2020-12-30 (140)	Protocol Deviation/ RECEIVED COVID VACCINE FROM OUTSIDE THE STUDY ON 29DEC2020		Yes/ 2020-09-16 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212170	2020-08-13	AMENDMENT 2	No/ 2020-12-21 (131)	Protocol Deviation/ SUBJECT DISCONTINUED FROM TRIAL ON 21DEC2020 AS HE RECEIVED PFIZER VACCINATION.		Yes/ 2020-09-15 (34)	
US3212192	2020-08-17	AMENDMENT 2	No/ 2020-12-18 (124)	Protocol Deviation/ RECEIVED PFIZER VACCINE ON 18DEC2020		Yes/ 2020-09-21 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212198	2020-08-17	AMENDMENT 2	No/ 2020-09-12 (26)	Withdrawal of Consent by Participant/ SUBJECT CALLED TO WITHDRAW CONSENT ON 12SEP2020 DUE TO PERSONAL CIRCUMSTANCES, ALL ATTEMPTS WERE MADE BY SITE STAFF TO KEEP SUBJECT IN THE STUDY, HOWEVER SHE WISHED TO DISCONTINUE FROM THE STUDY.		No/ 2020-09-11 (25)	Withdrawal of Consent by Participant/ SUBJECT CALLED TO WITHDRAW CONSENT ON 12SEP2020 DUE TO PERSONAL CIRCUMSTANCES, ALL ATTEMPTS WERE MADE BY SITE STAFF TO KEEP SUBJECT IN THE STUDY, HOWEVER SHE WISHED TO DISCONTINUE FROM THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212209	2020-08-17	AMENDMENT 2	No/ 2021-03-18 (214)	Other/ SUBJECT DISCONTINUED FROM THE STUDY BASED ON RELOCATION TO CHINA DURING THE DURATION OF THE STUDY		Yes/ 2020-09-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212212	2020-08-18	AMENDMENT 2	No/ 2021-01-08 (144)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE TO WITHDRAW FROM THE STUDY, ALL POSSIBLE ATTEMPTS WERE MADE TO KEEP THE SUBJECT IN THE STUDY AND AN EOS STUDY VISIT WAS OFFERED AS WELL.		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212225	2020-08-18	AMENDMENT 2	No/ 2020-09-15 (29)	Withdrawal of Consent by Participant/ SUBJECT DENIED COMING IN FOR AN ILLNESS VISIT ON 11SEP2020 AND WITHDREW CONSENT ON 15SEP2020. ALL ATTEMPTS WERE MADE TO KEEP THE SUBJECT IN THE STUDY, HOWEVER HE DID NOT WISH TO CONTINUE.		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ SUBJECT DENIED COMING IN FOR AN ILLNESS VISIT ON 11SEP2020 AND WITHDREW CONSENT ON 15SEP2020. ALL ATTEMPTS WERE MADE TO KEEP THE SUBJECT IN THE STUDY, HOWEVER HE DID NOT WISH TO CONTINUE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212230	2020-08-18	AMENDMENT 2	No/ 2020-12-16 (121)	Protocol Deviation/ RECEIVED THE PFIZER VACCINE ON 16DEC2020 THROUGH HIS WORK.		Yes/ 2020-09-14 (28)	
US3212257	2020-08-19	AMENDMENT 2	No/ 2020-12-30 (132)	Protocol Deviation/ RECEIVED PFIZER VACCINE ON 30DEC2020 THROUGH HER WORK.		Yes/ 2020-09-23 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212262	2020-08-20	AMENDMENT 2	No/ 2020-12-31 (134)	Protocol Deviation/ RECEIVED THE PFIZER VACCINE ON 31DEC2020 THROUGH HIS WORK.		Yes/ 2020-09-17 (29)	
US3212289	2020-08-24	AMENDMENT 2	No/ 2020-12-18 (117)	Protocol Deviation/ RECEIVED THE PFIZER VACCINE ON 18DEC2020 THROUGH HER WORK.		Yes/ 2020-09-24 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212297	2020-08-25	AMENDMENT 3	No/ 2021-03-19 (207)	Protocol Deviation/ LATE ENTRY: SUBJECT RECEIVED MODERNA VACCINE IN THE COMMUNITY UNJAN2021 AND WAS NOTIFIED THIS CONSTITUTED DISCONTINUATION FROM THE TRIAL, SUBJECT IS WITHDRAWN FROM THE STUDY.		Yes/ 2020-09-30 (37)	
US3212342	2020-09-02	AMENDMENT 3	No/ 2020-10-06 (35)	Lost to Follow-Up		Yes/ 2020-09-29 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212397	2020-09-11	AMENDMENT 3	No/ 2021-01-08 (120)	Protocol Deviation/ VACCINATED OUT OF STUDY		Yes/ 2020-10-12 (32)	
US3222001	2020-08-06	AMENDMENT 1	No/ 2021-03-13 (220)	Protocol Deviation/ PATIENT RECEIVED VACCINE IN THE COMMUNITY.		Yes/ 2020-09-07 (33)	
US3222006	2020-08-06	AMENDMENT 1	No/ 2021-01-08 (156)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE AT OVIEDO L MALL ON 8/JAN/2021 AND SECOND 1/29/2021.		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222011	2020-08-06	AMENDMENT 1	No/ 2020-12-28 (145)	Protocol Deviation/ PT RECEIVED PFIZER VACCINE AT HIS WORK PLACE ON 26/DEC/2020		Yes/ 2020-09-03 (29)	
US3222015	2020-08-06	AMENDMENT 1	No/ 2020-09-12 (38)	Withdrawal of Consent by Participant/ PT W/D CONSENT		No/ 2020-09-02 (28)	Withdrawal of Consent by Participant/ PT W/D CONSENT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222018	2020-08-06	AMENDMENT 1	No/ 2021-01-07 (155)	Protocol Deviation/ THE PATIENT RECEIVED THE VACCINE FROM HER PLACE OF EMPLOYMENT.		Yes/ 2020-09-07 (33)	
US3222029	2020-08-07	AMENDMENT 1	No/ 2021-01-04 (151)	Other/ EMERGENCY USE AUTHORIZATION SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY FROM HER JOB		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222031	2020-08-07	AMENDMENT 1	No/ 2020-09-06 (31)	Withdrawal of Consent by Participant/ PT DOES NOT WANT FURTHER AES.		No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ DOES NOT WANT FURTHER AES
US3222033	2020-08-07	AMENDMENT 1	No/ 2021-02-19 (197)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE AT WORK.		Yes/ 2020-09-04 (29)	
US3222042	2020-08-08	AMENDMENT 1	No/ 2020-12-28 (143)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE ON 21/DEC/2020		Yes/ 2020-09-02 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222088	2020-08-11	AMENDMENT 1	No/ 2020-09-04 (25)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT BECAUSE SHE DID NOT WANT TO CONTINUE WITHOUT HER HUSBAND WHOM ALSO WITHDREW CONSENT.		No/ 2020-09-03 (24)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT BECAUSE SHE DID NOT WANT TO CONTINUE WITHOUT HER HUSBAND WHOM ALSO WITHDREW CONSENT.
US3222098	2020-08-12	AMENDMENT 1	No/ 2021-01-06 (148)	Protocol Deviation/ SUBJECT RECEIVED VACCINE 12/28/2020 FROM WORK		Yes/ 2020-09-11 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222102	2020-08-12	AMENDMENT 1	No/ 2020-08-25 (14)	Other/ THE SUBJECT IS WITHDRAWING CONSENT FROM TRIAL AND MOVING OUT OF STATE.		No/ 2020-08-24 (13)	Other/ THE SUBJECT IS WITHDRAWING CONSENT FROM TRIAL AND MOVING OUT OF STATE.
US3222104	2020-08-12	AMENDMENT 1	No/ 2020-09-16 (36)	Withdrawal of Consent by Participant/ PT W/C DUE TO DISTANCE		Yes/ 2020-09-09 (29)	
US3222145	2020-08-14	AMENDMENT 2	No/ 2020-12-01 (110)	Lost to Follow-Up		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222163	2020-08-15	AMENDMENT 2	No/ 2020-12-15 (123)	Withdrawal of Consent by Participant/ SUBJECT WILL RECEIVE EUA VACCINE AT WORK.		Yes/ 2020-09-12 (29)	
US3222168	2020-08-15	AMENDMENT 2	No/ 2021-02-10 (180)	Protocol Deviation/ SUBJECT RECEIVED VACCINE AT HER PLACE OF WORK.		Yes/ 2020-09-12 (29)	
US3222185	2020-08-17	AMENDMENT 2	No/ 2021-01-27 (164)	Protocol Deviation/ SUBJECT RECEIVED VACCINE IN THE COMMUNITY ON 01/07/21		Yes/ 2020-09-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222195	2020-08-17	AMENDMENT 2	No/ 2021-01-08 (145)	Other/ SUBJECT RECEIVED VACCINE IN COMMUNITY		Yes/ 2020-09-16 (31)	
US3222199	2020-08-18	AMENDMENT 2	No/ 2021-03-03 (198)	Protocol Deviation/ SUBJECT CALLED CLINIC ON 03/MAR/2021 AND SAID THEY RECEIVED EUA VACCINE OUTSIDE THE TRIAL BUT COULDNT REMEMBER WHEN IN JANUARY 2021 HE TOOK THE VACCINE.		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222206	2020-08-18	AMENDMENT 2	No/ 2020-12-31 (136)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE OUTSIDE THE CLINICAL TRIAL.		Yes/ 2020-09-15 (29)	
US3222224	2020-08-19	AMENDMENT 2	No/ 2020-12-29 (133)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE FROM EMPLOYER		Yes/ 2020-09-18 (31)	
US3222229	2020-08-19	AMENDMENT 2	No/ 2020-09-24 (37)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT		Yes/ 2020-09-17 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222238	2020-08-20	AMENDMENT 2	No/ 2020-12-17 (120)	Withdrawal of Consent by Participant/ PT WAS UNBLINDED PER EAU REQUEST. HER JOB WAS OFFERING VACCINE NEED TO GET THE VACCINE OR NOT BE ABLE TO WORK.		Yes/ 2020-09-24 (36)	
US3222247	2020-08-20	AMENDMENT 2	No/ 2021-01-21 (150)	Protocol Deviation/ SUBJECT OBTAINED COVID 19 VACCINE OUTSIDE TRIAL		Yes/ 2020-09-24 (31)	
US3222249	2020-08-20	AMENDMENT 2	No/ 2020-09-26 (38)	Lost to Follow-Up		No/ 2020-09-16 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222259	2020-08-21	AMENDMENT 2	No/ 2021-01-14 (147)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE THE TRIAL.		Yes/ 2020-09-17 (28)	
US3222271	2020-08-22	AMENDMENT 2	No/ 2020-09-12 (22)	Withdrawal of Consent by Participant/ CANNOT COMPLY WITH VISIT SCHEDULE		No/ 2020-09-11 (21)	Withdrawal of Consent by Participant/ CANNOT COMPLY WITH VISIT SCHEDULE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222275	2020-08-22	AMENDMENT 2	No/ 2021-03-10 (201)	Withdrawal of Consent by Participant/ SUBJECT STATES SHE WANTS TO BE DROPPED SHE CAN GET VACCINE FROM HER PCP		Yes/ 2020-09-19 (29)	
US3222288	2020-08-23	AMENDMENT 2	No/ 2020-10-19 (58)	Withdrawal of Consent by Participant/ CONFLICT WITH VISIT SCHEDULED		No/ 2020-09-19 (28)	Withdrawal of Consent by Participant/ CONFLICT WITH VISIT SCHEDULE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222305	2020-08-24	AMENDMENT 2	No/ 2020-12-29 (128)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY ON 28/DEC/2020.		Yes/ 2020-09-29 (37)	
US3222326	2020-08-25	AMENDMENT 2	No/ 2020-12-21 (119)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER VACCINE AT THEIR PLACE OF EMPLOYMENT.		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222343	2020-08-26	AMENDMENT 3	No/ 2020-12-15 (112)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO BE UNBLINDED AND IF ON PLACEBO HE WANTED TO BE WITHDRAWN FROM THE TRIAL.		Yes/ 2020-09-24 (30)	
US3222344	2020-08-26	AMENDMENT 3	No/ 2021-01-21 (149)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE IN SEMINOLE COUNTY 20/JAN/2021		Yes/ 2020-09-25 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222361	2020-08-27	AMENDMENT 3	No/ 2021-01-31 (158)	Protocol Deviation/ RECEIVED VACCINE JAN 7 AT PUBLIX		Yes/ 2020-09-25 (30)	
US3222363	2020-08-27	AMENDMENT 3	No/ 2020-12-23 (119)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE THE STUDY.		Yes/ 2020-09-24 (29)	
US3222376	2020-08-28	AMENDMENT 3	No/ 2020-12-02 (97)	Lost to Follow-Up		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222424	2020-08-31	AMENDMENT 3	No/ 2020-11-07 (69)	Withdrawal of Consent by Participant/ STUDY DISCONTINUATION DUE TO PERSONAL CONFLICT.		No/ 2020-09-27 (28)	Due to SARS-CoV-2
US3222432	2020-09-01	AMENDMENT 3	No/ 2021-01-29 (151)	Protocol Deviation/ SUBJECT RECEIVED COVID 19 VACCINE UNDER EUA OUTSIDE THE TRIAL.		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222434	2020-09-01	AMENDMENT 3	No/ 2020-11-07 (68)	Withdrawal of Consent by Participant/ AFTER MULTIPLE ATTEMPTS TO CONTACT SUBJECT RECEPTIONIST GOT A CALL AND SHE JUST ISN'T INTERESTED ANY LONGER.		Yes/ 2020-10-01 (31)	
US3222435	2020-09-01	AMENDMENT 3	No/ 2020-10-01 (31)	Withdrawal of Consent by Participant/ SUBJECT STATED NO LONGER INTERESTED		No/ 2020-09-28 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED NO LONGER INTERESTED

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222443	2020-09-02	AMENDMENT 3	No/ 2021-02-19 (171)	Protocol Deviation/ RECEIVED PFIZER VACCINE ON 04/JAN/2021		Yes/ 2020-09-30 (29)	
US3222464	2020-09-03	AMENDMENT 3	No/ 2020-10-26 (54)	Withdrawal of Consent by Participant/ WORK CONFLICT		No/ 2020-09-30 (28)	Withdrawal of Consent by Participant/ DUE TO SCHEDULING CONFLICT WITH WORK UNABLE TO CONTINUE THE TRIAL.
US3222466	2020-09-03	AMENDMENT 3	No/ 2020-10-26 (54)	Withdrawal of Consent by Participant/ SCHEDULING CONFLICT		No/ 2020-09-30 (28)	Withdrawal of Consent by Participant/ SCHEDULING CONFLICT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222472	2020-09-03	AMENDMENT 3	No/ 2021-01-26 (146)	Withdrawal of Consent by Participant/ SUBJECT RECEIVED VACCINE OUT IN COMMUNITY		Yes/ 2020-10-03 (31)	
US3222475	2020-09-03	AMENDMENT 3	No/ 2020-12-28 (117)	Protocol Deviation/ RECEIVED PFIZER VACCINE IN COMMUNITY		Yes/ 2020-10-01 (29)	
US3222493	2020-09-04	AMENDMENT 3	No/ 2021-01-21 (140)	Protocol Deviation/ SUBJECT RECEIVED COVID 19 VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-10-06 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222550	2020-09-07	AMENDMENT 2	No/ 2020-12-30 (115)	Protocol Deviation/ THIS SUBJECT RECEIVED HIS VACCINE AT PLACE OF EMPLOYMENT-MANDATORY 12/23/2020.		Yes/ 2020-10-04 (28)	
US3222580	2020-09-11	AMENDMENT 3	No/ 2020-12-02 (83)	Lost to Follow-Up		No/ 2020-10-08 (28)	Lost to Follow-Up
US3222585	2020-09-12	AMENDMENT 3	No/ 2020-12-02 (82)	Lost to Follow-Up		No/ 2020-10-09 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222615	2020-09-17	AMENDMENT 3	No/ 2020-12-15 (90)	Other/ EMERGENCY USE AUTHORIZATION. HE RECEIVED VACCINE AT WORK		Yes/ 2020-10-20 (34)	
US3222628	2020-09-22	AMENDMENT 3	No/ 2020-11-07 (47)	Other/ PT MOVED TO HAWAII FOR WORK AND CANNOT CONTINUE STUDY DUE TO TRANSPORTION		Yes/ 2020-10-17 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222632	2020-09-24	AMENDMENT 3	No/ 2020-12-21 (89)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE AT WORK ON 21/DEC/2020.		Yes/ 2020-10-23 (30)	
US3222655	2020-10-01	AMENDMENT 3	No/ 2021-02-01 (124)	Protocol Deviation/ SUBJECT IS PATHOLOGIST AND WAS VACCINATED AT HER PLACE OF EMPLOYMENT.		Yes/ 2020-10-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222657	2020-10-01	AMENDMENT 3	No/ 2021-02-05 (128)	Withdrawal of Consent by Participant/ SUBJECT STATES HE IS ABLE TO GET VACCINATED THROUGH THE COMMUNITY AND WILL MAKE ARRANGEMENTS TO DO SO. STATES HE WANTS TO BE DROPPED. HE IS UNABLE TO TRAVEL DUE TO HEALTH AND LENGTH OF TIME.		Yes/ 2020-10-30 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222661	2020-10-02	AMENDMENT	3 No/ 2021-02-23 (145)	Lost to Follow-Up		Yes/ 2020-11-06 (36)	
US3232048	2020-08-14	AMENDMENT	2 No/ 2020-12-12 (114)	Death	2020-12-12/ N	Yes/ 2020-09-18 (29)	
US3232068	2020-08-19	AMENDMENT	2 No/ 2021-01-05 (140)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-23 (36)	
US3232132	2020-08-31	AMENDMENT	3 No/ 2021-03-12 (194)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3232140	2020-09-02	AMENDMENT 3	No/ 2021-01-07 (128)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-30 (29)	
US3232141	2020-09-02	AMENDMENT 3	No/ 2021-01-06 (127)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3232158	2020-09-10	AMENDMENT 3	No/ 2021-01-08 (121)	Protocol Deviation/ PATIENT RECEIVED NON-STUDY EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-17 (38)	
US3232182	2020-09-19	AMENDMENT 3	No/ 2021-02-18 (153)	Protocol Deviation/ PATIENT RECEIVED MODERNA VACCINE OUTSIDE OF STUDY FACILITY		Yes/ 2020-10-20 (32)	
US3242002	2020-08-06	AMENDMENT 1	ONGOING			No/ 2020-09-02 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242019	2020-08-07	AMENDMENT 1	No/ 2020-12-30 (146)	Withdrawal of Consent by Participant/ SUBJECT WISH TO RECEIVE VACCINE FROM EMPLOYER		Yes/ 2020-09-08 (33)	
US3242089	2020-08-14	AMENDMENT 2	No/ 2021-03-04 (203)	Death	2021-03-04/ Y	Yes/ 2020-09-11 (29)	
US3242091	2020-08-14	AMENDMENT 2	No/ 2020-12-31 (140)	Withdrawal of Consent by Participant/ SUBJECT CHOOSES TO WITHDRAW IN ORDER TO RECEIVE PFIZER VACCINE UNDER EAU		Yes/ 2020-09-15 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242115	2020-08-17	AMENDMENT 2	No/ 2020-11-27 (103)	Lost to Follow-Up		Yes/ 2020-09-15 (30)	
US3242182	2020-08-21	AMENDMENT 2	No/ 2020-12-30 (132)	Withdrawal of Consent by Participant/ WANTED TO BE UNBLINDED		Yes/ 2020-09-18 (29)	
US3242195	2020-08-24	AMENDMENT 2	No/ 2020-12-17 (116)	Withdrawal of Consent by Participant/ TO RECEIVE EUA COVID VACCINE		Yes/ 2020-09-18 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242225	2020-08-26	AMENDMENT 3	No/ 2020-12-21 (118)	Withdrawal of Consent by Participant/ TO UNBLIND AND RECEIVE EUA VACCINE		Yes/ 2020-09-23 (29)	
US3242255	2020-08-31	AMENDMENT 3	No/ 2021-01-19 (142)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINATION AT ANOTHER LOCATION		Yes/ 2020-09-28 (29)	
US3242258	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242350	2020-09-18	AMENDMENT 3	No/ 2021-03-05 (169)	Other/ MOVED OUT OF STATE		Yes/ 2020-10-20 (33)	
US3242400	2020-09-30	AMENDMENT 3	No/ 2021-01-27 (120)	Other/ MOVING OUT OF STATE		Yes/ 2020-10-28 (29)	
US3242413*	2020-10-06	AMENDMENT 4	No/ 2021-02-03 (121)	Other/ SUBJECT IN MILITARY AND LEAVING STATE		Yes/ 2020-11-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252009	2020-08-03	AMENDMENT 1	No/ 2021-01-13 (164)	Other/ PATIENT REQUESTED TO BE UNBLINDED FROM STUDY DUE TO MOVING TO A DIFFERENT STATE, MINNESOTA. PATIENT STATES SHE CAN NO LONGER MAKE SITE VISITS.		No/ 2020-08-30 (28)	Pregnancy

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252013	2020-08-03	AMENDMENT 1	No/ 2021-01-12 (163)	Protocol Deviation/ POST EUA UNBLINDING, PATIENT RECEIVED MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-09-01 (30)	
US3252015	2020-08-03	AMENDMENT 1	No/ 2021-01-29 (180)	Protocol Deviation/ POST EUA UNBLINDING, PATIENT GOT MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-08-29 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252020	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252039	2020-08-05	AMENDMENT 1	No/ 2021-02-01 (181)	Protocol Deviation/ PATIENT CALLED STATING HE HAD ALREADY RECEIVED THE MODERNA VACCINE ELSEWHERE. PATIENT STATES HE RECEIVED THE FIRST DOSE ON 23-DEC-2020 AND SECOND DOSE ON 22-JAN-2021. PATIENT WAS UNBLINDED TODAY 01-FE		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252057	2020-08-06	AMENDMENT 1	No/ 2020-12-18 (135)	Other/ SUBJECT OPTED TO GET PFIZER VACCINE OUTSIDE OF THE STUDY AND AS PER PROTOCOL NO LONGER IN THE STUDY.		Yes/ 2020-09-01 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252062	2020-08-06	AMENDMENT 1	No/ 2021-03-17 (224)	Protocol Deviation/ PATIENT CONTACTED US TO NOTIFY US THAT SHE RECEIVED THE MODERNA MRNA VACCINE OUTSIDE OF THE STUDY ON 11-MAR-2021. DUE TO THIS SHE WAS DISCONTINUED.		Yes/ 2020-09-03 (29)	
US3252077	2020-08-07	AMENDMENT 1	No/ 2020-12-29 (145)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-03 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252131	2020-08-12	AMENDMENT 2	No/ 2021-03-09 (210)	Protocol Deviation/ PATIENT RECEIVED A EUA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-09-08 (28)	
US3252132	2020-08-12	AMENDMENT 2	No/ 2021-03-08 (209)	Protocol Deviation/ RECEIVED EUA APPROVED VACCINE, PFIZER		Yes/ 2020-09-09 (29)	
US3252134	2020-08-12	AMENDMENT 2	No/ 2020-12-31 (142)	Other/ UNBLINDING DUE TO EUA APPROVED COVID VACCINE.		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252147	2020-08-12	AMENDMENT 2	No/ 2021-01-04 (146)	Other/ PATIENT UNBLINDING FOR EUA OF COVID VACCINE		Yes/ 2020-09-08 (28)	
US3252155	2020-08-13	AMENDMENT 2	No/ 2021-03-13 (213)	Protocol Deviation/ PATIENT RECEIVED A VACCINE OUT OF THE STUDY		Yes/ 2020-09-12 (31)	
US3252162	2020-08-13	AMENDMENT 2	No/ 2021-02-17 (189)	Other/ POST UNBLINDING EUA APPROVED VACCINE.		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252196	2020-08-15	AMENDMENT 2	No/ 2020-12-28 (136)	Other/ OTHER- REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-15 (32)	
US3252212	2020-08-17	AMENDMENT 2	No/ 2021-02-02 (170)	Protocol Deviation/ PATIENT CONTACTED US LETTING US KNOW THAT HE HAD RECEIVED THE EUA APPROVED VACCINE PFIZER 2 MONTHS AGO. PATIENT WAS UNBLINDED AT THIS TIME AND RECEIVED THE PLACEBO.		Yes/ 2020-09-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252226	2020-08-18	AMENDMENT 2	No/ 2020-12-31 (136)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-17 (31)	
US3252234	2020-08-18	AMENDMENT 2	No/ 2021-03-08 (203)	Protocol Deviation/ PATIENT RECEIVED MODERNA VACCINE OUTSIDE OF THE STUDY ON 25-DEC-2020		Yes/ 2020-09-14 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252242	2020-08-19	AMENDMENT 2	No/ 2021-01-22 (157)	Protocol Deviation/ POST UNBLINDING EUA PATIENT RECEIVED VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-15 (28)	
US3252256	2020-08-19	AMENDMENT 2	No/ 2021-03-06 (200)	Protocol Deviation/ POST EUA UNBLINDING- PATIENT GOT PFIZER VACCINE.		Yes/ 2020-09-16 (29)	
US3252264	2020-08-20	AMENDMENT 2	No/ 2020-12-31 (134)	Other/ UNBLINDED DUE TO APPROVED EUA COVID VACCINE.		Yes/ 2020-09-21 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252267	2020-08-20	AMENDMENT 2	No/ 2020-12-18 (121)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-09-18 (30)	
US3252276	2020-08-21	AMENDMENT 2	No/ 2021-02-25 (189)	Lost to Follow-Up		Yes/ 2020-09-23 (34)	
US3252283	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-17 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252293	2020-08-21	AMENDMENT 2	No/ 2021-03-08 (200)	Protocol Deviation/ POST EUA UNBLINDING- PATIENT GOT PFIZER VACCINE.		Yes/ 2020-09-18 (29)	
US3252297	2020-08-22	AMENDMENT 2	No/ 2021-03-10 (201)	Other/ PATIENT WILL BE DISCONTINUED FROM STUDY. STATES HE IS MOVING TO NEBRASKA ON 3/11/21 AND CAN NO LONGER COME IN FOR SITE VISITS.		Yes/ 2020-09-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252321	2020-08-24	AMENDMENT 2	No/ 2021-03-26 (215)	Withdrawal of Consent by Participant/ SUBJECT IS A PHYSICIAN AND WILL GET THE PFIZER VACCINE OUTSIDE OF THE STUDY. SUBJECT WAS ALSO HAVING DIFFICULTY MAKING HIS APPOINTMENTS DUE TO HIS WORK SCHEDULE. HE WITHDREW CONSENT.		Yes/ 2020-09-26 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252333	2020-08-25	AMENDMENT 3	No/ 2020-12-22 (120)	Protocol Deviation/ REQUEST TO UNBLIND/ PATIENT REPORTED THAT HE GOT PFIZER VACCINE TODAY (22-DEC-2020) DURING HIS D199 M4 SAFETY CALL.		Yes/ 2020-09-22 (29)	
US3252340	2020-08-26	AMENDMENT 2	No/ 2020-12-23 (120)	Other/ REQUEST UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252363	2020-08-28	AMENDMENT 3	No/ 2020-12-28 (123)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-09-24 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252370	2020-08-28	AMENDMENT 3	No/ 2020-10-02 (36)	Withdrawal of Consent by Participant/ PATIENT HAD HER SECOND VISIT SCHEDULED FOR 09/25/2020 AND DID NOT COME. PRIOR TO HER SECOND VISIT, PATIENT WAS CALLED AS A REMINDER TO COME TO HER VISIT HOWEVER DID NOT ANSWER. SHE WAS CALLED MULTIPLE		No/ 2020-09-24 (28)	Other/ PATIENT CANCELLED THE VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252376	2020-08-29	AMENDMENT 3	No/ 2021-03-06 (190)	Protocol Deviation/ POST EUA- PATIENT RECEIVED EUA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-09-26 (29)	
US3252397	2020-08-31	AMENDMENT 3	No/ 2020-09-10 (11)	Lost to Follow-Up		No/ 2020-09-09 (10)	Lost to Follow-Up
US3252400	2020-09-01	AMENDMENT 3	No/ 2021-03-09 (190)	Protocol Deviation/ POST EUA- PATIENT GOT PFIZER VACCINE.		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252427	2020-09-04	AMENDMENT 3	No/ 2021-01-08 (127)	Protocol Deviation/ PATIENT RECEIVED OUTSIDE VACCINE		Yes/ 2020-10-02 (29)	
US3252428	2020-09-04	AMENDMENT 3	No/ 2020-12-17 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-10-02 (29)	
US3252434	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE.		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252445	2020-09-09	AMENDMENT 3	No/ 2021-03-05 (178)	Protocol Deviation/ PATIENT GOT AN EUA VACCINE OUTSIDE OF STUDY. PATIENT WAS UNBLINDED AND RECEIVED PLACEBO. PATIENT WAS NOTIFIED HE WOULD BE DISCONTINUED AND HE VERBALIZED UNDERSTANDING.		Yes/ 2020-10-09 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252478	2020-09-14	AMENDMENT 3	No/ 2021-02-23 (163)	Protocol Deviation/ PATIENT RECEIVED A MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-10-13 (30)	
US3252486	2020-09-15	AMENDMENT 3	No/ 2021-02-08 (147)	Protocol Deviation/ POST EUA UNBLINDING-PATIENT GOT MODERNA OUTSIDE OF THE STUDY		Yes/ 2020-10-10 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252533	2020-09-22	AMENDMENT 3	No/ 2020-12-16 (86)	Withdrawal of Consent by Participant/ PATIENT MOVED OUT OF TOWN AND WANTED TO WITHDRAWAL FROM STUDY		Yes/ 2020-10-22 (31)	
US3252539	2020-09-23	AMENDMENT 3	No/ 2021-03-05 (164)	Protocol Deviation/ PATIENT RECEIVED OUTSIDE MODERNA VACCINE		Yes/ 2020-10-20 (28)	
US3252542	2020-09-24	AMENDMENT 3	No/ 2021-03-09 (167)	Other/ POST EUA UNBLINDING		Yes/ 2020-10-21 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252547	2020-09-24	AMENDMENT 3	No/ 2021-03-11 (169)	Protocol Deviation/ PATIENT RECEIVED AN OUTSIDE EUA APPROVED VACCINE AND WITHDREW CONSENT AFTER UNBLINDING.		Yes/ 2020-10-22 (29)	
US3252553	2020-09-24	AMENDMENT 2	ONGOING			No/ 2020-10-21 (28)	Adverse Event/ PATIENT DISCONTINUED DUE TO AE# 9,8,7,6,5,4
US3252554	2020-09-24	AMENDMENT 3	No/ 2020-12-23 (91)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE.		Yes/ 2020-10-28 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252568	2020-09-28	AMENDMENT 3	No/ 2021-03-08 (162)	Protocol Deviation/ POST EUA UNBLINDING, PATIENT RECEIVED MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-10-30 (33)	
US3252577	2020-09-28	AMENDMENT 3	No/ 2021-01-28 (123)	Protocol Deviation/ POST EUA UNBLINDING, PATIENT GOT MODERNA OUTSIDE OF THE STUDY.		Yes/ 2020-10-26 (29)	
US3252583	2020-09-30	AMENDMENT 3	ONGOING			No/ 2020-10-27 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252585	2020-09-30	AMENDMENT 3	No/ 2020-12-17 (79)	Other/ EUA COVID VACCINE- PATIENT GOT PFIZER.		Yes/ 2020-10-29 (30)	
US3252599	2020-10-02	AMENDMENT 3	ONGOING			No/ 2020-10-29 (28)	Due to SARS-CoV-2
US3252600	2020-10-02	AMENDMENT 3	No/ 2021-03-09 (159)	Other/ POST EUA- PATIENT GOT EUA APPROVED VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-10-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252612	2020-10-03	AMENDMENT 3	No/ 2021-03-10 (159)	Protocol Deviation/ THE SUBJECT RECEIVED 2ND DOSE OUTSIDE OF THE STUDY AND WAS DISCONTINUED.		Yes/ 2020-10-30 (28)	
US3252619	2020-10-05	AMENDMENT 3	No/ 2020-11-30 (57)	Lost to Follow-Up		Yes/ 2020-11-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252620	2020-10-05	AMENDMENT 3	No/ 2021-01-24 (112)	Protocol Deviation/ PATIENT LET US KNOW THAT HE ENDED UP GETTING THE MODERNA VACCINE OUTSIDE OF THE STUDY. THE PATIENT HAS BEEN DISCONTINUED FROM THE STUDY.		Yes/ 2020-11-02 (29)	
US3252627	2020-10-06	AMENDMENT 4	No/ 2020-12-18 (74)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE.		Yes/ 2020-11-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252630	2020-10-06	AMENDMENT 4	No/ 2021-01-18 (105)	Protocol Deviation/ PATIENT WITHDREW CONSENT DUE TO RECEIVING THE MODERNA VACCINE FROM HIS PCP		Yes/ 2020-11-03 (29)	
US3252634	2020-10-06	AMENDMENT 4	No/ 2021-03-05 (151)	Protocol Deviation/ POST EUA- PATIENT RECEIVED MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-11-03 (29)	
US3252638	2020-10-07	AMENDMENT 4	ONGOING			No/ 2020-11-03 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252650	2020-10-10	AMENDMENT 3	No/ 2020-11-14 (32)	Withdrawal of Consent by Participant/ SUBJECT REPORTED THAT SHE AND HER HUSBAND (US3252652) NO LONGER WANTED TO PARTICIPATE IN THE TRIAL AND WOULD LIKE TO WITHDRAW CONSENT		No/ 2020-11-10 (28)	Withdrawal of Consent by Participant/ NO LONGER WANTED TO PARTICIPATE IN THE TRIAL AND WOULD LIKE TO WITHDRAW CONSENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252652	2020-10-10	AMENDMENT 4	No/ 2020-11-13 (31)	Withdrawal of Consent by Participant/ ON 13-NOV-2020 WE WERE MADE AWARE THAT PATIENT NO LONGER WOULD LIKE TO PARTICIPATE IN THE TRIAL AND WOULD LIKE TO WITHDRAW CONSENT.		No/ 2020-11-10 (28)	Withdrawal of Consent by Participant/ ON 13-NOV-2020 WE WERE MADE AWARE THAT PATIENT NO LONGER WOULD LIKE TO PARTICIPATE IN THE TRIAL AND WOULD LIKE TO WITHDRAW CONSENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252657	2020-10-12	AMENDMENT 4	No/ 2021-01-22 (103)	Protocol Deviation/ PATIENT WAS DISCONTINUED ON 22-JAN-2021 DUE TO RECENTLY HAVING RECEIVED THE PFIZER VACCINE.		Yes/ 2020-11-10 (30)	
US3252660	2020-10-13	AMENDMENT 4	No/ 2020-12-18 (67)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE.		Yes/ 2020-11-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252662	2020-10-13	AMENDMENT 4	No/ 2021-03-12 (151)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE ON MARCH 1, 2021.		Yes/ 2020-11-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252666	2020-10-14	AMENDMENT 4	No/ 2021-01-09 (88)	Protocol Deviation/ PATIENT GOT PFIZER VACCINE ON 28-DEC-2020 AND CAME IN TO CLINIC 09-JAN-2020 SIGNED CONSENT SAYING HE WANTED TO WITHDRAW FROM THE STUDY AND THAT IS WHEN HE LET US KNOW HE RECEIVED ANOTHER VACCINE.		Yes/ 2020-11-19 (37)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252672	2020-10-15	AMENDMENT 4	No/ 2021-03-12 (149)	Protocol Deviation/ POST EUA-PATIENT GOT OUTSIDE OF STUDY VACCINE.		Yes/ 2020-11-12 (29)	
US3252680	2020-10-16	AMENDMENT 4	No/ 2021-01-12 (89)	Other/ REQUEST UNBLINDING, WILL RECEIVE VACCINE UNDER EUA		Yes/ 2020-11-13 (29)	
US3252702	2020-10-23	AMENDMENT 3	No/ 2021-03-05 (134)	Protocol Deviation/ PATIENT NON-COMPLIANT WITH STUDY PROCEDURES		Yes/ 2020-11-24 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252704	2020-10-23	AMENDMENT 4	No/ 2021-03-06 (135)	Protocol Deviation/ PATIENT DECIDED TO GET VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-11-19 (28)	
US3262011	2020-07-28	AMENDMENT 1	No/ 2021-01-21 (178)	Protocol Deviation/ PATIENT DOSED WITH VACCINE OUTSIDE OF THE STUDY. AN EPIP WAS SUBMITTED. THEY DOSED 1/19/2021		Yes/ 2020-09-04 (39)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262020	2020-07-28	AMENDMENT 1	No/ 2021-02-01 (189)	Protocol Deviation/ PATIENT DOSED WITH VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-08-25 (29)	
US3262024	2020-07-28	AMENDMENT 1	No/ 2020-12-23 (149)	Other/ SUBJECT WAS HOSTILE TOWARD STAFF		Yes/ 2020-08-26 (30)	
US3262025	2020-07-28	AMENDMENT 1	No/ 2020-12-23 (149)	Physician Decision/ SPOUSE IS ABUSIVE TOWARDS THE STAFF		Yes/ 2020-08-26 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262031	2020-07-29	AMENDMENT 1	No/ 2021-01-27 (183)	Protocol Deviation/ SUBJECT WAS SCHEDULED FOR OPEN LABEL APPOINTMENT 28 JAN 2021 WHEN CONTACTED BY SITE STAFF TO REMIND OF APPT, SUBJECT STATED HE HAD ALREADY RECEIVED VACCINE ELSEWHERE		Yes/ 2020-08-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262042	2020-07-29	AMENDMENT 1	No/ 2021-01-20 (176)	Other/ PATIENT WOULD NOT REPLY TO ANY OF OUR CALLS, AND THEY WERE A NO SHOW FOR DAY 57. THEY CALLED 1/20/21 ASKING TO BE IN THE STUDY, AND GAVE NO REASON FOR BEING NON-RESPONSIVE.		Yes/ 2020-08-31 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262067	2020-08-03	AMENDMENT 1	No/ 2020-10-01 (60)	Withdrawal of Consent by Participant/ PER SUBJECT STATED IT WAS TIME CONSUMING WITH HIS SCHEDULE NO LONGER WANTED TO PARTICIPATE WITH TRIAL		Yes/ 2020-09-01 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262075	2020-08-03	AMENDMENT 1	No/ 2021-03-10 (220)	Other/ UPON CONDUCTING CONFIRMATION OF APPT BEING SCHEDULED FOR 11 MAR 2021 FOR SECOND DOSE SUBJECT STATED HE HAD RECEIVED SECOND DOSE FROM PCP THEREFORE SUBJECT HAS BEEN ET'D -		Yes/ 2020-09-01 (30)	
US3262082	2020-08-04	AMENDMENT 1	No/ 2020-09-04 (32)	Lost to Follow-Up		No/ 2020-08-31 (28)	Lost to Follow-Up
US3262091	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262118	2020-08-06	AMENDMENT 1	No/ 2021-01-25 (173)	Protocol Deviation/ PATIENT RECEIVED OUTSIDE VACCINATION AGAINST OUR ADVICE		Yes/ 2020-09-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262121	2020-08-06	AMENDMENT 1	No/ 2020-08-28 (22)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTED TO CONTINUE DUE TO SUBJECT STATING " I KNOW I GOT THE PLACEBO" I DONT WANT TO CONTINUE WITH TRIAL		No/ 2020-08-27 (21)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTED TO CONTINUE DUE TO SUBJECT STATING " I KNOW I GOT THE PLACEBO" I DONT WANT TO CONTINUE WITH TRIAL

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262122	2020-08-07	AMENDMENT 1	No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED " I KNOW I RECEIVED THE PLACEBO" AND NO LONGER WANT TO CONTINUE WITH THE TRIAL		No/ 2020-09-02 (27)	Withdrawal of Consent by Participant/ SUBJECT STATED " I KNOW I RECEIVED THE PLACEBO" AND NO LONGER WANT TO CONTINUE WITH THE TRIAL

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262136	2020-08-08	AMENDMENT 2	No/ 2020-12-23 (138)	Other/ PATIENT WANTED TO BE UNBLINDED, KNOWING IT WOULD REMOVE HER FROM THE STUDY. AN EPIP WAS SUBMITTED AS WELL.		Yes/ 2020-09-04 (28)	
US3262165	2020-08-11	AMENDMENT 2	No/ 2020-09-01 (22)	Lost to Follow-Up		No/ 2020-08-31 (21)	Lost to Follow-Up
US3262186	2020-08-15	AMENDMENT 2	No/ 2020-10-05 (52)	Lost to Follow-Up		Yes/ 2020-09-21 (38)	
US3262196	2020-08-17	AMENDMENT 2	No/ 2020-10-02 (47)	Lost to Follow-Up		No/ 2020-09-13 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262210	2020-08-19	AMENDMENT 2	No/ 2020-09-23 (36)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WANT TO CONTINUE WITH TRIAL		No/ 2020-09-15 (28)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WANT TO CONTINUE WITH TRIAL

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262213	2020-08-19	AMENDMENT 2	No/ 2020-12-01 (105)	Withdrawal of Consent by Participant/ PER PI STATED SUBJECTS VOICED CONCERNS REGARDING TRAVELING FOR (b) (6) HRS WHILE FAMILY MEMBERS WERE PLACED IN HOSPITAL AND NOT WANTING TO LEAVE THEIR SIDE		Yes/ 2020-09-17 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262214	2020-08-19	AMENDMENT 2	No/ 2020-12-01 (105)	Withdrawal of Consent by Participant/ PER PI STATED SUBJECTS VOICED CONCERNS REGARDING TRAVELING FOR FOUR HRS WHILE FAMILY MEMBERS WERE PLACED IN HOSPITAL AND NOT WANTING TO LEAVE THEIR SIDE		Yes/ 2020-09-17 (30)	
US3262221	2020-08-20	AMENDMENT 2	No/ 2021-03-26 (219)	Withdrawal of Consent by Participant		Yes/ 2020-09-21 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262246	2020-08-26	AMENDMENT 3	No/ 2021-03-15 (202)	Other/ MOVED OUT OF STATE		Yes/ 2020-09-30 (36)	
US3262257	2020-08-31	AMENDMENT 2	No/ 2020-11-16 (78)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT NO LONGER INTERESTED IN PARTICIPATING		Yes/ 2020-10-20 (51)	
US3272005	2020-07-29	AMENDMENT 1	ONGOING			No/ 2020-08-25 (28)	Other/ SUBJECT TAKING EXCLUSIONARY MEDICATION. SUBJECT ONLY IN SAFETY FOLLOWUP

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272023	2020-07-31	AMENDMENT 1	No/ 2020-12-24 (147)	Withdrawal of Consent by Participant/ SUBJECT IS DENTIST AND REQUESTED TO BE UNBLINDED AS HE HAS ACCESS TO COVID-19 VACCINE.		Yes/ 2020-08-28 (29)	
US3272025	2020-07-31	AMENDMENT 1	No/ 2020-09-22 (54)	Lost to Follow-Up		No/ 2020-08-27 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272026	2020-08-01	AMENDMENT 1	No/ 2021-03-25 (237)	Protocol Deviation/ SUBJECT RECEIVED NON-STUDY VACCINE OUTSIDE OF STUDY. PER SPONSOR SUBJECT IS TO BE DISCONTINUED.		Yes/ 2020-09-08 (39)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272031	2020-08-01	AMENDMENT 1	No/ 2021-01-20 (173)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO BE IN STUDY CAME IN FOR UNBLINDING APPOINTMENT AND SIGNED NEW CONSENT THAT SHE NO LONGER WISHED TO CONTINUE IN STUDY AND WAS UNBLINDED AS WELL.		No/ 2020-08-28 (28)	Other/ SUBJECT UNDERGOING CANCER TREATMENT. SUBJECT STILL IN STUDY FOR SAFETY FOLLOWUP

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272055	2020-08-05	AMENDMENT 1	No/ 2021-02-15 (195)	Protocol Deviation/ SUBJECT RECEIVED NON-STUDY VACCINE AT WORK PRIOR TO WITHDRAWAL FROM THE STUDY PER SPONSOR SUBJECT NO ABLE TO CONTINUE IN THE STUDY.		Yes/ 2020-09-03 (30)	
US3272070	2020-08-06	AMENDMENT 1	No/ 2020-10-01 (57)	Death	2020-10-01/ UNK	Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272073	2020-08-07	AMENDMENT 1	No/ 2021-02-15 (193)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHED TO BE IN STUDY AND EPIP WAS SENT TO UNBLIND OVER PHONE AND SUBJECT WAS UNBLINDED OVER PHONE AND WANTED VACCINATED ELSEWHERE		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272082	2020-08-07	AMENDMENT 1	No/ 2020-12-23 (139)	Withdrawal of Consent by Participant/ SUBJECT UNBLINDED DUE TO WANTING TO RECEIVE COVID VACCINE AT PLACE OF EMPLOYEMENT.		Yes/ 2020-09-04 (29)	
US3272100	2020-08-11	AMENDMENT 1	No/ 2021-02-18 (192)	Protocol Deviation/ SUBJECT RECIEVED NON-STUDY COVID-19 VACCINE AND WANTED TO WITHDRAW FROM THE STUDY.		Yes/ 2020-09-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272114	2020-08-12	AMENDMENT 2	No/ 2020-10-27 (77)	Lost to Follow-Up		No/ 2020-09-08 (28)	Lost to Follow-Up
US3272158	2020-08-15	AMENDMENT 2	No/ 2020-11-30 (108)	Lost to Follow-Up		Yes/ 2020-09-17 (34)	
US3272159	2020-08-15	AMENDMENT 2	No/ 2020-10-27 (74)	Lost to Follow-Up		No/ 2020-09-11 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272192	2020-08-19	AMENDMENT 2	No/ 2020-12-23 (127)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO GET VACCINATED AT CLINIC WHERE SHE WORKS. SHE SEES PATIENTS AND WANTS TO BE PROTECTED.		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272201	2020-08-20	AMENDMENT 2	No/ 2020-11-06 (79)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WISH TO CONTINUE IN STUDY AND DOESN'T SPECIFY WHY		Yes/ 2020-09-18 (30)	
US3272225	2020-08-21	AMENDMENT 2	No/ 2021-01-12 (145)	Withdrawal of Consent by Participant/ SUBJECT ASKED TO LEAVE STUDY AFTER BEING UNBLINDED		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272324	2020-08-23	AMENDMENT 2	No/ 2021-01-14 (145)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT TO END STUDY PARTICIPATION.		Yes/ 2020-09-25 (34)	
US3272375	2020-09-28	AMENDMENT 3	No/ 2021-02-10 (136)	Lost to Follow-Up		Yes/ 2020-10-30 (33)	
US3282022	2020-08-07	AMENDMENT 1	No/ 2021-01-04 (151)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-02 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3282031	2020-08-11	AMENDMENT 2	No/ 2020-08-26 (16)	Withdrawal of Consent by Participant/ PT DOES NOT WISH TO CONTINUE, NO FURTHER DETAILS GIVEN.		No/ 2020-08-25 (15)	Withdrawal of Consent by Participant/ PT DOES NOT WISH TO CONTINUE, NO FURTHER DETAILS GIVEN.
US3282060	2020-08-18	AMENDMENT 2	No/ 2021-01-05 (141)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-17 (31)	
US3282065	2020-08-19	AMENDMENT 2	No/ 2021-01-13 (148)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3282071	2020-08-20	AMENDMENT 2	No/ 2020-12-21 (124)	Protocol Deviation/ SUBJECT RECEIVED COVID19 EUA VACCINE		Yes/ 2020-09-22 (34)	
US3282080	2020-08-25	AMENDMENT 3	No/ 2020-12-21 (119)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-28 (35)	
US3292010	2020-08-04	AMENDMENT 1	No/ 2020-12-30 (149)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY WHEN ORIGINALLY ASSIGNED TO PLACEBO.		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292024	2020-08-04	AMENDMENT 1	No/ 2021-01-04 (154)	Physician Decision/ THEIR NEUROLOGIST SUGGESTED THEY BE UNBLINDED. SUBJECT WAS UNBLINDED AND DROPPED FROM STUDY.		Yes/ 2020-09-01 (29)	
US3292026	2020-08-04	AMENDMENT 1	No/ 2020-12-21 (140)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID-19 VACCINE		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292027	2020-08-04	AMENDMENT 1	No/ 2020-12-16 (135)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3292028	2020-08-04	AMENDMENT 1	No/ 2020-12-21 (140)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6. SUBJECT WITHDREW TO RECEIVE NON STUDY EUA VACCINE		Yes/ 2020-09-03 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292038	2020-08-06	AMENDMENT 1	No/ 2020-11-03 (90)	Withdrawal of Consent by Participant/ SUBJECT VERBALIZED WITHDRAWAL.		Yes/ 2020-09-03 (29)	
US3292045	2020-08-06	AMENDMENT 1	No/ 2020-12-21 (138)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-03 (29)	
US3292053	2020-08-08	AMENDMENT 1	No/ 2021-01-13 (159)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292054	2020-08-08	AMENDMENT 1	No/ 2020-12-23 (138)	Protocol Deviation/ SUBJECT RECEIVED PFIZER CONVID-19 VACCINE.		Yes/ 2020-09-05 (29)	
US3292058	2020-08-08	AMENDMENT 1	No/ 2021-01-29 (175)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-03 (27)	
US3292063	2020-08-08	AMENDMENT 1	No/ 2021-01-04 (150)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292070	2020-08-08	AMENDMENT 1	No/ 2020-12-21 (136)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-05 (29)	
US3292092	2020-08-08	AMENDMENT 1	No/ 2020-12-23 (138)	Other/ SUBJECT SCHEDULED FOR MODERNA COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292100	2020-08-08	AMENDMENT 1	No/ 2021-01-06 (152)	Protocol Deviation/ SUBJECT DEMANDED TO BE UNBLINDED EARLY. EPIP SUBMITTED AND APPROVED. PT RECEIVED PLACEBO. DROPPED FROM TRIAL AS PER SPONSOR INSTRUCTIONS PRIOR TO RECEIVING OUTSIDE VACCINATION.		Yes/ 2020-09-03 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292110	2020-08-11	AMENDMENT 2	No/ 2020-12-28 (140)	Protocol Deviation/ SUBJECT UNBLINDED BEFORE AMENDMENT 6 TO RECEIVE PFIZER COVID-19 VACCINE		Yes/ 2020-09-10 (31)	
US3292125	2020-08-11	AMENDMENT 2	No/ 2021-01-06 (149)	Protocol Deviation/ SUBJECT RECEIVED TOZINAMERAN		Yes/ 2020-09-08 (29)	
US3292134	2020-08-11	AMENDMENT 2	No/ 2020-12-21 (133)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292144	2020-08-13	AMENDMENT 2	No/ 2020-09-17 (36)	Withdrawal of Consent by Participant/ PT NO LONGER WANTS TO PARTICIPATE DUE TO NOT HAVING ANY TIME TO COMPLETE STUDY PROCEDURES. VERBALLY WITHDREW CONSENT.		No/ 2020-09-09 (28)	Withdrawal of Consent by Participant/ PT NO LONGER WANTS TO PARTICIPATE DUE TO NOT HAVING ANY TIME TO COMPLETE STUDY PROCEDURES. VERBALLY WITHDREW CONSENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292148	2020-08-13	AMENDMENT 2	No/ 2020-12-29 (139)	Protocol Deviation/ SUBJECT WAS UNBLINDED BY PI AND FOUND TO HAVE RECEIVED PLACEBO. AS PER SPONSOR, PATIENT WAS NOTIFIED AND REMOVED FROM THE TRIAL.		Yes/ 2020-09-15 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292159	2020-08-13	AMENDMENT 2	No/ 2020-09-28 (47)	Withdrawal of Consent by Participant/ PT REPORTS FAMILY MEMBER FALLING ILL, UNABLE TO COMMIT TO STUDY PROCEDURES AND VISITS. VERBALLY WITHDREW CONSENT.		No/ 2020-09-09 (28)	Withdrawal of Consent by Participant/ PT REPORTS FAMILY MEMBER FALLING ILL, UNABLE TO COMMIT TO STUDY PROCEDURES AND VISITS. VERBALLY WITHDREW CONSENT.
US3292164	2020-08-13	AMENDMENT 2	No/ 2020-12-21 (131)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-15 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292170	2020-08-13	AMENDMENT 2	No/ 2020-12-21 (131)	Protocol Deviation/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-12 (31)	
US3292176	2020-08-15	AMENDMENT 2	No/ 2021-01-06 (145)	Protocol Deviation/ SUBJECT REQUESTED AND WAS GRANTED UNBLINDING BEFORE VISIT AND SIGNING OF NEW ICF.		Yes/ 2020-09-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292192	2020-08-15	AMENDMENT 2	No/ 2020-09-25 (42)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO CONCERN OF RECEIVING PLACEBO		No/ 2020-09-11 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO CONCERN OF RECEIVING PLACEBO, OPTIONS TO STAY IN THE STUDY WERE DISCUSSED WITH SUBJECT, BUT HE WAS ADAMANT WITH DECISION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292194	2020-08-15	AMENDMENT 2	No/ 2020-12-21 (129)	Other/ SUBJECT REQUESTED UNBLINDED BEFORE AMENDMENT 6 AND WAS FOUND TO HAVE RECEIVED PLACEBO.		Yes/ 2020-09-12 (29)	
US3292205	2020-08-18	AMENDMENT 2	No/ 2020-12-21 (126)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED BEFORE AMENDMENT 6.		Yes/ 2020-09-15 (29)	
US3292211	2020-08-18	AMENDMENT 2	No/ 2020-12-28 (133)	Other/ SUBJECT WILL RECEIVE COMIRNATY.		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292212	2020-08-18	AMENDMENT 2	No/ 2020-12-18 (123)	Protocol Deviation/ SUBJECT RECEIVED COMIRNATY.		Yes/ 2020-09-15 (29)	
US3292229	2020-08-18	AMENDMENT 2	No/ 2021-01-04 (140)	Withdrawal of Consent by Participant/ PATIENT WISHED TO RECEIVE COVID-19 VACCINE OUTSIDE OF STUDY PROTOCOL.		Yes/ 2020-09-15 (29)	
US3292247	2020-08-20	AMENDMENT 2	No/ 2021-02-01 (166)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292248	2020-08-20	AMENDMENT 2	No/ 2021-01-04 (138)	Protocol Deviation/ SUBJECT RECEIVED MRNA-1273 OUTSIDE OF STUDY.		Yes/ 2020-09-17 (29)	
US3292258	2020-08-20	AMENDMENT 2	No/ 2021-01-04 (138)	Other/ SUBJECT UNBLINDED W/ SPONSOR APPROVAL (EPIP). RECEIVED PLACEBO. DROPPED AS PER SPONSOR 4JAN21. DROPPED PRIOR TO RECEIVING OUTSIDE VACCINATION.		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292268	2020-08-21	AMENDMENT 2	No/ 2021-01-11 (144)	Protocol Deviation/ SUBJECT RECEIVED MRNA-1273 OUTSIDE OF STUDY.		Yes/ 2020-09-18 (29)	
US3292273	2020-08-21	AMENDMENT 2	No/ 2020-12-17 (119)	Protocol Deviation/ SUBJECT RECEIVED COMIRNATY.		Yes/ 2020-09-19 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292289	2020-08-25	AMENDMENT 3	No/ 2020-12-29 (127)	Other/ SUBJECT RECEIVED PLACEBO AND WAS UNBLINDED; SUBJECT DISCONTINUED AS THEY WERE TO RECEIVE NON STUDY EUA VACCINE		Yes/ 2020-09-22 (29)	
US3292293	2020-08-25	AMENDMENT 3	No/ 2021-01-11 (140)	Protocol Deviation/ SUBJECT REFUSED TO RECEIVE NASAL SWAB. SUBJECT WAS UNBLINDED AND HAD RECEIVED PLACEBO.		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292329	2020-08-27	AMENDMENT 3	No/ 2021-01-04 (131)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO RECEIVE COVID-19 VACCINE OUTSIDE OF STUDY PROTOCOL. SUBJECT UNBLINDED AND RECEIVED PLACEBO.		Yes/ 2020-09-24 (29)	
US3292335	2020-08-27	AMENDMENT 3	No/ 2021-01-05 (132)	Protocol Deviation/ SUBJECT RECEIVED COMIRNATY.		Yes/ 2020-09-25 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292346	2020-08-27	AMENDMENT 3	No/ 2021-01-09 (129)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-01 (29)	
US3292358	2020-08-29	AMENDMENT 3	No/ 2020-12-21 (115)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE WITHOUT INFORMING STAFF		Yes/ 2020-09-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292360	2020-08-29	AMENDMENT 3	No/ 2020-12-23 (117)	Other/ SUBJECT WAS UNBLINDED W/ SPONSOR APPROVAL (EPIP) 23DEC2020. SHE WAS SCHEDULED TO RECEIVE VACCINE THROUGH EMPLOYER ON 24DEC2020. SUBJECT RECEIVED PLACEBO AND WAS DROPPED 23DEC2020 AS PER SPONSOR.		Yes/ 2020-09-29 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292361	2020-08-29	AMENDMENT 3	No/ 2020-12-21 (115)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO RECEIVE EUA VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-29 (32)	
US3292374	2020-08-29	AMENDMENT 3	No/ 2021-01-21 (146)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292379	2020-08-29	AMENDMENT 3	No/ 2021-01-15 (140)	Other/ PATIENT INSTRUCTED STAFF TO UNBLIND OVER THE PHONE BECAUSE HE DID NOT WANT TO RETURN TO CLINIC TO UNBLIND. SPONSOR NOTIFIED AND APPROVED. SUBJECT DROPPED AFTER UNBLINDING TO PLACEBO, AS PER SPONSOR.		Yes/ 2020-09-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292394	2020-09-15	AMENDMENT 3	No/ 2020-12-21 (98)	Other/ SUBJECT UNBLINDED PRIOR TO AMENDMENT 6; RECEIVED PLACEBO.		Yes/ 2020-10-13 (29)	
US3292405	2020-09-22	AMENDMENT 3	No/ 2020-12-23 (93)	Protocol Deviation/ SUBJECT RECEIVED COMIRNATY.		Yes/ 2020-10-20 (29)	
US3292414	2020-09-24	AMENDMENT 3	No/ 2020-12-17 (85)	Lost to Follow-Up		Yes/ 2020-10-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292416	2020-09-24	AMENDMENT 3	No/ 2020-12-29 (97)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT IN ORDER TO RECEIVE COMIRNATY.		Yes/ 2020-10-22 (29)	
US3292446	2020-10-22	AMENDMENT 4	No/ 2021-01-08 (79)	Other/ SUBJECT UNBLINDED AND HAD RECEIVED PLACEBO.		Yes/ 2020-11-23 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302009	2020-08-03	AMENDMENT 1	No/ 2020-10-05 (64)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW DUE TO WORK SCHEDULE CONFLICT		Yes/ 2020-09-02 (31)	
US3302032	2020-08-04	AMENDMENT 1	No/ 2021-01-08 (158)	Protocol Deviation/ PT UNBLINDED BECAUSE SHE ALREADY RECEIVED PFIZER VACCINE.		Yes/ 2020-08-31 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302055	2020-08-05	AMENDMENT 1	No/ 2021-03-02 (210)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO NOT CONTINUE ON STUDY		Yes/ 2020-09-02 (29)	
US3302065	2020-08-06	AMENDMENT 1	No/ 2020-12-29 (146)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-02 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302094	2020-08-07	AMENDMENT 1	No/ 2021-01-05 (152)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-04 (29)	
US3302100	2020-08-07	AMENDMENT 1	No/ 2020-12-29 (124)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302102	2020-08-07	AMENDMENT 1	No/ 2020-12-29 (145)	Protocol Deviation/ SUBJECT TOOK PFIZER VACCINE PRIOR TO UNBLINDING. PER EPIP SUBJECT WAS TO BE UNBLINDED		Yes/ 2020-09-04 (29)	
US3302103	2020-08-07	AMENDMENT 1	No/ 2021-01-18 (165)	Other/ PATIENT WITHDREW CONSENT FROM STUDY AS HE IS ON ACTIVE DUTY WITH THE		Yes/ 2020-09-02 (27)	

D
(b) (6)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302107	2020-08-08	AMENDMENT 1	No/ 2020-12-21 (136)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-02 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302108	2020-08-08	AMENDMENT 1	No/ 2021-01-21 (167)	Withdrawal of Consent by Participant/ SUBJECT PRESENTED TO SITE FOR THE OPEN LABEL VISIT 0. SUBJECT SIGNED THE NEW CONSENT STATING THAT SHE DIDN'T WANT TO CONTINUE TO PARTICIPATE IN THE STUDY BUT DID HOWEVER WANT TO BE UNBLINDED.		Yes/ 2020-09-04 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302152	2020-08-12	AMENDMENT 1	No/ 2020-12-18 (129)	Protocol Deviation/ SUBJECT TOOK PFIZER VACCINE PRIOR TO UNBLINDING.		Yes/ 2020-09-09 (29)	
US3302163	2020-08-12	AMENDMENT 1	No/ 2020-11-04 (85)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302173	2020-08-12	AMENDMENT 1	No/ 2021-02-11 (184)	Withdrawal of Consent by Participant/ WITHDREW CONSENT; PATIENT WISHED TO NO LONGER PARTICIPATE IN THE STUDY.		Yes/ 2020-09-10 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302177	2020-08-12	AMENDMENT 1	No/ 2021-03-09 (210)	Withdrawal of Consent by Participant/ SUBJECT CALLED THE SITE AND WITHDREW CONSENT. SUBJECT CONFIRMED SHE NO LONGER WANTED TO PARTICIPATE IN THE STUDY.		Yes/ 2020-09-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302179	2020-08-13	AMENDMENT 2	No/ 2020-09-21 (40)	Withdrawal of Consent by Participant/ SUBJECT STATES HE IS NO LONGER ABLE TO PARTICIPATE IN TRIAL.		No/ 2020-09-09 (28)	Withdrawal of Consent by Participant/ SUBJECT STATES HE IS NO LONGER ABLE TO PARTICIPATE IN TRIAL.
US3302223	2020-08-17	AMENDMENT 2	No/ 2020-10-06 (51)	Lost to Follow-Up		Yes/ 2020-09-14 (29)	
US3302246	2020-08-18	AMENDMENT 2	No/ 2021-02-16 (183)	Withdrawal of Consent by Participant/ WITHDREW FROM STUDY ON 2/16/2021		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302325	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-22 (33)	
US3302367	2020-08-25	AMENDMENT 3	No/ 2020-12-26 (124)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-24 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302383	2020-08-26	AMENDMENT 3	No/ 2020-10-19 (55)	Withdrawal of Consent by Participant/ SUBJECT WITH DREW CONSENT AFTER COMPLETING ILLNESS VISITS.		No/ 2020-09-22 (28)	Due to SARS-CoV-2
US3302395	2020-08-27	AMENDMENT 3	No/ 2021-01-04 (131)	Death	2021-01-04/ UNK	Yes/ 2020-09-24 (29)	
US3302433	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-09-23 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302442	2020-08-28	AMENDMENT 3	No/ 2021-01-14 (140)	Protocol Deviation/ SUBJECT REPORTED THAT HE RECEIVED THE PFIZER VACCINE		Yes/ 2020-09-28 (32)	
US3302446	2020-08-31	AMENDMENT 3	No/ 2020-09-28 (29)	Other/ SUBJECT MOVING STATES		No/ 2020-09-27 (28)	Other/ SUBJECT WITHDREW DUE TO MOVING TO A DIFFERENT STATE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302483	2020-10-23	AMENDMENT 4	No/ 2020-12-26 (65)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UNBLINDED DUE TO BEING ELIGIBLE FOR PFIZER VACCINE		Yes/ 2020-11-20 (29)	
US3312060	2020-08-13	AMENDMENT 2	No/ 2021-01-13 (154)	Protocol Deviation/ UNBLINDED DUE TO RECEIPT OF EAU COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-10 (29)	
US3312068	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312073	2020-08-13	AMENDMENT 2	No/ 2020-12-22 (132)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-16 (35)	
US3312093	2020-08-14	AMENDMENT 2	No/ 2021-03-23 (222)	Withdrawal of Consent by Participant/ SUBJECTS WORK SITUATION HAS CHANGED		Yes/ 2020-09-11 (29)	
US3312095	2020-08-17	AMENDMENT 2	No/ 2021-03-10 (206)	Other/ COVID 19 EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-21 (36)	
US3312097	2020-08-17	AMENDMENT 2	No/ 2020-09-08 (23)	Lost to Follow-Up		No/ 2020-09-07 (22)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312101	2020-08-17	AMENDMENT 2	No/ 2021-01-13 (150)	Protocol Deviation/ UNBLINDED DUE TO RECEIPT OF EAU COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-14 (29)	
US3312123	2020-08-18	AMENDMENT 2	No/ 2021-01-13 (149)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-15 (29)	
US3312194	2020-08-20	AMENDMENT 2	No/ 2021-03-15 (208)	Lost to Follow-Up		Yes/ 2020-09-17 (29)	
US3312201	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Adverse Event/ AE#1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312212	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Serious Adverse Event/ SAE#1
US3312228	2020-08-24	AMENDMENT 2	No/ 2020-12-17 (116)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312256	2020-08-25	AMENDMENT 3	No/ 2021-03-19 (207)	Other/ SUBJECT WITHDREW CONSENT, HE IS RELOCATING ON 3/20/21. HE DECLINED OFFER TO TRANSFER TO ANOTHER SITE OR CONTINUE IN STUDY WITH P/C ONLY VISITS.		Yes/ 2020-09-22 (29)	
US3312308	2020-08-26	AMENDMENT 3	No/ 2020-12-21 (118)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312312	2020-08-26	AMENDMENT 3	No/ 2020-12-16 (113)	Other/ REQUEST TO UNBLIND-EUA COVID-19 VACCINE		Yes/ 2020-09-22 (28)	
US3312334	2020-08-27	AMENDMENT 3	No/ 2020-12-29 (125)	Other/ REQUEST TO UNBLIND/EUA COVID- 19 VACCINE		Yes/ 2020-09-25 (30)	
US3312366	2020-08-28	AMENDMENT 3	No/ 2021-01-13 (139)	Other/ REQUEST TO UNBLIND-EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312381	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3312398	2020-08-31	AMENDMENT 3	No/ 2020-12-23 (115)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID- 19 VACCINE		Yes/ 2020-09-28 (29)	
US3312447	2020-09-02	AMENDMENT 3	No/ 2020-12-17 (107)	Other/ REQUEST TO UNBLIND/EUA COVID- 19 VACCINE		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312467	2020-09-02	AMENDMENT 3	No/ 2020-12-17 (107)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-02 (31)	
US3312470	2020-09-02	AMENDMENT 3	No/ 2020-09-23 (22)	Lost to Follow-Up		No/ 2020-09-22 (21)	Lost to Follow-Up
US3312501	2020-09-04	AMENDMENT 3	No/ 2020-12-22 (110)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312513	2020-09-04	AMENDMENT 3	No/ 2021-03-13 (191)	Withdrawal of Consent by Participant/ SUBJECT IS NO LONGER INTERESTED IN CONTINUING WITH THE STUDY		Yes/ 2020-10-02 (29)	
US3312526	2020-09-08	AMENDMENT 3	No/ 2021-01-29 (144)	Protocol Deviation/ UNBLINDED DUE TO RECEIPT OF EAU COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-12 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312527	2020-09-08	AMENDMENT 3	No/ 2020-12-22 (106)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-06 (29)	
US3312539	2020-09-08	AMENDMENT 3	No/ 2021-02-26 (172)	Protocol Deviation/ DUE TO RECEIPT OF PFIZER EAU COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-06 (29)	
US3312548	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312564	2020-09-09	AMENDMENT 3	No/ 2021-01-05 (119)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3312573	2020-09-09	AMENDMENT 3	No/ 2020-10-31 (53)	Lost to Follow-Up		Yes/ 2020-10-07 (29)	
US3312587	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Due to SARS-CoV-2
US3312592	2020-09-10	AMENDMENT 3	No/ 2020-12-21 (103)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312605	2020-09-10	AMENDMENT 3	No/ 2020-11-16 (68)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO PARTICIPATE IN THE TRIAL.		Yes/ 2020-10-08 (29)	
US3322006	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Due to SARS-CoV-2
US3322013	2020-08-17	AMENDMENT 2	No/ 2020-09-14 (29)	Lost to Follow-Up		No/ 2020-09-13 (28)	Lost to Follow-Up
US3322027	2020-08-18	AMENDMENT 2	No/ 2020-12-22 (127)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322037	2020-08-18	AMENDMENT 2	No/ 2020-12-22 (110)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-09 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322041	2020-08-19	AMENDMENT 2	No/ 2021-03-12 (206)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED AND CONFIRMED THAT HE DOES NOT WANT TO CONTINUE IN THE STUDY AND WOULD LIKE TO WITHDRAW CONSENT. SITE WILL PROCEED TO DISCONTINUE AS SUBJECT WITHDREW CONSENT.		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322047	2020-08-20	AMENDMENT 2	No/ 2021-03-08 (201)	Protocol Deviation/ RECEIVED THE MODERNA VACCINE OUTSIDE THE STUDY, RECEIPT OF AN EUA VACCINE		Yes/ 2020-09-17 (29)	
US3322055	2020-08-20	AMENDMENT 2	No/ 2021-02-21 (186)	Protocol Deviation/ SUBJECT WAS CONTACTED BY SITE AND SHE INFORMED US THAT SHE RECEIVED THE PFIZER VACCINE A COUPLE OF WEEKS AGO.		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322061	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2
US3322071	2020-08-21	AMENDMENT 2	No/ 2021-02-10 (174)	Protocol Deviation/ SUBJECT REPORTED RECEIVING THE FIRST DOSE OF MODERNA VACCINE ON 3-FEB-2021, OUTSIDE OF THE STUDY.		Yes/ 2020-09-16 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322073	2020-08-21	AMENDMENT 2	No/ 2021-01-07 (140)	Protocol Deviation/ SUBJECT WAS CONTACTED BY SITE, RECEIVED THE EUA MODERNA VACCINE ON 24 DEC 2020 FROM HIS PLACE OF EMPLOYMENT		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322074	2020-08-21	AMENDMENT 2	No/ 2021-03-19 (211)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE TO EXPRESS HE IS NO LONGER INTERESTED TO CONTINUE HIS PARTICIPATION IN THE STUDY AND WOULD LIKE TO WITHDRAW CONSENT.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322081	2020-08-24	AMENDMENT 2	No/ 2020-12-28 (127)	Protocol Deviation/ EUA COVID 19 VACCINE OUTSIDE THE STUDY		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322082	2020-08-24	AMENDMENT 2	No/ 2020-11-09 (78)	Withdrawal of Consent by Participant/ ON 09 NOV 2020, SITE REACHED OUT TO SUBJECT TO RE-SCHEDULE HIS APPOINTMENT, EXPRESSED HE IS NO LONGER INTERESTED TO CONTINUE HIS PARTICIPATION IN THE STUDY.DISCONTINU ED AS SUBJECT WITHDREW CONSENT.		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322098	2020-08-25	AMENDMENT 2	No/ 2020-12-21 (119)	Protocol Deviation/ EUA COVID 19 VACCINE OUTSIDE THE STUDY		Yes/ 2020-09-24 (31)	
US3322111	2020-08-26	AMENDMENT 2	No/ 2020-09-23 (29)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO PERSONAL REASONS.		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO PERSONAL REASONS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322118	2020-08-27	AMENDMENT 3	No/ 2021-01-21 (148)	Protocol Deviation/ SUBJECT HAS DISCONTINUED FROM THE STUDY, DUE TO RECEIVING PFIZER COVID VACCINE ON 11-JAN-2021 THROUGH HIS EMPLOYER.		Yes/ 2020-09-24 (29)	
US3322135	2020-08-29	AMENDMENT 3	No/ 2021-01-15 (140)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-10-01 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322143	2020-08-31	AMENDMENT 3	No/ 2020-12-21 (113)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-28 (29)	
US3322175	2020-09-01	AMENDMENT 3	No/ 2021-01-18 (140)	Protocol Deviation/ EUA VACCINE		Yes/ 2020-09-29 (29)	
US3322199	2020-09-02	AMENDMENT 3	No/ 2020-11-16 (76)	Death	2020-11-16/ UNK	Yes/ 2020-10-01 (30)	
US3322204	2020-09-03	AMENDMENT 3	No/ 2021-01-18 (138)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322240	2020-09-06	AMENDMENT 3	No/ 2021-03-23 (197)	Protocol Deviation/ SUBJECT INFORMED SITE THAT HE RECEIVED THE PFIZER VACCINE ON 18 MAR 2021. THE SUBJECT IS WITHDRAWN FROM THE MODERNA STUDY GIVEN HIS RECEIPT OF AN EUA VACCINE.		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322256	2020-09-08	AMENDMENT 3	No/ 2021-01-23 (138)	Withdrawal of Consent by Participant/ SUBJECT CAME IN FOR PARTICIPATION DECISION VISIT AND EXPRESSED SHE IS NO LONGER INTERESTED TO CONTINUE HER PARTICIPATION IN THE STUDY. SITE WILL PROCEED TO DISCONTINUED AS SUBJECT WITHDREW CONSENT.		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322258	2020-09-08	AMENDMENT 3	No/ 2021-01-07 (122)	Protocol Deviation/ RECEIVED EUA VACCINE FROM PLACE OF EMPLOYMENT		Yes/ 2020-10-09 (32)	
US3322262	2020-09-08	AMENDMENT 3	No/ 2021-01-14 (129)	Protocol Deviation/ EUA VACCINE: SUBJECT STATED THAT SHE RECEIVED THE FIRST DOSE OF PFIZER VACCINE ON 18 DEC 2020 AND SECOND DOSE OF PFIZER ON 08 JAN 2021.		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322277	2020-09-09	AMENDMENT 3	No/ 2020-12-16 (99)	Other/ REQUEST TO UN-BLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3322294	2020-09-10	AMENDMENT 3	No/ 2021-01-12 (125)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-10-05 (26)	
US3322313	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Other/ SUBJECT WILL SKIP DAY 29 AND DAY 57 VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322316	2020-09-11	AMENDMENT 3	No/ 2020-12-21 (102)	Protocol Deviation/ EUA COVID 19 VACCINE OUTSIDE THE STUDY		Yes/ 2020-10-09 (29)	
US3322318	2020-09-11	AMENDMENT 3	No/ 2020-12-22 (103)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-14 (34)	
US3322338	2020-09-12	AMENDMENT 3	No/ 2020-12-21 (101)	Protocol Deviation/ EUA COVID 19 VACCINE OUTSIDE THE STUDY		Yes/ 2020-10-14 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322410	2020-10-02	AMENDMENT 4	No/ 2021-03-07 (152)	Protocol Deviation/ RECEIPT OF AN EUA VACCINE		Yes/ 2020-11-11 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322435	2020-10-15	AMENDMENT 4	No/ 2020-11-19 (36)	Withdrawal of Consent by Participant/ MISSED D29 VISIT, SITE REACHED OUT TO SUBJECT ONE MORE TIME TO RE-SCHEDULE HER APPOINTMENT AND SUBJECT EXPRESSED SHE IS NO LONGER INTERESTED TO CONTINUE HER PARTICIPATION IN THE STUDY.		No/ 2020-11-11 (28)	Withdrawal of Consent by Participant/ MISSED D29, SITE REACHED OUT TO SUBJECT ONE MORE TIME TO RE-SCHEDULE HER APPOINTMENT AND SUBJECT EXPRESSED SHE IS NO LONGER INTERESTED TO CONTINUE HER PARTICIPATION IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3332004	2020-08-04	AMENDMENT	1 No/ 2020-12-15 (134)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3332007	2020-08-04	AMENDMENT	1 No/ 2020-12-17 (136)	Other/ REQUEST TO UNBLIND/EUA		Yes/ 2020-09-08 (36)	
US3332025	2020-08-07	AMENDMENT	1 No/ 2020-12-30 (146)	Protocol Deviation/ RECEIPT OF NON-STUDY COVID VACCINE		Yes/ 2020-09-11 (36)	
US3332032	2020-08-07	AMENDMENT	1 No/ 2020-12-17 (133)	Other/ REQUEST TO UNBLIND/EUA		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3332042	2020-08-11	AMENDMENT 2	No/ 2020-12-31 (143)	Other/ EUA- EMERGENCY USE AUTHORIZATION		Yes/ 2020-09-15 (36)	
US3332050	2020-08-13	AMENDMENT 2	No/ 2020-12-31 (141)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-10 (29)	
US3332058	2020-08-21	AMENDMENT 2	No/ 2021-01-11 (144)	Other/ REQUEST TO UNBLIND, EUA		Yes/ 2020-09-21 (32)	
US3332066	2020-08-27	AMENDMENT 3	No/ 2020-12-31 (127)	Other/ REQUEST TO UNBLIND, EUA		Yes/ 2020-09-21 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3332067	2020-08-28	AMENDMENT 3	No/ 2020-12-31 (126)	Other/ REQUEST TO UNBLIND, EUA		Yes/ 2020-09-22 (26)	
US3332068	2020-08-28	AMENDMENT 3	No/ 2021-03-16 (201)	Lost to Follow-Up		Yes/ 2020-09-22 (26)	
US3332092	2020-09-23	AMENDMENT 3	No/ 2020-10-20 (28)	Withdrawal of Consent by Participant/ DOESN'T HAVE TIME		No/ 2020-10-19 (27)	Withdrawal of Consent by Participant/ DOESN'T HAVE TIME
US3332097	2020-10-12	AMENDMENT 4	No/ 2020-11-12 (32)	Withdrawal of Consent by Participant/ DOESN'T HAVE TIME FOR THE STUDY.		Yes/ 2020-11-06 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342002	2020-08-10	AMENDMENT 1	No/ 2021-01-29 (173)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 16DEC2020 AND 05JAN2021 (PFIZER PRODUCT OFFERED BY EMPLOYER, WORKS AS HCW).		Yes/ 2020-09-08 (30)	
US3342004	2020-08-10	AMENDMENT 1	No/ 2020-12-29 (142)	Other/ UNBLINDED PRIOR TO AMENDMENT 6 AND RECEIVED PLACEBO		Yes/ 2020-09-09 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342012	2020-08-10	AMENDMENT 2	No/ 2020-12-17 (130)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-04 (26)	
US3342019	2020-08-11	AMENDMENT 2	No/ 2021-01-26 (169)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 21DEC2020 (PFIZER PRODUCT OFFERED BY EMPLOYER, WORKS AS HCW).		Yes/ 2020-09-08 (29)	
US3342037	2020-08-12	AMENDMENT 2	No/ 2021-02-09 (182)	Lost to Follow-Up		Yes/ 2020-09-15 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342043	2020-08-12	AMENDMENT 2	No/ 2020-09-17 (37)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT FROM STUDY WHEN PI INFORMED SUBJECT THAT HE WOULDNOT RECEIVE 2ND DOSE		No/ 2020-09-08 (28)	Physician Decision/ PI WITHDREW SUBJECT FROM DOSING DUE TO NUMEROUS HEALTH PROBLEMS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342046	2020-08-13	AMENDMENT 2	No/ 2021-01-04 (145)	Protocol Deviation/ SUBJECT REPORTED GETTING MODERNA VACCINE ON 28DEC2020 AND EXPRESSED THAT HE NO LONGER WANTED TO PARTICIPATE IN STUDY		Yes/ 2020-09-16 (35)	
US3342060	2020-08-14	AMENDMENT 2	No/ 2020-12-16 (125)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-16 (34)	
US3342066	2020-08-14	AMENDMENT 2	No/ 2020-10-05 (53)	Lost to Follow-Up		No/ 2020-09-10 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342067	2020-08-14	AMENDMENT 2	No/ 2020-12-21 (130)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-15 (33)	
US3342083	2020-08-17	AMENDMENT 2	No/ 2021-01-12 (149)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 29DEC2020 (MODERNA mRNA-1273)		Yes/ 2020-09-17 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342087	2020-08-17	AMENDMENT 2	No/ 2021-01-22 (159)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 28DEC2020 (MODERNA PRODUCT OFFERED BY EMPLOYER, WORKS AS HCW).		Yes/ 2020-09-16 (31)	
US3342088	2020-08-17	AMENDMENT 2	No/ 2021-01-22 (159)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF SITE (MODERNA PRODUCT MRNA-1273)		No/ 2020-09-13 (28)	Serious Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342105	2020-08-18	AMENDMENT 2	No/ 2020-12-23 (128)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-16 (30)	
US3342142	2020-08-24	AMENDMENT 2	No/ 2021-01-19 (149)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 12JAN2021 (PFIZER PRODUCT OFFERED BY EMPLOYER, WORKS AS HCW).		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342157	2020-08-31	AMENDMENT 3	No/ 2021-01-15 (138)	Protocol Deviation/ RECEIVED MRNA-1273 OUTSIDE OF STUDY ON 30DEC2020		Yes/ 2020-10-02 (33)	
US3342162	2020-09-01	AMENDMENT 3	No/ 2020-11-23 (84)	Lost to Follow-Up		Yes/ 2020-09-29 (29)	
US3342179	2020-09-03	AMENDMENT 3	No/ 2020-12-21 (110)	Other/ REQUEST TO UNBLIND? EUA COVID-19 VACCINE		Yes/ 2020-10-02 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342183	2020-09-03	AMENDMENT 3	No/ 2021-01-05 (125)	Other/ UNBLINDED AND RECEIVED PLACEBO, GETTING VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-02 (30)	
US3342204	2020-09-08	AMENDMENT 3	No/ 2021-02-10 (156)	Protocol Deviation/ SUBJECT RECEIVED SECOND DOSE OF MRNA-1273 OUTSIDE OF STUDY SITE. PD NOTED.		Yes/ 2020-10-26 (49)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342209	2020-09-08	AMENDMENT 3	No/ 2020-10-16 (39)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO WITHDRAW FROM STUDY		No/ 2020-10-05 (28)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO EXIT STUDY
US3342218	2020-09-09	AMENDMENT 3	No/ 2021-01-22 (136)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 30DEC2020 (PFIZER PRODUCT OFFERED BY EMPLOYER, WORKS AS EMERGENCY RESPONSE).		Yes/ 2020-10-14 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342221	2020-09-09	AMENDMENT 3	No/ 2020-12-28 (111)	Other/ SUBJECT WAS UNBLINDED BEFORE AMENDMENT 6 AND RECEIVED PLACEBO. SUBJECT WAS A RN AND WAS OFFERED THE PFIZER VACCINE.		Yes/ 2020-10-12 (34)	
US3342253	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Adverse Event/ AE #1
US3342256	2020-09-14	AMENDMENT 3	No/ 2020-09-20 (7)	Death	2020-09-20/ Y	No/ 2020-09-20 (7)	Death
US3342259	2020-09-14	AMENDMENT 3	No/ 2020-10-16 (33)	Adverse Event/ AE #2		No/ 2020-10-11 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342275	2020-09-21	AMENDMENT 3	No/ 2020-12-28 (99)	Other/ UNBLINDED PRIOR TO AMENDMENT 6 AND RECEIVED PLACEBO		Yes/ 2020-11-03 (44)	
US3342285	2020-09-26	AMENDMENT 3	No/ 2021-01-22 (119)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 05JAN2021 (MODERNA mRNA-1273; SUBJECT IS IN PHASE 1B OF ROLLOUT)		Yes/ 2020-10-21 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342323	2020-10-02	AMENDMENT 3	ONGOING			No/ 2020-11-11 (28)	Due to SARS-CoV-2
US3342334	2020-10-05	AMENDMENT 3	No/ 2021-03-16 (155)	Withdrawal of Consent by Participant/ SPOKE TO PT BY PHONE WHO REPORTS SHE WOULD LIKE TO WITHDRAW HER CONSENT FOR THE TIME TIME AS SHE HAS CHANGED HER MIND AND WOULD NO LONGER LIKE TO PARTICIPATE IN RESEARCH.		Yes/ 2020-11-12 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342343	2020-10-06	AMENDMENT 4	ONGOING			No/ 2020-11-08 (28)	Adverse Event/ AE#2
US3342358	2020-10-13	AMENDMENT 4	No/ 2020-12-07 (56)	Lost to Follow-Up		Yes/ 2020-11-10 (29)	
US3342359	2020-10-14	AMENDMENT 4	No/ 2020-12-09 (57)	Withdrawal of Consent by Participant/ PATIENT MOVED OUT OF THE AREA AND DOES NOT HAVE TIME TO CONTINUE IN THE STUDY		Yes/ 2020-11-11 (29)	
US3342362	2020-10-15	AMENDMENT 4	No/ 2021-01-19 (97)	Lost to Follow-Up		Yes/ 2020-11-24 (41)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352003	2020-08-04	AMENDMENT 1	No/ 2021-03-16 (225)	Protocol Deviation/ SUBJECT HAS BEEN DISCONTINUED DUE TO RECEIVING ANOTHER COVID-19 VACCINE OUTSIDE OF THE TRIAL.		Yes/ 2020-09-01 (29)	
US3352006	2020-08-04	AMENDMENT 1	No/ 2020-12-17 (136)	Other/ REQUEST RO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3352008	2020-08-04	AMENDMENT 1	No/ 2020-12-15 (134)	Other/ REQUEST TO UNBLIND/EUACOV -19 VACCINE		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352013	2020-08-04	AMENDMENT	1 No/ 2020-09-02 (30)	Lost to Follow-Up		No/ 2020-08-31 (28)	Lost to Follow-Up
US3352021	2020-08-06	AMENDMENT	1 No/ 2020-12-30 (147)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-01 (27)	
US3352023	2020-08-06	AMENDMENT	1 No/ 2020-12-22 (139)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-01 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352035	2020-08-06	AMENDMENT 1	No/ 2020-10-28 (84)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO PERSONAL REASONS, DID NOT DISCLOSE DETAILS.		Yes/ 2020-09-01 (27)	
US3352038	2020-08-06	AMENDMENT 1	No/ 2020-12-30 (147)	Lost to Follow-Up		Yes/ 2020-09-01 (27)	
US3352072	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3352106	2020-08-18	AMENDMENT 2	No/ 2020-12-23 (128)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352258	2020-08-25	AMENDMENT	3 No/ 2020-09-15 (22)	Lost to Follow-Up		No/ 2020-09-14 (21)	Lost to Follow-Up
US3352276	2020-08-25	AMENDMENT	3 No/ 2021-01-28 (157)	Protocol Deviation/ RECEIVED COVID-19 EUA VACCINE		Yes/ 2020-09-22 (29)	
US3352280	2020-08-25	AMENDMENT	3 No/ 2021-03-25 (213)	Lost to Follow-Up		Yes/ 2020-09-19 (26)	
US3352303	2020-09-01	AMENDMENT	3 No/ 2020-09-30 (30)	Withdrawal of Consent by Participant/ SUBJECT WAS NO LONGER INTERESTED IN THE STUDY.		No/ 2020-09-28 (28)	Withdrawal of Consent by Participant/ SUBJECT WAS NO LONGER INTERESTED IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352307	2020-09-01	AMENDMENT 3	No/ 2021-03-25 (206)	Lost to Follow-Up		Yes/ 2020-09-29 (29)	
US3352310	2020-09-10	AMENDMENT 3	No/ 2020-12-18 (100)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-08 (29)	
US3352347	2020-09-10	AMENDMENT 3	No/ 2021-01-13 (126)	Withdrawal of Consent by Participant/ WITHDREW OF CONSENT		Yes/ 2020-10-06 (27)	
US3352354	2020-09-10	AMENDMENT 3	No/ 2020-12-09 (91)	Other/ SPONSOR REMOVAL DUE TO ENROLLMENT AT OTHER SITE		Yes/ 2020-10-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352357	2020-09-10	AMENDMENT	3 No/ 2021-03-25 (197)	Lost to Follow-Up		Yes/ 2020-10-08 (29)	
US3352368	2020-09-10	AMENDMENT	3 No/ 2020-10-03 (24)	Lost to Follow-Up		No/ 2020-10-02 (23)	Lost to Follow-Up
US3352379	2020-09-19	AMENDMENT	3 No/ 2021-01-28 (132)	Protocol Deviation/ RECEIVED COVID-19 EUA VACCINE		Yes/ 2020-10-17 (29)	
US3352388	2020-09-19	AMENDMENT	3 No/ 2020-10-10 (22)	Lost to Follow-Up		No/ 2020-10-09 (21)	Lost to Follow-Up
US3352434	2020-09-29	AMENDMENT	3 No/ 2020-12-17 (80)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352462	2020-09-29	AMENDMENT 3	No/ 2021-01-21 (115)	Withdrawal of Consent by Participant/ SUBJECT STATED HE IS UNABLE TO CONTINUE DUE TO BUSY WORK SCHEDULE.		Yes/ 2020-11-03 (36)	
US3352483	2020-09-29	AMENDMENT 3	No/ 2020-12-22 (85)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-27 (29)	
US3352541	2020-10-15	AMENDMENT 4	ONGOING			No/ 2020-11-11 (28)	Other/ SUBJECT NEVER CAME FOR DAY 29 VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352547	2020-10-15	AMENDMENT 4	No/ 2021-03-17 (154)	Protocol Deviation/ SUBJECT WAS PARTICIPATING IN ANOTHER CLINICAL TRIAL.		Yes/ 2020-11-12 (29)	
US3352557	2020-10-15	AMENDMENT 4	No/ 2021-03-10 (147)	Withdrawal of Consent by Participant/ SUBJECT STATED HE DOES NOT HAVE ANY TRANSPORTATION AND WILL NOT BE ABLE TO COME IN TO SITE FOR FURTHER VISITS.		No/ 2020-11-11 (28)	Other/ SUBJECT NEVER CAME FOR DAY 29 VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352567	2020-10-15	AMENDMENT 4	ONGOING			No/ 2020-11-11 (28)	Other/ SUBJECT NEVER CAME IN FOR DAY 29 VISIT. SEVERAL ATTEMPTS MADE TO RESCHDULED VISIT.
US3352581	2020-10-15	AMENDMENT 4	No/ 2020-12-17 (64)	Lost to Follow-Up		No/ 2020-11-11 (28)	Lost to Follow-Up
US3352600	2020-10-22	AMENDMENT 4	ONGOING			No/ 2020-11-18 (28)	Other/ SUBJECT NEVER CAME IN FOR DAY 29.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362012	2020-08-01	AMENDMENT 1	No/ 2020-12-16 (138)	Withdrawal of Consent by Participant/ SUBJECT RECIEVED PFIZER VACCINE THROUGH EUA AND WAS GIVEN VACCINE BY EMPLOYER		Yes/ 2020-09-02 (33)	
US3362017	2020-08-03	AMENDMENT 1	No/ 2021-01-04 (155)	Withdrawal of Consent by Participant/ APPROVED FOR VACCINE THROUGH EUA		Yes/ 2020-09-03 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362038	2020-08-04	AMENDMENT 1	No/ 2020-12-16 (122)	Withdrawal of Consent by Participant/ PARTICIPANT MET CRITERIA TO RECEIVE PFIZER INJECTION UNDER EUA THROUGH EMPLOYER		Yes/ 2020-09-21 (36)	
US3362045	2020-08-05	AMENDMENT 1	No/ 2020-10-29 (86)	Lost to Follow-Up		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362053	2020-08-05	AMENDMENT 1	No/ 2020-12-18 (136)	Withdrawal of Consent by Participant/ SUBJECT RECIEVED PFIZER VACCINE THROUGH EUA AND WAS GIVEN VACCINE BY EMPLOYER		Yes/ 2020-09-04 (31)	
US3362083	2020-08-08	AMENDMENT 1	ONGOING			No/ 2020-09-04 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362111	2020-08-11	AMENDMENT 2	No/ 2021-01-25 (168)	Withdrawal of Consent by Participant/ PATIENT NO LONGER WISHES TO PARTICIPATE IN THE STUDY		Yes/ 2020-09-08 (29)	
US3362143	2020-08-14	AMENDMENT 2	No/ 2021-03-02 (201)	Withdrawal of Consent by Participant/ NO LONGER WISHES TO PARTICIPATE		Yes/ 2020-09-14 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362146	2020-08-15	AMENDMENT 2	No/ 2021-03-02 (200)	Withdrawal of Consent by Participant/ PATIENT NO LONGER WISHED TO CONTINUE STUDY, DID NOT COMPLETE OPEN LABEL		Yes/ 2020-09-15 (32)	
US3362156	2020-08-15	AMENDMENT 2	No/ 2020-10-15 (62)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT, DID NOT DISCLOSE REASONING		Yes/ 2020-09-16 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362175	2020-08-17	AMENDMENT 2	No/ 2021-01-25 (162)	Withdrawal of Consent by Participant/ PATIENT REQUESTED UNBLINDING DUE TO EUA ACCESS AND MOVING, UNABLE TO MAKE SCHEDULED VISITS		Yes/ 2020-09-18 (33)	
US3362186	2020-08-18	AMENDMENT 2	No/ 2020-09-16 (30)	Withdrawal of Consent by Participant/ UNABLE TO MAKE STUDY VISITS		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ UNABLE TO MAKE STUDY VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362189	2020-08-18	AMENDMENT 2	No/ 2020-10-30 (74)	Withdrawal of Consent by Participant/ UNABLE TO COMPLY WITH STUDY VISITS		Yes/ 2020-09-22 (36)	
US3362206	2020-08-20	AMENDMENT 2	No/ 2020-09-15 (27)	Withdrawal of Consent by Participant/ WITHDRAWAL OF CONSENT-NO EXPLANATION PROVIDED		No/ 2020-09-14 (26)	Withdrawal of Consent by Participant/ WITHDREW CONSENT-NO EXPLANATION PROVIDED

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362290	2020-09-26	AMENDMENT 3	ONGOING			No/ 2020-10-23 (28)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT FOR SECOND INJECTION
US3362305	2020-10-08	AMENDMENT 4	No/ 2020-12-17 (71)	Withdrawal of Consent by Participant/ PATIENT WITHDREW, ABLE TO RECEIVE PFIZER VACCINE WITH EUA		Yes/ 2020-11-11 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372028	2020-08-04	AMENDMENT 1	No/ 2020-08-27 (24)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE PATIENT CAN NO LONGER PARTICIPATE IN STUDY		No/ 2020-08-26 (23)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE PATIENT HAD TO WITHDRAW FROM STUDY
US3372107	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Other/ SUBJECT DID NOT WANT TO RECEIVE SECOND SHOT
US3372110	2020-08-13	AMENDMENT 1	ONGOING			No/ 2020-09-09 (28)	Adverse Event/ #3 POSITIVE FOR COVID 19

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372139	2020-08-17	AMENDMENT 2	No/ 2020-12-21 (127)	Withdrawal of Consent by Participant/ BLIND BROKEN BY PI DUE TO SUBJECT HAVING ACCESS TO RECEIVE COVID VACCINE THROUGH THEIR PLACE OF EMPLOYMENT		Yes/ 2020-09-16 (31)	
US3372179	2020-08-19	AMENDMENT 2	No/ 2021-01-18 (153)	Other/ SUBJECT RECEIVED ANOTHER VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-18 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372208	2020-08-21	AMENDMENT 2	No/ 2021-01-04 (137)	Protocol Deviation/ SUBJECT RECEIVED APPROVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-21 (32)	
US3372228	2020-08-24	AMENDMENT 2	No/ 2021-01-25 (155)	Death	2021-01-25/ N	Yes/ 2020-09-28 (36)	
US3372229	2020-08-24	AMENDMENT 2	No/ 2021-03-01 (190)	Protocol Deviation/ SUBJECT IS PREGNANT AND DID NOT WANT TO CONTINUE WITH THE STUDY. CONSENT WAS WITHDRAWN.		No/ 2020-09-20 (28)	Pregnancy

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372255	2020-08-26	AMENDMENT 3	No/ 2020-10-12 (48)	Withdrawal of Consent by Participant/ SUBJECT NOT COMFORTABLE TO CONTINUE STUDY SO WITHDREW CONSENT		Yes/ 2020-09-24 (30)	
US3372283	2020-08-28	AMENDMENT 3	No/ 2020-10-02 (36)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO COMPLY WITH STUDY VISITS		No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO NOT BEING ABLE TO COMPLY WITH STUDY VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372353	2020-09-07	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Protocol Deviation/ SUBJECT WAS UNABLE TO COMPLETE VISIT 2 DUE TO WORK OBLIGATIONS AND TRAVEL.
US3372384	2020-09-10	AMENDMENT 3	No/ 2021-01-11 (120)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUT OF STUDY		Yes/ 2020-10-12 (29)	
US3372407	2020-09-13	AMENDMENT 3	No/ 2021-01-08 (95)	Protocol Deviation/ SUBJECT RECEIVED MODERNA COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-11-02 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372461	2020-09-30	AMENDMENT 3	No/ 2021-02-18 (142)	Withdrawal of Consent by Participant/ HE LIVED FAR FROM THE OFFICE AND DID NOT WANT TO DRIVE F THAN (b) (6) (b) (6) TO CO ETE VISITS		Yes/ 2020-10-28 (29)	
US3372469	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-12 (28)	Physician Decision/ SUBJECT HAS A HISTORY OF REACTIONS AFTER RECEIVING VACCINES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372477	2020-10-15	AMENDMENT 4	No/ 2020-11-11 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO SCHEDULE CONCERNS		No/ 2020-11-10 (27)	Withdrawal of Consent by Participant/ UNABLE TO COMPLY WITH STUDY VISITS
US3382055	2020-08-18	AMENDMENT 2	No/ 2020-12-21 (126)	Other/ SUBJECT REPORTS WILL BE RECEIVING MODERNA VACCINE THROUGH THEIR EMPLOYER AND WOULD LIKE TO MOVE FORWARD WITH UNBLINDING. EPIP SUBMITTED.		Yes/ 2020-09-16 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382085	2020-08-20	AMENDMENT 2	No/ 2020-09-25 (37)	Adverse Event/ AE #1		No/ 2020-09-16 (28)	Adverse Event/ AE #1
US3382094	2020-08-24	AMENDMENT 2	No/ 2021-03-23 (212)	Withdrawal of Consent by Participant/ I SPOKE WITH SUBJECT TODAY, 23 MAR 2021 REGARDING HER DECISION TO DISCONTINUE HER CURRENT BIRTH CONTROL METHOD [5 MAR 2021] SEE PROG NOTE IN CRIO DUE TO SPACE RESTRICTIONS		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382110	2020-08-26	AMENDMENT 3	No/ 2020-12-21 (118)	Other/ PT HAS ACCESS TO COVID VACCINE OUTSIDE OF PROTOCOL. MANDATORY BY EMPLOYER		Yes/ 2020-09-24 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382131	2020-08-27	AMENDMENT 3	No/ 2021-01-08 (135)	Protocol Deviation/ SUBJECT IS A HEALTHCARE PROVIDER. HE RECEIVED PFIZER VACCINATION FROM THE HOSPITAL HE WORKED AT BECAUSE MODERNA HAD NOT DECIDED TO UNBLIND AT THAT TIME AND COVID-19 VACCINATION WAS MANDATORY FOR HIM		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382133	2020-08-27	AMENDMENT 3	No/ 2021-01-25 (152)	Protocol Deviation/ PT RECEIVED PFIZER COVID VACCINE		Yes/ 2020-09-23 (28)	
US3382152	2020-08-31	AMENDMENT 3	No/ 2020-11-22 (84)	Lost to Follow-Up		Yes/ 2020-10-02 (33)	
US3382180	2020-09-02	AMENDMENT 3	No/ 2020-12-21 (111)	Other/ PT HAS ACCESS TO COVID VACCINE OUTSIDE OF PROTOCOL. REQUIRED PER EMPLOYER		Yes/ 2020-10-05 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382195	2020-09-03	AMENDMENT 3	No/ 2021-01-25 (145)	Protocol Deviation/ RECEIVED MANDATORY MODERNA COVID VACCINE AT WORK. MODERNA HAD NOT DECIDED ABOUT UNBLINDING AT THAT TIME.		Yes/ 2020-10-08 (36)	
US3392033	2020-08-17	AMENDMENT 2	No/ 2021-03-22 (218)	Other/ RELOCATION: SUBJECT RELOCATED AND COULD NO LONGER MAKE IT TO APPOINTMENTS.		Yes/ 2020-09-11 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392045	2020-08-18	AMENDMENT 2	No/ 2021-03-12 (207)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT HE DID NOT WANT TO BE UNBLINDED AND WITHDREW CONSENT FROM STUDY.		Yes/ 2020-09-14 (28)	
US3392068	2020-08-21	AMENDMENT 2	No/ 2020-12-22 (124)	Protocol Deviation/ EUA VACCINE FROM OUTSIDE SOURCE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392080	2020-08-25	AMENDMENT 3	No/ 2021-03-17 (205)	Protocol Deviation/ SUBJECT IS NON-COMPLIANT WITH STUDY PROCEDURES		Yes/ 2020-09-28 (35)	
US3392104	2020-08-28	AMENDMENT 3	No/ 2020-11-10 (68)	Lost to Follow-Up		Yes/ 2020-10-02 (29)	
US3392105	2020-08-28	AMENDMENT 3	No/ 2020-11-10 (68)	Lost to Follow-Up		Yes/ 2020-10-02 (29)	
US3392111	2020-08-28	AMENDMENT 3	No/ 2021-01-14 (140)	Protocol Deviation/ SUBJECT WITHDREW CONSENT AND RECEIVED EUA VACCINE		Yes/ 2020-09-22 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392140	2020-09-02	AMENDMENT 3	No/ 2021-01-20 (139)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF SITE.		Yes/ 2020-10-01 (28)	
US3392159	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ SUBJECT WAS LOST TO FOLLOW-UP VISIT 02 MONTH 1 WINDOW. PATIENT RESURFACED - PER CTM AND MEDICAL MONITOR INSTRUCTIONS SUBJECT WILL NOT COMPLETE VISIT 02 AND WILL CONTINUE PARTICIPATION IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392195	2020-09-09	AMENDMENT 3	No/ 2020-12-21 (104)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY.		Yes/ 2020-10-12 (34)	
US3392254	2020-09-12	AMENDMENT 3	No/ 2021-01-28 (139)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA VACCINE		Yes/ 2020-10-08 (27)	
US3392262	2020-09-12	AMENDMENT 3	No/ 2020-12-04 (84)	Other/ PATIENT MOVED TO HAWAII AND WITHDREW CONSENT VIA PHONE.		Yes/ 2020-10-07 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392280	2020-09-14	AMENDMENT 3	No/ 2021-02-04 (144)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA VACCINE		Yes/ 2020-10-15 (32)	
US3392330	2020-09-18	AMENDMENT 3	No/ 2020-12-22 (96)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE		Yes/ 2020-10-16 (29)	
US3392341	2020-09-21	AMENDMENT 3	No/ 2021-03-04 (165)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA VACCINE		Yes/ 2020-10-19 (29)	
US3392352	2020-10-01	AMENDMENT 3	No/ 2020-10-23 (23)	Lost to Follow-Up		No/ 2020-10-22 (22)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402044	2020-07-28	AMENDMENT 1	No/ 2020-12-22 (148)	Other/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY.		Yes/ 2020-08-27 (31)	
US3402104	2020-07-30	AMENDMENT 1	No/ 2021-01-27 (182)	Protocol Deviation/ SUBJECT RECEIVED VACCINATION FOR COVID OUTSIDE OF STUDY		Yes/ 2020-09-01 (34)	
US3402105	2020-07-30	AMENDMENT 1	No/ 2021-01-27 (182)	Lost to Follow-Up		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402112	2020-07-30	AMENDMENT 1	No/ 2021-02-02 (188)	Protocol Deviation/ SUBJECT MOVED OUT OF STATE DECIDED THEY NO LONGER WANTED TO BE IN THE STUDY. WITHDREW CONSENT. IT IS UNKNOWN WHAT VACCINE THEY GOT, SUBJECT RECEIVED MODERNA VACCINE THROUGH STUDY.		Yes/ 2020-08-27 (29)	
US3402114	2020-07-30	AMENDMENT 1	No/ 2021-02-20 (206)	Lost to Follow-Up		Yes/ 2020-09-01 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402137	2020-08-01	AMENDMENT 1	No/ 2020-12-29 (151)	Protocol Deviation/ SUBJECT REMOVED FROM TRIAL DUE TO RECEIVING A COVID 19 VACCINE OUTSIDE OF THE TRIAL		Yes/ 2020-08-31 (31)	
US3402190	2020-08-02	AMENDMENT 1	No/ 2020-11-27 (118)	Lost to Follow-Up		No/ 2020-08-29 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402192	2020-08-02	AMENDMENT 1	No/ 2020-09-04 (34)	Withdrawal of Consent by Participant/ SUBJECT WAS IN OFFICE FOR VISIT 2 BUT REFUSED TO WAIT FOR VACCINE PREPARATION. AT THAT TIME SUBJECT WITHDREW CONSENT AND LEFT FACILITY.		No/ 2020-08-29 (28)	Withdrawal of Consent by Participant/ SUBJECT WAS NOT WILLING TO WAIT TO RECEIVE VACCINE OR THE 30 MINUTES REQUIRED AFTER PER PROTOCOL.
US3402199	2020-08-03	AMENDMENT 1	No/ 2021-02-05 (187)	Lost to Follow-Up		Yes/ 2020-08-31 (29)	
US3402214	2020-08-04	AMENDMENT 1	No/ 2020-10-11 (69)	Lost to Follow-Up		Yes/ 2020-09-08 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402246	2020-08-05	AMENDMENT 1	No/ 2020-09-02 (29)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHED TO PARTICIPATE		No/ 2020-09-01 (28)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHED TO PARTICIPATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402261	2020-08-06	AMENDMENT 1	No/ 2021-01-08 (156)	Protocol Deviation/ SUBJECT PHONED SITE TO MAKE AWARE HE WENT OUTSIDE OF THE STUDY TO RECEIVE THE COVID VACCINE DUE TO NEGATIVE ANTIBODY TESTING. SUBJECT HAS BEEN REMOVED.		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402294	2020-08-08	AMENDMENT 2	No/ 2020-12-31 (146)	Protocol Deviation/ SUBJECT RECEIVED COVID VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-09 (33)	
US3402295	2020-08-08	AMENDMENT 2	No/ 2020-10-16 (70)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTED TO TRAVEL TO SITE		Yes/ 2020-09-11 (35)	
US3402329	2020-08-11	AMENDMENT 2	No/ 2020-12-11 (123)	Other/ DROPPED PER SUBJECT MOVED OUT OF STATE		Yes/ 2020-09-14 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402332	2020-08-12	AMENDMENT 2	No/ 2020-12-03 (114)	Withdrawal of Consent by Participant/ AFTER COMING TO SITE FOR ILLNESS VISIT 03DEC2020, SUBJECT DID NOT RETURN ANY OF THE CONVALESCENT CALL. WHEN SUBJECT WAS FINALLY REACHED AND INFORMED THAT THEY'RE COVID POSITIVE, THE SUBJECT WITHDREW.		Yes/ 2020-09-15 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402405	2020-08-21	AMENDMENT 2	No/ 2021-02-09 (173)	Lost to Follow-Up		Yes/ 2020-09-15 (26)	
US3402421	2020-08-22	AMENDMENT 2	No/ 2021-01-20 (152)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WISH TO WAIT FOR UNBLINDING VISITS.		Yes/ 2020-09-25 (35)	
US3402425	2020-08-22	AMENDMENT 2	No/ 2021-01-08 (140)	Protocol Deviation/ SUBJECT RECEIVED COVID VACCINATION OUTSIDE OF STUDY		Yes/ 2020-09-25 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402430	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Adverse Event/ AE #1
US3402441	2020-09-01	AMENDMENT 3	No/ 2020-11-07 (68)	Lost to Follow-Up		Yes/ 2020-09-28 (28)	
US3402464	2020-10-22	AMENDMENT 4	No/ 2021-01-28 (99)	Physician Decision/ SUBJECT NOT ALLOWED ON UHS PROPERTY DUE TO (b) (6)		Yes/ 2020-11-23 (33)	
US3402470	2020-10-22	AMENDMENT 4	No/ 2020-11-30 (40)	Lost to Follow-Up		No/ 2020-11-18 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412105	2020-08-03	AMENDMENT 1	No/ 2020-12-28 (148)	Protocol Deviation/ UNBLINDED UNDER AMENDMENT 5 AND FOUND TO BE ON PLACEBO		Yes/ 2020-08-31 (29)	
US3412183	2020-08-10	AMENDMENT 1	No/ 2020-12-31 (144)	Other/ SUBJECT RECEIVED VACCINE THROUGH THEIR EMPLOYER		Yes/ 2020-09-08 (30)	
US3412192	2020-08-10	AMENDMENT 1	No/ 2021-01-06 (150)	Protocol Deviation/ SUBJECT RECEIVED VACCINE THROUGH THEIR EMPLOYER		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412234	2020-08-13	AMENDMENT 2	No/ 2021-03-04 (204)	Other/ SUBJECT STATED THAT HE WAS MOVING AWAY FROM CINCINNATI AND IS WITHDRAWING CONSENT FROM THE STUDY. SUBJECT STATED THAT HE DID NOT WANT TO TRANSFER SITES EITHER.		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412245	2020-08-14	AMENDMENT 2	No/ 2021-01-22 (162)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTED TO PARTAKE IN STUDY AND DID NOT WANT TO BE UNBLINDED DUE TO CONSISTENT BLOOD DRAWS. SUBJECT STATED HE WOULD LIKE TO WITHDRAW CONSENT		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412247	2020-08-14	AMENDMENT 2	No/ 2020-12-28 (137)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-11 (29)	
US3412278	2020-08-19	AMENDMENT 2	No/ 2021-02-02 (168)	Protocol Deviation/ SUBJECT RECEIVED A VACCINE THROUGH THEIR EMPLOYER		No/ 2020-09-15 (28)	Other/ DURING MONITOR VISIT OUR CRA IDENTIFIED SUBJECT AS (b) (6)

(b) (6)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412284	2020-08-20	AMENDMENT 2	No/ 2020-12-30 (133)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE OUTSIDE OF THE STUDY AND PER PROTOCOL IS WITHDRAWN FROM THE STUDY		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412314	2020-08-25	AMENDMENT 3	No/ 2021-02-04 (164)	Protocol Deviation/ SUBJECT RECEIVED THE VACCINE OUTSIDE OF THE STUDY SITE		No/ 2020-09-21 (28)	Protocol Deviation/ SUBJECT WAS REQUESTED BY SPONSOR TO BE WITHDRAWN DUE TO (b) (6)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412328	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Other/ SUBJECT HAD CHEST PAIN BETWEEN VISIT 1 AND VISIT 2. SUBJECT WAS MEDICALLY CLEARED OF SYMPTOMS BY VISIT 2, BUT HAS DECIDED THAT THEY DID NOT WANT THE SECOND DOSAGE. SUBJECT WILL CONTINUE IN STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412332	2020-08-27	AMENDMENT 2	ONGOING			No/ 2020-09-23 (28)	Protocol Deviation/ SUBJECT WAS OUT OF WINDOW FOR SUBJECTS SECOND INJECTION AND WHEN SITE SUBMITTED E-PIP THEY STATED TO CONTINUE ON WITH VISIT 3 AND SKIP INJECTION #2
US3412365	2020-09-03	AMENDMENT 3	No/ 2020-12-28 (117)	Protocol Deviation/ SUBJECT ELIGIBLE FOR EUA VACCINE THROUGH WORK		Yes/ 2020-10-02 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412369	2020-09-03	AMENDMENT 3	No/ 2021-01-05 (125)	Protocol Deviation/ SUBJECT RECEIVED VACCINE THROUGH THEIR WORK		Yes/ 2020-10-01 (29)	
US3412372	2020-09-15	AMENDMENT 3	No/ 2020-10-27 (43)	Other/ SUBJECT MOVED OUT OF STATE AND NO LONGER WANTED TO PARTAKE IN THE STUDY.		No/ 2020-10-12 (28)	Withdrawal of Consent by Participant/ SUBJECT MOVED OUT OF STATE AND WOULD BE UNABLE TO ATTEND ANY VISITS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422003	2020-08-12	AMENDMENT 2	No/ 2020-12-21 (132)	Other/ UNBLINDING FOR EUA FOR PFIZER VACCINE FOR HEALTHCARE WORKERS		Yes/ 2020-09-10 (30)	
US3422005	2020-08-12	AMENDMENT 2	No/ 2020-12-18 (129)	Other/ UNBLINDED FOR EUA VACCINE FOR HEALTH CARE WORKER		Yes/ 2020-09-11 (31)	
US3422011	2020-08-13	AMENDMENT 2	No/ 2020-12-22 (132)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKER		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422016	2020-08-14	AMENDMENT 2	No/ 2020-12-16 (125)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-11 (29)	
US3422017	2020-08-14	AMENDMENT 2	No/ 2020-12-29 (138)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-09-14 (32)	
US3422028	2020-08-17	AMENDMENT 2	No/ 2020-12-17 (123)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422039	2020-08-18	AMENDMENT 2	No/ 2020-12-22 (127)	Other/ EUA FOR PFIZER VACCINATION FOR HEALTH CARE WORKERS		Yes/ 2020-09-23 (37)	
US3422040	2020-08-18	AMENDMENT 2	No/ 2020-12-22 (127)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS.		Yes/ 2020-09-16 (30)	
US3422043	2020-08-18	AMENDMENT 2	No/ 2020-12-18 (123)	Other/ UNBLINDED FOR EUA VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-09-21 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422049	2020-08-19	AMENDMENT 2	No/ 2020-12-22 (126)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-09-17 (30)	
US3422071	2020-08-20	AMENDMENT 2	No/ 2020-12-22 (125)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKER.		Yes/ 2020-09-17 (29)	
US3422108	2020-08-25	AMENDMENT 3	No/ 2020-12-30 (128)	Other/ EUA FOR PFIZER FOR HEALTH CARE WORKERS		Yes/ 2020-09-21 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422118	2020-08-26	AMENDMENT 3	No/ 2020-12-22 (119)	Other/ EUA FOR PFIZER VACCINATION FOR HEALTH CARE WORKERS		Yes/ 2020-09-23 (29)	
US3422133	2020-08-27	AMENDMENT 3	No/ 2020-12-22 (118)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-09-24 (29)	
US3422160	2020-08-31	AMENDMENT 3	No/ 2020-12-18 (110)	Other/ UNBLINDED DUE TO EUA FOR HEALTH CARE WORKER FOR PFIZER M RNA VACCINE		Yes/ 2020-10-02 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422162	2020-09-01	AMENDMENT 3	No/ 2021-01-01 (123)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKER		Yes/ 2020-09-29 (29)	
US3422175	2020-09-01	AMENDMENT 3	No/ 2020-12-16 (107)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-30 (30)	
US3422180	2020-09-02	AMENDMENT 3	No/ 2020-12-30 (120)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-10-01 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422201	2020-09-03	AMENDMENT 3	No/ 2021-01-08 (128)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW TO RECEIVE PHIZER VACCINE.		Yes/ 2020-10-01 (29)	
US3422206	2020-09-03	AMENDMENT 3	No/ 2020-12-29 (118)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKERS		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422272	2020-09-14	AMENDMENT 3	No/ 2020-12-18 (96)	Other/ UNBLINDED DUE TO EUA FOR HEALTH CARE WORKER FOR PFIZER M RNA VACCINE		Yes/ 2020-10-12 (29)	
US3422275	2020-09-14	AMENDMENT 3	No/ 2020-12-23 (101)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKER		Yes/ 2020-10-12 (29)	
US3422277	2020-09-14	AMENDMENT 3	No/ 2020-12-16 (94)	Other/ REQUEST TO UNBLIND/EUA COVID 19		Yes/ 2020-10-19 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422301	2020-09-22	AMENDMENT 3	No/ 2020-12-24 (94)	Other/ EUA FOR PFIZER VACCINE FOR HEALTH CARE WORKER		Yes/ 2020-10-21 (30)	
US3432020	2020-08-05	AMENDMENT 2	No/ 2021-01-02 (149)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-02 (27)	
US3432023	2020-08-05	AMENDMENT 1	ONGOING			No/ 2020-09-01 (28)	Serious Adverse Event/ SAE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432038	2020-08-06	AMENDMENT 1	No/ 2021-01-02 (150)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-03 (29)	
US3432058	2020-08-07	AMENDMENT 1	No/ 2020-12-15 (131)	Protocol Deviation/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-03 (28)	
US3432082	2020-08-10	AMENDMENT 1	No/ 2020-12-29 (142)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432137	2020-08-13	AMENDMENT 2	No/ 2020-12-29 (139)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-10 (29)	
US3432149	2020-08-14	AMENDMENT 2	No/ 2021-01-28 (168)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF STUDY PRIOR TO EUA AMENDMENT 6		Yes/ 2020-09-11 (29)	
US3432169	2020-08-17	AMENDMENT 2	No/ 2020-12-15 (121)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432171	2020-08-17	AMENDMENT 2	No/ 2020-12-29 (135)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-15 (30)	
US3432211	2020-08-20	AMENDMENT 2	No/ 2021-01-07 (141)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-09-16 (28)	
US3432252	2020-08-24	AMENDMENT 2	No/ 2020-12-21 (120)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432256	2020-08-24	AMENDMENT 2	No/ 2020-12-18 (117)	Protocol Deviation/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-22 (30)	
US3432285	2020-08-25	AMENDMENT 3	No/ 2020-12-22 (120)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-23 (30)	
US3432289	2020-08-25	AMENDMENT 3	No/ 2020-12-21 (119)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-22 (29)	
US3432295	2020-08-26	AMENDMENT 3	No/ 2020-10-02 (38)	Death	2020-10-02/ UNK	No/ 2020-10-02 (38)	Death

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432309	2020-08-26	AMENDMENT 3	No/ 2020-12-17 (114)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-09-26 (32)	
US3432453	2020-09-05	AMENDMENT 3	No/ 2020-12-22 (109)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-10-05 (31)	
US3432473	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ UNABLE TO BRING PARTICIPANT IN DURING WINDOW

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432493	2020-09-12	AMENDMENT 3	No/ 2020-10-17 (36)	Withdrawal of Consent by Participant/ PARTICIPANT NOTED PERSONAL REASONS, STRESSORS, AND BUSY SCHEDULE AS REASONS FOR LEAVING THE STUDY.		No/ 2020-10-09 (28)	Withdrawal of Consent by Participant/ PARTICIPANT NOTED PERSONAL REASONS, STRESSORS, AND BUSY SCHEDULE AS REASONS FOR LEAVING THE STUDY.
US3432505	2020-09-16	AMENDMENT 3	No/ 2020-12-21 (97)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-10-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432521	2020-09-17	AMENDMENT 3	No/ 2021-01-05 (111)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-10-16 (30)	
US3432530	2020-09-19	AMENDMENT 3	No/ 2020-12-18 (91)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-10-24 (36)	
US3432537	2020-09-21	AMENDMENT 3	No/ 2020-12-21 (92)	Other/ UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-10-23 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432562	2020-09-25	AMENDMENT 3	No/ 2021-01-07 (105)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		Yes/ 2020-10-24 (30)	
US3432585	2020-10-02	AMENDMENT 3	No/ 2020-12-19 (79)	Other/ PARTICIPANT UNBLINDED PRIOR TO EUA AMENDMENT 6 ACTIVATION.		Yes/ 2020-10-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432592	2020-10-07	AMENDMENT 4	No/ 2020-12-29 (84)	Protocol Deviation/ PER EPIP, SUBJECT TERMINATED DUE TO RECEIPT OF ANOTHER COVID VACCINE PRIOR TO EUA PROTOCOL AMENDMENT 6 ACTIVATION.		Yes/ 2020-11-02 (27)	
US3432613	2020-10-16	AMENDMENT 4	No/ 2020-12-24 (70)	Other/ RECEIVED OUTSIDE EUA VACCINE PRIOR TO EUA AMENDMENT 6		Yes/ 2020-11-19 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432637	2020-10-22	AMENDMENT 4	No/ 2021-03-23 (153)	Protocol Deviation/ RECEIVED EUA VACCINATION OUTSIDE OF STUDY		Yes/ 2020-11-19 (29)	
US3432645	2020-10-22	AMENDMENT 4	No/ 2021-03-08 (138)	Protocol Deviation/ RECEIVED OUTSIDE EUA COVID VACCINE. UNBLINDED YESTERDAY. TERMINATED YESTERDAY.		Yes/ 2020-11-24 (34)	
US3442011	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442017	2020-08-14	AMENDMENT 2	No/ 2021-01-04 (144)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID VACCINE PRIOR TO UNBLINDING		Yes/ 2020-09-10 (28)	
US3442037	2020-08-20	AMENDMENT 2	No/ 2020-12-31 (134)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-09-15 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442049	2020-08-20	AMENDMENT 2	No/ 2021-01-04 (138)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE 28DEC2020 THOUGH EMPLOYER PRIOR TO UNBLINDING		Yes/ 2020-09-17 (29)	
US3442050	2020-08-20	AMENDMENT 2	No/ 2020-12-17 (120)	Other/ REQUEST TO UNBLIND/EUA COVID VACCINE		Yes/ 2020-09-17 (29)	
US3442056	2020-08-21	AMENDMENT 2	No/ 2020-12-30 (132)	Other/ REQUEST TO UNBLIND/ EUA COVID VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442063	2020-08-21	AMENDMENT 2	No/ 2021-01-13 (146)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID VACCINE PRIOR TO UNBLINDING		Yes/ 2020-09-18 (29)	
US3442065	2020-08-21	AMENDMENT 2	No/ 2020-12-28 (130)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442069	2020-08-21	AMENDMENT 2	No/ 2021-03-11 (203)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT, STATES TIME OBLIGATION IS TOO MUCH DUE TO CURRENT EMPLOYMENT		Yes/ 2020-09-22 (33)	
US3442071	2020-08-21	AMENDMENT 2	No/ 2020-12-31 (133)	Other/ REQUEST TO UNBLIND/EUA COVID VACCINE		Yes/ 2020-09-18 (29)	
US3442074	2020-08-25	AMENDMENT 3	No/ 2021-04-06 (225)	Death	2021-04-06/ UNK	Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442083	2020-08-25	AMENDMENT 3	No/ 2020-12-31 (129)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE THEN REQUESTED TO BECOME UNBLINDED.		Yes/ 2020-09-22 (29)	
US3442092	2020-08-26	AMENDMENT 3	No/ 2021-01-28 (156)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT. NOT WILLING TO RETURN TO SITE FOR FINAL SAFETY VISIT / SUBJECT UNBLINDED FOR SAFETY		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442102	2020-08-27	AMENDMENT 3	No/ 2020-11-21 (87)	Lost to Follow-Up		No/ 2020-09-23 (28)	Lost to Follow-Up
US3442104	2020-08-28	AMENDMENT 3	No/ 2021-01-20 (146)	Protocol Deviation/ THE SUBJECT WITHDREW CONSENT DUE TO EUA APPROVAL. SUBJECT RECEIVED VACCINE THROUGH EMPLOYER PRIOR TO UNBLINDING		Yes/ 2020-09-22 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442107	2020-08-28	AMENDMENT 3	No/ 2021-03-04 (189)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO BE A PART OF THE STUDY		Yes/ 2020-09-25 (29)	
US3442109	2020-09-01	AMENDMENT 3	No/ 2020-12-17 (108)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-09-28 (28)	
US3442116	2020-09-01	AMENDMENT 3	No/ 2020-12-18 (109)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442137	2020-09-14	AMENDMENT 3	No/ 2020-11-21 (69)	Lost to Follow-Up		No/ 2020-10-11 (28)	Lost to Follow-Up
US3442167	2020-09-15	AMENDMENT 3	No/ 2020-11-13 (60)	Withdrawal of Consent by Participant/ SUBJECT IS UNABLE TO COMMIT TO STUDY REQUIREMENTS. SUBJECT WITHDREW CONSENT AFTER MULTIPLE ATTEMPTS TO ACCOMMODATE SUBJECT'S SCHEDULE.		Yes/ 2020-10-12 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442176	2020-09-16	AMENDMENT 3	No/ 2020-10-13 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AND DOES NOT WISH TO CONTINUE IN THE STUDY.		No/ 2020-10-12 (27)	Withdrawal of Consent by Participant/ PT DECIDED TO WITHDRAW CONSENT
US3442190	2020-09-18	AMENDMENT 3	No/ 2020-12-28 (102)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-10-19 (32)	
US3442195	2020-09-18	AMENDMENT 3	No/ 2020-12-28 (102)	Other/ REQUEST TO UNBLIND / EUA VACCINE		Yes/ 2020-10-19 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442205	2020-09-30	AMENDMENT 3	No/ 2020-12-28 (90)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-10-29 (30)	
US3442212	2020-10-05	AMENDMENT 3	No/ 2020-12-17 (74)	Other/ REQUESTED TO UNBLIND/EUA COVID VACCINE		Yes/ 2020-11-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442234	2020-10-14	AMENDMENT 4	No/ 2020-12-01 (49)	Withdrawal of Consent by Participant/ SUBJECT CAME TO THIS VISIT BUT LEFT PRIOR TO GETTING VACCINE, SITE HAS BEEN TRYING TO GET AHOLD OF THE SUBJECT. SUBJECT HAS WITHDREW CONSENT		No/ 2020-11-10 (28)	Withdrawal of Consent by Participant/ SUBJECT CAME TO VISIT 2 BUT LEFT PRIOR TO GETTING VACCINE, SITE HAS BEEN TRYING TO GET AHOLD OF THE SUBJECT. SUBJECT HAS WITHDREW CONSENT OVER PHONE SAID I DO NOT WANT TO DO THIS ANYMORE AND HUNG UP

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442240	2020-10-15	AMENDMENT 4	No/ 2020-12-29 (76)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-11-10 (27)	
US3442244	2020-10-20	AMENDMENT 4	No/ 2020-12-28 (70)	Other/ REQUEST TO UNBLIND / EUA COVID VACCINE		Yes/ 2020-11-17 (29)	
US3452001	2020-07-30	AMENDMENT 1	No/ 2021-02-23 (209)	Protocol Deviation/ SUBJECT RECEIVED 2ND DOSE OF VACCINE AT WORK NOT SITE		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452026	2020-07-30	AMENDMENT 1	No/ 2021-02-10 (196)	Withdrawal of Consent by Participant/ PERSONAL DECISION TO WITHDRAW.		Yes/ 2020-08-24 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452030	2020-07-30	AMENDMENT 1	No/ 2020-12-24 (148)	Other/ SUBJECT MEETS THE CDC CRITERIA TO RECEIVE THE PFIZER VACCINE UNDER EUA AND CHOSE TO BE UNBLINDED PRIOR TO AM6. SUBJECT RECEIVED PLACEBO AND WAS WITHDRAWN FROM STUDY.		Yes/ 2020-09-01 (34)	
US3452072	2020-07-31	AMENDMENT 1	No/ 2020-12-17 (140)	Withdrawal of Consent by Participant/ DUE TO WROK.		Yes/ 2020-08-25 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452083	2020-08-01	AMENDMENT 1	No/ 2021-01-07 (160)	Withdrawal of Consent by Participant/ SUBJECT'S WORK SCHEDULE DIDN'T ALLOW THEM TO MAKE VISITS ANYMORE		Yes/ 2020-08-29 (29)	
US3452084	2020-08-01	AMENDMENT 1	No/ 2020-10-06 (67)	Withdrawal of Consent by Participant/ PATIENT SAID SHE CAN NO LONGER MAKE STUDY VISITS		Yes/ 2020-09-08 (39)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452090	2020-08-01	AMENDMENT 1	No/ 2021-01-04 (157)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO BE UNBLINDED AND WILL BE RECEIVING VACCINATION AT PCP		Yes/ 2020-08-26 (26)	
US3452095	2020-08-01	AMENDMENT 1	No/ 2020-10-29 (90)	Lost to Follow-Up		Yes/ 2020-08-27 (27)	
US3452096	2020-08-01	AMENDMENT 1	No/ 2021-01-27 (180)	Withdrawal of Consent by Participant/ NO LONGER WILLING TO MAKE VISITS		Yes/ 2020-08-31 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452114	2020-08-01	AMENDMENT 1	No/ 2021-03-02 (214)	Withdrawal of Consent by Participant/ SUBJECT ASKED TO BE WITHDRAWN		Yes/ 2020-08-28 (28)	
US3452135	2020-08-03	AMENDMENT 1	No/ 2021-01-04 (155)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WISH TO CONTINUE IN STUDY.		Yes/ 2020-09-02 (31)	
US3452138	2020-08-03	AMENDMENT 1	No/ 2020-12-23 (143)	Other/ SUBJECT REQUESTED TO BE UNBLINDED.		Yes/ 2020-08-31 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452165	2020-08-03	AMENDMENT 1	No/ 2020-10-05 (64)	Withdrawal of Consent by Participant/ PATIENT IS NO LONGER WILLING TO PARTICIPATE DUE TO PERSONAL REASONS		Yes/ 2020-09-01 (30)	
US3452166	2020-08-04	AMENDMENT 1	No/ 2021-02-01 (182)	Protocol Deviation/ SUBJECT CHOSE TO GET PFIZER VACCINES IN JANUARY 2021		Yes/ 2020-09-04 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452182	2020-08-04	AMENDMENT 1	No/ 2021-01-04 (154)	Withdrawal of Consent by Participant/ RECEIVING VACCINE THROUGH EMPLOYER		Yes/ 2020-09-01 (29)	
US3452186	2020-08-04	AMENDMENT 1	No/ 2020-12-30 (149)	Withdrawal of Consent by Participant/ SUBJECT WORKS IN HEALTHCARE AND CHOSE TO BE UNBLINDED AS THEY ARE ABLE TO RECEIVE AN EUA VACCINE AT WORK.		Yes/ 2020-09-03 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452194	2020-08-04	AMENDMENT 1	No/ 2020-12-29 (148)	Withdrawal of Consent by Participant/ SUBJECT HAD TO TAKE CARE OF GRANDPARENTS.		Yes/ 2020-09-03 (31)	
US3452206	2020-08-04	AMENDMENT 1	No/ 2020-12-29 (148)	Withdrawal of Consent by Participant/ SUBJECT HAD TO TAKE CARE OF PARENTS.		Yes/ 2020-09-03 (31)	
US3452221	2020-08-05	AMENDMENT 1	No/ 2021-01-06 (155)	Withdrawal of Consent by Participant/ W/D DUE TO OTHER VACCINE		Yes/ 2020-09-01 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452223	2020-08-05	AMENDMENT 1	No/ 2021-02-24 (204)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO WITHDRAW FROM STUDY		Yes/ 2020-08-31 (27)	
US3452227	2020-08-05	AMENDMENT 1	No/ 2021-01-29 (178)	Protocol Deviation/ PT WILL BE GIVEN VACCINATION AT WORK		Yes/ 2020-09-03 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452232	2020-08-05	AMENDMENT 1	No/ 2021-02-22 (202)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT HIS WORK SCHEDULE HAS INCREASED SO MUCH THAT HE IS UNABLE TO COME.		Yes/ 2020-09-08 (35)	
US3452235	2020-08-05	AMENDMENT 1	No/ 2020-10-21 (78)	Withdrawal of Consent by Participant/ SUBJECT COULD NOT PARTICIPATE DUE TO PERSONAL CIRCUMSTANCES		Yes/ 2020-09-04 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452236	2020-08-05	AMENDMENT 1	No/ 2021-01-14 (163)	Withdrawal of Consent by Participant/ WITHDREW ICF DUE TO WORK SCHEDULE		Yes/ 2020-08-31 (27)	
US3452255	2020-08-05	AMENDMENT 1	No/ 2020-08-26 (22)	Withdrawal of Consent by Participant/ SUBJECT DID NOT PROVIDE REASON FOR WITHDRAWING.		No/ 2020-08-25 (21)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WANT TO PARTICIPATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452276	2020-08-06	AMENDMENT 1	No/ 2020-12-28 (145)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AND CHOSE TO RECEIVE VACCINE FROM EMPLOYER.		Yes/ 2020-09-03 (29)	
US3452277	2020-08-06	AMENDMENT 1	No/ 2020-12-30 (147)	Withdrawal of Consent by Participant/ W/D FOR OTHER VACCINE AVAILABILITY		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452279	2020-08-06	AMENDMENT 1	No/ 2021-01-04 (152)	Withdrawal of Consent by Participant/ VACCINE AVAILABLE		Yes/ 2020-09-03 (29)	
US3452305	2020-08-07	AMENDMENT 1	No/ 2021-01-04 (151)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO BE UNBLINDED AND WILL BE RECEIVING VACCINATION AT WORK.		Yes/ 2020-09-08 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452340	2020-08-25	AMENDMENT 3	No/ 2020-12-22 (120)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE		Yes/ 2020-09-23 (30)	
US3452371	2020-09-17	AMENDMENT 3	No/ 2021-01-13 (119)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO PERSONAL CHANGE IN SCHEDULE.		Yes/ 2020-10-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452373	2020-09-21	AMENDMENT 3	No/ 2021-01-11 (112)	Withdrawal of Consent by Participant/ PT NO LONGER WISHED TO CONTINUE		Yes/ 2020-10-20 (29)	
US3452382	2020-09-22	AMENDMENT 3	No/ 2020-10-20 (29)	Withdrawal of Consent by Participant		No/ 2020-10-19 (28)	Withdrawal of Consent by Participant
US3452389	2020-09-22	AMENDMENT 3	No/ 2021-02-02 (134)	Withdrawal of Consent by Participant		Yes/ 2020-10-20 (29)	
US3452400	2020-09-24	AMENDMENT 3	No/ 2020-11-03 (41)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE		No/ 2020-10-21 (28)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO HIS WORK SCHEDULE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462007	2020-08-03	AMENDMENT 1	No/ 2020-10-26 (85)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WANT TO BE CONTACTED BY SITE ANYMORE.		Yes/ 2020-09-04 (33)	
US3462018	2020-08-04	AMENDMENT 1	No/ 2020-12-17 (136)	Withdrawal of Consent by Participant/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-09-08 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462043	2020-08-05	AMENDMENT 1	No/ 2020-12-17 (135)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO ELIGIBILITY FOR EUA VACCINE. PATIENT WITHDREW DUE TO SPONSOR ADVICE		Yes/ 2020-09-09 (36)	
US3462060	2020-08-06	AMENDMENT 2	No/ 2021-03-02 (209)	Protocol Deviation/ SUBJECT RECEIVED THE MODERNA VACCINE THRU HIS EMPLOYER AND SUBJECT WITHDREW CONSENT.		Yes/ 2020-09-10 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462061	2020-08-06	AMENDMENT 1	No/ 2020-12-17 (134)	Withdrawal of Consent by Participant/ PT WAS UNBLINDED DUE TO HAVING ACCESS TO COVID-19 VACCINE		Yes/ 2020-09-03 (29)	
US3462069	2020-08-06	AMENDMENT 1	No/ 2020-12-17 (134)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO ELIGIBILITY TO RECEIVE EUA		Yes/ 2020-09-01 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462073	2020-08-07	AMENDMENT 1	No/ 2020-12-17 (133)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AND WAS OFFERED THE EUA VACCINE.		Yes/ 2020-09-04 (29)	
US3462074	2020-08-07	AMENDMENT 1	No/ 2021-01-15 (162)	Other/ SUBJECT RECEIVED EUA VACCINE.		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462085	2020-08-07	AMENDMENT 1	No/ 2020-09-25 (50)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT BECAUSE THEY DID NOT WANT TO COMPLETE ANY FURTHER PROCEDURES		Yes/ 2020-09-04 (29)	
US3462086	2020-08-10	AMENDMENT 1	No/ 2020-12-18 (131)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-09-10 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462088	2020-08-10	AMENDMENT 2	No/ 2021-03-01 (204)	Withdrawal of Consent by Participant/ SUBJET CONTACTED US ON 1 MAR 2021 TO LET US KNOW THAT THEY WANTED TO WITHDREW DUE TO RECEIVING THE EUA MODERNA VACCINE ON 09 JAN 2021, SUBJECT DID NOT NOTIFY US PRIOR TO GETTING THE VACCINE.		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462100	2020-08-10	AMENDMENT 2	No/ 2020-12-18 (131)	Withdrawal of Consent by Participant/ PT WAS UNBLINDED DUE TO BEING A HEALTHCARE WORKER AND HAVING ACCESS TO VACCINE		Yes/ 2020-09-11 (33)	
US3462106	2020-08-10	AMENDMENT 2	No/ 2021-01-12 (156)	Withdrawal of Consent by Participant/ WITHDRAW OF CONSENT		Yes/ 2020-09-18 (40)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462130	2020-08-11	AMENDMENT 2	No/ 2020-12-28 (140)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-09-15 (36)	
US3462132	2020-08-12	AMENDMENT 2	No/ 2020-09-14 (34)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT DUE TO FAMILY PROBLEMS		No/ 2020-09-08 (28)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT DUE TO FAMILY PROBLEMS.
US3462142	2020-08-12	AMENDMENT 2	No/ 2020-12-17 (128)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462148	2020-08-12	AMENDMENT 2	No/ 2020-12-18 (129)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT, SUBJECT WORKS IN HEALTHCARE AND WAS OFFERED THE EUA VACCINE		Yes/ 2020-09-10 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462155	2020-08-12	AMENDMENT 2	No/ 2021-01-14 (156)	Protocol Deviation/ PATIENT CALLED TO WITHDRAW CONSENT FROM THE STUDY. PATIENT HAS ACCESS TO THE PFIZER VACCINE AND WISHES TO GO GET THAT VACCINE.		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462187	2020-08-14	AMENDMENT 2	No/ 2021-03-10 (209)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT, SUBJECT CAME IN FOR DECISION VISIT AND STATES THEY WOULD LIKE TO WITHDRAW FROM NO STUDY AND GET UN-BLINDED NO OTHER REASON WAS GIVEN OTHER THEN JUST WANTING TO WITHDRAW		Yes/ 2020-09-15 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462202	2020-08-17	AMENDMENT 2	No/ 2020-12-17 (123)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED UNBLINDING DUE TO HAVING ACCESS TO THE EUA VACCINE SINCE THEY ARE HEALTH CARE WORKER, SUBJECT RECEIVED PLACEBO AND WITHDREW CONSENT		Yes/ 2020-09-17 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462203	2020-08-17	AMENDMENT 2	No/ 2020-09-07 (22)	Withdrawal of Consent by Participant/ ON 07 SEP 2020 PATIENT DID NOT WANT TO GET SECOND VACCINE AND DID NOT WANT TO SPEND THE TIME ON ANY OTHER VISITS, ON 28 DEC 2020 PATIENT CALLED US TO GET UNBLINDED DUE TO BEING A HEALTHCARE WORKER.		No/ 2020-09-06 (21)	Withdrawal of Consent by Participant/ PATIENT DID NOT WANT TO GET SECOND VACCINE AND DID NOT WANT TO SPEND THE TIME ON ANY OTHER VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462222	2020-08-18	AMENDMENT 2	No/ 2020-11-09 (84)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WISHED TO BE CONTACTED BY SITE ANYMORE.		Yes/ 2020-09-15 (29)	
US3462223	2020-08-18	AMENDMENT 2	No/ 2020-12-17 (122)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-09-16 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462229	2020-08-18	AMENDMENT 2	No/ 2021-03-01 (196)	Withdrawal of Consent by Participant/ PATIENT WANTS TO WITHDRAW CONSENT TO ALL PROCEDURES AND SAFETY CALLS.		Yes/ 2020-09-22 (36)	
US3462234	2020-08-18	AMENDMENT 2	No/ 2020-12-17 (122)	Other/ EAU UNBLINDING		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462267	2020-08-20	AMENDMENT 2	No/ 2021-03-09 (202)	Withdrawal of Consent by Participant/ DUE TO DIFFICULTY IN TRANSFERRING TO ANOTHER CLINICAL SITE, PATIENT ELECTS TO WITHDRAW FROM STUDY AND OBTAIN VACCINATION THROUGH OTHER MEANS.		Yes/ 2020-09-16 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462273	2020-08-20	AMENDMENT 2	No/ 2020-12-17 (120)	Withdrawal of Consent by Participant/ PATIENT WANTS TO WITHDRAW CONSENT TO ALL PROCEDURES AND SAFETY CALLS		Yes/ 2020-09-17 (29)	
US3462299	2020-08-24	AMENDMENT 2	No/ 2020-12-21 (120)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE.		Yes/ 2020-09-23 (31)	
US3462301	2020-08-24	AMENDMENT 2	No/ 2020-12-18 (117)	Other/ REQUESTED TO BE UNBLINDED/EUA COVIA-19		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462307	2020-08-24	AMENDMENT 2	No/ 2021-02-01 (162)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO PATIENTS DECISION		Yes/ 2020-09-23 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462315	2020-08-24	AMENDMENT 2	No/ 2020-12-31 (130)	Withdrawal of Consent by Participant/ SUBJECT WANTS TO GET UNBLINDED SINCE THEY GOT OFFERED THE EUA DUE TO THEM WORKING IN HEALTHCARE, SUBJECT WAS UNBLINDED AND RECEIVED PLACEBO AND WITHDREW CONSENT TO GET THE EUA VACCINE.		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462322	2020-08-25	AMENDMENT 2	No/ 2020-12-18 (116)	Withdrawal of Consent by Participant/ SUBJECT ASKED TO BE UNBLINDED DUE TO THEM BEING ELIGIBLE FOR THE EUA VACCINE, SUBJECT WAS UNBLINDED , RECEIVED PLACEBO AND WITHDREW CONSENT		Yes/ 2020-09-29 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462324	2020-08-25	AMENDMENT 2	No/ 2020-12-18 (116)	Withdrawal of Consent by Participant/ SUBJECT IS A HEALTHCARE PROFESSIONAL AND WAS OFFERED THE EUA VACCINE THEIR FOR IS REQUESTING TO BE UNBLINDED , SUBJECT RECEIVED PLACEBO, SUBJECT WITHDREW CONSENT		Yes/ 2020-09-29 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462344	2020-08-26	AMENDMENT 2	No/ 2021-01-25 (153)	Protocol Deviation/ SUBJECT WITHDREW CONSENT FROM STUDY AFTER UN-BLINDING VISIT AS THEY WERE GOING TO RECEIVE THE EUA VACCINE.		Yes/ 2020-09-22 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462347	2020-08-26	AMENDMENT 3	No/ 2021-01-06 (134)	Withdrawal of Consent by Participant/ SUBJECT WAS ELIGIBLE FOR EUA VACCINE SO REQUESTED TO BE UNBLINDED, SUBJECT GOT UNBLINDED (RECEIVED PLACEBO) AND WITHDREW CONSENT		Yes/ 2020-09-25 (31)	
US3462348	2020-08-26	AMENDMENT 3	No/ 2020-12-03 (100)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT		Yes/ 2020-09-21 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462350	2020-08-26	AMENDMENT 3	No/ 2020-09-28 (34)	Withdrawal of Consent by Participant/ AFTER V2 PT DECIDED THEY DID NOT WANT TO BE IN THE STUDY ANYMORE		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ AFTER V2 PT DECIDED THEY DID NOT WANT TO BE IN THE STUDY ANYMORE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462352	2020-08-26	AMENDMENT 3	No/ 2020-12-17 (114)	Withdrawal of Consent by Participant/ SUBJECT REQUEST TO BE UNBLINDED SINCE THEY ARE ELIGIBLE FOR THE EUA VACCINE, SUBJECT WAS UNBLINDED , RECEIVED PLACEBO AND WITHDREW CONSENT.		Yes/ 2020-09-23 (29)	
US3462357	2020-08-27	AMENDMENT 3	No/ 2020-12-17 (113)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462363	2020-08-27	AMENDMENT 3	No/ 2020-12-30 (126)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT/ EUA VACCINE OFFERED		Yes/ 2020-09-25 (30)	
US3462369	2020-08-27	AMENDMENT 3	No/ 2020-12-29 (125)	Other/ PATIENT WAS UNBLINDED DUE TO ELIGIBILITY TO RECEIVE A COVID-19 VACCINE UNDER EUA. PATIENT RECEIVED PLACEBO AND IS REMOVED FROM THE STUDY.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462378	2020-08-28	AMENDMENT 3	No/ 2020-12-17 (112)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE		Yes/ 2020-10-15 (49)	
US3462382	2020-08-28	AMENDMENT 3	No/ 2021-01-04 (130)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT/ EUA VACCINE OFFERED / RECEIVED PLACEBO		Yes/ 2020-10-02 (36)	
US3462385	2020-08-28	AMENDMENT 3	No/ 2020-12-17 (112)	Other/ REQUESTED TO BE UNBLINDED/EUA COVID-19 VACCINE.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462386	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Withdrawal of Consent by Participant/ SUBJECT IS HEALTHCARE WORKER AND ELIGIBLE TO RECEIVE EUA VACCINE.		Yes/ 2020-09-25 (29)	
US3462400	2020-09-01	AMENDMENT 3	No/ 2021-03-05 (186)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE AND NO LONGER WANTS TO COMPLETE ANY STUDY PROCEDURES		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462417	2020-09-04	AMENDMENT 3	No/ 2021-01-13 (132)	Protocol Deviation/ SUBJECT CAME IN FOR UN-BLINDING AND IT WAS NOTED THAT THEY HAD BEEN UNBLINDED BACK IN DEC 17 2020 AND SUBJECT GOT EUA VACCINE LATE DECEMBER AND WITHDREW CONSENT AT TODAY'S VISIT		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462420	2020-09-08	AMENDMENT 3	No/ 2020-12-17 (101)	Withdrawal of Consent by Participant/ PATIENT WAS UNBLINDED DUE TO HAVING ACCESS TO THE PFIZER VACCINE		Yes/ 2020-10-12 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472019	2020-09-04	AMENDMENT 3	No/ 2020-10-09 (36)	Withdrawal of Consent by Participant/ PARTICIPANT'S FAMILY ASKED HIM TO DISCONTINUE HIS PARTICIPATION IN THE STUDY . PARTICIPANT WANTS TO BE RESPECTFUL OF THEIR WISHES.		No/ 2020-10-01 (28)	Withdrawal of Consent by Participant/ PARTICIPANT'S FAMILY ASKED HIM TO DISCONTINUE HIS PARTICIPATION IN THE STUDY . PARTICIPANT WANTS TO BE RESPECTFUL OF THEIR WISHES.
US3472024	2020-09-09	AMENDMENT 3	No/ 2021-01-02 (116)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472025	2020-09-09	AMENDMENT 3	No/ 2021-01-02 (116)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3472030	2020-09-11	AMENDMENT 3	No/ 2020-12-17 (98)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	
US3472037	2020-09-14	AMENDMENT 3	No/ 2020-12-21 (99)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472042	2020-09-15	AMENDMENT 3	No/ 2021-01-14 (122)	Withdrawal of Consent by Participant/ PARTICIPANT REPORTED WANTING TO RECEIVE THE PFIZER VACCINE POST UNBLINDING AND REFUSED FURTHER STUDY VISITS.		Yes/ 2020-10-13 (29)	
US3472047	2020-09-16	AMENDMENT 3	No/ 2020-12-15 (91)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472051	2020-09-16	AMENDMENT 3	No/ 2020-12-24 (100)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-14 (29)	
US3472052	2020-09-16	AMENDMENT 3	No/ 2020-12-27 (103)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-21 (36)	
US3472072	2020-09-24	AMENDMENT 3	No/ 2020-12-16 (84)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-22 (29)	
US3472077	2020-09-25	AMENDMENT 3	No/ 2020-12-16 (83)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472078	2020-09-25	AMENDMENT 3	No/ 2020-12-15 (82)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-20 (26)	
US3472082	2020-09-29	AMENDMENT 3	ONGOING			No/ 2020-10-26 (28)	Other/ PARTICIPANT REFUSED VACCINATION DUE TO SAFETY CONCERNS.
US3472087	2020-09-30	AMENDMENT 3	No/ 2021-01-10 (103)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-28 (29)	
US3472096	2020-10-07	AMENDMENT 4	ONGOING			No/ 2020-11-03 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472104	2020-10-09	AMENDMENT 4	No/ 2021-01-03 (87)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-09 (32)	
US3472130	2020-10-23	AMENDMENT 4	ONGOING			No/ 2020-11-19 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482016	2020-08-11	AMENDMENT 1	No/ 2021-01-05 (148)	Protocol Deviation/ 'PARTICIPANT DID NOT GET UNBLINDED BUT DECIDED TO GET EXTERNAL EUA VACCINE. SENT EMAIL TO CLINIC AS NOTICE THAT HE WAS ENDING HIS PARTICIPATION & EXITING THE STUDY		Yes/ 2020-09-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482081	2020-08-19	AMENDMENT 2	No/ 2020-12-19 (123)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-15 (28)	
US3482104	2020-08-21	AMENDMENT 3	No/ 2021-03-24 (216)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO NO LONGER WANTING TO PARTICIPATE IN THE STUDY.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482111	2020-08-21	AMENDMENT 2	No/ 2020-12-19 (121)	Protocol Deviation/ RECEIVED PFIZER EUA COVID-19 VACCINE.		Yes/ 2020-09-18 (29)	
US3482145	2020-08-26	AMENDMENT 2	ONGOING			No/ 2020-09-22 (28)	Other/ DOES NOT MEET INCLUSION CRITERIA NUMBER 7
US3482235	2020-09-04	AMENDMENT 3	No/ 2020-12-21 (109)	Protocol Deviation/ REQUEST TO UNBLIND / RECEIVED NON-STUDY EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482320	2020-10-22	AMENDMENT 4	No/ 2021-01-04 (75)	Protocol Deviation/ PARTICIPANT DIDN'T GET UNBLINDED BUT GOT EXTERNAL EUA VACCINE (MODERNA) ON 31 DEC 2020. ADVISED STUDY SITE 4 JAN 2021. WITHDRAWN DUE TO VIOLATING PROTOCOL & GETTING EXTERNAL COVID VACCINATION.		Yes/ 2020-11-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3482321	2020-10-22	AMENDMENT 4	ONGOING			No/ 2020-11-18 (28)	Protocol Deviation/ PARTICIPANT MET EXCLUSION CRITERIA
US3492008	2020-08-25	AMENDMENT 2	No/ 2020-12-17 (115)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492051	2020-09-03	AMENDMENT 2	No/ 2021-01-05 (125)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE. SUBJECT IN FLORIDA FOR WINTER, HAS OPPORTUNITY TO GET PFIZER VACCINE THIS WEEK SO HAS REQUESTED UNBLINDING		Yes/ 2020-10-01 (29)	
US3492059	2020-09-03	AMENDMENT 2	No/ 2020-12-28 (117)	Other/ REQUEST TO UNBLIND/EUA-COVID-19 VACCINE		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492074	2020-09-05	AMENDMENT 2	No/ 2021-03-17 (194)	Lost to Follow-Up		Yes/ 2020-10-05 (31)	
US3492094	2020-09-08	AMENDMENT 2	No/ 2021-01-06 (121)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-13 (36)	
US3492104	2020-09-09	AMENDMENT 2	No/ 2020-12-28 (111)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-09 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492111	2020-09-10	AMENDMENT 2	No/ 2021-01-10 (123)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE ON 19DEC2020 PRIOR TO EUA UNBLIND. WAS UNBLINDED 10JAN2021, ON PLACEBO, PER EPIP, MUST WITHDRAW FROM STUDY		Yes/ 2020-10-08 (29)	
US3492117	2020-09-10	AMENDMENT 2	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492194	2020-09-18	AMENDMENT 3	No/ 2020-12-22 (96)	Protocol Deviation/ SUBJECT IS AN MD, WANTED PFIZER VACCINE, HAD ANTIBODY TEST TO CONFIRM HIS SUSPICION THAT WAS ON PLACEBO, WAS NEGATIVE, WENT AHEAD AND GOT PFIZER VACCINE, THEN CALLED TO INFORM SITE. WAS NOT UNBLINDED		Yes/ 2020-10-19 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492200	2020-09-18	AMENDMENT 3	No/ 2021-01-16 (121)	Protocol Deviation/ SUBJECT REPORTED ON 14JAN2021 THAT RECEIVED PFIZER VACCINE ON 21DEC2020 AND 08JAN2021. UNBLIONDED 16JAN2021, ON PLACEBO, MUST WITHDRAW PER EPIP		Yes/ 2020-10-16 (29)	
US3492206	2020-09-18	AMENDMENT 3	No/ 2020-12-18 (92)	Other/ REQUEST TO UNBLIND/EUA COVID19 VACCINE		Yes/ 2020-10-15 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492239	2020-09-23	AMENDMENT 3	No/ 2020-12-23 (92)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-21 (29)	
US3492242	2020-09-23	AMENDMENT 3	ONGOING			No/ 2020-10-20 (28)	Due to SARS-CoV-2
US3492269	2020-09-29	AMENDMENT 3	No/ 2020-12-21 (84)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-11-02 (35)	
US3492299	2020-10-13	AMENDMENT 3	No/ 2021-01-20 (100)	Lost to Follow-Up		No/ 2020-11-09 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502014	2020-08-24	AMENDMENT 2	No/ 2020-12-22 (121)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	
US3502015	2020-08-24	AMENDMENT 2	No/ 2020-12-28 (127)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	
US3502016	2020-08-24	AMENDMENT 2	No/ 2021-01-12 (142)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW TO OBTAIN EUA VACCINE		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502017	2020-08-24	AMENDMENT 2	No/ 2020-12-16 (115)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	
US3502019	2020-08-25	AMENDMENT 3	No/ 2021-01-04 (133)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-23 (30)	
US3502022	2020-08-25	AMENDMENT 3	No/ 2021-01-04 (133)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-28 (35)	
US3502023	2020-08-25	AMENDMENT 3	No/ 2020-12-17 (115)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502025	2020-08-25	AMENDMENT 3	No/ 2021-01-04 (133)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	
US3502030	2020-08-26	AMENDMENT 3	No/ 2021-01-27 (155)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDRAWAL TO RECEIVE EUA VACCINE		Yes/ 2020-09-23 (29)	
US3502041	2020-08-27	AMENDMENT 3	No/ 2020-12-27 (123)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502057	2020-08-28	AMENDMENT 3	No/ 2020-12-24 (119)	Protocol Deviation/ PT RECEIVED OUTSIDE COVID VACCINE WITHOUT BEING UNBLINDED		Yes/ 2020-09-25 (29)	
US3502059	2020-08-28	AMENDMENT 3	No/ 2020-12-15 (110)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-01 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502070	2020-08-31	AMENDMENT 3	No/ 2021-02-24 (178)	Withdrawal of Consent by Participant/ SUBJECT WITHDRAW FROM STUDY DUE TO STUDY BURDEN/TRANSPORTATION		Yes/ 2020-09-28 (29)	
US3502071	2020-08-31	AMENDMENT 3	No/ 2020-12-16 (108)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-29 (30)	
US3502084	2020-09-02	AMENDMENT 3	No/ 2020-12-16 (106)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502085	2020-09-02	AMENDMENT 3	No/ 2020-12-24 (114)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-06 (35)	
US3502087	2020-09-02	AMENDMENT 3	No/ 2020-12-27 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-30 (29)	
US3502096	2020-09-03	AMENDMENT 3	No/ 2020-12-21 (110)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-01 (29)	
US3502097	2020-09-04	AMENDMENT 3	No/ 2020-12-17 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502098	2020-09-04	AMENDMENT 3	No/ 2020-12-17 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	
US3502103	2020-09-04	AMENDMENT 3	No/ 2020-10-30 (57)	Withdrawal of Consent by Participant/ PARTICIPANT CLAIMS SHE WAS NOT PAID IN A TIMELY MANNER		Yes/ 2020-10-02 (29)	
US3502105	2020-09-04	AMENDMENT 3	No/ 2020-12-17 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502114	2020-09-08	AMENDMENT	3 No/ 2021-01-04 (119)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-06 (29)	
US3502122	2020-09-09	AMENDMENT	3 No/ 2020-12-17 (100)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3502131	2020-09-10	AMENDMENT	3 No/ 2020-12-30 (112)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-08 (29)	
US3502132	2020-09-10	AMENDMENT	3 No/ 2020-12-18 (100)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-13 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502139	2020-09-10	AMENDMENT 3	No/ 2021-02-04 (148)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDRAWAL TO OBTAIN EUA VACCINE		Yes/ 2020-10-14 (35)	
US3502167	2020-09-17	AMENDMENT 3	No/ 2020-12-24 (99)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-15 (29)	
US3502192	2020-10-06	AMENDMENT 4	No/ 2020-12-21 (77)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-11-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502208	2020-10-15	AMENDMENT 4	No/ 2020-12-29 (76)	Other/ REQUEST TO UNBLIND; EUA COVID-19 VACCINE		Yes/ 2020-11-11 (28)	
US3512022	2020-08-06	AMENDMENT 1	No/ 2020-12-23 (140)	Protocol Deviation/ SUBJECT INFORMED SITE ON 23 DEC 2020 THAT THEY RECEIVED THE PFIZER VACCINE ON 16 DEC 2020		Yes/ 2020-09-09 (35)	
US3512033	2020-08-12	AMENDMENT 2	No/ 2020-12-29 (140)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-11 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512041	2020-08-12	AMENDMENT 2	No/ 2021-03-03 (204)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER COVID VACCINE ON 2/27/2021		Yes/ 2020-09-16 (36)	
US3512088	2020-08-15	AMENDMENT 2	No/ 2020-12-22 (130)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE IMMINENT ACCESS		Yes/ 2020-09-09 (26)	
US3512090	2020-08-15	AMENDMENT 2	No/ 2020-12-22 (130)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512092	2020-08-15	AMENDMENT 2	No/ 2020-12-22 (130)	Protocol Deviation/ PT INFORMED SITE OF COVID VACCINATION OUTSIDE OF STUDY.		Yes/ 2020-09-11 (28)	
US3512108	2020-08-20	AMENDMENT 2	No/ 2020-12-22 (125)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-18 (30)	
US3512126	2020-08-21	AMENDMENT 2	No/ 2020-12-28 (130)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512128	2020-08-21	AMENDMENT 2	No/ 2020-12-30 (132)	Lost to Follow-Up		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512138	2020-08-22	AMENDMENT 2	No/ 2020-09-23 (33)	Withdrawal of Consent by Participant/ PT CALLED ON 9/23/2020 AND SPOKE COORDINATOR AND STATED HE CHANGED HIS MIND, THE PT ALSO STATED HIS WIFE READ SOME THINGS ABOUT THE TRIAL AND FOR PERSONAL REASON, HE WOULD RATHER NOT CONTINUE.		No/ 2020-09-18 (28)	Withdrawal of Consent by Participant/ PT CALLED ON 9/23/2020 AND SPOKE COORDINATOR AND STATED HE CHANGED HIS MIND, THE PT ALSO STATED HIS WIFE READ SOME THINGS ABOUT THE TRIAL AND FOR PERSONAL REASON, HE WOULD RATHER NOT CONTINUE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512141	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Other/ PT RESCHEDULED APPT NUMEROUS TIMES DUE TO BEING A ESSENTIAL WORKER. THEN PATIENT HAD COVID SYMPTOM.
US3512148	2020-08-26	AMENDMENT 3	No/ 2020-10-15 (51)	Lost to Follow-Up		Yes/ 2020-09-24 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512157	2020-08-26	AMENDMENT 3	No/ 2021-01-05 (133)	Other/ SUBJECT REQUESTED EMERGENCY UNBLINDING, DUE TO ACCESS TO EUA VACCINE, REFUSED TO COME TO SITE FOR UNBLINDING VISIT. WITHDRAWN, PER SPONSOR INSTRUCTION.		Yes/ 2020-09-24 (30)	
US3512158	2020-08-26	AMENDMENT 3	No/ 2021-01-14 (142)	Protocol Deviation/ PT RECEIVED MODERNA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512165	2020-08-27	AMENDMENT 3	No/ 2021-01-29 (156)	Protocol Deviation/ PARTICIPANT RECEIVED PFIZER VACCINE OUTSIDE OF STUDY BEFORE BEING UNBLINDED. SUBJECT COULD NOT CONTINUE IN THE STUDY.		Yes/ 2020-09-23 (28)	
US3512169	2020-08-27	AMENDMENT 3	No/ 2020-12-28 (124)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-25 (30)	
US3512176	2020-08-29	AMENDMENT 3	ONGOING			No/ 2020-09-25 (28)	Adverse Event/ AE # 7

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512187	2020-09-02	AMENDMENT 3	No/ 2020-12-22 (112)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-02 (31)	
US3512194	2020-09-02	AMENDMENT 3	No/ 2021-01-04 (125)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY PRIOR TO UNBLINDING.		Yes/ 2020-09-30 (29)	
US3512218	2020-09-04	AMENDMENT 3	No/ 2021-01-05 (124)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-09 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512281	2020-09-23	AMENDMENT 3	No/ 2020-12-22 (91)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-21 (29)	
US3512283	2020-09-23	AMENDMENT 3	No/ 2020-12-29 (98)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE IMMINENT ACCESS		Yes/ 2020-10-21 (29)	
US3512286	2020-09-30	AMENDMENT 3	No/ 2020-12-29 (91)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512308	2020-10-22	AMENDMENT 4	No/ 2021-01-13 (84)	Protocol Deviation/ RECEIVED COVID VACCINE OUTSIDE OF STUDY.		Yes/ 2020-11-19 (29)	
US3522008	2020-08-05	AMENDMENT 1	No/ 2020-12-20 (138)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-02 (29)	
US3522010	2020-08-05	AMENDMENT 1	No/ 2020-12-21 (139)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-03 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522013	2020-08-05	AMENDMENT 1	No/ 2020-12-29 (147)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-02 (29)	
US3522015	2020-08-05	AMENDMENT 1	No/ 2021-01-22 (171)	Protocol Deviation/ RECEIVED COMPETING COVID VACCINE OUTSIDE STUDY		Yes/ 2020-09-04 (31)	
US3522019	2020-08-06	AMENDMENT 1	No/ 2020-12-20 (137)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-09 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522025	2020-08-06	AMENDMENT 1	No/ 2021-01-13 (161)	Other/ PARTICIPANT WITHDREW TO RECEIVE EUA APPROVED VACCINE		Yes/ 2020-09-08 (34)	
US3522026	2020-08-06	AMENDMENT 1	No/ 2020-12-31 (148)	Other/ WITHDREW TO RECEIVE EUA VACCINE		Yes/ 2020-09-08 (34)	
US3522042	2020-08-07	AMENDMENT 1	No/ 2020-12-24 (140)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		No/ 2020-09-03 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522045	2020-08-07	AMENDMENT 1	No/ 2020-12-18 (134)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-04 (29)	
US3522046	2020-08-07	AMENDMENT 1	No/ 2020-12-22 (138)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-04 (29)	
US3522049	2020-08-07	AMENDMENT 1	No/ 2020-12-18 (134)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522060	2020-08-10	AMENDMENT 1	No/ 2020-12-29 (142)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-09 (31)	
US3522062	2020-08-10	AMENDMENT 1	No/ 2020-12-19 (132)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-04 (26)	
US3522066	2020-08-10	AMENDMENT 1	No/ 2020-12-21 (134)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522068	2020-08-10	AMENDMENT 1	No/ 2020-12-29 (142)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-08 (30)	
US3522069	2020-08-10	AMENDMENT 1	No/ 2020-12-19 (132)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522077	2020-08-11	AMENDMENT 1	No/ 2020-12-29 (141)	Protocol Deviation/ PARTICIPANT TOOK ANOTHER COVID VACCINE OUTSIDE OF STUDY. HAD NOT INFORMED STAFF, FOUND ON 18 FEB2021 WHILE TRYING TO DETERMINE IF THEY WERE LTFU. DATE OF VACCINE IS CONSIDERED LAST CONTACT DATE.		Yes/ 2020-09-10 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522078	2020-08-11	AMENDMENT 1	No/ 2021-01-07 (150)	Protocol Deviation/ WITHDREW TO RECEIVE EUA COVID-19 VACCINE		Yes/ 2020-09-09 (30)	
US3522080	2020-08-11	AMENDMENT 1	No/ 2020-12-31 (143)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-11 (32)	
US3522083	2020-08-11	AMENDMENT 1	No/ 2020-12-30 (142)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522097	2020-08-12	AMENDMENT 1	No/ 2020-12-29 (140)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-09 (29)	
US3522098	2020-08-12	AMENDMENT 1	No/ 2020-12-31 (142)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522099	2020-08-12	AMENDMENT 1	No/ 2021-01-18 (160)	Withdrawal of Consent by Participant/ NEW ICF. WITHDREW CONSENT. CHOSE IN AMENDMENT SIX ADDENDUM I DO NOT WISH TO CONTINUE PARTICIPATION IN THE STUDY AND I WISH TO KNOW MY STUDY TREATMENT ASSIGNMENT.		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522104	2020-08-12	AMENDMENT 1	No/ 2020-10-12 (62)	Withdrawal of Consent by Participant/ PARTICIPANT EMAILED US STATING THEY WERE WITHDRAWING FROM THE STUDY.		Yes/ 2020-09-10 (30)	
US3522105	2020-08-12	AMENDMENT 1	No/ 2020-12-29 (140)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522110	2020-08-13	AMENDMENT 1	No/ 2020-12-24 (134)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-10 (29)	
US3522117	2020-08-13	AMENDMENT 1	No/ 2020-12-20 (130)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-10 (29)	
US3522129	2020-08-14	AMENDMENT 1	No/ 2020-12-29 (138)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-16 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522132	2020-08-14	AMENDMENT 1	No/ 2020-12-31 (140)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-15 (33)	
US3522138	2020-08-17	AMENDMENT 1	No/ 2020-12-23 (129)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-14 (29)	
US3522148	2020-08-17	AMENDMENT 1	No/ 2020-12-29 (135)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522150	2020-08-17	AMENDMENT 1	No/ 2020-12-30 (136)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-15 (30)	
US3522166	2020-08-18	AMENDMENT 1	No/ 2020-12-23 (128)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (32)	
US3522176	2020-08-18	AMENDMENT 1	No/ 2021-01-05 (141)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522177	2020-08-18	AMENDMENT	1 No/ 2021-02-12 (179)	Lost to Follow-Up		Yes/ 2020-09-16 (30)	
US3522183	2020-08-18	AMENDMENT	1 No/ 2020-12-21 (126)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (32)	
US3522188	2020-08-18	AMENDMENT	1 No/ 2020-12-20 (125)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-21 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522201	2020-08-19	AMENDMENT 1	No/ 2020-12-23 (127)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-15 (28)	
US3522207	2020-08-19	AMENDMENT 1	No/ 2020-12-29 (133)	Other/ LEFT TO TAKE OTHER EUA APPROVED VACCINE		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522211	2020-08-19	AMENDMENT 1	No/ 2021-03-23 (217)	Withdrawal of Consent by Participant/ PARTICIPANT SELECTED "I DO NOT WISH TO CONTINUE PARTICIPATION IN THE STUDY AND I WISH TO KNOW MY STUDY ASSIGNMENT" ON OLV CONSENT.		Yes/ 2020-09-17 (30)	
US3522213	2020-08-19	AMENDMENT 1	No/ 2021-01-11 (146)	Other/ PARTICIPANT WITHDREW TO RECEIVE EUA APPROVED VACCINE		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522214	2020-08-19	AMENDMENT 1	No/ 2020-12-29 (133)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (31)	
US3522215	2020-08-19	AMENDMENT 1	No/ 2020-12-29 (133)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-14 (27)	
US3522228	2020-08-19	AMENDMENT 1	No/ 2020-12-21 (125)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522236	2020-08-20	AMENDMENT 2	No/ 2020-12-19 (122)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-17 (29)	
US3522238	2020-08-20	AMENDMENT 2	No/ 2020-12-23 (126)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522242	2020-08-20	AMENDMENT 2	No/ 2020-09-25 (37)	Withdrawal of Consent by Participant/ PARTICIPANT DECIDED TO WITHDRAW AFTER MISSING THEIR SCHEDULED VISIT 2 APPOINTMENT.		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ PARTICIPANT TOLD US BY PHONE WHEN CONTACT WAS ATTEMPTED TO RESCHEDULE SECOND APPOINTMENT THAT THEY MISSED THAT THEY WERE WITHDRAWING
US3522257	2020-08-20	AMENDMENT 2	No/ 2020-12-29 (132)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522269	2020-08-21	AMENDMENT 2	No/ 2020-10-13 (54)	Lost to Follow-Up		Yes/ 2020-09-22 (33)	
US3522271	2020-08-21	AMENDMENT 2	No/ 2020-12-19 (121)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-21 (32)	
US3522276	2020-08-21	AMENDMENT 2	No/ 2020-12-31 (133)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-21 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522292	2020-08-21	AMENDMENT 2	No/ 2020-12-30 (132)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (29)	
US3522294	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (29)	
US3522295	2020-08-21	AMENDMENT 2	No/ 2020-12-21 (123)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522297	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2
US3522305	2020-08-24	AMENDMENT 2	No/ 2020-12-21 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-21 (29)	
US3522308	2020-08-24	AMENDMENT 2	No/ 2020-12-29 (128)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-25 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522315	2020-08-24	AMENDMENT 2	No/ 2020-12-23 (122)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-24 (32)	
US3522316	2020-08-24	AMENDMENT 2	No/ 2021-02-15 (176)	Protocol Deviation/ PARTICIPANT TOOK SECOND DOSE OF MODERNA VACCINE OUTSIDE STUDY		Yes/ 2020-09-22 (30)	
US3522317	2020-08-24	AMENDMENT 2	No/ 2021-02-15 (176)	Protocol Deviation/ PARTICIPANT TOOK DOSE OF MODERNA VACCINE OUTSIDE STUDY		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522320	2020-08-24	AMENDMENT 2	No/ 2020-12-21 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-23 (31)	
US3522327	2020-08-24	AMENDMENT 2	No/ 2020-12-20 (119)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-22 (30)	
US3522341	2020-08-25	AMENDMENT 2	No/ 2020-12-22 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-23 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522352	2020-08-25	AMENDMENT 2	No/ 2020-12-19 (93)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-16 (29)	
US3522359	2020-08-25	AMENDMENT 2	No/ 2020-12-18 (116)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-21 (28)	
US3522361	2020-08-26	AMENDMENT 2	No/ 2020-12-20 (117)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522366	2020-08-26	AMENDMENT 2	No/ 2020-12-19 (116)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-22 (28)	
US3522369	2020-08-26	AMENDMENT 2	No/ 2020-12-22 (119)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-23 (29)	
US3522381	2020-08-26	AMENDMENT 2	No/ 2020-12-30 (127)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-24 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522387	2020-08-26	AMENDMENT 2	No/ 2020-12-23 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-25 (31)	
US3522389	2020-08-27	AMENDMENT 2	No/ 2020-12-28 (124)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-30 (35)	
US3522392	2020-08-27	AMENDMENT 2	No/ 2020-12-19 (115)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-25 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522393	2020-08-27	AMENDMENT 2	No/ 2020-12-21 (117)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-24 (29)	
US3522415	2020-08-27	AMENDMENT 2	No/ 2020-12-29 (125)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-28 (33)	
US3522423	2020-08-28	AMENDMENT 3	No/ 2021-01-03 (129)	Other/ WITHDREW TO RECEIVE OFFERED EUA COVID-19 VACCINE OUTSIDE OF TRIAL		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522424	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3522427	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-29 (33)	
US3522429	2020-08-28	AMENDMENT 3	No/ 2021-01-18 (144)	Protocol Deviation/ PARTICIPANT TOOK EUA APPROVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522432	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-08 (42)	
US3522436	2020-08-28	AMENDMENT 3	No/ 2021-01-04 (130)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-02 (36)	
US3522441	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-30 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522450	2020-08-31	AMENDMENT 3	No/ 2020-12-21 (113)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-28 (29)	
US3522455	2020-08-31	AMENDMENT 3	No/ 2020-12-29 (121)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-28 (29)	
US3522467	2020-08-31	AMENDMENT 3	No/ 2020-12-30 (122)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-02 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522475	2020-08-31	AMENDMENT 3	No/ 2020-12-19 (111)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-05 (36)	
US3522476	2020-08-31	AMENDMENT 3	No/ 2020-12-23 (115)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-30 (31)	
US3522500	2020-09-01	AMENDMENT 3	No/ 2020-12-29 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522502	2020-09-01	AMENDMENT 3	No/ 2020-12-22 (113)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522506	2020-09-01	AMENDMENT 3	No/ 2021-01-26 (148)	Protocol Deviation/ PARTICIPANT STOPPED RESPONDING AFTER 14DEC2020. ON CHART REVIEW DISCOVERED ON 26JAN2021 THAT EXTERNAL PFIZER VACCINE TAKEN ON 18DEC2020. WITHDRAWN FROM STUDY.		Yes/ 2020-10-14 (44)	
US3522507	2020-09-01	AMENDMENT 3	No/ 2021-01-07 (122)	Other/ WITHDREW TO RECEIVE EUA COVID-19 VACCINE		Yes/ 2020-10-13 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522508	2020-09-01	AMENDMENT 3	No/ 2020-12-29 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-01 (31)	
US3522511	2020-09-02	AMENDMENT 3	No/ 2021-01-07 (128)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-30 (29)	
US3522524	2020-09-02	AMENDMENT 3	No/ 2020-12-30 (120)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522541	2020-09-03	AMENDMENT 3	No/ 2020-12-17 (106)	Other/ WITHDREW TO TAKE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-08 (36)	
US3522552	2020-09-03	AMENDMENT 3	No/ 2021-01-07 (127)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE UNDER EUA SO WAS WITHDRAWN		Yes/ 2020-10-01 (29)	
US3522560	2020-09-03	AMENDMENT 3	No/ 2020-12-29 (118)	Other/ PARTICIPANT WITHDREW TO RECEIVE EUA APPROVED VACCINE		Yes/ 2020-10-06 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522564	2020-09-03	AMENDMENT 3	No/ 2020-12-23 (112)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-06 (34)	
US3522582	2020-09-04	AMENDMENT 3	No/ 2020-12-31 (119)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-29 (26)	
US3522583	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-09 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522595	2020-09-04	AMENDMENT 3	No/ 2020-12-31 (119)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-05 (32)	
US3522596	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-05 (32)	
US3522598	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-06 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522600	2020-09-08	AMENDMENT 3	No/ 2020-12-29 (113)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-06 (29)	
US3522611	2020-09-08	AMENDMENT 3	No/ 2020-12-29 (113)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-07 (30)	
US3522614	2020-09-08	AMENDMENT 3	No/ 2020-12-19 (103)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-05 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522620	2020-09-09	AMENDMENT 3	No/ 2021-01-11 (125)	Protocol Deviation/ PARTICIPANT RECEIVED EUA APPROVED VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-10-13 (35)	
US3522633	2020-09-09	AMENDMENT 3	No/ 2020-12-29 (112)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3522650	2020-09-10	AMENDMENT 3	No/ 2020-12-29 (111)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522671	2020-09-11	AMENDMENT 3	No/ 2021-01-08 (120)	Protocol Deviation/ PARTICIPANT WITHDREW FOLLOWING UNBLINDING AFTER DISCLOSING TAKING A EUA APPROVED VACCINE		Yes/ 2020-10-16 (36)	
US3522672	2020-09-11	AMENDMENT 3	No/ 2021-01-08 (120)	Protocol Deviation/ INFORMED AT END OF ILLNESS VISIT THAT PARTICIPANT RECEIVED EUA APPROVED VACCINE TWO DAYS PRIOR		Yes/ 2020-10-14 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522679	2020-09-14	AMENDMENT 3	No/ 2020-12-29 (107)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-12 (29)	
US3522685	2020-09-15	AMENDMENT 3	No/ 2020-12-21 (98)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-13 (29)	
US3522690	2020-09-16	AMENDMENT 3	No/ 2020-12-30 (106)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522697	2020-09-17	AMENDMENT 3	No/ 2020-12-30 (105)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-16 (30)	
US3522707	2020-09-18	AMENDMENT 3	No/ 2020-12-17 (91)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-16 (29)	
US3522711	2020-09-18	AMENDMENT 3	No/ 2021-01-25 (130)	Protocol Deviation/ TOOK ANOTHER EUA APPROVED VACCINE BEFORE OL VISIT		Yes/ 2020-10-23 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522714	2020-09-22	AMENDMENT 3	No/ 2020-12-29 (99)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-20 (29)	
US3522717	2020-09-23	AMENDMENT 3	No/ 2020-12-23 (92)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-10-22 (30)	
US3522719	2020-09-23	AMENDMENT 3	No/ 2021-01-04 (104)	Other/ LEFT IN ORDER TO RECEIVE EUA APPROVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-26 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532015	2020-08-13	AMENDMENT 2	No/ 2020-12-19 (129)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE UNDER EUA FOR HEALTHCARE WORKERS PRIOR TO UNBLINDING		Yes/ 2020-09-16 (35)	
US3532020	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532080	2020-08-19	AMENDMENT 2	No/ 2021-01-12 (147)	Withdrawal of Consent by Participant/ SUBJECT WISHED TOO BE VACCINATED WITH SPOUSE, WHO IS NOT IN STUDY, UNDER EUA.		Yes/ 2020-09-21 (34)	
US3532098	2020-08-20	AMENDMENT 2	No/ 2020-12-23 (126)	Other/ HEALTHCARE WORKER/EUA COVID-19 VACCINE		Yes/ 2020-09-24 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532117	2020-08-24	AMENDMENT 2	No/ 2020-12-20 (119)	Other/ SUBJECT REQUEST UNBLINDING DUE TO EUA FOR HEALTHCARE WORKERS AND RECEIVED PFIZER VACCINE		Yes/ 2020-09-23 (31)	
US3532170	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Serious Adverse Event/ SAE #1
US3532196	2020-08-31	AMENDMENT 3	No/ 2020-12-21 (113)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532203	2020-09-01	AMENDMENT 3	No/ 2020-12-31 (122)	Protocol Deviation/ SUBJECT RECEIVED COVID VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-29 (29)	
US3532210	2020-09-01	AMENDMENT 3	No/ 2020-12-28 (119)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-29 (29)	
US3532212	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Adverse Event/ INCLUSION CRITERIA # 7 NOT MET DUE TO AE #4

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532217	2020-09-02	AMENDMENT 3	No/ 2020-12-18 (108)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-30 (29)	
US3532258	2020-09-09	AMENDMENT 3	No/ 2020-12-16 (99)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3532262	2020-09-09	AMENDMENT 3	No/ 2020-12-22 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-12 (34)	
US3542043	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542090	2020-08-28	AMENDMENT 3	No/ 2021-03-10 (195)	Withdrawal of Consent by Participant/ PARTICIPANT DOES NOT WANT TO RETURN TO CLINIC FOR DECISION VISIT AND JUST WANTS TO BE UNBLINDED OVER THE PHONE. PREFERS TO GET VACCINE OUTSIDE OF STUDY (DESPITE NOT KNOWING IF GOT VACCINE IN STUDY).		No/ 2020-09-24 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542168	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Physician Decision/ PHYSICIAN WITHHELD DOSE DUE TO HOSPITAL ADMISSIONS FOR PSYCHIATRIC REASONS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542197	2020-09-10	AMENDMENT 3	No/ 2020-12-31 (113)	Protocol Deviation/ PARTICIPANT INFORMED PI THAT HE HAD RECEIVED THE PFIZER COVID-19 VACCINE ON 28DEC2020 UNDER EUA. HE WAS UNBLINDED ON 31DEC2020 AND FOUND TO HAVE RECEIVED PLACEBO. WITHDRAWN PER SPONSOR INSTRUCTIONS.		Yes/ 2020-10-12 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542210	2020-09-11	AMENDMENT 3	No/ 2020-12-16 (97)	Withdrawal of Consent by Participant/ PARTICIPANT HAD ACCESS TO PFIZER VACCINE UNDER EUA DUE TO BEING A HEALTHCARE WORKER AND DID NOT WANT TO WAIT FOR PA6 TO BE APPROVED IN CURRENT TRIAL. REQUESTED TO BE UNBLINDED AND WITHDRAWN.		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542229	2020-09-15	AMENDMENT 3	No/ 2020-12-18 (95)	Withdrawal of Consent by Participant/ PARTICIPANT HAD ACCESS TO PFIZER VACCINE UNDER EUA DUE TO BEING A HEALTHCARE WORKER AND DID NOT WANT TO WAIT FOR PA6 TO BE APPROVED IN CURRENT TRIAL. REQUESTED TO BE UNBLINDED AND WITHDRAWN.		Yes/ 2020-10-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542254	2020-09-17	AMENDMENT 3	No/ 2021-03-13 (178)	Withdrawal of Consent by Participant/ PARTICIPANT IS DEALING WITH MULTIPLE FAMILY MEDICAL ISSUES AND CAN NO LONGER ARRANGE TO COME FOR STUDY VISITS.		Yes/ 2020-10-16 (30)	
US3552009	2020-08-12	AMENDMENT 2	No/ 2020-12-22 (133)	Other/ SUBJECT IS RECEIVING PFIZER THROUGH WORK VIA EUA		Yes/ 2020-09-07 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552019	2020-08-12	AMENDMENT 2	No/ 2020-12-22 (133)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-09 (29)	
US3552029	2020-08-13	AMENDMENT 2	No/ 2020-12-18 (128)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-14 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552036	2020-08-14	AMENDMENT 2	No/ 2020-12-28 (137)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-11 (29)	
US3552038	2020-08-14	AMENDMENT 2	No/ 2020-12-16 (125)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-08 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552046	2020-08-15	AMENDMENT 2	No/ 2020-12-23 (131)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-14 (31)	
US3552087	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Adverse Event/ AE #1
US3552103	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Adverse Event/ AE #1
US3552107	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Other/ SUBJECT IN ILLNESS PERIOD

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552135	2020-08-22	AMENDMENT 2	No/ 2020-12-29 (130)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-17 (27)	
US3552140	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Serious Adverse Event/ SAE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552162	2020-08-25	AMENDMENT 3	No/ 2020-12-22 (120)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-21 (28)	
US3552167	2020-08-25	AMENDMENT 3	No/ 2020-12-16 (114)	Other/ WILL RECEIVE PFIZER VACCINE THROUGH WORK VIA EUA		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552172	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (116)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE THROUGH HIS PLACE OF WORK, NOTIFIED SITE OF THIS ON 12/18/20 AFTER THE FACT.		Yes/ 2020-09-19 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552204	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Physician Decision/ SUBJECT TRAVELING FOR NEXT 2 WKS; UNABLE TO STAY WITHIN ONE HR OF SITE DURING EDIARY PERIOD; SUBJECT ALSO HAS A SINUS INFECTION AND IS ON PREDNISONE
US3552206*	2020-08-27	AMENDMENT 3	No/ 2020-12-17 (113)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 AND FOUND TO BE PLACEBO AND HAD ACCESS TO PFIZER EUA THROUGH WORK		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552232	2020-08-29	AMENDMENT 3	ONGOING			No/ 2020-09-25 (28)	Serious Adverse Event/ SAE #3
US3552261	2020-09-01	AMENDMENT 3	No/ 2020-12-23 (114)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552263	2020-09-01	AMENDMENT 3	No/ 2021-01-04 (126)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO ACCESS TO PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-29 (29)	
US3552273	2020-09-01	AMENDMENT 3	No/ 2021-03-01 (182)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY		No/ 2020-09-28 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552275	2020-09-01	AMENDMENT 3	No/ 2020-12-22 (113)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO BEING OFFERED PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-09-30 (30)	
US3552312	2020-09-03	AMENDMENT 3	No/ 2020-12-16 (105)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO BEING OFFERED PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552331	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Serious Adverse Event/ SAE #1
US3552334	2020-09-04	AMENDMENT 3	No/ 2020-12-23 (111)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO BEING OFFERED PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552346	2020-09-05	AMENDMENT 3	No/ 2020-12-16 (103)	Other/ SUBJECT WAS UNBLINDED UNDER PA5 DUE TO BEING OFFERED PFIZER EUA THROUGH WORK AND FOUND TO BE PLACEBO		Yes/ 2020-10-02 (28)	
US3552365	2020-09-08	AMENDMENT 3	No/ 2020-12-22 (106)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE THROUGH WORK		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552397	2020-09-09	AMENDMENT 3	No/ 2020-11-16 (68)	Withdrawal of Consent by Participant/ SUBJECT CALLED TO STATE HE IS NO LONGER WILLING TO COME TO THE SITE AND WISHES TO WITHDRAW CONSENT		Yes/ 2020-10-12 (33)	
US3552413	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Other/ SUBJECT IN ILLNESS PERIOD

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552427	2020-09-14	AMENDMENT 3	No/ 2021-02-16 (156)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA VACCINE; HAD NOT REPORTED EITHER DOSE AT PREVIOUS CONTACTS OR DECISION VISIT.		Yes/ 2020-10-19 (36)	
US3552429	2020-09-14	AMENDMENT 3	No/ 2020-12-22 (100)	Other/ SUBJECT WAS UNBLINDED DUE TO BEING OFFERED PFIZER EUA THROUGH WORK UNDER PA5 AND FOUND TO BE PLACEBO		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552436	2020-09-15	AMENDMENT 3	No/ 2021-01-12 (120)	Protocol Deviation/ SUBJECT NOTIFIED SITE AFTER THE FACT THAT SHE HAD RECEIVED EUA PFIZER		Yes/ 2020-10-14 (30)	
US3552444	2020-09-16	AMENDMENT 3	ONGOING			No/ 2020-10-13 (28)	Adverse Event/ AE #3
US3552465	2020-09-18	AMENDMENT 3	No/ 2020-12-22 (96)	Other/ SUBJECT BEING OFFERED PFIZER VACCINE THROUGH WORK VIA EUA		Yes/ 2020-10-19 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552474	2020-09-19	AMENDMENT 3	No/ 2021-01-20 (124)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-20 (32)	
US3552533	2020-10-15	AMENDMENT 4	No/ 2020-12-01 (48)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT 01DEC2020 DUE TO WORK SCHEDULE		No/ 2020-11-11 (28)	Other/ SUBJECT DID NOT SHOW UP FOR MULTIPLE APPOINTMENTS AND SITE HAS BEEN UNABLE TO REACH HIM

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562004	2020-08-04	AMENDMENT 1	No/ 2020-09-21 (49)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO CONTINUE WITH STUDY AND WITHDREW CONSENT. DID NOT PROVIDE SPECIFIC REASON FOR NOT TO CONTINUE		No/ 2020-08-31 (28)	Withdrawal of Consent by Participant/ PATIENT DOES NOT WANT TO CONTINUE WITH STUDY AND DID NOT PROVIDE SPECIFIC REASON FOR NOT TO CONTINUE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562015	2020-08-06	AMENDMENT 1	No/ 2021-03-23 (230)	Withdrawal of Consent by Participant/ SPONSOR DECIDED LAST DOSE FOR STUDY VACCINE MARCH 25TH2021 AND PT RECEIVED MONOCONOL ANITBODIES AND NOT ELIGIBLE TO RECEIVED VACCINE TILL APR9TH2021. PT WITHDREW CONSENT		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562031	2020-08-12	AMENDMENT 2	No/ 2020-12-15 (126)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-14 (34)	
US3562040	2020-08-14	AMENDMENT 2	No/ 2021-01-04 (144)	Protocol Deviation/ PT RECEIVED PFIZER VACCINE DURING WEEKEND		Yes/ 2020-09-18 (36)	
US3562043	2020-08-14	AMENDMENT 2	No/ 2021-01-04 (144)	Protocol Deviation/ PATIENT ALREADY RECEIVED MODERNA VACCINE FROM EMPLOYEE ON 12/26/2020		Yes/ 2020-09-18 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562049	2020-08-17	AMENDMENT 2	No/ 2021-03-10 (206)	Lost to Follow-Up		Yes/ 2020-09-15 (30)	
US3562052	2020-08-18	AMENDMENT 2	No/ 2021-01-12 (148)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562080	2020-08-26	AMENDMENT 3	No/ 2021-01-22 (150)	Other/ PT IS MOVING TO (b) (6) AND OTHER SITE IS NOT WILLING TO ACCEPT TRANSFER PATIENT ! PATIENT CAN NOT COME BACK FOR 2ND VACCINE AND WITHDREW CONSENT		Yes/ 2020-09-22 (28)	
US3562084	2020-08-27	AMENDMENT 3	No/ 2020-12-22 (118)	Other/ CDC CRITERIA MET TO RECEIVED PFIZER EUA VACCINE		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562101	2020-09-01	AMENDMENT 3	No/ 2020-11-25 (86)	Lost to Follow-Up		Yes/ 2020-09-29 (29)	
US3562136	2020-09-09	AMENDMENT 3	No/ 2021-02-02 (147)	Protocol Deviation/ PATIENT RECEIVED EUA MODERNA ON 12/27/21 FROM WORK AND DOES NOT WANT TO CONTINUE WITH STUDY		Yes/ 2020-10-05 (27)	
US3562158	2020-09-12	AMENDMENT 3	No/ 2020-12-22 (102)	Other/ CDC CRITERIA MET TO RECEIVE EUA PFIZER VACCINE		Yes/ 2020-10-13 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562195	2020-09-23	AMENDMENT 3	No/ 2020-10-21 (29)	Withdrawal of Consent by Participant/ PATIENT DENIED FOR NASAL SWAB AND WITHDREW CONSENT AS CAN NOT DISPEND VACCINE WITHOUT NASAL SWAB PER PROTOCOL		No/ 2020-10-20 (28)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO DO NASAL SWAB AND WITHDREW CONSENT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562201	2020-09-28	AMENDMENT 3	No/ 2021-03-11 (165)	Withdrawal of Consent by Participant/ TRANSPORTATION ISSUE TO TRAVEL ACROSS THE COUNTIES OVER THE LONG DISTANCE		Yes/ 2020-11-02 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562220	2020-10-08	AMENDMENT 4	No/ 2021-01-29 (114)	Other/ PT IS IN JAIL (b) (6) SITE DOES NOT HAVE INFORMATION WHEN PATIENT WILL RELEASE FROM JAIL AND PT IS NOT ELIGIBLE TO CONTINUE WITH STUDY		Yes/ 2020-11-05 (29)	
US3562232	2020-10-16	AMENDMENT 4	No/ 2020-12-14 (60)	Lost to Follow-Up		No/ 2020-11-12 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562236	2020-10-20	AMENDMENT 4	No/ 2020-11-19 (31)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO DO BLOOD DRAW ANYMORE AND SITE CAN NOT DOSE PATIENT WITHOUT BLOOD DRAW AND SWAB. PT WITHDREW CONSENT AND WALKED OUT		No/ 2020-11-16 (28)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO DO BLOOD DRAW ANYMORE AND SITE CAN NOT DOSE PATIENT WITHOUT BLOOD DRAW AND SWAB. PT WITHDREW CONSENT AND WALKED OUT
US3572004	2020-08-17	AMENDMENT 2	No/ 2021-03-12 (208)	Protocol Deviation/ SUBJECT DOSED OUTSIDE OF THE STUDY.		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572005	2020-08-17	AMENDMENT 2	No/ 2021-01-18 (155)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-14 (29)	
US3572012	2020-08-18	AMENDMENT 2	No/ 2021-02-23 (190)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE THROUGH EMPLOYER BECAUSE HE IS A EMERGENCY ROOM PHYSICIAN.		No/ 2020-09-14 (28)	Other/ OUT OF WINDOW FOR SECOND DOSE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572017	2020-08-19	AMENDMENT 2	No/ 2020-12-18 (122)	Protocol Deviation/ SUBJECT GOT VACCINE OUTSIDE OF STUDY CONFINES SO AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-22 (35)	
US3572022	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Protocol Deviation/ PATIENT OUT OF WINDOW BY 5 DAYS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572024	2020-08-19	AMENDMENT 2	No/ 2021-02-11 (177)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-22 (35)	
US3572028	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572045	2020-08-20	AMENDMENT 2	No/ 2021-01-18 (152)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-24 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572062	2020-08-21	AMENDMENT 2	No/ 2021-01-18 (151)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-21 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572064	2020-08-21	AMENDMENT 2	No/ 2021-03-04 (196)	Protocol Deviation/ SUBJECT GOT COVID-19 PFIZER VACCINE OUTSIDE THE CONFINES OF THE STUDY		No/ 2020-09-17 (28)	Withdrawal of Consent by Participant/ SUBJECT DID NOT RETURN FOR 2ND DOSE DESPITE NUMEROUS CALLS. SUBJECT RECEIVED PFIZER VACCINE OFF STUDY AND WAS WITHDRAWN

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572074	2020-08-24	AMENDMENT 2	No/ 2021-02-22 (183)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-22 (30)	
US3572078	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Lost to Follow-Up
US3572086	2020-08-25	AMENDMENT 3	No/ 2021-02-12 (172)	Death	2021-02-12/ UNK	Yes/ 2020-09-23 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572094	2020-08-26	AMENDMENT 3	No/ 2020-10-14 (50)	Withdrawal of Consent by Participant/ STUDY NURSE CALLED SITE AND INFORMED US THAT PATIENT WANTED TO WITHDRAW.		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ STUDY NURSE CALLED SITE AND INFORMED US THAT PATIENT WANTED TO WITHDRAW.
US3572095	2020-08-26	AMENDMENT 3	No/ 2020-12-09 (106)	Withdrawal of Consent by Participant/ LACK OF AVAILABLE TIME TO CONTINUE PARTICIPATING IN THE STUDY		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW CONSENT DUE TO A LACK OF AVAILABLE TIME TO CONTINUE IN THE STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572110	2020-08-27	AMENDMENT 3	No/ 2021-01-08 (135)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572130	2020-08-28	AMENDMENT 3	No/ 2021-01-20 (146)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-29 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572139	2020-08-28	AMENDMENT 3	No/ 2020-12-28 (123)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572145	2020-08-31	AMENDMENT 3	No/ 2021-02-12 (166)	Protocol Deviation/ SUBJECT GOT VACCINE OUTSIDE OF STUDY CONFINES AND AS PER SPONSOR DIRECTIVES THE SUBJECT NEEDS TO BE WITHDRAWN FROM STUDY.		Yes/ 2020-09-29 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572147	2020-08-31	AMENDMENT 3	No/ 2021-01-26 (149)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-29 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572160	2020-09-01	AMENDMENT 3	No/ 2020-12-28 (119)	Protocol Deviation/ SUBJECT WAS UNBLINDED BY PI BECAUSE SUBJECT WAS ELIGIBLE FOR VACCINE OUTSIDE OF THE STUDY. SUBJECT WILL BE WITHDRAWN BECAUSE IT WAS BEFORE A6.		Yes/ 2020-10-05 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572163	2020-09-01	AMENDMENT 3	No/ 2021-01-06 (128)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-09-30 (30)	
US3572186	2020-09-04	AMENDMENT 3	No/ 2021-03-18 (196)	Protocol Deviation/ SUBJECT GOT PFIZER VACCINE. AS PER SPONSOR DIRECTIVE PLEASE WITHDRAW.		Yes/ 2020-10-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572191	2020-09-04	AMENDMENT 3	No/ 2021-01-18 (137)	Protocol Deviation/ SUBJECT GOT VACCINE OUTSIDE OF STUDY CONFINES SO AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572198	2020-09-04	AMENDMENT 3	No/ 2021-01-23 (142)	Protocol Deviation/ SUBJECT WITHDRAWN FROM STUDY BECAUSE SHE RECEIVED THE VACCINE OUTSIDE OF STUDY. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN FROM STUDY.		No/ 2020-10-01 (28)	Other/ SUBJECT WITHDRAWN FROM STUDY BECAUSE SHE RECEIVED THE VACCINE OUTSIDE OF STUDY. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN FROM STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572205	2020-09-07	AMENDMENT 3	No/ 2021-02-02 (149)	Protocol Deviation/ SUBJECT RECIEVED VACCINE OUTSIDE OF THE STUDY CONFINES. SUBJECT NEEDS TO BE WITHDRAWN AS PER EPIP DIRECTIVE.		Yes/ 2020-10-06 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572219	2020-09-08	AMENDMENT 3	No/ 2021-01-06 (121)	Protocol Deviation/ SUBJECT WITHDRAWN FROM STUDY BECAUSE SHE RECEIVED THE VACCINE OUTSIDE OF STUDY. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN FROM STUDY.		Yes/ 2020-10-07 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572222	2020-09-08	AMENDMENT 3	No/ 2021-03-09 (183)	Protocol Deviation/ SUBJECT WAS VACCINATED OUTSIDE OF THE STUDY CONFINES.		Yes/ 2020-10-05 (28)	
US3572229	2020-09-09	AMENDMENT 3	No/ 2021-01-06 (120)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572236	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ NON-RESPONSIVE
US3572262	2020-09-10	AMENDMENT 3	No/ 2021-01-08 (121)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-09 (30)	
US3572281	2020-09-14	AMENDMENT 3	ONGOING			No/ 2020-10-11 (28)	Other/ PATIENT DID NOT MEET WINDOW FOR SECOND DOSE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572288	2020-09-14	AMENDMENT 3	No/ 2021-01-18 (127)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-14 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572301	2020-09-15	AMENDMENT 3	No/ 2021-01-11 (118)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-13 (28)	
US3572305	2020-09-16	AMENDMENT 3	No/ 2021-02-16 (154)	Protocol Deviation/ SUBJECT GOT PFIZER VACCINE OUTSIDE OF THE STUDY SO SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-13 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572308	2020-09-16	AMENDMENT 3	No/ 2021-03-24 (190)	Withdrawal of Consent by Participant/ SUBJECT WISHES TO WITHDRAW BECAUSE HE CAN GET VACCINE THROUGH HIS PCP.		Yes/ 2020-10-12 (27)	
US3572331	2020-09-21	AMENDMENT 3	No/ 2021-01-20 (122)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		No/ 2020-10-18 (28)	Other/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572339	2020-09-23	AMENDMENT 3	No/ 2021-02-11 (142)	Protocol Deviation/ SUBJECT GOT VACCINE OUTSIDE OF STUDY CONFINES. SUBJECT IS TO BE WITHDRAWN AS PER SPONSOR DIRECTIVE.		No/ 2020-10-20 (28)	Other/ PATIENT OUT OF WINDOW FOR SECOND DOSE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572349	2020-09-25	AMENDMENT 3	No/ 2020-12-22 (89)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY SO SUBJECT NEEDS TO BE WITHDRAWN AS PER SPONSOR DIRECTIVE.		Yes/ 2020-10-26 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572351	2020-09-28	AMENDMENT 3	No/ 2021-03-11 (165)	Withdrawal of Consent by Participant/ SUBJECT HAD THE OPPORTUNITY TO GET VACCINE THROUGH OUTSIDE THE STUDY AND WOULD LIKE TO WITHDRAW BECAUSE HE DOES NOT HAVE TIME TO MAKE APPOINTMENTS.		Yes/ 2020-10-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572353	2020-09-29	AMENDMENT 3	No/ 2021-01-27 (121)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY. SUBJECT NEEDS TO BE WITHDRAWN AS PER EPIP DIRECTIVE.		Yes/ 2020-10-28 (30)	
US3572365	2020-10-05	AMENDMENT 3	ONGOING			No/ 2020-11-01 (28)	Other/ TECHNICAL DIFFICULTIES WITH ENDPOINT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572367	2020-10-06	AMENDMENT 3	No/ 2020-11-03 (29)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW FROM STUDY (b) (6)		No/ 2020-11-02 (28)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW FROM STUDY (b) (6)
US3572369	2020-10-06	AMENDMENT 3	No/ 2020-11-05 (31)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW FROM STUDY (b) (6)		No/ 2020-11-02 (28)	Withdrawal of Consent by Participant/ PATIENT DECIDED TO WITHDRAW FROM STUDY (b) (6)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572370	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-02 (28)	Other/ AS PER MODERNA THE PATIENT IS NOT ELIGIBLE FOR THE SECOND DOSE.
US3572371	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-02 (28)	Other/ PER MODERNA PATIENT IS NOT ELIGIBLE TO GET DOSED.
US3572378	2020-10-07	AMENDMENT 3	No/ 2021-03-19 (164)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE.		Yes/ 2020-11-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572395	2020-10-13	AMENDMENT 4	No/ 2021-02-10 (121)	Protocol Deviation/ SUBJECT GOT VACCINE OUTSIDE OF STUDY CONFINES SO AS PER SPONSOR DIRECTIVES THE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-11-11 (30)	
US3572405	2020-10-20	AMENDMENT 4	ONGOING			No/ 2020-11-16 (28)	Other/ SUBJECT WAS A POTENTIAL LOST TO FOLLOW BUT HE CAME BACK FOR DECISION VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572407	2020-10-22	AMENDMENT 4	ONGOING			No/ 2020-11-18 (28)	Lost to Follow-Up
US3582006	2020-08-18	AMENDMENT 2	No/ 2020-12-28 (133)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-16 (30)	
US3582015	2020-08-20	AMENDMENT 2	No/ 2020-12-22 (125)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	
US3582017	2020-08-20	AMENDMENT 2	No/ 2020-12-23 (126)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582020	2020-08-21	AMENDMENT 2	No/ 2020-12-18 (120)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-18 (29)	
US3582024	2020-08-21	AMENDMENT 2	No/ 2021-01-06 (139)	Protocol Deviation/ PARTICIPANT RECEIVED NON-STUDY EUA COVID-19 VACCINE		Yes/ 2020-09-18 (29)	
US3582029	2020-08-24	AMENDMENT 2	No/ 2020-12-21 (120)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582031	2020-08-24	AMENDMENT 2	No/ 2020-12-28 (127)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	
US3582032	2020-08-24	AMENDMENT 2	No/ 2020-12-31 (130)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-23 (31)	
US3582046	2020-08-25	AMENDMENT 3	No/ 2020-12-17 (115)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-21 (28)	
US3582047	2020-08-25	AMENDMENT 3	No/ 2020-12-23 (121)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582053	2020-08-26	AMENDMENT 3	No/ 2020-12-16 (113)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-22 (28)	
US3582069	2020-08-28	AMENDMENT 3	No/ 2020-12-16 (111)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-23 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582080	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Other/ PARTICIPANT UNABLE TO COMPLETE VISIT 2 WITHIN WINDOW DUE TO FAMILY EMERGENCY. DATE OF DOSE DISCONTINUATION BASED ON DOSE 2 TARGET DATE.
US3582089	2020-09-02	AMENDMENT 3	No/ 2020-12-23 (113)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582116	2020-09-08	AMENDMENT 3	No/ 2021-01-27 (142)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-07 (30)	
US3582130	2020-09-10	AMENDMENT 3	No/ 2021-01-06 (119)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-08 (29)	
US3582166	2020-09-30	AMENDMENT 3	No/ 2020-12-16 (78)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582182	2020-10-12	AMENDMENT 4	No/ 2021-01-04 (85)	Protocol Deviation/ PARTICIPANT RECEIVED NON-STUDY EUA COVID-19 VACCINE		Yes/ 2020-11-10 (30)	
US3582190	2020-10-19	AMENDMENT 4	No/ 2021-01-11 (85)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-11-16 (29)	
US3592005	2020-08-05	AMENDMENT 1	No/ 2020-08-21 (17)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WANT TO DO E-DIARY		No/ 2020-08-20 (16)	Withdrawal of Consent by Participant/ WITHDREW CONSENT DUE TO NOT WANTING TO DO E-DIARY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592054	2020-08-07	AMENDMENT 1	No/ 2021-01-25 (172)	Protocol Deviation/ NO LONGER MEETS INCLUSION#2 RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY WAS NOT UNBLINDED PRIOR		Yes/ 2020-09-04 (29)	
US3592071	2020-08-08	AMENDMENT 1	No/ 2020-12-30 (145)	Protocol Deviation/ NO LONGER MEETS INCLUSION #2 VACCINATED OUT OF STUDY WITHOUT CONTACTING SITE PRIOR FOR UNBLINDING.		Yes/ 2020-09-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592078	2020-08-09	AMENDMENT 1	No/ 2020-08-28 (20)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO CONFLICTING SCHEDULES FOR RETURN VISITS		No/ 2020-08-27 (19)	Withdrawal of Consent by Participant/ DUE TO CONFLICTING SCHEDULE WITH RETURN APPOINTMENTS
US3592118	2020-08-11	AMENDMENT 2	No/ 2021-01-05 (148)	Other/ UNBLINDED UNDER AMENDMENT 5, ASSIGNED PLACEBO		Yes/ 2020-09-08 (29)	
US3592156	2020-08-14	AMENDMENT 2	No/ 2021-01-11 (151)	Other/ SUBJECT OUT OF STATE, NO LONGER MEETS INCLUSION CRITERIA #3		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592157	2020-08-14	AMENDMENT 2	No/ 2021-01-11 (151)	Other/ SUBJECT TO MOVE OUT OF STATE, NO LONGER MEETS INCLUSION #3.		Yes/ 2020-09-11 (29)	
US3592178	2020-08-15	AMENDMENT 2	No/ 2021-01-08 (147)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592202	2020-08-16	AMENDMENT 2	No/ 2020-11-25 (102)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED TO DROP DUE TO NEW DIAGNOSIS OF HIV (HUMAN IMMUNODEFICIENCY VIRUS).		Yes/ 2020-09-13 (29)	
US3592207	2020-08-16	AMENDMENT 2	No/ 2020-12-31 (138)	Other/ UNBLINDED UNDER AMENDMENT 5, ASSIGNED PLACEBO		Yes/ 2020-09-13 (29)	
US3592218	2020-08-17	AMENDMENT 2	No/ 2020-10-15 (60)	Lost to Follow-Up		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602002	2020-09-01	AMENDMENT 3	No/ 2020-12-17 (108)	Other/ REQUEST TO UNBLIND BY THE SUBJECT AND MEETS THE EUA FOR COVID-19 VACCINE NOW AND IS ABLE TO GET IT AT WORKPLACE		Yes/ 2020-09-30 (30)	
US3602008	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602009	2020-09-03	AMENDMENT 3	No/ 2020-12-28 (117)	Protocol Deviation/ RECEIVED NON-STUDY EUA PFIZER COVID-19 VACCINE ON 16/DEC/2021		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602014	2020-09-03	AMENDMENT 3	No/ 2020-12-16 (105)	Withdrawal of Consent by Participant/ RECEIVED EPIP APPROVAL TO UNBLIND AS PER SUBJECT'S REQUEST (HEALTHCARE WORKER WHO IS ELIGIBLE FOR THE PFIZER VACCINE).		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602022	2020-09-09	AMENDMENT 3	No/ 2020-12-28 (111)	Other/ REQUEST TO UNBLIND BY THE SUBJECT. REASON FOR UNBLINDING: MEETS CDC CRITERIA TO RECEIVE MODERNA VACCINE UNDER EUA IN TIER 1A AT HER FACILITY.		Yes/ 2020-10-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602048	2020-09-17	AMENDMENT 3	No/ 2021-02-19 (156)	Protocol Deviation/ RECEIVED NON-STUDY EUA MODERNA COVID-19 VACCINE ON 30/DEC/2020 OUTSIDE OF THE STUDY.		Yes/ 2020-10-15 (29)	
US3602065	2020-09-21	AMENDMENT 3	No/ 2021-01-23 (125)	Protocol Deviation/ RECEIVED NON-STUDY EUA PFIZER COVID-19 VACCINE ON 30/DEC/2021.		Yes/ 2020-10-22 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602068	2020-09-21	AMENDMENT 3	No/ 2020-12-29 (100)	Other/ REQUEST TO UNBLIND BY THE SUBJECT AND MEETS THE EUA FOR COVID-19 VACCINE NOW AND IS ABLE TO GET IT AT WORKPLACE.		Yes/ 2020-10-23 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602073	2020-09-21	AMENDMENT 3	No/ 2021-01-21 (123)	Protocol Deviation/ SUBJECT RECEIVED NON-STUDY EUA MODERNA COVID-19 VACCINE ON 5/JAN/2021 FROM WORK (SUBJECT KNEW, WITHOUT UNBLINDING, THEY RECEIVED PLACEBO DUE TO TESTING AND LACK OF SYMPTOMS) AND IS MOVING OUT OF STATE		Yes/ 2020-10-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602096	2020-09-24	AMENDMENT 3	No/ 2021-03-16 (174)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO WITHDRAW FROM THE STUDY.		Yes/ 2020-10-22 (29)	
US3602097	2020-09-24	AMENDMENT 3	No/ 2021-03-16 (174)	Withdrawal of Consent by Participant/ SUBJECT WOULD LIKE TO WITHDRAW FROM THE STUDY		Yes/ 2020-10-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602111	2020-09-29	AMENDMENT 3	No/ 2021-02-06 (131)	Protocol Deviation/ RECEIVED NON-STUDY EUA PFIZER COVID-19 VACCINE ON 13/JAN/2021 OUTSIDE OF THE CLINICAL TRIAL		No/ 2020-10-26 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602118	2020-10-01	AMENDMENT 3	No/ 2020-12-16 (77)	Withdrawal of Consent by Participant/ RECEIVED EPIP APPROVAL TO UNBLIND SUBJECTS REQUEST (HCW WHO IS ELIGIBLE FOR THE PFIZER VACCINE)		Yes/ 2020-11-03 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602137	2020-10-08	AMENDMENT 3	No/ 2020-12-16 (70)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FROM STUDY SINCE, AS A TIER 1 HEALTHCARE WORKER, HAS ACCESS TO PFIZER VACCINE, DOES NOT WANT TO WAIT ADDITIONAL 2-3 WEEKS FOR MODERNA VACCINE UNBLINDING. UNBLINDED AND W/D 16DEC2020.		Yes/ 2020-11-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3612069	2020-10-06	AMENDMENT 3	No/ 2020-12-18 (74)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-11 (37)	
US3612078	2020-10-19	AMENDMENT 4	No/ 2020-12-18 (61)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-16 (29)	
US3622002	2020-08-07	AMENDMENT 1	No/ 2020-12-24 (137)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-10 (32)	
US3622006	2020-08-10	AMENDMENT 1	No/ 2020-12-16 (129)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622008	2020-08-10	AMENDMENT	1 No/ 2020-12-23 (136)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-09 (31)	
US3622012	2020-08-11	AMENDMENT	1 No/ 2020-11-13 (95)	Other/ PARTICIPANT MOVED OUT OF STATE.		No/ 2020-09-07 (28)	Adverse Event/ AE #1
US3622017	2020-08-13	AMENDMENT	1 No/ 2020-12-21 (131)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-10 (29)	
US3622019	2020-08-13	AMENDMENT	1 No/ 2020-12-22 (132)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622026	2020-08-14	AMENDMENT 2	No/ 2020-12-23 (132)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-11 (29)	
US3622027	2020-08-14	AMENDMENT 2	No/ 2020-12-30 (139)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-11 (29)	
US3622031	2020-08-14	AMENDMENT 2	No/ 2020-12-14 (123)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-15 (33)	
US3622049	2020-08-20	AMENDMENT 2	No/ 2020-12-23 (126)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622054	2020-08-20	AMENDMENT 2	No/ 2021-01-05 (139)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (29)	
US3622056	2020-08-21	AMENDMENT 2	No/ 2020-12-22 (124)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-17 (28)	
US3622076	2020-08-25	AMENDMENT 2	No/ 2020-12-28 (126)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	
US3622079	2020-08-26	AMENDMENT 2	No/ 2020-12-16 (113)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-24 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622081	2020-08-26	AMENDMENT 2	No/ 2020-12-17 (114)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-26 (32)	
US3622087	2020-08-27	AMENDMENT 2	No/ 2020-12-16 (112)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-24 (29)	
US3622093	2020-08-28	AMENDMENT 2	No/ 2020-12-14 (109)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3622099	2020-08-28	AMENDMENT 2	No/ 2020-12-18 (113)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-29 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622101	2020-08-28	AMENDMENT 2	No/ 2020-10-20 (54)	Withdrawal of Consent by Participant		Yes/ 2020-09-26 (30)	
US3622102	2020-08-28	AMENDMENT 2	No/ 2020-10-19 (53)	Withdrawal of Consent by Participant		Yes/ 2020-09-26 (30)	
US3622107	2020-08-29	AMENDMENT 2	No/ 2020-12-23 (117)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-26 (29)	
US3622127	2020-09-01	AMENDMENT 3	No/ 2021-01-04 (126)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622145	2020-09-03	AMENDMENT 3	No/ 2020-09-28 (26)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT		No/ 2020-09-27 (25)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT
US3622167	2020-09-08	AMENDMENT 3	No/ 2021-01-13 (128)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-06 (29)	
US3622175	2020-09-11	AMENDMENT 3	No/ 2020-12-29 (110)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-14 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622183	2020-09-14	AMENDMENT 3	No/ 2020-12-24 (102)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-15 (32)	
US3622202	2020-09-18	AMENDMENT 3	No/ 2020-12-28 (102)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-20 (33)	
US3622212	2020-09-21	AMENDMENT 3	No/ 2021-01-21 (123)	Lost to Follow-Up		Yes/ 2020-10-19 (29)	
US3622227	2020-09-25	AMENDMENT 3	No/ 2020-12-22 (89)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622234	2020-09-26	AMENDMENT 3	No/ 2021-01-12 (109)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-30 (35)	
US3622251	2020-10-03	AMENDMENT 3	No/ 2020-12-17 (76)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-02 (31)	
US3622253	2020-10-05	AMENDMENT 3	No/ 2020-12-16 (73)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622282	2020-10-21	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Other/ UNABLE TO COMPLY WITH PROTOCOL VISIT REQUIREMENTS FOR SECOND VACCINATION
US3622288	2020-10-23	AMENDMENT 4	No/ 2021-01-07 (77)	Withdrawal of Consent by Participant		Yes/ 2020-11-20 (29)	
US3632002	2020-08-20	AMENDMENT 2	No/ 2021-01-17 (151)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-15 (27)	
US3632004	2020-08-21	AMENDMENT 2	No/ 2020-12-20 (122)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3632020	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-01 (35)	
US3632025	2020-08-31	AMENDMENT 3	No/ 2020-12-24 (107)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-06 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3632032	2020-09-01	AMENDMENT 3	No/ 2020-10-19 (34)	Withdrawal of Consent by Participant/ PARTICIPANT REQUESTED TO WITHDRAW DUE TO HEALTH CHALLENGES AND A NEW JOB, MAKING IT DIFFICULT TO KEEP VISITS/STUDY PROCEDURES.		No/ 2020-10-13 (28)	Withdrawal of Consent by Participant/ PARTICIPANT REQUESTED TO WITHDRAW DUE TO HEALTH CHALLENGES AND A NEW JOB, MAKING IT DIFFICULT TO KEEP VISITS/STUDY PROCEDURES.
US3632042	2020-09-03	AMENDMENT 3	No/ 2020-12-20 (109)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3632076	2020-09-11	AMENDMENT 3	No/ 2020-12-23 (104)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3632080	2020-09-14	AMENDMENT 3	No/ 2020-10-30 (47)	Withdrawal of Consent by Participant/ THE PARTICIPANT WITHDREW FROM THE STUDY BECAUSE HE IS LEAVING THE STATE DUE TO (b) (6)		Yes/ 2020-10-09 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3632092	2020-09-17	AMENDMENT 3	No/ 2020-12-23 (98)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-15 (29)	
US3632110	2020-10-01	AMENDMENT 3	No/ 2021-01-21 (113)	Lost to Follow-Up		Yes/ 2020-10-27 (27)	
US3632112	2020-10-02	AMENDMENT 3	No/ 2021-03-05 (155)	Lost to Follow-Up		Yes/ 2020-11-05 (35)	
US3632117	2020-10-07	AMENDMENT 4	No/ 2021-01-13 (99)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-11-02 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642029	2020-08-27	AMENDMENT 2	No/ 2021-02-27 (185)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		No/ 2020-09-23 (28)	Protocol Deviation/ PT HAS ONGOING DIAGNOSIS OF CHRONIC LYMPHOID LEUKEMIA THAT IS EXCLUSIONARY BUT WAS MISSED AT SCREENING. PT REC'D FIRST DOSE OF VACCINE, BUT D/C PRIOR TO RECEIVING 2ND DOSE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642152	2020-09-09	AMENDMENT 3	No/ 2020-12-23 (106)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-08 (30)	
US3642160	2020-09-10	AMENDMENT 3	No/ 2021-01-06 (119)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642175	2020-09-12	AMENDMENT 3	No/ 2021-01-08 (119)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-12 (31)	
US3642210	2020-09-14	AMENDMENT 3	No/ 2021-01-23 (132)	Withdrawal of Consent by Participant/ PATIENT UNBLINDED IN ERROR AND WITHDREW CONSENT FOLLOWING UNBLINDING.		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642211	2020-09-14	AMENDMENT 3	No/ 2020-12-21 (99)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-16 (33)	
US3642216	2020-09-15	AMENDMENT 3	No/ 2020-12-30 (107)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-15 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642237	2020-09-18	AMENDMENT 3	No/ 2021-01-05 (110)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-15 (28)	
US3642244	2020-09-18	AMENDMENT 3	No/ 2021-01-08 (113)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642261	2020-09-19	AMENDMENT 3	No/ 2020-12-27 (100)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		No/ 2020-10-16 (28)	Adverse Event/ AE # 1
US3642265	2020-09-19	AMENDMENT 3	No/ 2021-01-16 (120)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642278	2020-09-26	AMENDMENT 3	No/ 2021-01-06 (103)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-24 (29)	
US3642281	2020-09-26	AMENDMENT 3	No/ 2021-03-09 (165)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642283	2020-09-28	AMENDMENT 3	No/ 2020-12-30 (94)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-29 (32)	
US3642290	2020-10-01	AMENDMENT 3	No/ 2020-12-30 (91)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642300	2020-10-03	AMENDMENT 3	No/ 2020-12-26 (85)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-11-03 (32)	
US3642310	2020-10-12	AMENDMENT 3	No/ 2021-01-07 (88)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-11-12 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642313	2020-10-13	AMENDMENT 3	No/ 2021-01-09 (89)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-11-13 (32)	
US3642342	2020-10-23	AMENDMENT 4	No/ 2021-03-10 (139)	Other/ PARTICIPANT RELOCATED TO MEXICO AND REQUESTED TO WITHDRAW CONSENT AND UNBLIND.		Yes/ 2020-11-20 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3652012	2020-09-09	AMENDMENT 3	No/ 2020-12-22 (104)	Other/ PATIENT REQUESTED UNBLINDING AS HE IS A PHYSICIAN AND HAS ACCESS EUA VACCINE (PFIZER)		Yes/ 2020-10-07 (28)	
US3652039	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-26 (28)	Adverse Event/ AE #2
US3662019	2020-08-27	AMENDMENT 3	No/ 2020-12-21 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-25 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3662057	2020-09-08	AMENDMENT 3	No/ 2020-12-15 (90)	Protocol Deviation/ PT. RECIEVED PFIZER COVID-19 VACCINE UNDER EUA ON 12/15/2020		Yes/ 2020-10-19 (33)	
US3662079	2020-09-11	AMENDMENT 3	No/ 2020-12-21 (102)	Other/ OTHER- REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	
US3662103	2020-09-16	AMENDMENT 3	No/ 2020-12-18 (94)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3662133	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-21 (28)	Protocol Deviation/ DAY 29 VISIT >2 WEEKS OUT OF WINDOW, PER STUDY TEAM INSTRUCTIONS
US3662175	2020-10-20	AMENDMENT 4	No/ 2021-01-12 (85)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-11-17 (29)	
US3672013	2020-08-06	AMENDMENT 1	No/ 2020-09-09 (35)	Withdrawal of Consent by Participant/ PATIENT NO LONGER HAS TIME TO PARTICIPATE		No/ 2020-09-02 (28)	Other/ PATIENT NO LONGER HAS TIME TO PARTICIPATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672015	2020-08-07	AMENDMENT 1	No/ 2020-12-16 (132)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-09 (34)	
US3672026	2020-08-07	AMENDMENT 1	No/ 2021-01-06 (153)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-04 (29)	
US3672053	2020-08-11	AMENDMENT 2	No/ 2020-09-24 (45)	Lost to Follow-Up		No/ 2020-09-07 (28)	Lost to Follow-Up
US3672064	2020-08-11	AMENDMENT 2	No/ 2021-02-03 (177)	Other/ PATIENT OUT OF (b) (6)		Yes/ 2020-09-09 (30)	
US3672090	2020-08-13	AMENDMENT 2	No/ 2021-01-12 (153)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672097	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Adverse Event/ AE#1
US3672101	2020-08-13	AMENDMENT 2	No/ 2020-12-28 (138)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-10 (29)	
US3672103	2020-08-13	AMENDMENT 2	No/ 2020-12-17 (127)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-11 (30)	
US3672108	2020-08-13	AMENDMENT 2	No/ 2020-12-16 (126)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-11 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672117	2020-08-14	AMENDMENT 2	No/ 2020-12-30 (139)	Protocol Deviation/ SUBJECT UNBLINDED TO RECEIVE THE PFIZER COVID VACCINE		Yes/ 2020-09-11 (29)	
US3672121	2020-08-14	AMENDMENT 2	No/ 2020-12-18 (127)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-15 (33)	
US3672126	2020-08-14	AMENDMENT 2	No/ 2021-02-08 (179)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE		Yes/ 2020-09-15 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672128	2020-08-17	AMENDMENT 2	No/ 2020-12-23 (129)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE 12/18/20		Yes/ 2020-09-15 (30)	
US3672138	2020-08-17	AMENDMENT 2	No/ 2020-12-28 (134)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-14 (29)	
US3672150	2020-08-17	AMENDMENT 2	No/ 2020-12-18 (124)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-15 (30)	
US3672151	2020-08-17	AMENDMENT 2	No/ 2021-01-13 (150)	Other/ REQUEST TO UNBLIND		No/ 2020-09-13 (28)	Adverse Event/ AE#1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672169	2020-08-18	AMENDMENT 2	No/ 2020-11-09 (84)	Lost to Follow-Up		Yes/ 2020-09-16 (30)	
US3672181	2020-08-19	AMENDMENT 2	No/ 2020-12-21 (125)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-22 (35)	
US3672187	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Adverse Event/ AE #1
US3672203	2020-08-19	AMENDMENT 2	No/ 2020-12-13 (117)	Death	2020-12-13/ UNK	Yes/ 2020-09-18 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672206	2020-08-19	AMENDMENT 2	No/ 2020-12-22 (126)	Protocol Deviation/ SUBJECT WAS UNBLINDED AND WILL BE RECEIVING THE PFIZER COVID VACCINE		Yes/ 2020-09-16 (29)	
US3672207	2020-08-19	AMENDMENT 2	No/ 2021-02-27 (193)	Withdrawal of Consent by Participant/ UNABLE TO JUGGLE STUDY AND MEDICAL SCHOOL		Yes/ 2020-09-22 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672219	2020-08-20	AMENDMENT 2	No/ 2020-12-30 (133)	Other/ REQUEST TO BE UNBLINDED AND WILL BE RECEIVING THE PFIZER COVID VACCINE		Yes/ 2020-09-22 (34)	
US3672222	2020-08-20	AMENDMENT 2	No/ 2021-02-12 (177)	Protocol Deviation/ SUBJECT UNBLINDED AND RECEIVED PFIZER EUA COVID-19 VACCINE. SUBJECT IS DROPPED FROM STUDY.		Yes/ 2020-09-16 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672230	2020-08-20	AMENDMENT 2	No/ 2021-01-06 (140)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-17 (29)	
US3672233	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Protocol Deviation/ SUBJECT RECEIVED TETANUS VACCINE, MEETS EXCLUSION #9
US3672234	2020-08-20	AMENDMENT 2	No/ 2020-12-28 (131)	Protocol Deviation/ SUBJECT RECEIVED PFIZER CORONAVIRUS VACCINE		Yes/ 2020-09-21 (33)	
US3672238	2020-08-20	AMENDMENT 2	No/ 2020-12-28 (131)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-21 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672239	2020-08-20	AMENDMENT 2	No/ 2021-01-18 (152)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-16 (28)	
US3672263	2020-08-21	AMENDMENT 2	No/ 2021-01-18 (151)	Protocol Deviation/ RECEIVED EUA VACCINE ELSEWHERE, WITHDRAWN FROM STUDY		Yes/ 2020-09-24 (35)	
US3672270	2020-08-24	AMENDMENT 2	No/ 2020-12-17 (116)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-25 (33)	
US3672278	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-27 (28)	Serious Adverse Event/ AE#1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672282	2020-08-24	AMENDMENT 2	No/ 2020-12-18 (117)	Protocol Deviation/ REQUEST TO UNBLIND		Yes/ 2020-09-23 (31)	
US3672299	2020-08-25	AMENDMENT 2	No/ 2020-12-28 (126)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-21 (28)	
US3672301	2020-08-25	AMENDMENT 2	No/ 2020-12-28 (126)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-23 (30)	
US3672305	2020-08-25	AMENDMENT 2	No/ 2020-12-17 (115)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-29 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672328	2020-08-26	AMENDMENT 2	No/ 2020-12-21 (118)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-24 (30)	
US3672332	2020-08-26	AMENDMENT 2	No/ 2021-01-21 (142)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINATION WITHOUT NOTIFYING US PRIOR, NO LONGER MEETS I AND E FOR OPEN LABEL		Yes/ 2020-10-02 (31)	
US3672333	2020-08-26	AMENDMENT 2	ONGOING			No/ 2020-09-22 (28)	Adverse Event/ AE#2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672335	2020-08-26	AMENDMENT 2	No/ 2020-12-17 (114)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-24 (30)	
US3672357	2020-08-27	AMENDMENT 3	No/ 2020-10-09 (44)	Lost to Follow-Up		No/ 2020-09-23 (28)	Lost to Follow-Up
US3672371	2020-08-28	AMENDMENT 3	No/ 2021-01-28 (154)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE		Yes/ 2020-09-25 (29)	
US3672375	2020-08-28	AMENDMENT 3	No/ 2020-12-16 (111)	Other/ REQUESTED TO UNBLIND		Yes/ 2020-09-25 (29)	
US3672393	2020-09-01	AMENDMENT 3	No/ 2020-12-16 (107)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-28 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672394	2020-09-01	AMENDMENT 3	No/ 2020-12-17 (108)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-29 (29)	
US3672402	2020-09-03	AMENDMENT 3	No/ 2020-12-21 (110)	Protocol Deviation/ PATIENT RECEIVED PFIZER COVID VACCINE		Yes/ 2020-10-01 (29)	
US3672407	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Adverse Event/ AE#1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3682012	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (116)	Other/ PT. IN 1A GROUP WITH CDC AND REQUESTED UNBLINDING TO BE ABLE TO GET PFIZER VACCINE.		Yes/ 2020-09-21 (28)	
US3682022	2020-08-27	AMENDMENT 3	No/ 2021-02-10 (168)	Protocol Deviation/ PARTICIPANT RECEIVED 2ND DOSE OF VACCINE FROM AN OUTSIDE AGENCY, NOT THROUGH THE STUDY.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3682040	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Adverse Event/ AE #2
US3682080	2020-09-10	AMENDMENT 3	No/ 2021-02-05 (149)	Withdrawal of Consent by Participant/ PT. STATES HE NO LONGER WANTS TO BE CONTACTED TO PARTICIPATE IN THE STUDY		Yes/ 2020-10-08 (29)	
US3682148	2020-09-18	AMENDMENT 3	No/ 2020-12-18 (92)	Other/ PT. IN 1A GROUP WITH CDC AND REQUESTED UNBLINDING TO BE ABLE TO GET PFIZER VACCINE.		Yes/ 2020-10-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692006	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (114)	Other/ UNBLINDED TO RECEIVE EUA VACCINE.		Yes/ 2020-09-24 (29)	
US3692010	2020-08-27	AMENDMENT 3	No/ 2020-12-18 (114)	Protocol Deviation/ PARTICIPANT RECEIVED THE EUA VACCINE WHILE ENROLLED AND WAS SUBSEQUENTLY UNBLINDED/WITHDRAWN FROM STUDY.		Yes/ 2020-09-30 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692013	2020-08-27	AMENDMENT 3	No/ 2020-12-18 (112)	Other/ UNBLINDED IN ORDER TO RECEIVE PFIZER VACCINE UNDER EUA.		Yes/ 2020-09-28 (31)	
US3692042	2020-09-02	AMENDMENT 3	No/ 2021-01-04 (124)	Other/ UNBLINDED/WITHDRAWN FROM STUDY TO RECEIVE PFIZER EUA VACCINE.		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692059	2020-09-04	AMENDMENT 3	No/ 2021-01-07 (125)	Protocol Deviation/ PARTICIPANT ELECTED TO WITHDRAW FROM STUDY IN ORDER TO RECEIVE EUA VACCINE.		Yes/ 2020-10-06 (32)	
US3692076	2020-09-07	AMENDMENT 3	No/ 2021-01-04 (119)	Other/ PARTICIPANT UNBLINDED/WITHDREW FROM STUDY TO RECEIVE PFIZER EUA VACCINE		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692107	2020-09-11	AMENDMENT 3	No/ 2021-01-04 (116)	Protocol Deviation/ PARTICIPANT RECEIVED MODERNA EUA VACCINE PRIOR TO NOTIFYING SITE. HE HAS BEEN UNBLINDED AND WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692114	2020-09-11	AMENDMENT 3	No/ 2021-01-02 (111)	Protocol Deviation/ PARTICIPANT RECEIVED THE MODERNA EUA VACCINE PRIOR TO NOTIFYING SITE. HE HAS BEEN UNBLINDED AND WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-14 (31)	
US3692138	2020-09-17	AMENDMENT 3	No/ 2021-03-16 (180)	Protocol Deviation/ PARTICIPANT RECEIVED PFIZER EUA COVID-19 VACCINE		Yes/ 2020-10-23 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3692146	2020-09-21	AMENDMENT 3	No/ 2020-12-17 (86)	Other/ UNBLINDED IN ORDER TO RECEIVE EUA VACCINE.		Yes/ 2020-10-23 (31)	
US3692149	2020-09-22	AMENDMENT 3	ONGOING			No/ 2020-10-21 (28)	Due to SARS-CoV-2
US3692189	2020-10-09	AMENDMENT 3	No/ 2021-01-04 (85)	Protocol Deviation/ PARTICIPANT RECEIVED PFIZER EUA VACCINE PRIOR TO NOTIFYING SITE. SHE HAS BEEN UNBLINDED/WITHDRAWN FROM THE STUDY.		Yes/ 2020-11-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3702038	2020-09-14	AMENDMENT 3	No/ 2020-12-24 (98)	Withdrawal of Consent by Participant/ PT IS A PHYSICIAN WHO WANTED TO RECEIVE PFIZER VACCINE AFTER EUA.		Yes/ 2020-10-16 (29)	
US3712009	2020-08-26	AMENDMENT 3	No/ 2021-03-03 (176)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-12 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712010	2020-08-26	AMENDMENT 3	No/ 2021-03-05 (178)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-12 (34)	
US3712015	2020-08-27	AMENDMENT 3	No/ 2020-12-23 (106)	Withdrawal of Consent by Participant/ SUBJECT WAS UNBLINDED AND HAD PLACEBO. SUBJECT IS GETTING APPROVED COVID-19 VACCINATION AT THEIR WORKPLACE		Yes/ 2020-10-06 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712020	2020-08-28	AMENDMENT 3	No/ 2021-03-04 (177)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-06 (28)	
US3712060	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-12 (28)	Adverse Event/ AE #1
US3712063	2020-09-09	AMENDMENT 3	No/ 2021-03-05 (172)	Lost to Follow-Up		Yes/ 2020-10-14 (30)	
US3712070	2020-09-10	AMENDMENT 3	No/ 2021-02-22 (159)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-14 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712078	2020-09-11	AMENDMENT 3	No/ 2021-03-04 (169)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-15 (29)	
US3712105	2020-09-14	AMENDMENT 3	No/ 2021-02-15 (148)	Withdrawal of Consent by Participant/ SUBJECT STATES THAT THEY HAVE A FAMILY MEMBER DYING AND CANNOT CONTINUE IN STUDY		Yes/ 2020-10-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712111	2020-09-15	AMENDMENT 3	No/ 2021-03-05 (165)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-20 (29)	
US3712124	2020-09-16	AMENDMENT 3	No/ 2021-03-05 (164)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-21 (29)	
US3712131	2020-09-17	AMENDMENT 3	No/ 2021-03-15 (173)	Protocol Deviation/ RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712136	2020-09-17	AMENDMENT 3	No/ 2020-12-22 (93)	Withdrawal of Consent by Participant/ SUBJECT HAD PLACEBO THEREFORE HAD TO WITH DRAWL CONSENT		Yes/ 2020-10-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712143	2020-09-18	AMENDMENT 3	No/ 2021-03-04 (163)	Withdrawal of Consent by Participant/ SUBJECT REFUSES TO COME IN AND RECEIVE VACCINE AFTER BEING UNBLINDED AND REFUSES TO DO ILLNESS VISIT AFTER COVID SYMPTOMS		Yes/ 2020-10-21 (29)	
US3712164	2020-09-23	AMENDMENT 3	No/ 2021-03-05 (163)	Lost to Follow-Up		Yes/ 2020-10-22 (29)	
US3712167	2020-09-23	AMENDMENT 3	No/ 2021-03-15 (172)	Lost to Follow-Up		Yes/ 2020-10-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712197	2020-10-14	AMENDMENT 4	No/ 2020-12-22 (64)	Withdrawal of Consent by Participant/ SUBJECT HAD PLACEBO AND WITHDREW CONSENT		Yes/ 2020-11-16 (28)	
US3712230	2020-10-15	AMENDMENT 4	No/ 2021-02-23 (124)	Protocol Deviation/ RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-11-23 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712235	2020-10-15	AMENDMENT 4	No/ 2020-12-21 (61)	Withdrawal of Consent by Participant/ SUBJECT WAS UNBLINDED AND HAD PLACEBO. SUBJECT IS GETTING APPROVED COVID-19 VACCINATION AT HER WORKPLACE		Yes/ 2020-11-19 (29)	
US3712263	2020-10-16	AMENDMENT 4	No/ 2021-01-29 (99)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-11-20 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712278	2020-10-20	AMENDMENT 4	No/ 2021-02-25 (127)	Protocol Deviation/ SUBJECT RECEIVED PFIZER PRIOR TO BEING UNBLINDED		Yes/ 2020-11-19 (29)	
US3712286	2020-10-21	AMENDMENT 4	No/ 2020-12-23 (63)	Withdrawal of Consent by Participant/ SUBJECT WAS UNBLINDED AND HAD PLACEBO. SUBJECT IS GETTING APPROVED COVID-19 VACCINATION AT THEIR WORKPLACE		Yes/ 2020-11-18 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712300	2020-10-22	AMENDMENT 4	No/ 2021-01-28 (98)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-11-17 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722082	2020-08-04	AMENDMENT 1	No/ 2021-01-22 (152)	Protocol Deviation/ SUBJECT SPOKE TO SITE AND STATED THAT SHE TOOK THE PFIZER VACCINE. SUBJECT WAS INFORMED THAT THEY WOULD HAVE TO BE DISCONTINUED IN THE STUDY. SUBJECT VERBALIZED UNDERSTANDING.		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722112	2020-08-05	AMENDMENT 1	No/ 2021-01-13 (162)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 EUA UNBLINDING. SUBJECT HAD RECEIVED DOSE OF PFIZER VACCINE. SUBJECT WAS REMOVED PER PROTOCOL.		Yes/ 2020-09-03 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722116	2020-08-06	AMENDMENT 1	No/ 2021-02-05 (184)	Protocol Deviation/ SUBJECT CAME TO SITE FOR HER OL-0 AND TOLD SITE STAFF THAT SHE RECEIVED THE PFIZER VACCINE. SUBJECT WAS EDUCATED ON BEING DISCONTINUED SUBJECT UNDERSTOOD. SUBJECT WAS UNBLINDED AND WAS PLACEBO		Yes/ 2020-09-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722143	2020-08-07	AMENDMENT 1	No/ 2021-01-13 (160)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 EUA UNBLINDING. SUBJECT HAD RECEIVED DOSE OF PFIZER VACCINE. SUBJECT WAS REMOVED PER PROTOCOL.		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722204	2020-08-12	AMENDMENT 2	No/ 2021-01-13 (155)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 EUA UNBLINDING. SUBJECT HAD RECEIVED DOSE OF PFIZER VACCINE. SUBJECT WAS REMOVED PER PROTOCOL.		Yes/ 2020-09-10 (30)	
US3722223	2020-08-13	AMENDMENT 2	No/ 2020-10-09 (58)	Lost to Follow-Up		No/ 2020-09-09 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722264	2020-08-14	AMENDMENT 2	No/ 2021-01-12 (152)	Protocol Deviation/ SUBJECT WANTED TO UNBLIND BEFORE AMENDMENT 6. SUBJECT QUALIFIED UNDER EUA GUIDELINES. SUBJECT GOT OTHER VACCINE SO PER PROTOCOL SUBJECT IS DISCONTINUED.		Yes/ 2020-09-12 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722266	2020-08-14	AMENDMENT 2	No/ 2021-02-02 (173)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO WITHDRAW FORM STUDY		Yes/ 2020-09-15 (33)	
US3722298	2020-08-19	AMENDMENT 2	No/ 2021-01-13 (148)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 EUA UNBLINDING. SUBJECT HAD RECEIVED DOSE OF PFIZER VACCINE. SUBJECT WAS REMOVED PER PROTOCOL.		Yes/ 2020-09-17 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722322	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-22 (28)	Other/ SUBJECT STATED THAT HE DID NOT WANT TO TAKE THE 2ND DOSE BUT WANTED TO CONTINUE IN THE STUDY.
US3722328	2020-08-20	AMENDMENT 2	No/ 2020-10-16 (58)	Lost to Follow-Up		No/ 2020-09-16 (28)	Lost to Follow-Up
US3722354	2020-08-24	AMENDMENT 2	No/ 2021-01-08 (138)	Protocol Deviation/ SUBJECT RECEIVED ANOTHER VACCINE		Yes/ 2020-09-23 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722369	2020-08-24	AMENDMENT 2	No/ 2021-01-08 (138)	Protocol Deviation/ SUBJECT TOOK A DIFFERENT VACCINE WHILE ON STUDY.		Yes/ 2020-09-28 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722385	2020-08-25	AMENDMENT 3	No/ 2021-01-12 (141)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT SHE WANTED TO BE UNBLINDED TO RECEIVE PFIZER. SUBJECT WAS EDUCATED ON THE MODERNA UNBLINDING BUT STATED THAT SHE DID NOT WANT TO WAIT. SUBJECT WAS DISCONTINUED.		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722401	2020-08-26	AMENDMENT 3	No/ 2021-01-05 (133)	Protocol Deviation/ SUBJECT RECEIVED ANOTHER COVID 19 VACCINE		Yes/ 2020-09-23 (29)	
US3722412	2020-09-08	AMENDMENT 3	No/ 2020-10-07 (30)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO THE FACT THAT THEY DIDN'T WANT TO GET THE NP SWAB AGAIN. CONSENT WITHDREW.		No/ 2020-10-05 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT HE DID NOT WANT TO GET SECOND INJECTION DUE TO THE FACT THAT HE HATED HAVING THE NP SWAB DONE. SUBJECT WITHDREW CONSENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722413	2020-09-10	AMENDMENT 3	No/ 2021-02-01 (145)	Protocol Deviation/ SUBJECT TOOK THE PFIZER VACCINE		Yes/ 2020-10-22 (43)	
US3732010	2020-08-05	AMENDMENT 1	No/ 2020-12-16 (134)	Other/ EUA COVID-19 VACCINE / UNBLINDING		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732019	2020-08-06	AMENDMENT 1	No/ 2020-12-29 (146)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE OUTSIDE OF THE STUDY ON 17DEC2020. RELAYED INFORMATION TO SITE ON 29DEC2020.		Yes/ 2020-09-03 (29)	
US3732026	2020-08-07	AMENDMENT 1	No/ 2020-12-28 (144)	Other/ UNBLINDING/EUA VACCINE		Yes/ 2020-09-03 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732032	2020-08-10	AMENDMENT 1	No/ 2021-01-18 (162)	Protocol Deviation/ RECEIVED OUTSIDE VACCINE		Yes/ 2020-09-07 (29)	
US3732036	2020-08-10	AMENDMENT 1	No/ 2021-01-07 (151)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE MODERNA EUA VACCINE ON 26DEC2020. INFORMED SITE ON 07JAN2021.		Yes/ 2020-09-07 (29)	
US3732049	2020-08-11	AMENDMENT 2	No/ 2021-01-06 (149)	Other/ UNBLINDING / EUA VACCINE		Yes/ 2020-09-30 (51)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732050	2020-08-12	AMENDMENT 2	No/ 2021-01-07 (149)	Other/ EUA COVID 19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-09-08 (28)	
US3732051	2020-08-12	AMENDMENT 2	No/ 2021-01-07 (149)	Other/ EUA VACCINE ACCESS/REQUEST TO UNBLIND		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732061	2020-08-13	AMENDMENT 2	No/ 2020-10-12 (61)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE (12-OCT-20) INFORMING HE WOULD LIKE TO WITHDRAW CONSENT		Yes/ 2020-09-10 (29)	
US3732070	2020-08-14	AMENDMENT 2	No/ 2021-03-25 (224)	Protocol Deviation/ SUBJECT DISCONTINUED FROM STUDY DUE TO RECEIVING OUTSIDE EUA VACCINE		Yes/ 2020-09-16 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732085	2020-08-18	AMENDMENT 2	No/ 2020-10-13 (57)	Withdrawal of Consent by Participant/ SUBJECT DECISION TO WITHDRAW FROM STUDY DUE TO WORK SCHEDULE		Yes/ 2020-09-15 (29)	
US3732101	2020-08-19	AMENDMENT 2	No/ 2020-12-21 (125)	Other/ EUA VACCINE/ UNBLINDING		Yes/ 2020-09-16 (29)	
US3732107	2020-08-20	AMENDMENT 2	No/ 2020-12-21 (124)	Other/ EUA COVID-19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732110	2020-08-20	AMENDMENT 2	No/ 2021-02-03 (168)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE MODERNA VACCINE (FIRST DOSE) ON 24JAN2021. RELAYED TO SITE 03FEB2021.		Yes/ 2020-09-17 (29)	
US3732111	2020-08-20	AMENDMENT 2	No/ 2020-09-17 (29)	Withdrawal of Consent by Participant/ SUBJECT WISHES TO NO LONGER PARTICIPATE		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ SUBJECT WISHES TO NO LONGER PARTICIPATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732117	2020-08-20	AMENDMENT 2	No/ 2021-01-19 (153)	Protocol Deviation/ RECEIVED EUA MODERN A VACCINE OUTSIDE OF TRIAL		Yes/ 2020-09-17 (29)	
US3732122	2020-08-20	AMENDMENT 2	No/ 2020-12-18 (121)	Other/ EUA VACCINE/UNBLINDING		Yes/ 2020-09-17 (29)	
US3732137	2020-08-24	AMENDMENT 2	No/ 2020-12-18 (117)	Other/ REQUESTED UNBLINDING/EUA COVID-19 VACCINE		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732144	2020-08-24	AMENDMENT 2	No/ 2021-01-20 (150)	Protocol Deviation/ RECEIVED OUTSIDE VACCINE		Yes/ 2020-09-21 (29)	
US3732145	2020-08-24	AMENDMENT 2	No/ 2020-12-23 (122)	Protocol Deviation/ RECEIVED OUTSIDE VACCINE		Yes/ 2020-09-21 (29)	
US3732163	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (116)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	
US3732165	2020-08-25	AMENDMENT 3	No/ 2020-10-16 (53)	Lost to Follow-Up		Yes/ 2020-09-23 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732190	2020-08-27	AMENDMENT 3	No/ 2021-01-06 (133)	Other/ UNBLINDING / EUA VACCINE		Yes/ 2020-09-24 (29)	
US3732191	2020-08-27	AMENDMENT 3	No/ 2020-12-18 (114)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE. SUBJECT RECEIVED EUA VACCINE AFTER BEING UNBLINDED TO PLACEBO. PER SPONSOR SUBJECT IS TO BE WITHDRAWN FROM THE STUDY.		Yes/ 2020-09-23 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732207	2020-08-27	AMENDMENT 3	No/ 2020-09-24 (29)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE DUE TO TOO MANY FOLLOW-UP CALLS/VISITS (SINCE THEY ARE CONFIRMED COVID POSITIVE)		No/ 2020-09-23 (28)	Due to SARS-CoV-2
US3732210	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Other/ EUA COVID-19 VACCINE/UNBLINDING REQUEST		Yes/ 2020-09-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732220	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Other/ EUA VACCINE/UNBLINDING		Yes/ 2020-09-25 (29)	
US3732225	2020-08-31	AMENDMENT 3	No/ 2020-11-19 (81)	Lost to Follow-Up		Yes/ 2020-09-30 (31)	
US3732237	2020-08-31	AMENDMENT 3	No/ 2020-12-29 (121)	Other/ EUA COVID-19 VACCINE / UNBLIND REQUEST		Yes/ 2020-09-25 (26)	
US3732248	2020-09-01	AMENDMENT 3	No/ 2020-12-29 (120)	Other/ EUA COVID-19 VACCINE/UN-BLINDING REQUEST		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732258	2020-09-02	AMENDMENT 3	No/ 2020-09-27 (26)	Withdrawal of Consent by Participant/ NO LONGER WILLING TO PARTICIPATE DUE TO BLOOD/SWAB BEING "UNCOMFORTABLE" AND NOT WILLING TO GIVE BLOOD/SWAB AT ANY FUTURE VISITS. AND NOW UNABLE TO RECEIVE 2ND DOSE (PER SPONSOR)		No/ 2020-09-26 (25)	Withdrawal of Consent by Participant/ NO LONGER WILLING TO PARTICIPATE DUE TO BLOOD/SWAB BEING "UNCOMFORTABLE" AND NOT WILLING TO GIVE BLOOD/SWAB AT ANY FUTURE VISITS. AND NOW UNABLE TO RECEIVE 2ND DOSE (PER SPONSOR)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732265	2020-09-02	AMENDMENT 3	No/ 2020-12-30 (120)	Other/ EUA VACCINE ACCESS/UNBLINDING		Yes/ 2020-09-30 (29)	
US3732273	2020-09-03	AMENDMENT 3	No/ 2020-12-18 (107)	Other/ SUBJECT UNBLINDED FROM STUDY AND RECEIVED PLACEBO		Yes/ 2020-10-06 (34)	
US3732281	2020-09-04	AMENDMENT 3	No/ 2020-12-19 (107)	Other/ EUA COVID 19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-10-06 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732289	2020-09-08	AMENDMENT	3 No/ 2020-12-21 (105)	Other/ EUA COVID-19 VACCINE/ UNBLINDING		Yes/ 2020-10-07 (30)	
US3732290	2020-09-08	AMENDMENT	3 No/ 2021-01-11 (126)	Other/ UNBLINDING/ EUA VACCINE		Yes/ 2020-10-12 (35)	
US3732292	2020-09-08	AMENDMENT	3 No/ 2020-12-18 (102)	Other/ UNBLINDING / EUA VACCINE		Yes/ 2020-10-06 (29)	
US3732303	2020-09-09	AMENDMENT	3 No/ 2020-12-31 (114)	Protocol Deviation/ EUA COVID 19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-10-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732316	2020-09-10	AMENDMENT 3	No/ 2020-12-18 (100)	Other/ UNBLINDING / EUA VACCINE		Yes/ 2020-10-08 (29)	
US3732328	2020-09-14	AMENDMENT 3	No/ 2020-12-18 (96)	Other/ EUA COVID 19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-10-12 (29)	
US3732329	2020-09-14	AMENDMENT 3	No/ 2021-01-13 (122)	Other/ REQUEST TO UNBLIND/RECEIVED OUTSIDE VACCINE		Yes/ 2020-10-12 (29)	
US3732331	2020-09-15	AMENDMENT 3	No/ 2020-11-30 (77)	Lost to Follow-Up		Yes/ 2020-10-16 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732337	2020-09-15	AMENDMENT 3	No/ 2021-03-16 (183)	Protocol Deviation/ DISCONTINUING DUE TO INABILITY TO RELIABLY MAKE IT TO CLINIC VISITS.		Yes/ 2020-11-11 (58)	
US3732341	2020-09-15	AMENDMENT 3	No/ 2020-12-16 (93)	Other/ EUA COVID-19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-11-11 (58)	
US3732343	2020-09-15	AMENDMENT 3	No/ 2021-03-02 (169)	Lost to Follow-Up		Yes/ 2020-10-22 (38)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732346	2020-09-15	AMENDMENT 3	No/ 2020-10-22 (38)	Other/ SUBJECT IS UNWILLING TO FOLLOW-UP WITH SITE FOR THE REMAINDER OF THE STUDY DUE TO ACCEPTING JOB OFFER OUT OF STATE.		Yes/ 2020-10-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732365	2020-09-21	AMENDMENT 3	No/ 2020-11-13 (54)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE STATING THAT THEY NO LONGER WISH TO PARTICIPATE FOR UNDISCLOSED PERSONAL REASONS		Yes/ 2020-10-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732376	2020-09-25	AMENDMENT 3	No/ 2021-03-15 (172)	Physician Decision/ MOVED OUT OF STATE - INABILITY TO COMPLETE PROTOCOL-MANDATED PROCEDURES.		Yes/ 2020-10-23 (29)	
US3732381	2020-09-28	AMENDMENT 3	No/ 2021-02-24 (150)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA VACCINE		Yes/ 2020-10-28 (31)	
US3732383	2020-09-28	AMENDMENT 3	No/ 2020-12-18 (82)	Other/ EUA VACCINE/ UNBLINDING		Yes/ 2020-11-09 (43)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732385	2020-09-29	AMENDMENT 3	No/ 2020-12-18 (81)	Other/ EUA COVID-19 VACCINE/ UNBLINDING REQUEST		Yes/ 2020-10-29 (31)	
US3732389	2020-10-07	AMENDMENT 4	No/ 2020-12-23 (78)	Other/ EUA VACCINATION/UN-BLINDING REQUEST		Yes/ 2020-11-04 (29)	
US3732392	2020-10-14	AMENDMENT 4	No/ 2020-12-21 (69)	Other/ UNBLINDING / EUA VACCINE		Yes/ 2020-11-11 (29)	
US3732403	2020-10-22	AMENDMENT 4	No/ 2020-12-31 (71)	Other/ EUA COVID 19 VACCINE/ UNBLINDING		Yes/ 2020-11-25 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732406	2020-10-23	AMENDMENT 4	No/ 2021-01-13 (83)	Other/ REQUEST TO UNBLIND/EUA VACCINE ACCESS		Yes/ 2020-11-20 (29)	
US3742010	2020-08-18	AMENDMENT 2	No/ 2020-12-18 (123)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-15 (29)	
US3742011	2020-08-18	AMENDMENT 2	No/ 2021-01-07 (143)	Other/ REQUEST TO UNBLIND EUA COVID-19 VACCINE		Yes/ 2020-09-15 (29)	
US3742030	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742032	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-21 (32)	
US3742073	2020-08-25	AMENDMENT 2	No/ 2020-12-24 (122)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	
US3742086	2020-08-25	AMENDMENT 3	No/ 2020-12-28 (126)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (32)	
US3742093	2020-08-26	AMENDMENT 3	No/ 2020-12-18 (115)	Other/ REQUEST TO UNBLIND/EUA COVID19 VACCINE		Yes/ 2020-09-22 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742096	2020-08-26	AMENDMENT 3	No/ 2020-12-18 (115)	Other/ REQUEST TO UNBIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-23 (29)	
US3742099	2020-08-26	AMENDMENT 3	No/ 2021-02-24 (183)	Withdrawal of Consent by Participant/ SENT TEXT MESSAGE TO STUDY STAFF STATING THAT SHE LONGER WANTS TO PARTICIPATE.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742101	2020-08-26	AMENDMENT 3	No/ 2020-10-28 (64)	Withdrawal of Consent by Participant/ PARTICIPANT STATES HE IS UNABLE TO CONTINUE DUE TO TIME COMMITMENT		No/ 2020-09-22 (28)	Other/ PARTICIPANT OUT OF AREA FOR SEVERAL WEEKS AND WILL NOT BE VACCINATED WITHIN TOLERANCE WINDOW.
US3742109	2020-08-27	AMENDMENT 3	No/ 2020-12-28 (124)	Other/ REQUEST TO UNBLIND/ EUA COVID 19 VACCINE		Yes/ 2020-09-24 (29)	
US3742136	2020-08-28	AMENDMENT 3	No/ 2020-12-30 (125)	Other/ REQUEST TO UNBLIND / EUA COVID 19 VACCINE		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742147	2020-08-28	AMENDMENT 3	No/ 2020-12-27 (122)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3742164	2020-08-29	AMENDMENT 3	No/ 2020-09-12 (15)	Other/ MOVING TO CALIFORNIA IMMEDIATELY		No/ 2020-09-11 (14)	Other/ MOVING TO CALIFORNIA IMMEDIATELY
US3742172	2020-08-31	AMENDMENT 3	No/ 2020-12-18 (110)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-03 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742186	2020-08-31	AMENDMENT 3	No/ 2020-12-29 (121)	Other/ REQUEST TO UNBLIND/ RECEIVED PFIZER EUA COVID VACCINE		Yes/ 2020-09-29 (30)	
US3742203	2020-09-01	AMENDMENT 3	No/ 2020-12-18 (109)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-28 (28)	
US3742205	2020-09-01	AMENDMENT 3	No/ 2020-12-22 (113)	Other/ REQUEST TO BE UNBLINDED/ EUA COVID-19 VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742222	2020-09-02	AMENDMENT 3	No/ 2020-12-22 (112)	Other/ REQUEST TO UNBLIND - EUA COVID-19 VACCINE		Yes/ 2020-09-29 (28)	
US3742253	2020-09-04	AMENDMENT 3	No/ 2021-01-07 (126)	Other/ REQUEST TO UNBLIND EUA VACCINE COVID-19		No/ 2020-10-01 (28)	Due to SARS-CoV-2
US3742284	2020-09-08	AMENDMENT 3	No/ 2020-12-21 (105)	Other/ REQUEST TO UNBLIND/ EUA COVID 19 VACCINE		Yes/ 2020-10-14 (37)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742293	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ UNABLE TO ATTEND DAY 29 VISIT DUE TO WORK SCHEDULE CONFLICTS
US3742322	2020-09-10	AMENDMENT 3	No/ 2020-12-30 (112)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-06 (27)	
US3742334	2020-09-11	AMENDMENT 3	No/ 2020-12-28 (109)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742338	2020-09-11	AMENDMENT 3	No/ 2020-12-31 (112)	Other/ REQUEST TO UNBLIND/EUA COVID 19 VACCINE		Yes/ 2020-10-09 (29)	
US3742341	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Other/ PARTICIPANT NOT INTERESTED IN 2ND DOSE BECAUSE OF AE 2+4+5
US3742343	2020-09-11	AMENDMENT 3	No/ 2020-12-30 (111)	Other/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742358	2020-09-14	AMENDMENT 3	No/ 2020-12-07 (82)	Withdrawal of Consent by Participant/ SHE REFUSED ILLNESS VISIT AND STATED THAT SHE NO LONGER WANTED TO PARTICIPATE		Yes/ 2020-10-19 (33)	
US3742395	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-14 (28)	Adverse Event/ AE #1
US3742434	2020-09-19	AMENDMENT 3	No/ 2020-12-21 (94)	Other/ REQUESTED TO UNBLIND/ EUA COVID 19 VACCINE		Yes/ 2020-10-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742449	2020-09-21	AMENDMENT 3	No/ 2020-12-31 (102)	Other/ REQUEST TO UNBLIND/ EUA COVID 19 VACCINE		Yes/ 2020-10-21 (31)	
US3742457	2020-09-22	AMENDMENT 3	No/ 2020-10-27 (36)	Withdrawal of Consent by Participant/ PARTICIPANT STATED THAT HE NO LONGER WANTED TO PARTICIPATE.		No/ 2020-10-19 (28)	Withdrawal of Consent by Participant/ PT NO LONGER WANTED TO REMAIN IN STUDY AND WITHDREW CONSENT TO REMAIN.
US3742477	2020-09-28	AMENDMENT 3	ONGOING			No/ 2020-10-28 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752021	2020-08-10	AMENDMENT 1	No/ 2021-02-08 (183)	Protocol Deviation/ SUBJECT RECIEVED PFIZER VACCINATION		Yes/ 2020-09-11 (33)	
US3752027	2020-08-10	AMENDMENT 1	No/ 2020-12-10 (123)	Lost to Follow-Up		No/ 2020-09-06 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752029	2020-08-10	AMENDMENT 1	No/ 2021-01-06 (150)	Protocol Deviation/ PATIENT RECIEVED PFIZER COVID VACCINE OUTSIDE OF THE STUDY UNDER EUA GUIDELINES. SHE WAS UNBLINDED AND IS BEING WITHDRAWN.		Yes/ 2020-09-09 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752030	2020-08-10	AMENDMENT 1	No/ 2020-12-17 (130)	Protocol Deviation/ MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA SO THE SUBJECT WAS UNBLINDED		Yes/ 2020-09-08 (30)	
US3752032	2020-08-10	AMENDMENT 1	No/ 2021-02-22 (197)	Lost to Follow-Up		Yes/ 2020-09-09 (31)	
US3752053	2020-08-12	AMENDMENT 2	No/ 2020-09-08 (28)	Other/ SUBJECT IS MOVING OUT OF STATE		No/ 2020-09-07 (27)	Other/ SUBJECT IS MOVING OUT OF STATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752069	2020-08-13	AMENDMENT 2	No/ 2021-02-25 (197)	Lost to Follow-Up		Yes/ 2020-09-10 (29)	
US3752073	2020-08-13	AMENDMENT 2	No/ 2021-01-18 (159)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID VACCINE		Yes/ 2020-09-10 (29)	
US3752083	2020-08-13	AMENDMENT 2	No/ 2021-02-03 (175)	Protocol Deviation/ PATIENT REPORTED RECEIVING THE PFIZER VACCINE OUTSIDE OF THE STUDY SO IS THEREFORE BEING WITHDRAWN.		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752111	2020-08-17	AMENDMENT 2	No/ 2020-12-28 (134)	Other/ PATIENT IS A HEALTHCARE WORKER AND HAS IMMEDIATE ACCESS TO PFIZER COVID-19 VACCINE. MEETS THE EUA CRITERIA.		Yes/ 2020-09-14 (29)	
US3752114	2020-08-17	AMENDMENT 2	No/ 2020-12-10 (116)	Lost to Follow-Up		No/ 2020-09-13 (28)	Lost to Follow-Up
US3752117	2020-08-17	AMENDMENT 2	No/ 2021-03-01 (197)	Lost to Follow-Up		Yes/ 2020-09-17 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752157	2020-08-19	AMENDMENT 2	No/ 2021-02-03 (169)	Protocol Deviation/ PATIENT REPORTED RECEIVING THE PFIZER VACCINE OUTSIDE OF THE STUDY SO IS THEREFORE BEING DROPPED DUE TO MODERNA GUIDELINES		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752160	2020-08-19	AMENDMENT 2	No/ 2021-01-07 (142)	Protocol Deviation/ SUBJECT RECEIVED THE MODERNA VACCINE OUTSIDE OF THE STUDY AND IS BEING WITHDRAWN.		Yes/ 2020-09-16 (29)	
US3752179	2020-08-20	AMENDMENT 2	No/ 2021-01-06 (140)	Protocol Deviation/ PATIENT RECEIVED PFIZER UNDER THE EUA AT HIS WORK PLACE. HE WAS UNBLINDED AND IS BEING WITHDRAWN		Yes/ 2020-09-16 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752193	2020-08-21	AMENDMENT 2	No/ 2020-12-18 (120)	Protocol Deviation/ SUBJECT UNBLINDED DUE TO RECEIVING PFIZER COVID 19 VACCINE		Yes/ 2020-09-18 (29)	
US3752194	2020-08-21	AMENDMENT 2	No/ 2021-01-05 (138)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE MODERNA STUDY. WAS UNBLINDED AND WITHDRAWN.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752196	2020-08-21	AMENDMENT 2	No/ 2021-02-03 (167)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE STUDY SO IS THEREFORE BEING WITHDRAWN BASED ON MODERNA GUIDELINES.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752198	2020-08-21	AMENDMENT 2	No/ 2021-02-26 (190)	Protocol Deviation/ SUBJECT REPORTED RECEIVING THE MODERNA VACCINE OUTSIDE OF THE STUDY. HE WAS UNBLINDED TODAY AND IS BEING WITHDRAWN DUE TO GETTING IT OUTSIDE OF THE STUDY.		Yes/ 2020-09-21 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752209	2020-08-21	AMENDMENT 2	No/ 2020-12-21 (123)	Protocol Deviation/ SUBJECT REQUESTED TO BE UNBLINDED SO THEY COULD GET THE PFIZER COVID 19 VACCINE		Yes/ 2020-09-18 (29)	
US3752211	2020-08-21	AMENDMENT 2	No/ 2020-12-23 (125)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER COVID 19 VACCINE ON 22 DEC 2020		Yes/ 2020-09-23 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752229	2020-08-24	AMENDMENT 2	No/ 2020-12-22 (121)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID 19 VACCINE ON 16 DEC 2020		Yes/ 2020-09-21 (29)	
US3752240	2020-08-25	AMENDMENT 3	No/ 2020-12-21 (119)	Protocol Deviation/ RECEIVED PFIZER COVID 19 VACCINE		Yes/ 2020-09-23 (30)	
US3752241	2020-08-25	AMENDMENT 3	No/ 2020-12-21 (119)	Protocol Deviation/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE PFIZER COVID 19 VACCINE		Yes/ 2020-09-23 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752249	2020-08-25	AMENDMENT 3	No/ 2021-01-07 (136)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE MODERNA STUDY		Yes/ 2020-09-22 (29)	
US3752259	2020-08-26	AMENDMENT 2	No/ 2021-02-03 (162)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER COVID VACCINE OUTSIDE OF THE STUDY SO IS THEREFORE BEING WITHDRAWN		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752261	2020-08-26	AMENDMENT 2	No/ 2020-12-21 (118)	Protocol Deviation/ SUBJECT RECIEVED PFIZER COVID-19 VACCINE, THEREFORE, HE WAS UNBLINDED AND WITHDRAWN FROM THE MODERNA STUDY.		Yes/ 2020-09-22 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752262	2020-08-26	AMENDMENT 2	No/ 2020-12-23 (120)	Protocol Deviation/ PATIENT REQUESTED UNBLINDING DUE TO BEING A FRONTLINE HEALTHCARE WORKER AND HAVING IMMEDIATE ACCESS TO THE PFIZER VACCINE		Yes/ 2020-09-21 (27)	
US3752265	2020-08-26	AMENDMENT 2	No/ 2021-03-10 (197)	Lost to Follow-Up		Yes/ 2020-09-25 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752269	2020-08-26	AMENDMENT 2	No/ 2021-02-04 (163)	Protocol Deviation/ RECEIVED NON STUDY EUA VACCINE		Yes/ 2020-09-24 (30)	
US3752270	2020-08-26	AMENDMENT 2	No/ 2021-03-22 (209)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-23 (29)	
US3752275	2020-08-27	AMENDMENT 3	No/ 2021-03-10 (196)	Lost to Follow-Up		Yes/ 2020-09-23 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752277	2020-08-27	AMENDMENT 3	No/ 2021-01-06 (133)	Protocol Deviation/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE EAU COVID19 VACCINE		Yes/ 2020-09-24 (29)	
US3752278	2020-08-27	AMENDMENT 3	No/ 2020-11-02 (68)	Withdrawal of Consent by Participant/ SENT EMAIL STATING HE NO LONGER WANTED TO PARTICIPATE		Yes/ 2020-09-29 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752280	2020-08-27	AMENDMENT 3	No/ 2020-12-22 (118)	Protocol Deviation/ SUBJECT HAD ACCESS TO PFIZER COVID 19 VACCINE DUE TO BEING A FRONTLINE HEALTHCARE WORKER		Yes/ 2020-09-29 (34)	
US3752300	2020-08-28	AMENDMENT 3	No/ 2020-12-17 (112)	Protocol Deviation/ MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA SO THE SUBJECT WAS UNBLINDED.		Yes/ 2020-09-24 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752304	2020-08-28	AMENDMENT 3	No/ 2021-01-06 (132)	Protocol Deviation/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE EUA PFIZER COVID 19 VACCINE		Yes/ 2020-09-22 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752322	2020-08-31	AMENDMENT 3	No/ 2020-12-29 (121)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER COVID-19 VACCINE VIA HIS WORKPLACE UNDER THE EUA. HE IS BEING WITHDRAWN DUE TO THE MODERNA GUIDELINES SET FOR AMENDMENT 5.		Yes/ 2020-09-29 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752324	2020-08-31	AMENDMENT 3	No/ 2021-01-05 (128)	Protocol Deviation/ SUBJECT RECIEVED THE PFIZER COVID VACCINE OUTSIDE OF THE MODERNA STUDY.		Yes/ 2020-10-01 (32)	
US3752331	2020-09-01	AMENDMENT 3	No/ 2020-12-10 (101)	Lost to Follow-Up		No/ 2020-09-28 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752338	2020-09-01	AMENDMENT 3	No/ 2021-01-05 (127)	Protocol Deviation/ PATIENT WAS UNBLINDED AND WITHDRAWN DUE TO HIM RECEIVING THE PFIZER VACCINE UNDER THE EUA.		Yes/ 2020-09-29 (29)	
US3752344	2020-09-01	AMENDMENT 3	No/ 2021-02-03 (156)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER COVID VACCINE OUTSIDE OF THE STUDY SO IS THEREFORE BEING WITHDRAWN		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752366	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Due to SARS-CoV-2
US3752392	2020-09-03	AMENDMENT 3	No/ 2021-01-25 (145)	Lost to Follow-Up		Yes/ 2020-09-29 (27)	
US3752415	2020-09-04	AMENDMENT 3	No/ 2021-01-06 (125)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE OUTSIDE OF STUDY UNDER EUA, WAS UNBLINDED AND IS BEING WITHDRAWN		Yes/ 2020-10-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752418	2020-09-04	AMENDMENT 3	No/ 2021-01-05 (124)	Protocol Deviation/ PATIENT RECEIVED THE MODERNA VACCINE OUTSIDE OF THE STUDY. AN EPIP WAS SUBMITTED AND THE PATIENT WAS UNBLINDED PER MODERNA AND IS BEING WITHDRAWN		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752422	2020-09-09	AMENDMENT 3	No/ 2020-12-29 (112)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER COVID-19 VACCINE VIA HER WORKPLACE. PER MODERNA GUIDELINES UNDER AMENDMENT 5 SHE IS TO BE WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-05 (27)	
US3762008	2020-08-20	AMENDMENT 2	No/ 2021-03-06 (199)	Lost to Follow-Up		Yes/ 2020-09-24 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3762044	2020-08-25	AMENDMENT 2	No/ 2021-01-07 (136)	Protocol Deviation/ PATIENT RECEIVED MODERNA VACCINE BEFORE BEING UNBLINDED.		Yes/ 2020-09-22 (29)	
US3762075	2020-08-27	AMENDMENT 2	No/ 2020-12-23 (119)	Other/ PATIENT WAS UNBLINDED BEFORE EUA AND PATIENT PLANS TO RECEIVE PFIZER VACCINE		Yes/ 2020-09-23 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3762112	2020-08-31	AMENDMENT 2	No/ 2021-01-05 (128)	Protocol Deviation/ PRIOR TO UNBLINDING PATIENT RECEIVED PFIZER VACCINE AND WAS DISCONTINUED FROM TRIAL		Yes/ 2020-09-28 (29)	
US3762122	2020-08-31	AMENDMENT 3	No/ 2020-12-28 (120)	Protocol Deviation/ PT WITHDREW TO RECEIVE PFIZER COVID 19 VACCINE		Yes/ 2020-09-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3762132	2020-09-01	AMENDMENT 3	No/ 2021-01-07 (129)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT BECAUSE HE NO LONGER WANTED TO PARTICIPATE IN THE STUDY.		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3762227	2020-09-09	AMENDMENT 3	No/ 2020-12-21 (104)	Withdrawal of Consent by Participant/ PATIENT WAS UNBLINDED EARLY FROM STUDY, PATIENT RECEIVED PLACEBO AND CHOSE TO GET THE PFIZER VACCINE. PATIENT WAS WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-05 (27)	
US3772023	2020-08-06	AMENDMENT 1	No/ 2020-10-15 (71)	Other/ RELOCATION		Yes/ 2020-09-09 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772025	2020-08-06	AMENDMENT 1	No/ 2020-11-05 (92)	Withdrawal of Consent by Participant/ SUBJECT W/C NOT DUE TO AN SAE/AE BUT DUE TO "NOT WANTING TO DEAL WITH THIS STUDY ANYMORE"		Yes/ 2020-09-09 (35)	
US3772032	2020-08-10	AMENDMENT 2	No/ 2020-12-22 (135)	Other/ IMMINENT AVAILABILITY OF MODERNA VACCINE		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772048	2020-08-12	AMENDMENT 2	No/ 2020-08-27 (16)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT NOT DUE TO AN AE OR SAE		No/ 2020-08-26 (15)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT NOT DUE TO AN AE OR SAE
US3772051	2020-08-12	AMENDMENT 2	No/ 2020-09-28 (48)	Serious Adverse Event/ SAE #1		No/ 2020-09-08 (28)	Serious Adverse Event/ SAE#1
US3772052	2020-08-12	AMENDMENT 2	No/ 2020-12-23 (134)	Other/ UNBLINDING UNDER EUA FOR PFIZER VACCINE		Yes/ 2020-09-11 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772058	2020-08-13	AMENDMENT 2	No/ 2020-12-17 (127)	Other/ EUA RECEIPT OF PFIZER COVID VACCINE		Yes/ 2020-09-09 (28)	
US3772130	2020-08-22	AMENDMENT 2	No/ 2020-12-22 (123)	Other/ UNBLINDED DUE TO EUA PFIZER VACCINE		Yes/ 2020-09-16 (26)	
US3772151	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Other/ SUBJECT DECLINED SECOND DOSE
US3772154	2020-08-27	AMENDMENT 3	No/ 2020-12-24 (120)	Lost to Follow-Up		Yes/ 2020-09-21 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772177	2020-08-28	AMENDMENT 3	No/ 2020-11-18 (83)	Withdrawal of Consent by Participant/ THIS SUBJECT REPORTS BEING FRUSTRATED WITH THE SAFETY FOLLOW UP DIARY ENTRIES AND WISHES TO W/C.		Yes/ 2020-09-25 (29)	
US3772178	2020-08-28	AMENDMENT 3	No/ 2020-12-28 (123)	Other/ IMMINENT AVAILABILITY OF PFIZER COVID VACCINE		Yes/ 2020-09-25 (29)	
US3772179	2020-08-28	AMENDMENT 3	No/ 2021-02-25 (182)	Lost to Follow-Up		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772189	2020-08-31	AMENDMENT 3	No/ 2020-12-17 (109)	Other/ EUA RECEIPT OF PFIZER VACCINE		Yes/ 2020-09-29 (30)	
US3772205	2020-09-02	AMENDMENT 3	No/ 2021-01-11 (132)	Lost to Follow-Up		Yes/ 2020-09-28 (27)	
US3772255	2020-09-11	AMENDMENT 3	No/ 2021-01-15 (127)	Protocol Deviation/ RECEIPT OF MODERNA VACCINE OUTSIDE OF THE SITE		Yes/ 2020-10-09 (29)	
US3772269	2020-09-12	AMENDMENT 3	No/ 2021-01-29 (140)	Protocol Deviation/ RECEIPT OF THE PFIZER COVID VACCINE		Yes/ 2020-10-14 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782002	2020-08-11	AMENDMENT 2	No/ 2020-12-16 (128)	Other/ UNBLINDED - MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-08 (29)	
US3782016	2020-08-14	AMENDMENT 2	No/ 2020-12-16 (125)	Other/ UNBLINDED - MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-11 (29)	
US3782038	2020-08-17	AMENDMENT 2	No/ 2021-03-17 (213)	Lost to Follow-Up		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782072	2020-08-21	AMENDMENT 2	No/ 2020-12-16 (118)	Other/ MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-21 (32)	
US3782073	2020-08-24	AMENDMENT 2	No/ 2020-12-24 (123)	Other/ PARTICIPANT HAS BEEN UNBLINDED. REASON: OTHER " REQUEST TO UNBLIND / EUA COVID-19 VACCINE		No/ 2020-09-20 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782087	2020-08-25	AMENDMENT 3	No/ 2020-12-16 (114)	Other/ UNBLINDED - MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-22 (29)	
US3782097	2020-08-27	AMENDMENT 3	No/ 2020-12-16 (112)	Other/ UNBLINDED - MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782103	2020-08-28	AMENDMENT 3	No/ 2020-12-22 (117)	Other/ OTHER- REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3782109	2020-08-28	AMENDMENT 3	No/ 2020-12-21 (116)	Other/ OTHER æ" REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-02 (36)	
US3782129	2020-09-01	AMENDMENT 3	No/ 2020-12-16 (107)	Other/ UNBLINDED - MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782158	2020-09-08	AMENDMENT 3	No/ 2020-12-16 (100)	Other/ UNBLINDED AS MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-10-05 (28)	
US3782172	2020-09-16	AMENDMENT 3	No/ 2020-12-17 (93)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-14 (29)	
US3782182	2020-10-15	AMENDMENT 4	No/ 2020-12-21 (68)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-11-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782187	2020-10-19	AMENDMENT 4	No/ 2020-12-16 (59)	Other/ MEETS CDC CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-11-17 (30)	
US3782193	2020-10-22	AMENDMENT 4	No/ 2020-12-21 (61)	Other/ PARTICIPANT HAS BEEN UNBLINDED. REASON: OTHER " REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3792013	2020-08-12	AMENDMENT 2	No/ 2020-12-31 (142)	Protocol Deviation/ RECEIVED PFIZER VACCINE UNDER EUA		Yes/ 2020-09-09 (29)	
US3792021	2020-08-17	AMENDMENT 2	No/ 2020-12-26 (132)	Protocol Deviation/ PROTOCOL DEVIATION SUBJECT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-15 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3792026	2020-08-21	AMENDMENT 2	No/ 2020-12-18 (120)	Withdrawal of Consent by Participant/ MEETS CRITERIA TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-09-18 (29)	
US3792031	2020-08-24	AMENDMENT 2	No/ 2020-10-07 (45)	Withdrawal of Consent by Participant/ REASON FOR DISCONTINUING STUDY IS FEAR OF VACCINE REACTION		No/ 2020-09-20 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3792074	2020-09-24	AMENDMENT 3	No/ 2021-01-05 (104)	Withdrawal of Consent by Participant/ SUBJECT REPORTED COVID-19 INFECTION AND ASKED TO WITHDRAW CONSENT AND TO NOT BE CONTACTED IN THE FUTURE.		Yes/ 2020-10-26 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3792078	2020-09-29	AMENDMENT 3	No/ 2021-01-04 (98)	Protocol Deviation/ SUBJECT WAS UNBLINDED UNDER AMENDMENT 5 AND RECEIVED A NON-STUDY VACCINE		Yes/ 2020-11-03 (36)	
US3792092	2020-10-08	AMENDMENT 4	No/ 2021-01-04 (89)	Withdrawal of Consent by Participant/ SUBJECT WAS UNBLINDED PRIOR TO AMENDMENT 6 AND RECEIVED THE VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-11-05 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802009	2020-08-19	AMENDMENT 2	No/ 2021-01-05 (140)	Withdrawal of Consent by Participant/ RECEIVED PFIZER VACCINE		Yes/ 2020-09-16 (29)	
US3802024	2020-08-24	AMENDMENT 2	No/ 2020-12-28 (127)	Protocol Deviation/ RECEIVED PFIZER VACCINE		Yes/ 2020-09-21 (29)	
US3802047	2020-08-27	AMENDMENT 3	No/ 2020-09-20 (25)	Lost to Follow-Up		No/ 2020-09-19 (24)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802138	2020-09-04	AMENDMENT 3	No/ 2021-03-26 (204)	Withdrawal of Consent by Participant/ PARTICIPANT SENT EMAIL TO INFORM THAT SHE IS NO LONGER INTERESTED IN FOLLOWING STUDY PROCEDURES.		Yes/ 2020-10-05 (32)	
US3802175	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Protocol Deviation/ SUBJECT TAKING ACCUTANE AND ADVISED VIA EPIP NOT TO GET SECOND DOSE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802199	2020-09-10	AMENDMENT 3	No/ 2021-01-07 (120)	Protocol Deviation/ PARTICIPANT RECEIVED EUA VACCINE OUTSIDE OF STUDY.		Yes/ 2020-10-08 (29)	
US3802204	2020-09-10	AMENDMENT 3	No/ 2020-12-30 (112)	Protocol Deviation/ RECEIVED PFIZER VACCINE		Yes/ 2020-10-13 (34)	
US3802210	2020-09-10	AMENDMENT 3	No/ 2020-12-21 (103)	Protocol Deviation/ RECEIVED PFIZER VACCINE		Yes/ 2020-10-14 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802234	2020-09-15	AMENDMENT 3	No/ 2021-01-11 (119)	Protocol Deviation/ RECEIVED PFIZER VACCINE		Yes/ 2020-10-14 (30)	
US3812012	2020-08-03	AMENDMENT 1	No/ 2020-12-21 (141)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-08-31 (29)	
US3812018	2020-08-03	AMENDMENT 1	No/ 2020-12-22 (142)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-08-31 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812041	2020-08-05	AMENDMENT 1	No/ 2021-01-26 (175)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-08-31 (27)	
US3812056	2020-08-06	AMENDMENT 1	No/ 2020-12-29 (146)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-03 (29)	
US3812059	2020-08-06	AMENDMENT 1	No/ 2021-03-23 (230)	Other/ SUBJECT WOULD LIKE TO RECEIVE THE COVID-19 VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-01 (27)	
US3812060	2020-08-06	AMENDMENT 1	No/ 2020-11-24 (111)	Death	2020-11-24/ UNK	Yes/ 2020-08-31 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812072	2020-08-07	AMENDMENT 1	No/ 2020-12-22 (138)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-01 (26)	
US3812079	2020-08-07	AMENDMENT 1	No/ 2020-12-28 (144)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-01 (26)	
US3812083	2020-08-07	AMENDMENT 1	No/ 2020-11-12 (98)	Other/ RELOCATION		Yes/ 2020-09-02 (27)	
US3812100	2020-08-10	AMENDMENT 1	No/ 2020-12-22 (135)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-04 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812101	2020-08-10	AMENDMENT	1 No/ 2020-12-31 (144)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-08 (30)	
US3812118	2020-08-11	AMENDMENT	1 No/ 2020-12-22 (134)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-15 (36)	
US3812125	2020-08-11	AMENDMENT	1 No/ 2020-10-02 (53)	Lost to Follow-Up		Yes/ 2020-09-11 (32)	
US3812138	2020-08-12	AMENDMENT	1 No/ 2020-12-22 (133)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812142	2020-08-12	AMENDMENT 1	No/ 2020-12-17 (128)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-09 (29)	
US3812150	2020-08-12	AMENDMENT 2	No/ 2020-12-28 (139)	Protocol Deviation/ EUA - REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-14 (34)	
US3812174	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812196	2020-08-17	AMENDMENT 2	No/ 2020-12-17 (123)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-15 (30)	
US3812197	2020-08-17	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Due to SARS-CoV-2
US3812211	2020-08-19	AMENDMENT 2	No/ 2020-09-24 (37)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO UNDERGO ANY NASAL SWABBING FOR THE REMAINDER OF THE STUDY		No/ 2020-09-15 (28)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO UNDERGO ANY NASAL SWABBING FOR THE REMAINDER OF THE STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812215	2020-08-19	AMENDMENT 2	No/ 2020-12-23 (127)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-25 (38)	
US3812216	2020-08-19	AMENDMENT 2	No/ 2020-12-30 (134)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-17 (30)	
US3812239	2020-08-21	AMENDMENT 2	No/ 2021-01-07 (140)	Protocol Deviation/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-23 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812272	2020-08-26	AMENDMENT 2	No/ 2020-12-17 (114)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-24 (30)	
US3812274	2020-08-27	AMENDMENT 2	No/ 2020-12-24 (120)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-24 (29)	
US3812275	2020-08-27	AMENDMENT 2	No/ 2020-12-29 (125)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-24 (29)	
US3812299	2020-08-28	AMENDMENT 2	No/ 2020-12-18 (113)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-02 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812304	2020-09-01	AMENDMENT 1	No/ 2020-09-01 (1)	Withdrawal of Consent by Participant/ PER PI, SUBJECT WITHDREW CONSENT "DUE TO ANGER AT BEING ASKED TO PROPERLY MASK WHILE IN THE PUBLIC AREA (WAITING ROOM) "		No	Discontinuation from Study

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812313	2020-09-03	AMENDMENT 3	No/ 2021-03-10 (189)	Withdrawal of Consent by Participant/ SUBJECT VERBALIZED THAT SHE DOES NOT WANT TO PARTICIPANT IN ANYMORE STUDY PROCEDURES		Yes/ 2020-10-02 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822006	2020-08-04	AMENDMENT 1	No/ 2020-12-30 (149)	Withdrawal of Consent by Participant/ PATIENT WAS UNABLE TO RECEIVE VACCINE DUE TO AE THEREFORE SHE CHOOSE TO WITHDRAW		No/ 2020-08-31 (28)	Adverse Event/ AE LOG LINE #1
US3822008	2020-08-04	AMENDMENT 1	No/ 2020-12-30 (149)	Other/ SUBJECT RECEIVED THE PFIZER VACCINE ON 31DEC2020		Yes/ 2020-09-03 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822090	2020-08-12	AMENDMENT 2	No/ 2021-02-15 (188)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE VACCINE		Yes/ 2020-09-11 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822092	2020-08-12	AMENDMENT 2	No/ 2020-12-28 (139)	Other/ THE SUBJECT IS A PHARMACIST AND IS SCHEDULED TO RECEIVE THE MODERNA VACCINE THROUGH HIS EMPLOYER TODAY. HE IS UNABLE TO WAIT UNTIL 30DEC2020 WHEN WE WILL HAVE VACCINE ONSITE. HE WAS UNBLINDED.		Yes/ 2020-09-14 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822112	2020-08-13	AMENDMENT 2	No/ 2020-12-22 (132)	Other/ SUBJECT IS A PHYSICIAN AND QUALIFIES TO RECEIVE THE PFIZER VACCINE THROUGH EUA. HE REQUESTED TO BE UNBLINDED AND WAS INFORMED THAT HE RECEIVED PLACEBO. HE WILL DISCONTINUE THE STUDY AND RECEIVE PFIZER		Yes/ 2020-09-17 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822214	2020-08-20	AMENDMENT 2	No/ 2021-02-17 (182)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE		Yes/ 2020-09-18 (30)	
US3822270	2020-08-26	AMENDMENT 2	No/ 2021-01-20 (148)	Withdrawal of Consent by Participant/ SUBJECT DECIDED NOT TO PARTICIPATE AFTER V1		No/ 2020-09-22 (28)	Withdrawal of Consent by Participant/ SUBJECT DECIDED AFTER V1 THAT SHE DID NOT WANT TO PARTICIPATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822299	2020-08-27	AMENDMENT 2	No/ 2020-12-23 (119)	Protocol Deviation/ SUBJECT IS A PHYSICIAN AND IS ABLE TO RECEIVE THE PFIZER VACCINE THROUGH EUA. HE RECEIVED THE PFIZER VACCINE ON 19-DEC-2020 AND WOULD LIKE TO DISCONTINUE THE STUDY.		Yes/ 2020-09-22 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822320	2020-08-31	AMENDMENT 3	No/ 2020-12-22 (114)	Other/ SUBJECT IS A PHYSICIAN AND QUALIFIES TO RECEIVE THE PFIZER VACCINE UNDER EUA. SHE CAME IN FOR AN UNBLINDING VISIT ON 18-DEC-2020 AND WAS INFORMED THAT SHE RECEIVED PLACEBO. SHE DECIDED TO WITHDRAW.		Yes/ 2020-09-30 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822357	2020-09-03	AMENDMENT 3	No/ 2020-12-22 (111)	Other/ SUBJECT IS A PHYSICIAN AND QUALIFIES TO RECEIVE THE PFIZER VACCINE THROUGH EUA. SHE REQUESTED TO BE UNBLINDED AND WAS INFORMED THAT SHE RECEIVED PLACEBO. SHE WILL DISCONTINUE THE STUDY.		Yes/ 2020-10-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822361	2020-09-03	AMENDMENT 3	No/ 2021-03-10 (189)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED TO BE DISCONTINUED FROM THE STUDY AND REFUSED TO COME IN FOR AN EARLY EXIT VISIT.		Yes/ 2020-09-29 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822365	2020-09-03	AMENDMENT 3	No/ 2020-12-18 (107)	Other/ SUBJECT DISCONTINUED FROM STUDY DUE NOT BEEN ABLE TO RECEIVE OL-VACCINATION ON EXPECTED DATE.		Yes/ 2020-10-13 (41)	
US3822393	2020-09-14	AMENDMENT 3	ONGOING			No/ 2020-10-11 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822402	2020-09-17	AMENDMENT 3	No/ 2020-12-17 (92)	Other/ SUBJECT IS A PHYSICIAN AND QUALIFIES TO RECEIVE THE PFIZER VACCINE UNDER EUA. HE WAS UNBLINDED AND FOUND TO HAVE RECEIVED PLACEBO. HE HAS DECIDED TO WITHDRAW FROM THE STUDY.		Yes/ 2020-10-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822407	2020-09-18	AMENDMENT 3	No/ 2020-12-30 (104)	Protocol Deviation/ SUBJECT WAS UNABLE TO RECEIVE THE MODERNA VACCINE AND INSTEAD RECEIVED THE PFIZER VACCINE.		Yes/ 2020-10-23 (36)	
US3832039	2020-08-02	AMENDMENT 1	No/ 2020-09-23 (53)	Lost to Follow-Up		Yes/ 2020-09-02 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3832074	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Other/ SUBJECT DID NOT WITHDRAW CONSENT FOR THE STUDY, BUT DID NOT WISH TO RECEIVE SECOND IP DOSE. SUBJECT AGREED TO CONTINUE STUDY PARTICIPATION WITH ALL OTHER PROCEDURES/ASSESSMENTS PER PROTOCOL.
US3832075	2020-08-04	AMENDMENT 1	No/ 2021-01-04 (154)	Withdrawal of Consent by Participant/ DESIRE FOR PREGNANCY.		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3832109	2020-08-06	AMENDMENT 1	No/ 2021-03-09 (216)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO BE UN-BLINDED BUT NO LONGER WISHES TO PARTICIPATE IN THE TRIAL		Yes/ 2020-09-03 (29)	
US3832158	2020-08-11	AMENDMENT 1	No/ 2020-09-20 (41)	Lost to Follow-Up		Yes/ 2020-09-10 (31)	
US3832169	2020-08-12	AMENDMENT 2	No/ 2020-09-30 (50)	Lost to Follow-Up		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3832199	2020-08-17	AMENDMENT 2	No/ 2021-03-24 (220)	Withdrawal of Consent by Participant/ PRIMARY CARE TAKER FOR PARENTS THAT LIVE OUT OF STATE		Yes/ 2020-09-14 (29)	
US3832237	2020-08-20	AMENDMENT 2	No/ 2020-11-19 (92)	Death	2020-11-19/ UNK	Yes/ 2020-09-17 (29)	
US3842007	2020-08-31	AMENDMENT 3	No/ 2020-12-23 (115)	Other/ REQUEST TO UNBLIND UNDER EUA FOR VACCINATION		Yes/ 2020-10-01 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3842009	2020-09-01	AMENDMENT 3	No/ 2020-12-17 (108)	Other/ REQUEST TO UNBLIND EUA COVID-19 VACCINE		Yes/ 2020-10-02 (32)	
US3842012	2020-09-02	AMENDMENT 3	No/ 2020-12-23 (113)	Other/ REQUEST TO UNBLIND/EUA COVID-19		Yes/ 2020-10-02 (31)	
US3842015	2020-09-03	AMENDMENT 3	No/ 2020-12-29 (118)	Other/ UNBLINDED UNDER THE EUA DUE TO IMMINENT ACCESS AND ELIGIBILITY TO RECEIVE COVID19 VACCINATION		Yes/ 2020-09-30 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3842017	2020-09-03	AMENDMENT 3	No/ 2020-12-17 (105)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-30 (27)	
US3842054*	2020-10-02	AMENDMENT 4	No/ 2020-12-29 (89)	Other/ ACCESS TO COVID 19 VACCINATION UNDER EUA		Yes/ 2020-10-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852001	2020-08-20	AMENDMENT 2	No/ 2021-01-14 (148)	Protocol Deviation/ NOTIFIED OF SUBJECT RECEIVING VACCINE OUTSIDE OF THE STUDY. PLACEBO ARM. WITHDRAWN. UNABLE TO REACH BY PHONE TO DISCUSS FURTHER. PI NOTIFIED.		Yes/ 2020-09-18 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852009	2020-08-24	AMENDMENT 2	No/ 2020-12-22 (121)	Withdrawal of Consent by Participant/ REQUESTED UNBLINDING. PLACEBO ARM. WITHDRAWN PER PROTOCOL.		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852011	2020-08-24	AMENDMENT 2	No/ 2020-10-22 (60)	Withdrawal of Consent by Participant/ PT CHOSE TO WITHDRAW FROM STUDY AFTER RECEIVING BOTH DOSES. PT FELT THAT BECAUSE OF NO SYMPTOMS AND NEG AB TEST, HE DID NOT NEED TO CONTINUE. PT WAS EDUCATED ON SAFETY AND CHOSE TO WITHDRAW FROM STUDY		Yes/ 2020-09-18 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852033	2020-08-26	AMENDMENT 3	No/ 2020-12-29 (126)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY. WITHDRAWN. PI NOTIFIED. EPIP NOTIFIED.		Yes/ 2020-09-23 (29)	
US3852035	2020-08-26	AMENDMENT 3	No/ 2020-12-22 (119)	Protocol Deviation/ PATIENT REPORTED RECEIVING THE PFIZER VACCINE AND WAS UNBLINDED		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852039	2020-08-26	AMENDMENT 3	No/ 2020-12-17 (114)	Withdrawal of Consent by Participant/ PATIENT UNBLINDED		Yes/ 2020-09-28 (34)	
US3852050	2020-08-27	AMENDMENT 3	No/ 2020-12-28 (124)	Protocol Deviation/ PATIENT REQUESTED UNBLINDING AND RECEIVED THE MODERNA VACCINE FROM HER EMPLOYER		Yes/ 2020-09-22 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852057	2020-08-28	AMENDMENT 3	No/ 2020-09-28 (32)	Withdrawal of Consent by Participant/ PATIENT MAY HAVE RECEIVED THE WRONG DOSE DUE TO COORDINATOR/PHARMACY ERROR. PATIENT WITHDREW CONSENT BEFORE HER VISIT 2. SHE DID NOT SEE WHY SHE SHOULD CONTINUE IF THE DOSES WERE GOING TO BE DIFFERENT		No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ PATIENT WANTED TO WITHDRAW FROM STUDY DUE TO MIX UP INITIALLY WITH HER NUMBER AND HER SISTER'S PATINET ID NUMBER.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852063	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Withdrawal of Consent by Participant/ PATIENT REQUESTED UNBLINDING. PLACEBO ARM. WITHDRAWN PER PROTOCOL.		Yes/ 2020-09-25 (29)	
US3852064	2020-08-28	AMENDMENT 3	No/ 2020-12-23 (118)	Withdrawal of Consent by Participant/ PATIENT REQUESTED TO BE UNBLINDED AND WAS WITHDRAWN FROM THE GROUP		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852079	2020-09-01	AMENDMENT 3	No/ 2020-10-09 (39)	Lost to Follow-Up		No/ 2020-09-28 (28)	Lost to Follow-Up
US3852095	2020-09-03	AMENDMENT 3	No/ 2020-12-22 (111)	Protocol Deviation/ PATIENT REQUESTED UNBLINDING AND REPORTED RECEIVING THE MODERNA VACCINE OUTSIDE OF THE TRIAL		Yes/ 2020-10-06 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852096	2020-09-03	AMENDMENT 3	No/ 2020-12-29 (118)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED UNBLINDING. PLACEBO ARM. WITHDRAWN. PI NOTIFIED.		Yes/ 2020-09-30 (28)	
US3852109	2020-09-04	AMENDMENT 3	No/ 2020-12-30 (118)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-01 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852116	2020-09-04	AMENDMENT 3	No/ 2020-12-31 (119)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY. WITHDRAWN. PI NOTIFIED. EPIP NOTIFIED.		Yes/ 2020-10-02 (29)	
US3852124	2020-09-08	AMENDMENT 3	No/ 2020-12-17 (101)	Withdrawal of Consent by Participant/ PATIENT UNBLINDED		Yes/ 2020-10-23 (46)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852130	2020-09-08	AMENDMENT 3	No/ 2020-09-23 (16)	Withdrawal of Consent by Participant/ SPOKE WITH PATIENT TODAY REGARDING HIS DESIRE TO WITHDRAW FROM THE TRIAL. HE STATED HE FELT IT WAS MORE IMPORTANT TO GET HIS FLU VACCINE INSTEAD OF WAITING THE 14 DAYS POST HIS SECOND COVE VACCINE		No/ 2020-09-22 (15)	Withdrawal of Consent by Participant/ SPOKE WITH PATIENT TODAY REGARDING HIS DESIRE TO WITHDRAW FROM THE TRIAL. HE STATED HE FELT IT WAS MORE IMPORTANT TO GET HIS FLU VACCINE INSTEAD OF WAITING THE 14 DAYS POST HIS SECOND COVE VACCINE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852144	2020-09-09	AMENDMENT 3	No/ 2021-01-05 (119)	Withdrawal of Consent by Participant/ PATIENT UNBLINDED UNDER THE EUA APPROVAL		Yes/ 2020-10-07 (29)	
US3852147	2020-09-09	AMENDMENT 3	No/ 2021-02-11 (156)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE IN THE STUDY. WITHDRAWN. PI NOTIFIED.		Yes/ 2020-10-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852148	2020-09-09	AMENDMENT 3	No/ 2021-01-26 (140)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WISHES TO REMAIN IN THE STUDY OR BE UNBLINDED.		Yes/ 2020-10-07 (29)	
US3852149	2020-09-09	AMENDMENT 3	No/ 2021-02-11 (156)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE AT WORK PRIOR TO UNBLINDING. SUBJECT WITHDRAWN. PI NOTIFIED.		Yes/ 2020-10-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852174	2020-09-11	AMENDMENT 3	No/ 2020-12-31 (112)	Protocol Deviation/ SUBJECT REQUESTED UNBLINDING. PLACEBO ARM. WITHDRAWN. PI NOTIFIED.		Yes/ 2020-10-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852175	2020-09-11	AMENDMENT 3	No/ 2020-12-31 (112)	Protocol Deviation/ SUBJECT REQUESTED UNBLINDING. PLACEBO ARM. WITHDRAWN. PI NOTIFIED. RECEIVED VACCINE OUTSIDE OF STUDY AFTER WITHDRAWING.		Yes/ 2020-10-09 (29)	
US3852176	2020-09-11	AMENDMENT 3	No/ 2020-12-28 (109)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852184	2020-09-15	AMENDMENT 3	No/ 2021-01-14 (122)	Protocol Deviation/ RECEIVED COVID VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-16 (32)	
US3852185	2020-09-16	AMENDMENT 3	No/ 2021-03-03 (169)	Withdrawal of Consent by Participant/ NO LONGER WANTS TO REMAIN IN THE STUDY. WITHDRAWN. PI NOTIFIED. EPIP SENT. PLACEBO ARM.		Yes/ 2020-10-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852198	2020-10-02	AMENDMENT 4	No/ 2020-12-29 (89)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY. WITHDRAWN. PI NOTIFIED. EPIP NOTIFIED.		Yes/ 2020-11-06 (36)	
US3862004	2020-08-11	AMENDMENT 1	No/ 2020-12-17 (129)	Other/ REQUEST TO UNBLIND / UA COVID-19 VACCINE		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862011	2020-08-13	AMENDMENT 2	No/ 2020-12-20 (130)	Protocol Deviation/ REQUEST TO UNBLIND / PARTICIPANT RECEIVED EUA COVID-19 VACCINE		Yes/ 2020-09-10 (29)	
US3862019	2020-08-17	AMENDMENT 2	No/ 2020-12-16 (122)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-14 (29)	
US3862033	2020-08-19	AMENDMENT 2	No/ 2020-12-16 (120)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862044	2020-08-21	AMENDMENT 2	No/ 2020-12-15 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		No/ 2020-09-17 (28)	Adverse Event/ #1
US3862048	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Protocol Deviation/ SUBJECT HAD SHINGRIX VACCINE ON 22SEP2020 MEETING EXCLUSION CRITERION #9
US3862050	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Adverse Event/ AE#1
US3862061	2020-08-25	AMENDMENT 3	No/ 2021-01-14 (143)	Protocol Deviation/ PROHIBITED MEDICATION		Yes/ 2020-09-24 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862067	2020-08-26	AMENDMENT 3	No/ 2020-12-15 (112)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-23 (29)	
US3862086	2020-08-28	AMENDMENT 3	No/ 2021-01-14 (140)	Other/ SUBJECT UBLINDED FOR EUA VACCINE		No/ 2020-09-24 (28)	Pregnancy
US3862087	2020-08-28	AMENDMENT 3	No/ 2020-12-18 (113)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-25 (29)	
US3862098	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862105	2020-09-01	AMENDMENT 3	No/ 2020-12-15 (106)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-06 (36)	
US3862109	2020-09-02	AMENDMENT 3	No/ 2020-12-29 (119)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED TO BE UNBLINDED TO RECEIVE EUA COVID-19 VACCINE FROM EMPLOYER		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862137	2020-09-08	AMENDMENT 3	No/ 2020-12-28 (112)	Protocol Deviation/ #1; SUBJECT REQUESTED TO BE UNBLINDED FROM STUDY TO RECEIVE NON STUDY EUA COVID VACCINE		Yes/ 2020-10-06 (29)	
US3862138	2020-09-08	AMENDMENT 3	No/ 2020-12-16 (100)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-06 (29)	
US3862149	2020-09-08	AMENDMENT 3	No/ 2020-12-15 (99)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862151	2020-09-09	AMENDMENT 3	No/ 2020-12-15 (98)	Other/ REQUESTED TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3862158	2020-09-09	AMENDMENT 3	No/ 2020-12-18 (101)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-07 (29)	
US3862166	2020-09-10	AMENDMENT 3	No/ 2020-11-15 (67)	Withdrawal of Consent by Participant/ SUBJECT SUSPECTED THEY RECEIVED PLACEBO AND WOULD NOT LIKE TO CONTINUE.		Yes/ 2020-10-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862171	2020-09-11	AMENDMENT 3	No/ 2021-01-05 (117)	Protocol Deviation/ #1; SUBJECT RECEIVED NON STUDY EUA COVID19 VACCINE		Yes/ 2020-10-09 (29)	
US3862177	2020-09-11	AMENDMENT 3	No/ 2020-12-15 (96)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	
US3862185	2020-09-14	AMENDMENT 3	No/ 2020-12-17 (95)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862187	2020-09-14	AMENDMENT 3	No/ 2020-12-18 (96)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-12 (29)	
US3862204	2020-09-17	AMENDMENT 3	No/ 2020-12-21 (96)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-15 (29)	
US3862206	2020-09-17	AMENDMENT 3	No/ 2020-12-23 (98)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862208	2020-09-17	AMENDMENT 3	No/ 2021-01-14 (120)	Protocol Deviation/ PD#2 SUBJECT RECEIVED NON STUDY EUA COVID 19 VACCINE		Yes/ 2020-10-15 (29)	
US3862213	2020-09-18	AMENDMENT 3	No/ 2020-12-16 (90)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE RECEIVED		Yes/ 2020-10-21 (34)	
US3862227	2020-09-21	AMENDMENT 3	No/ 2020-12-18 (82)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862241	2020-09-24	AMENDMENT 3	No/ 2021-01-20 (119)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-10-22 (29)	
US3862263	2020-09-29	AMENDMENT 3	No/ 2021-03-24 (177)	Other/ REQUEST TO UNBLIND		Yes/ 2020-10-27 (29)	
US3862268	2020-09-30	AMENDMENT 3	No/ 2021-01-07 (98)	Other/ EUA VACCINE		Yes/ 2020-10-30 (29)	
US3862269	2020-09-30	AMENDMENT 3	No/ 2020-12-22 (84)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-30 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862279	2020-10-02	AMENDMENT 3	No/ 2020-12-15 (75)	Other/ REQUEST TO BE UNBLINDED / EUA COVID-19 VACCINE		Yes/ 2020-10-30 (29)	
US3862281	2020-10-13	AMENDMENT 4	No/ 2020-12-15 (64)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-12 (31)	
US3862282	2020-10-13	AMENDMENT 4	No/ 2021-01-08 (88)	Other/ REQUEST TO UNBLIND TO RECEIVE EUA VACCINE		Yes/ 2020-11-12 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872012	2020-07-31	AMENDMENT 1	No/ 2020-12-17 (140)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-08-28 (29)	
US3872023	2020-08-03	AMENDMENT 1	No/ 2020-12-22 (142)	Other/ UNBLINDED AT SUBJECTS REQUEST TO RECEIVE EUA VACCINE FROM EMPLOYER		Yes/ 2020-09-01 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872029	2020-08-03	AMENDMENT 1	No/ 2020-12-22 (142)	Other/ SUBJECT MET EUA CRITERIA AND WAS OFFERED EUA COVID -19 VACCINE FROM EMPLOYER		Yes/ 2020-08-31 (29)	
US3872039	2020-08-04	AMENDMENT 1	No/ 2020-12-22 (141)	Other/ SUBJECT MET EUA CRITERIA AND WAS OFFERED EUA COVID -19 VACCINE FROM EMPLOYER		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872088	2020-08-07	AMENDMENT 1	No/ 2020-09-16 (41)	Withdrawal of Consent by Participant/ STUDY WAS TOO INVOLVED, DOESN'T HAVE THE TIME		No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ STUDY WAS TOO INVOLVED , DOESN'T HAVE THE TIME
US3872100	2020-08-07	AMENDMENT 1	No/ 2021-01-20 (167)	Protocol Deviation/ SUBJECT GOT EUA MODERNA VACCINE OUTSIDE OF SITE AND DID NOT INFORM SITE		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872131	2020-08-11	AMENDMENT 1	No/ 2021-03-03 (205)	Withdrawal of Consent by Participant/ INTERFERED WITH WORK		Yes/ 2020-09-08 (29)	
US3872138	2020-08-11	AMENDMENT 1	ONGOING			No/ 2020-09-07 (28)	Other/ PER SUBJECTS REQUEST. SHE REPORTS THAT SHE THINKS THE VACCINE CAUSED HER TO GET A UTI. DOES NOT WANT THE SECOND DOSE PT WILL REMAIN IN STUDY AS INTENT TO TX

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872191	2020-08-14	AMENDMENT 1	No/ 2020-10-14 (62)	Withdrawal of Consent by Participant/ SHE HAS CHANGED HER MIND AND DOES NOT WISH TO PARTICIPATE		No/ 2020-09-10 (28)	Protocol Deviation/ SUBJECT WAS TOO FAR OUT OF WINDOW PER MM , IT WAS RECOMMENDED PER EPIP TO SKIP V2 AND PROCEED TO V3
US3872209	2020-08-17	AMENDMENT 1	No/ 2020-12-28 (134)	Other/ SUBJECT MET EUA CRITERIA AND WAS OFFERED EUA COVID -19 VACCINE FROM EMPLOYER		Yes/ 2020-09-16 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872215	2020-08-17	AMENDMENT 2	No/ 2020-12-22 (128)	Other/ SUBJECT MET EUA CRITERIA AND WAS OFFERED EUA COVID -19 VACCINE FROM EMPLOYER		Yes/ 2020-09-15 (30)	
US3872253	2020-08-21	AMENDMENT 2	No/ 2021-02-25 (189)	Lost to Follow-Up		Yes/ 2020-09-24 (35)	
US3872260	2020-08-24	AMENDMENT 2	No/ 2020-12-28 (127)	Other/ SUBJECT REQUEST UNBLINDING SO HE MAY RECEIVE OPEN LABEL PFIZER COVID VACCINE AT WORK TOMORROW 29 DEC. 2020.		Yes/ 2020-09-28 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872295	2020-08-25	AMENDMENT 2	No/ 2021-01-05 (134)	Other/ EUA UNBLINDING		Yes/ 2020-10-05 (42)	
US3872322	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872331	2020-08-27	AMENDMENT 2	ONGOING			No/ 2020-09-23 (28)	Protocol Deviation/ SUBJECT HAD TO BE RESCHEDULED NUMEROUS TIMES DUE TO SCHEDULING CONFLICTS. VISIT WAS TOO FAR OOW AND WAS RECOMMENDED TO SKIP V2 AND MOVE TO V3
US3872369	2020-08-29	AMENDMENT 2	ONGOING			No/ 2020-09-25 (28)	Protocol Deviation/ SUBJECT'S V2 NOT COMPLETED DUE TO BEING TOO FAR OOW

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872376	2020-08-29	AMENDMENT 2	No/ 2021-01-07 (132)	Protocol Deviation/ SUBJECT RECEIVED EUA PFIZER VACCINE AND DID NOT INFORM SITE PRIOR.		No/ 2020-09-25 (28)	Other/ SUBJECT WAS NO SHOW TIMES 2 FOR V2 AND WAS TOO FAR OOW WHEN CONTACT WAS MADE.
US3872395	2020-08-31	AMENDMENT 3	No/ 2020-09-12 (13)	Lost to Follow-Up		No/ 2020-09-11 (12)	Lost to Follow-Up
US3872398	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Protocol Deviation/ V2 NOT DONE DUE TO SWAB RESULT NOT BEING BACK.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872408	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Physician Decision/ ;SUBJECT WAS HAVING SX OF COVID-19 AT VISIT AND WAS SEEN FOR ILLNESS VISIT INSTEAD
US3872419	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ V2 TOO FAR OOW

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872428	2020-09-02	AMENDMENT 3	No/ 2021-01-13 (134)	Withdrawal of Consent by Participant/ SUBJECT IS BEING OFFERED THE MODERNA VACCINE BY HIS EMPLOYER AND REQUESTS TO BE UNBLINDED AND NO LONGER WANTS TO PARTICIPATE IN THE STUDY.		No/ 2020-09-29 (28)	Protocol Deviation/ V2 TOO FAR OOW WAS INSTRUCTED TO SKIP V2 AND GO TO V3. SWAB RESULTS WERE NOT BACK
US3872430	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ NO KIT A AT SITE DUE TO STUDY SHORTAGE , THEN OOW TO FAR FOR VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872433	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ PT COULD NOT HAVE V2 DONE DUE TO OOW TOO FAR AND WAS INSTRUCTED BY SPONSOR TO SKIP V2 AND GO TO V3
US3872434	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ V2 TOO FAR OOW WAS INSTRUCTED TO SKIP V2 AND GO TO V3
US3872436	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Other/ NP SWAB RESULT NOT BACK .

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872438	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V2 OOW AND WILL SKIP V2 AND GO TO V3
US3872446	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ SWAB RESULTS WERE NOT BACK AND THE V2 WAS TOO FAR OOW PER MM AND EPIPS IT IS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872447	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ NO SWAB RESULTS AT SITE AT V2, OOW WHEN THEY CAME BACK. SUBJECT WAS NO CALL NO SHOW FOR V3 DUE TO HIS WORK SCHEDULE.
US3872450	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V1 SWAB RESULTS NOT BACK BEFORE V2 . WHEN RESULTS RECEIVED AT SITE TOO FAR OOW TO CONDUCT 2,

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872451	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V2 TOO FAR OOW PER SPONSOR SKIP V2 AND GO V3.
US3872482	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ V2 TOO FAR OOW PER SPONSOR SKIP V2 AND GO V3 IN THESE CASES.
US3872483	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ ,V2 TOO FAR OOW NO KITS , PER SPONSOR SKIP V2 AND GO V3.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872486	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ SITE HAD NO SPONSOR PROVIDED LAB KITS DUE TO SHORTAGE. V2 NOT COMPLETED.
US3872492	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ SUBJECT WAS ON ANTIBIOTICS WHEN SHE CAME IN FOR V2. THEN COULD NOT BE SEEN DUE TO SITE HAD NO KITS FROM SPONSOR. VISIT TOO FAR OOW TO BE COMPLETED

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3882003	2020-08-27	AMENDMENT 3	No/ 2021-01-13 (136)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT		No/ 2020-09-27 (28)	Physician Decision/ PI AND MEDICAL MONITOR DETERMINED IT WAS IN THE BEST INTEREST OF THE SUBJECT TO SKIP DOSE 2 AND PROCEED IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3882004	2020-08-27	AMENDMENT 3	No/ 2021-02-22 (176)	Protocol Deviation/ SUBJECT IS UNABLE TO COMPLY WITH STUDY PROTOCOLS		No/ 2020-09-27 (28)	Other/ DOSING DISCONTINUATION COMES AT THE REQUEST OF THE SPONSOR AS THE SUBJECT WILL NOT BE AVAILABLE TO RECEIVE 2ND DOSE BEFORE MODERNA RECEIVES EUA
US3882011	2020-09-02	AMENDMENT 3	No/ 2021-01-06 (126)	Death	2021-01-06/ UNK	Yes/ 2020-10-02 (30)	
US3882034	2020-10-05	AMENDMENT 4	No/ 2020-12-22 (79)	Other/ UNBLINDED DUE TO PFIZER EUA		Yes/ 2020-11-05 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3882039	2020-10-13	AMENDMENT 4	No/ 2020-12-18 (60)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-18 (30)	
US3882051	2020-10-19	AMENDMENT 4	No/ 2020-12-16 (55)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-18 (27)	
US3882053	2020-10-20	AMENDMENT 4	No/ 2020-12-15 (54)	Other/ OTHER "REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-11-20 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3892037	2020-08-31	AMENDMENT 3	No/ 2020-12-18 (110)	Withdrawal of Consent by Participant/ REQUESTE UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-09-28 (29)	
US3902019	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Adverse Event/ AE #1
US3902064	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3902066	2020-09-10	AMENDMENT 3	No/ 2021-01-25 (138)	Lost to Follow-Up		Yes/ 2020-10-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3902074	2020-09-11	AMENDMENT 3	No/ 2020-12-29 (110)	Lost to Follow-Up		No/ 2020-10-08 (28)	Other/ SUBJECT LEFT IN THE MIDST OF THEIR SECOND DOSING VISIT AND DID NOT RETURN
US3902079	2020-09-14	AMENDMENT 3	No/ 2020-12-01 (79)	Physician Decision/ NON-COMPLIANCE		Yes/ 2020-10-12 (29)	
US3902095	2020-09-17	AMENDMENT 3	No/ 2020-12-31 (106)	Lost to Follow-Up		Yes/ 2020-10-19 (33)	
US3902104	2020-09-18	AMENDMENT 3	No/ 2021-01-19 (124)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE VACCINE AND MOVED OUT OF STATE		Yes/ 2020-10-13 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3902107	2020-09-23	AMENDMENT 3	No/ 2020-11-11 (50)	Lost to Follow-Up		Yes/ 2020-10-21 (29)	
US3902108	2020-09-23	AMENDMENT 3	No/ 2021-01-27 (127)	Lost to Follow-Up		Yes/ 2020-10-21 (29)	
US3902115	2020-09-28	AMENDMENT 3	No/ 2020-11-23 (57)	Lost to Follow-Up		Yes/ 2020-11-02 (36)	
US3912007	2020-08-26	AMENDMENT 2	No/ 2021-03-12 (199)	Protocol Deviation/ SUBJECT REPORTED THAT HE RECEIVED PFIZER COVID-19 VACCINE ON 09MAR2021.		No/ 2020-09-22 (28)	Other/ SUBJECT NON-COMPLIANCE AND UNSTABLE MEDICAL CONDITIONS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912026	2020-08-28	AMENDMENT 3	No/ 2021-03-17 (202)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT. HE COMPLETED OPEN LABEL DECISION VISIT BUT WAS NOT DOSED DUE TO RECENT SHINGLES VACCINE AND LATER RETURNED AND WAS NOT DOSED DUE TO GRADE 3 BP.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912028	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Physician Decision/ SUBJECT HAD SCHEDULED SURGERY BETWEEN DOSE 1 AND 2; DOSE 2 COULD NOT BE ADMINISTERED IN ACCORDANCE WITH THE PROTOCOL AND WAS THEREFORE 'SKIPPED', A PD.
US3912063	2020-09-01	AMENDMENT 3	No/ 2020-12-21 (112)	Other/ RECEIVING NON-STUDY COVID VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912075	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Other/ SUBJECT REPORTED THAT SHE COULD NOT MISS WORK FOR A LONG STUDY VISIT AND THAT'S THE REASON HER SECOND INJECTION WAS NOT GIVEN.
US3912105	2020-09-04	AMENDMENT 3	No/ 2020-10-30 (57)	Lost to Follow-Up		No/ 2020-10-01 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912111	2020-09-04	AMENDMENT 3	No/ 2021-03-22 (200)	Withdrawal of Consent by Participant/ SUBJECT MOVED OUT OF THE AREA AND DOES NOT PLAN TO RETURN TO THE SITE.		Yes/ 2020-10-01 (28)	
US3912117	2020-09-04	AMENDMENT 3	No/ 2020-12-31 (119)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID-19 VACCINE		Yes/ 2020-10-02 (29)	
US3912125	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Physician Decision/ UNABLE TO COLLECT LAB SAMPLES

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912139	2020-09-09	AMENDMENT 3	No/ 2021-03-16 (189)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE		Yes/ 2020-10-07 (29)	
US3912149	2020-09-11	AMENDMENT 3	No/ 2021-01-19 (131)	Protocol Deviation/ SUBJECT RECEIVED NON-STUDY COVID-19 VACCINATION		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912151	2020-09-11	AMENDMENT 3	No/ 2021-01-12 (124)	Withdrawal of Consent by Participant/ SUBJECT HAS MOVED OUT OF STATE AND DOES NOT PLAN TO RETURN FOR ANY FURTHER STUDY VISITS		Yes/ 2020-10-09 (29)	
US3912153	2020-09-11	AMENDMENT 3	No/ 2020-11-02 (53)	Lost to Follow-Up		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912186	2020-09-18	AMENDMENT 3	No/ 2020-12-21 (95)	Other/ SUBJECT TO RECEIVE NON-STUDY COVID VACCINE AT HER WORK		Yes/ 2020-10-14 (27)	
US3912206	2020-09-23	AMENDMENT 3	No/ 2020-12-31 (100)	Other/ SUBJECT REQUEST TO UNBLIND		Yes/ 2020-10-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912239	2020-10-12	AMENDMENT 3	No/ 2020-12-21 (71)	Withdrawal of Consent by Participant/ SUBJECT WAS A HEALTHCARE WORKER AND INFORMED US THAT HE INTENDED TO RECEIVE VACCINE OUTSIDE THE STUDY. SUBJECT WAS UNBLINDED UNDER A5 BY PI.		Yes/ 2020-11-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912241	2020-10-12	AMENDMENT 4	No/ 2021-02-04 (116)	Physician Decision/ SUBJECT WAS WITHDRAWN DUE TO HIS REFUSAL TO MEDICALLY MANAGE HIS MENTAL HEALTH (SCHIZOPHRENIA); REALIZING THAT THIS CONDITION WILL LIKELY WORSEN WITHOUT TREATMENT, SUBJECT WITHDRAWN.		No/ 2020-11-08 (28)	Serious Adverse Event/ AE #3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3922006	2020-08-18	AMENDMENT 2	No/ 2021-01-22 (158)	Withdrawal of Consent by Participant/ SUBJECT WC WHEN THE SITE DID NOT UNBLIND HIM WHEN HE REQUESTED DUE TO HIM BEING COVID POSITIVE AT THE TIME OF HIS REQUEST.		Yes/ 2020-09-15 (29)	
US3922041	2020-08-27	AMENDMENT 2	ONGOING			No/ 2020-09-23 (28)	Physician Decision/ 2ND DOSE WITHHELD, SUB-I DISCRETION, EPIP SUBMITTED DUE TO SUBJECT NON-COMPLIANCE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3922051	2020-08-29	AMENDMENT 3	No/ 2020-12-30 (124)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE ON 15/DEC/2020, SUBJECT WAS UN-BLINDED ON 30/DEC/2020		Yes/ 2020-10-02 (35)	
US3922067	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Serious Adverse Event/ SAE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3922129	2020-09-22	AMENDMENT 3	No/ 2021-03-05 (165)	Physician Decision/ SUBJECT NO LONGER ELIGIBLE. DOES NOT MEET IC/EC SUBJECT FAILED TO DISCLOSE MH THAT IS EXCLUSIONARY.		Yes/ 2020-10-23 (32)	
US3922131	2020-09-22	AMENDMENT 3	No/ 2020-11-19 (59)	Lost to Follow-Up		No/ 2020-10-19 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3922154	2020-10-19	AMENDMENT 4	No/ 2020-12-15 (58)	Withdrawal of Consent by Participant/ SUBJECT IS UNABLE TO ATTEND ON SITE APPOINTMENTS		No/ 2020-11-15 (28)	Physician Decision/ SUB-I DID NOT DOSE SUBJECT DUE TO COVID LIKE SYMPTOMS REPORTED AT V2.
US3932003	2020-08-25	AMENDMENT 2	ONGOING			No/ 2020-09-21 (28)	Adverse Event/ AE #4
US3932065	2020-09-02	AMENDMENT 3	No/ 2021-02-09 (148)	Protocol Deviation/ PATIENT DECIDED TO RECEIVE MODERNA VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-10-12 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932078	2020-09-04	AMENDMENT 3	No/ 2021-03-26 (204)	Lost to Follow-Up		Yes/ 2020-10-02 (29)	
US3932087	2020-09-08	AMENDMENT 3	No/ 2021-02-09 (155)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF STUDY. (PT DID NOT DISCLOSE WHICH VACCINE)		Yes/ 2020-10-07 (30)	
US3932096	2020-09-09	AMENDMENT 3	No/ 2020-10-01 (23)	Lost to Follow-Up		No/ 2020-09-30 (22)	Lost to Follow-Up
US3932114	2020-09-11	AMENDMENT 3	No/ 2021-03-09 (180)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932127	2020-09-14	AMENDMENT 3	No/ 2021-02-15 (155)	Withdrawal of Consent by Participant/ ORAL WITHDRAWAL OF CONSENT PER PHONE CALL WITH SUBJECT. SUBJECT NEEDED AN ILLNESS VISIT AND REFUSED TO COMPLY. SUBJECT STATED "TOO MUCH GOING ON RIGHT NOW" AND CAN'T CONTINUE IN THE STUDY.		Yes/ 2020-10-12 (29)	
US3932128	2020-09-14	AMENDMENT 3	No/ 2020-09-14 (1)	Lost to Follow-Up		No	Discontinuation from Study

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932147	2020-09-16	AMENDMENT 3	No/ 2021-01-21 (128)	Death	2021-01-21/ UNK	No/ 2020-10-13 (28)	Serious Adverse Event/ AE #2
US3932154	2020-09-17	AMENDMENT 3	No/ 2020-09-17 (1)	Lost to Follow-Up		No	Discontinuation from Study
US3932221	2020-10-03	AMENDMENT 4	ONGOING			No/ 2020-10-30 (28)	Lost to Follow-Up
US3932238	2020-10-13	AMENDMENT 4	ONGOING			No/ 2020-11-09 (28)	Due to SARS-CoV-2
US3932253	2020-10-14	AMENDMENT 4	No/ 2021-02-11 (121)	Protocol Deviation/ PATIENT RECEIVED VACCINE OUTSIDE OF STUDY.		Yes/ 2020-11-10 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942023	2020-08-28	AMENDMENT	3 No/ 2020-09-17 (21)	Lost to Follow-Up		No/ 2020-09-16 (20)	Lost to Follow-Up
US3942043	2020-09-02	AMENDMENT	3 No/ 2020-12-29 (119)	Protocol Deviation/ EUA COVID-19 VACCINE		Yes/ 2020-09-30 (29)	
US3942044	2020-09-02	AMENDMENT	3 ONGOING			No/ 2020-09-29 (28)	Other/ OOW DUE TO CONVALESCENT PERIOD
US3942079	2020-09-08	AMENDMENT	3 ONGOING			No/ 2020-10-05 (28)	Due to SARS-CoV-2
US3942084	2020-09-08	AMENDMENT	3 No/ 2021-01-04 (119)	Lost to Follow-Up		Yes/ 2020-10-07 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942115	2020-09-17	AMENDMENT 3	No/ 2020-11-19 (57)	Physician Decision/ VULNERABLE POPULATION		Yes/ 2020-10-23 (30)	
US3942127	2020-09-21	AMENDMENT 3	No/ 2020-11-16 (57)	Lost to Follow-Up		No/ 2020-10-18 (28)	Lost to Follow-Up
US3942129	2020-09-22	AMENDMENT 3	No/ 2020-11-16 (56)	Lost to Follow-Up		No/ 2020-10-19 (28)	Lost to Follow-Up
US3942151	2020-10-12	AMENDMENT 4	ONGOING			No/ 2020-11-08 (28)	Serious Adverse Event/ #1 AND 2
US3942157	2020-10-13	AMENDMENT 4	No/ 2020-10-27 (15)	Lost to Follow-Up		No/ 2020-10-26 (14)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952025	2020-09-01	AMENDMENT 2	No/ 2021-02-12 (165)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA COVID-19 VACCINE		Yes/ 2020-10-01 (31)	
US3952033	2020-09-02	AMENDMENT 2	No/ 2021-01-20 (141)	Physician Decision/ NOT MEDICALLY STABLE TO PROCEED TO OPEN LABEL VACCINE. WILL GET OUTSIDE EUA LEADING TO WITHDRAW.		No/ 2020-09-29 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952051	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Other/ PATIENT WAS UNABLE TO PRESENT FOR VACCINE #2 (VISIT 2/DAY 29) WITHIN STUDY SPECIFIED VISIT WINDOW DUE TO FUNERAL OF A FAMILY MEMBER.
US3952056	2020-09-08	AMENDMENT 2	No/ 2021-03-11 (185)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA VACCINATION		Yes/ 2020-10-07 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952064	2020-09-09	AMENDMENT 2	ONGOING			No/ 2020-10-06 (28)	Physician Decision/ OUT OF WINDOW DUE TO PATIENT UNAVAILABILITY
US3952075	2020-09-11	AMENDMENT 3	No/ 2020-12-10 (91)	Withdrawal of Consent by Participant/ WD, NO REASON GIVEN BY SUBJECT		Yes/ 2020-10-09 (29)	
US3952080	2020-09-11	AMENDMENT 3	No/ 2021-01-29 (141)	Other/ SUBJECT IS MOVING		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952090	2020-09-15	AMENDMENT 3	No/ 2021-01-08 (116)	Protocol Deviation/ SUBJECT OBTAINED OUTSIDE EUA ON 05 JAN 2021		Yes/ 2020-10-13 (29)	
US3952094	2020-09-15	AMENDMENT 3	No/ 2021-01-30 (138)	Death	2021-01-30/ N	Yes/ 2020-10-14 (30)	
US3952102	2020-09-17	AMENDMENT 3	No/ 2021-03-24 (189)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA PFIZER VACCINE.		Yes/ 2020-10-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952116	2020-09-18	AMENDMENT 3	ONGOING			No/ 2020-10-15 (28)	Adverse Event/ AE #2 [WORSENING OF BASELINE ELEVATED GRADE 3 BLOOD PRESSURE]
US3952148	2020-09-24	AMENDMENT 3	No/ 2021-03-05 (163)	Withdrawal of Consent by Participant/ WANTS TO SPEED VACCINATION, LIVES TO FAR AWAY FROM SITE.		Yes/ 2020-10-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952191	2020-10-05	AMENDMENT 3	ONGOING			No/ 2020-11-01 (28)	Other/ DID NOT MEET INCLUSION/EXCLUSION CRITERIA FOR V2 DUE TO RECEIVING AN OUT OF STUDY VACCINATION WITHIN 28 DAYS OF THE VISIT
US3962033	2020-08-29	AMENDMENT 3	No/ 2021-01-07 (132)	Protocol Deviation/ SUBJECT WAS DROPPED FROM THE STUDY DUE TO RECEIVING THE MODERNA COVID VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-10-02 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3962067	2020-09-04	AMENDMENT 3	No/ 2021-01-06 (125)	Protocol Deviation/ SUBJECT WAS DROPPED FROM THE STUDY DUE TO RECEIVING THE MODERNA COVID VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-10-05 (32)	
US3962097	2020-09-11	AMENDMENT 3	No/ 2021-01-13 (125)	Protocol Deviation/ SUBJECT WANTED THE STUDY BLIND BROKE SO SO COULD RECEIVE THE MODERNA VACCINE FROM HER EMPLOYER		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3962099	2020-09-11	AMENDMENT 3	No/ 2021-03-22 (193)	Physician Decision/ SUBJECT IS DEALING WITH AN INFESTATION OF BED BUGS AND IS UNABLE TO COME BACK INTO THE STUDY SITE.		Yes/ 2020-10-09 (29)	
US3962106	2020-10-12	AMENDMENT 3	No/ 2020-12-14 (64)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTED TO PARTICIPATE IN THE STUDY		Yes/ 2020-11-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3972089	2020-09-02	AMENDMENT 3	No/ 2021-02-05 (157)	Protocol Deviation/ SUBJECT RECEIVED THE MODERNA VACCINE OUTSIDE THE STUDY		Yes/ 2020-09-30 (29)	
US3972171	2020-09-15	AMENDMENT 3	No/ 2020-11-11 (58)	Lost to Follow-Up		Yes/ 2020-10-13 (29)	
US3982004	2020-08-24	AMENDMENT 2	No/ 2020-10-02 (36)	Withdrawal of Consent by Participant/ CLAIMED HE WILL NO LONGER BE ABLE TO PARTICIPATE.		No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ CLAIMED HE WILL NO LONGER BE ABLE TO PARTICIPATE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982011	2020-08-25	AMENDMENT 2	No/ 2020-12-23 (121)	Lost to Follow-Up		Yes/ 2020-09-22 (29)	
US3982021	2020-08-27	AMENDMENT 3	No/ 2020-09-18 (23)	Lost to Follow-Up		No/ 2020-09-17 (22)	Lost to Follow-Up
US3982022	2020-08-27	AMENDMENT 3	No/ 2021-01-20 (147)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE (MODERNA) OUTSIDE OF THE STUDY.		Yes/ 2020-09-25 (30)	
US3982051	2020-08-31	AMENDMENT 3	No/ 2020-12-31 (123)	Lost to Follow-Up		Yes/ 2020-09-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982071	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Protocol Deviation/ PATIENT RECEIVED FLU VACCINE ON 22OCT2020.
US3982085	2020-09-02	AMENDMENT 3	No/ 2020-12-11 (101)	Lost to Follow-Up		Yes/ 2020-09-30 (29)	
US3982086	2020-09-02	AMENDMENT 3	No/ 2021-02-04 (156)	Lost to Follow-Up		Yes/ 2020-09-29 (28)	
US3982120	2020-09-07	AMENDMENT 3	No/ 2020-10-05 (29)	Lost to Follow-Up		Yes/ 2020-10-05 (29)	
US3982149	2020-09-10	AMENDMENT 3	No/ 2020-10-01 (22)	Lost to Follow-Up		No/ 2020-09-30 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982151	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Physician Decision/ PI DECIDED NOT TO PROCEED WITH SECOND DOSE DUE TO SAFETY REASONS BECAUSE THE SUBJECT WAS ILL WITH ABDOMINAL PAINS 2ND TO STOMACH ULCERS. REACTION TO FIRST DOSE NOT APPLICABLE AT ALL
US3982175	2020-09-15	AMENDMENT 3	No/ 2020-09-26 (12)	Lost to Follow-Up		No/ 2020-09-25 (11)	Lost to Follow-Up
US3982180	2020-09-16	AMENDMENT 3	No/ 2021-01-18 (125)	Lost to Follow-Up		Yes/ 2020-10-12 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982184	2020-09-16	AMENDMENT 3	ONGOING			No/ 2020-10-13 (28)	Protocol Deviation/ SUBJECT RECEIVED PNEUMONIA VACCINE ON 12OCT2020. DAY 29 VISIT OCCURRED ON 14OCT2020.
US3982196	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-14 (28)	Protocol Deviation/ SUBJECT MISSED DAY 29 VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982215	2020-09-21	AMENDMENT 3	No/ 2021-02-19 (152)	Protocol Deviation/ SUBJECT RECEIVED MODERNA COVID-19 VACCINE OUTSIDE OF STUDY. INFORMATION OBTAINED ON 29JAN2021.		Yes/ 2020-10-19 (29)	
US3982217	2020-09-22	AMENDMENT 3	No/ 2020-12-16 (86)	Lost to Follow-Up		Yes/ 2020-10-20 (29)	
US3982245	2020-09-28	AMENDMENT 3	No/ 2020-10-08 (11)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW PARTICIPATION		No/ 2020-10-07 (10)	Other/ SUBJECT WITHDREW PARTICIPATION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982256	2020-09-30	AMENDMENT 3	No/ 2021-02-13 (137)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO COMMIT TO REST OF 2 YR STUDY AND MAY BE INTERESTED IN ANOTHER STUDY. AT ANOTHER FACILITY		Yes/ 2020-10-28 (29)	
US3982259	2020-10-05	AMENDMENT 4	No/ 2021-03-15 (162)	Lost to Follow-Up		Yes/ 2020-11-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3992062	2020-10-03	AMENDMENT 3	No/ 2020-12-22 (81)	Withdrawal of Consent by Participant/ SUBJECT HAS INTENTION TO RECEIVE THE PFIZER VACCINE THEREFORE IS WITHDRAWN FROM STUDY		Yes/ 2020-11-03 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3992079	2020-10-09	AMENDMENT 4	No/ 2020-12-22 (75)	Withdrawal of Consent by Participant/ SUBJECT HAS INTENTIONS TO RECEIVE THE PFIZER VACCINE THEREFORE HE IS WITHDRAWN FROM STUDY.		Yes/ 2020-11-10 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3992120	2020-10-21	AMENDMENT 4	No/ 2020-12-17 (58)	Withdrawal of Consent by Participant/ SUBJECT ISA HEALTHCARE WORKER AND HAS BEEN INFORMED HE WILL BE WITHDRAWN FROM STUDY AS THE SUBJECT HAS INTENTION TO RECEIVE PFIZER VACCINE.		Yes/ 2020-11-17 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002014	2020-07-28	AMENDMENT	1 No/ 2021-01-06 (163)	Withdrawal of Consent by Participant/ PT. UNBLINDED		Yes/ 2020-08-31 (35)	
US3002060	2020-07-29	AMENDMENT	1 No/ 2021-01-07 (163)	Withdrawal of Consent by Participant/ PT. UNBLINDED		Yes/ 2020-08-26 (29)	
US3002072	2020-07-30	AMENDMENT	1 No/ 2021-01-19 (174)	Withdrawal of Consent by Participant/ NO LONGER WANTS TO PARTICIPATE		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002135	2020-08-07	AMENDMENT 1	No/ 2021-02-08 (186)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-09-09 (34)	
US3002150	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Physician Decision/ COULD NOT COME IN WITHIN WINDOW
US3002172	2020-08-20	AMENDMENT 2	No/ 2020-09-10 (22)	Lost to Follow-Up		No/ 2020-09-09 (21)	Lost to Follow-Up
US3002206	2020-08-28	AMENDMENT 3	No/ 2020-10-27 (61)	Lost to Follow-Up		No/ 2020-09-24 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002264	2020-09-08	AMENDMENT 3	No/ 2020-12-17 (101)	Withdrawal of Consent by Participant/ SUBJECT GETTING EUA		Yes/ 2020-10-08 (31)	
US3002337	2020-09-30	AMENDMENT 3	No/ 2020-11-10 (42)	Lost to Follow-Up		No/ 2020-10-27 (28)	Lost to Follow-Up
US3002363	2020-10-13	AMENDMENT 4	No/ 2020-12-17 (66)	Withdrawal of Consent by Participant/ PATIENT NO LONGER WANTS TO COME IN FOR VISITS AND HUNG UP ON STAFF.		Yes/ 2020-11-12 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012046	2020-07-31	AMENDMENT 2	No/ 2021-01-11 (165)	Protocol Deviation/ RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY , WITHDRAWN PER SPONSOR INSTRUCTION		Yes/ 2020-08-28 (29)	
US3012053	2020-08-06	AMENDMENT 2	No/ 2020-09-03 (29)	Physician Decision/ SUBJECT IS NOT MENTALLY STABLE, PROVIDED INCORRECT INFORMATION		No/ 2020-09-02 (28)	Physician Decision/ SUBJECT IS NOT STABLE, PROVIDED INCORRECT INFORMATION
US3012087	2020-08-10	AMENDMENT 2	No/ 2021-03-18 (221)	Lost to Follow-Up		No/ 2020-09-06 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012098	2020-08-10	AMENDMENT 2	No/ 2020-12-02 (115)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FOR PERSONAL REASONS		Yes/ 2020-09-08 (30)	
US3012150	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Protocol Deviation/ OBTAINED FLU SHOT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012185	2020-08-19	AMENDMENT 2	No/ 2021-01-11 (146)	Protocol Deviation/ SUBJECT RECEIVED EUA COVID-19 VACCINE OUTSIDE OF STUDY AND WAS WITHDRAWN, PER SPONSOR INSTRUCTIONS/PROTOCOL.		Yes/ 2020-09-18 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3012288	2020-09-10	AMENDMENT 3	No/ 2020-11-10 (62)	Withdrawal of Consent by Participant/ SUBJECT REQUESTED TO BE UNBLINDED TO STUDY TREATMENT. SITE INFORMED SUBJECT THAT WAS NOT POSSIBLE AT THIS STAGE IN THE STUDY AND SUBJECT ENDED STUDY PARTICIPATION DUE TO THIS.		Yes/ 2020-10-15 (36)	
US3012349	2020-10-19	AMENDMENT 4	No/ 2021-03-12 (145)	Lost to Follow-Up		Yes/ 2020-11-20 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022021	2020-07-29	AMENDMENT 1	ONGOING			No/ 2020-08-25 (28)	Adverse Event/ AE#1
US3022031	2020-07-27	AMENDMENT 1	ONGOING			No/ 2020-08-23 (28)	Serious Adverse Event/ AE#1
US3022122	2020-08-05	AMENDMENT 1	No/ 2020-12-16 (134)	Protocol Deviation/ SUBJECT WAS UNBLINDED DUE TO WORKING IN A HOSPITAL. SUBJECT DIDN'T WAIT TO HEAR BACK, SUBJECT RECEIVED PFIZER COVID-19 VACCINE.		Yes/ 2020-09-03 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022166	2020-08-17	AMENDMENT 2	No/ 2020-08-31 (15)	Withdrawal of Consent by Participant/ SUBJECT STATES THAT SHE DOESN'T WANT TO PARTICIPATE ANYMORE.		No/ 2020-08-30 (14)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT
US3022225	2020-08-20	AMENDMENT 2	No/ 2020-12-03 (106)	Lost to Follow-Up		No/ 2020-09-16 (28)	Lost to Follow-Up
US3022238	2020-08-20	AMENDMENT 2	No/ 2021-01-18 (152)	Protocol Deviation/ SUBJECT RECEIVED MODERNA VACCINE AT WORK ON 30DEC2020		Yes/ 2020-09-24 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032033	2020-07-29	AMENDMENT 1	No/ 2021-01-08 (164)	Lost to Follow-Up		Yes/ 2020-09-01 (35)	
US3032054	2020-07-30	AMENDMENT 1	No/ 2021-01-22 (177)	Withdrawal of Consent by Participant/ SUBJECT DID NOT WANT TO GO THROUGH ANY MORE BLOOD DRAWS.		Yes/ 2020-09-03 (36)	
US3032093	2020-08-05	AMENDMENT 2	No/ 2020-11-13 (101)	Lost to Follow-Up		Yes/ 2020-09-02 (29)	
US3032126	2020-08-06	AMENDMENT 1	No/ 2020-11-05 (92)	Lost to Follow-Up		No/ 2020-09-02 (28)	Lost to Follow-Up
US3032243	2020-08-19	AMENDMENT 2	No/ 2021-03-04 (198)	Lost to Follow-Up		Yes/ 2020-09-18 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032297	2020-08-21	AMENDMENT 2	No/ 2020-10-23 (64)	Withdrawal of Consent by Participant/ MOVED OUT OF STATE, SUBJECT WILL NOT BE ABLE TO COMPLY WITH STUDY VISITS. SUBJECT STATED THE MOVE WAS NOT PLANNED.		Yes/ 2020-09-18 (29)	
US3032305	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3032313	2020-08-21	AMENDMENT 3	No/ 2020-10-01 (42)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO UNFORESEEN ISSUES		No/ 2020-09-17 (28)	Withdrawal of Consent by Participant/ DUE TO UNFORESEEN HEALTH ISSUES. SUBJECT DECLINED TO SIGN RELEASE FOR MEDICAL RECORDS AND DENIED COMING TO STUDY SITE FOR END OF STUDY VISIT.
US3042001	2020-07-27	AMENDMENT 1	No/ 2021-03-16 (233)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-31 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042004	2020-07-28	AMENDMENT 1	No/ 2021-03-16 (232)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-25 (29)	
US3042005	2020-07-28	AMENDMENT 1	No/ 2021-03-10 (226)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-28 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042010	2020-07-28	AMENDMENT 1	No/ 2021-03-10 (226)	Withdrawal of Consent by Participant/ PATIENT TO MOVE INTO PHASE 2 CROSSOVER		Yes/ 2020-08-25 (29)	
US3042014	2020-07-29	AMENDMENT 1	No/ 2021-03-18 (233)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042016	2020-07-29	AMENDMENT 1	No/ 2021-03-11 (226)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-28 (31)	
US3042017	2020-07-29	AMENDMENT 1	No/ 2021-03-10 (225)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-02 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042021	2020-07-29	AMENDMENT 1	No/ 2021-03-17 (232)	Withdrawal of Consent by Participant/ PATIENT MOVED TO PHASE 2 CROSSOVER		Yes/ 2020-08-26 (29)	
US3042022	2020-07-29	AMENDMENT 1	No/ 2021-03-16 (231)	Other/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-26 (29)	
US3042024	2020-07-29	AMENDMENT 1	No/ 2021-03-18 (233)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042029	2020-07-29	AMENDMENT 1	No/ 2021-03-12 (227)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-01 (35)	
US3042031	2020-07-29	AMENDMENT 1	No/ 2021-03-17 (232)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-28 (31)	
US3042032	2020-07-29	AMENDMENT 1	No/ 2020-08-27 (30)	Adverse Event/ AE #1		No/ 2020-08-25 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042034	2020-07-30	AMENDMENT 1	No/ 2021-03-16 (230)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-27 (29)	
US3042038	2020-07-30	AMENDMENT 1	No/ 2021-03-15 (229)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-02 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042039	2020-07-30	AMENDMENT 1	No/ 2021-03-12 (226)	Withdrawal of Consent by Participant/ PATIENT MOVED TO PHASE 2 CROSSOVER		Yes/ 2020-08-27 (29)	
US3042040	2020-07-30	AMENDMENT 1	No/ 2021-03-16 (230)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042042	2020-07-30	AMENDMENT 1	No/ 2021-03-16 (230)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-02 (35)	
US3042044	2020-07-31	AMENDMENT 1	No/ 2021-03-18 (231)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-31 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042046	2020-08-03	AMENDMENT 1	No/ 2021-01-27 (178)	Protocol Deviation/ PATIENT RECEIVED COVID VACCINE THROUGH EMPLOYER PRIOR TO CALLING SITE STAFF		Yes/ 2020-08-31 (29)	
US3042048	2020-08-03	AMENDMENT 1	No/ 2021-03-18 (228)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-31 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042058	2020-08-03	AMENDMENT 1	No/ 2021-03-17 (227)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-08-31 (29)	
US3042071	2020-08-05	AMENDMENT 1	No/ 2021-03-11 (219)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-03 (30)	
US3042075	2020-08-05	AMENDMENT 1	No/ 2021-02-12 (192)	Lost to Follow-Up		Yes/ 2020-09-09 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042076	2020-08-05	AMENDMENT 1	No/ 2021-03-11 (219)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-03 (30)	
US3042077	2020-08-05	AMENDMENT 1	No/ 2021-01-05 (154)	Lost to Follow-Up		Yes/ 2020-09-09 (36)	
US3042086	2020-08-06	AMENDMENT 1	No/ 2021-03-18 (225)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042092	2020-08-06	AMENDMENT 1	No/ 2020-11-05 (92)	Withdrawal of Consent by Participant/ SUBJECT CALLED AND WITHDREW FROM STUDY; STATING THEY NO LONGER ARE ABLE TO COMMIT TIME TO VISITS AND FOLLOW UPS.		Yes/ 2020-09-10 (36)	
US3042097	2020-08-06	AMENDMENT 1	No/ 2021-03-22 (229)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042099	2020-08-06	AMENDMENT 1	No/ 2021-03-11 (218)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-03 (29)	
US3042117	2020-08-07	AMENDMENT 1	No/ 2021-03-16 (222)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-04 (29)	
US3042121	2020-08-07	AMENDMENT 1	No/ 2020-09-11 (36)	Withdrawal of Consent by Participant/ PATIENT'S CHOICE		No/ 2020-09-03 (28)	Withdrawal of Consent by Participant/ PATIENTS CHOICE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042124	2020-08-07	AMENDMENT 1	No/ 2021-03-17 (223)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-09 (34)	
US3042133	2020-08-10	AMENDMENT 2	No/ 2021-03-22 (225)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-14 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042138	2020-08-11	AMENDMENT 2	No/ 2021-03-18 (220)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-08 (29)	
US3042141	2020-08-11	AMENDMENT 2	No/ 2021-03-15 (217)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042142	2020-08-11	AMENDMENT 2	No/ 2021-03-15 (217)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-08 (29)	
US3042143	2020-08-11	AMENDMENT 2	No/ 2021-03-17 (219)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042151	2020-08-12	AMENDMENT 2	No/ 2021-03-17 (218)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-16 (36)	
US3042154	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Other/ SUBJECT WAS ON PREDNISONE FROM STAPEDECTOMY; TOO FAR OUTSIDE OF VISIT 2 WINDOW TO VACCINATE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042160	2020-08-12	AMENDMENT 2	No/ 2020-12-23 (134)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT AFTER BEING UNBLINDED TO RECEIVE VACCINE THROUGH EMPLOYER		Yes/ 2020-09-09 (29)	
US3042162	2020-08-12	AMENDMENT 2	No/ 2021-03-12 (213)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-09 (29)	
US3042166	2020-08-12	AMENDMENT 2	No/ 2020-10-20 (70)	Lost to Follow-Up		No/ 2020-09-08 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042180	2020-08-13	AMENDMENT 2	No/ 2021-03-18 (218)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (36)	
US3042183	2020-08-13	AMENDMENT 2	No/ 2021-03-18 (218)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042186	2020-08-13	AMENDMENT 2	No/ 2021-03-18 (218)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-14 (33)	
US3042188	2020-08-13	AMENDMENT 2	No/ 2021-03-16 (216)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-15 (34)	
US3042190	2020-08-13	AMENDMENT 2	No/ 2020-09-17 (36)	Serious Adverse Event/ SAE #1		No/ 2020-09-09 (28)	Serious Adverse Event/ SAE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042192	2020-08-14	AMENDMENT 2	No/ 2020-09-14 (32)	Adverse Event/ AE #1		No/ 2020-09-10 (28)	Adverse Event/ AE #1
US3042204	2020-08-14	AMENDMENT 2	No/ 2021-03-18 (217)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042211	2020-08-17	AMENDMENT 2	No/ 2021-01-05 (142)	Protocol Deviation/ PATIENT RECEIVED COVID VACCINE VIA EMPLOYER ON 29DEC2020. PARTICIPANT DID NOT CALL STUDY TEAM PRIOR TO RECEIVING VACCINE. PATIENT WITHDRAWN FROM STUDY.		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042215	2020-08-17	AMENDMENT 2	No/ 2021-03-17 (213)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-15 (30)	
US3042217	2020-08-17	AMENDMENT 2	No/ 2021-03-15 (211)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042225	2020-08-18	AMENDMENT 2	No/ 2021-03-16 (211)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-15 (29)	
US3042233	2020-08-18	AMENDMENT 2	No/ 2021-03-17 (212)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-10-02 (46)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042236	2020-08-18	AMENDMENT 2	No/ 2021-03-17 (212)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-15 (29)	
US3042243	2020-08-19	AMENDMENT 2	No/ 2021-03-18 (212)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042249	2020-08-19	AMENDMENT 2	No/ 2020-09-03 (16)	Withdrawal of Consent by Participant/ SUBJECT STATES THEIR PSYCHIATRIST ADVISED THEM TO DISCONTINUE THE STUDY. SUBJECT WITHDRAW FROM THE STUDY.		No/ 2020-09-02 (15)	Withdrawal of Consent by Participant/ SUBJECT STATES THEIR PSYCHIATRIST ADVISED THEM TO DISCONTINUE THE STUDY. SUBJECT WITHDRAW FROM THE STUDY.
US3042250	2020-08-19	AMENDMENT 2	No/ 2021-03-17 (211)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042258	2020-08-20	AMENDMENT 2	No/ 2021-03-16 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	
US3042259	2020-08-20	AMENDMENT 2	No/ 2021-03-17 (210)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042263	2020-08-20	AMENDMENT 2	No/ 2021-03-16 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	
US3042265	2020-08-20	AMENDMENT 2	No/ 2021-03-17 (210)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042269	2020-08-20	AMENDMENT 2	No/ 2021-03-16 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	
US3042274	2020-08-20	AMENDMENT 2	No/ 2021-03-11 (204)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042276	2020-08-20	AMENDMENT 2	No/ 2021-03-16 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	
US3042277	2020-08-20	AMENDMENT 2	No/ 2021-03-18 (211)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042280	2020-08-20	AMENDMENT 2	No/ 2021-03-17 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-18 (29)	
US3042289	2020-08-21	AMENDMENT 2	No/ 2021-03-22 (214)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-24 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042301	2020-08-22	AMENDMENT 2	No/ 2021-03-12 (203)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-25 (35)	
US3042307	2020-08-22	AMENDMENT 2	No/ 2020-12-01 (102)	Withdrawal of Consent by Participant/ PARTICIPANT CAN NO LONGER DEDICATE TIME THE STUDY DUE TO JOB PROMOTION		Yes/ 2020-09-25 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042308	2020-08-22	AMENDMENT 2	No/ 2021-03-12 (203)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-21 (31)	
US3042311	2020-08-22	AMENDMENT 2	No/ 2021-03-18 (209)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-21 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042321	2020-08-27	AMENDMENT 3	No/ 2021-03-17 (203)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-10-07 (42)	
US3052026	2020-07-30	AMENDMENT 1	No/ 2020-10-20 (83)	Other/ PT MOVED TO FLORIDA		Yes/ 2020-08-26 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052292	2020-08-21	AMENDMENT 2	No/ 2020-09-28 (39)	Withdrawal of Consent by Participant/ PATIENT DECIDED THAT THEY WANT TO BE WITHDREW FROM THE STUDY		No/ 2020-09-17 (28)	Withdrawal of Consent by Participant/ PT STATED THAT SHE LIVES TO FAR AWAY FORM THE SITE AND THAT SHE NO LONGER WISHES TO PARTICIPATE.
US3052301	2020-08-24	AMENDMENT 2	No/ 2020-08-24 (1)	Lost to Follow-Up		No	Discontinuation from Study
US3052322	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ WITHDRAW FROM STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3052328	2020-08-31	AMENDMENT 2	No/ 2020-10-30 (61)	Lost to Follow-Up		No/ 2020-09-27 (28)	Lost to Follow-Up
US3062103	2020-08-05	AMENDMENT 1	No/ 2020-08-31 (27)	Withdrawal of Consent by Participant/ TOO MUCH HAPPENING IN PERSONAL LIFE		No/ 2020-08-30 (26)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FOR REASON OF "TOO MUCH HAPPENING IN PERSONAL LIFE".
US3062265	2020-08-15	AMENDMENT 2	No/ 2020-11-20 (98)	Physician Decision/ INACCURATE DATA AND TO ALLOW TIME FOR SUBJECT TO GET HEALTH IN ORDER.		Yes/ 2020-09-23 (40)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082005	2020-08-07	AMENDMENT 2	No/ 2020-12-28 (144)	Protocol Deviation/ REQUEST TO UNBLIND POST-EUA		Yes/ 2020-09-08 (33)	
US3082050	2020-08-18	AMENDMENT 2	No/ 2021-03-09 (204)	Lost to Follow-Up		Yes/ 2020-09-16 (30)	
US3082051	2020-08-18	AMENDMENT 2	No/ 2020-09-08 (22)	Serious Adverse Event/ SAE #1		No/ 2020-09-07 (21)	Serious Adverse Event/ SAE#1
US3082078	2020-08-21	AMENDMENT 3	No/ 2021-01-07 (140)	Other/ REQUEST TO UNBLIND AND WITHDRAW FROM STUDY POST EUA		Yes/ 2020-09-25 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3082151	2020-08-29	AMENDMENT 3	No/ 2020-09-01 (4)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WISH TO ATTEND ANY FUTURE STUDY VISITS.		No/ 2020-08-31 (3)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AND STATED SHE DOES NOT INTEND TO RETURN FOR ANY FUTURE STUDY VISITS.
US3082231	2020-09-11	AMENDMENT 3	No/ 2021-01-05 (117)	Other/ REQUEST TO UNBLIND/EUA COVID-19 VACCINE		Yes/ 2020-10-09 (29)	
US3092002	2020-08-04	AMENDMENT 1	No/ 2021-03-01 (210)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092014	2020-08-04	AMENDMENT 1	No/ 2021-03-01 (210)	Protocol Deviation/ RECEIVED EUA OUTSIDE OF STUDY		Yes/ 2020-09-14 (42)	
US3092081	2020-08-08	AMENDMENT 1	No/ 2021-02-05 (182)	Withdrawal of Consent by Participant/ SUBJECT DECISION		Yes/ 2020-09-09 (33)	
US3092119	2020-08-12	AMENDMENT 2	No/ 2020-09-24 (44)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT- CONFIRMED NOT DUE TO AE		No/ 2020-09-08 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092146	2020-08-15	AMENDMENT 2	No/ 2021-03-15 (213)	Lost to Follow-Up		Yes/ 2020-09-11 (28)	
US3092214	2020-08-25	AMENDMENT 3	No/ 2021-02-26 (186)	Withdrawal of Consent by Participant/ NO LONGER WANTS TO PARTICIPATE IN STUDY.		Yes/ 2020-09-25 (32)	
US3092239	2020-08-27	AMENDMENT 3	No/ 2020-09-28 (33)	Withdrawal of Consent by Participant/ REASON NOT GIVEN		No/ 2020-09-23 (28)	Withdrawal of Consent by Participant/ NO REASON GIVEN

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3092279	2020-09-01	AMENDMENT 3	No/ 2021-03-09 (190)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT		Yes/ 2020-10-01 (31)	
US3102054	2020-07-29	AMENDMENT 1	No/ 2021-02-08 (195)	Protocol Deviation/ RECEIVED COVID-19 VACCINE, DOES NOT KNOW WHICH BRAND/TYPE RECEIVED.		Yes/ 2020-08-25 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102067	2020-07-30	AMENDMENT 1	No/ 2021-02-08 (194)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE. RECEIVED PFIZER VACCINE.		Yes/ 2020-08-26 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102086	2020-08-03	AMENDMENT 1	No/ 2020-08-13 (11)	Withdrawal of Consent by Participant/ PARTICIPANT WITH ILLNESS SYMPTOMS REFUSED TO DO AN ILLNESS VISIT (IN-CLINIC OR AT-HOME). UPON FURTHER CONTACT, PARTICIPANT WITHDREW CONSENT AND DROPPED OUT OF THE STUDY.		No/ 2020-08-12 (10)	Withdrawal of Consent by Participant/ PARTICIPANT REFUSED TO DO AN ILLNESS VISIT (IN-CLINIC OR AT-HOME). UPON FURTHER CONTACT, PARTICIPANT WITHDREW CONSENT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102102	2020-08-04	AMENDMENT 1	No/ 2021-01-16 (166)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-01 (29)	
US3102141	2020-08-07	AMENDMENT 1	No/ 2021-01-19 (166)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE WHILE ON STUDY.		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102148	2020-08-10	AMENDMENT 2	No/ 2021-02-01 (176)	Withdrawal of Consent by Participant/ SUBJECT CALLED ON 01FEB2021 AND STATED HE WANTS TO BE UNBLINDED FROM STUDY AND WITHDRAWS CONSENT.		Yes/ 2020-09-04 (26)	
US3102155	2020-08-10	AMENDMENT 2	No/ 2021-02-22 (197)	Lost to Follow-Up		Yes/ 2020-09-04 (26)	
US3102156	2020-08-10	AMENDMENT 2	No/ 2020-09-29 (51)	Other/ SUBJECT STATED THAT HE IS MOVING OUT OF STATE		Yes/ 2020-09-04 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102173	2020-08-11	AMENDMENT 2	No/ 2021-02-03 (177)	Protocol Deviation/ REQUEST TO UNBLIND/ COVID-19 VACCINE. SUBJECT DOES NOT RECALL WHICH VACCINE OR DATE OF IMMUNIZATION.		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102183	2020-08-11	AMENDMENT 2	No/ 2020-09-14 (35)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO NOT WANTING TO RECEIVE VACCINATION TWO, DUE TO REACTIONS EXPERIENCED WHEN RECEIVED VACCINATION ONE.		No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO NOT WANTING TO RECEIVE VACCINATION TWO, DUE TO REACTIONS EXPERIENCED WHEN RECEIVED VACCINATION ONE.
US3102260	2020-08-24	AMENDMENT 2	No/ 2021-01-14 (144)	Protocol Deviation/ RECEIVED PFIZER VACCINE WHILE ON-STUDY		Yes/ 2020-09-18 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102282	2020-08-27	AMENDMENT 3	No/ 2021-03-17 (203)	Protocol Deviation/ RECEIVED COVID-19 VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-09-25 (30)	
US3102289	2020-08-28	AMENDMENT 3	No/ 2021-01-13 (139)	Protocol Deviation/ REQUEST TO UNBLIND, MEETS EUA COVID-19 AND RECEIVED PFIZER VACCINE DECEMBER 2020.		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3102321	2020-09-04	AMENDMENT 3	No/ 2021-03-08 (186)	Protocol Deviation/ RECEIVED PFIZER VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-30 (27)	
US3112101	2020-08-05	AMENDMENT 1	No/ 2021-01-26 (175)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT AT DECISION VISIT PER ICF OPTIONS.		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112122	2020-08-05	AMENDMENT 1	No/ 2020-08-24 (20)	Physician Decision/ ADMITTED TO ALCOHOLISM, PT ADVISED HE IS NOT A GOOD CANDIDATE FOR STUDY. HAS BEEN NON COMPLIANT AND UNABLE TO GIVE AN ACCURATE ACCOUNT OF SYMPTOMS, SOUNDS CONFUSED. BECAME UPSET AND VERBALLY ABUSIVE		No/ 2020-08-23 (19)	Physician Decision/ ADMITTED TO ALCOHOLISM, PT ADVISED HE IS NOT A GOOD CANDIDATE FOR STUDY. HAS BEEN NON COMPLIANT AND UNABLE TO GIVE AN ACCURATE ACCOUNT OF SYMPTOMS, SOUNDS CONFUSED. BECAME UPSET AND VERBALLY ABUSIVE
US3112126	2020-08-06	AMENDMENT 1	No/ 2020-11-17 (104)	Lost to Follow-Up		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112128	2020-08-06	AMENDMENT 1	ONGOING			No/ 2020-09-02 (28)	Adverse Event/ PT. UNABLE TO CONTINUE DUE TO RLQ (AE#2) CONCERNS RELATED TO ONGOING AE, PER PI
US3112141	2020-08-06	AMENDMENT 1	No/ 2021-01-20 (168)	Lost to Follow-Up		Yes/ 2020-09-08 (34)	
US3112257	2020-08-14	AMENDMENT 2	No/ 2021-01-14 (154)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-14 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112282	2020-08-17	AMENDMENT 2	No/ 2020-08-26 (10)	Withdrawal of Consent by Participant/ STIPENDS ARE TAXABLE INCOME		No/ 2020-08-25 (9)	Withdrawal of Consent by Participant/ STIPEND IS TAXABLE INCOME. SUBJECT DOES NOT WANT INCOME THAT IS TAXABLE
US3112311	2020-08-18	AMENDMENT 2	No/ 2020-10-21 (65)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT DUE TO AVERSION TO REQUIRED CONTINUED BLOODWORK.		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT DUE TO AVERSION TO REQUIRED CONTINUED BLOODWORK

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3112313	2020-08-18	AMENDMENT 2	No/ 2021-01-05 (141)	Withdrawal of Consent by Participant/ SUBJECT CAME IN TO BE UNBLINDED WITHOUT ANY PROCEDURES DONE.		Yes/ 2020-09-14 (28)	
US3112347	2020-08-21	AMENDMENT 2	No/ 2020-10-08 (49)	Lost to Follow-Up		No/ 2020-09-17 (28)	Lost to Follow-Up
US3112452	2020-09-08	AMENDMENT 3	No/ 2021-01-04 (119)	Protocol Deviation/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-10-05 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122010	2020-07-27	AMENDMENT 1	No/ 2020-11-25 (122)	Physician Decision/ REOCCURRENCE OF THROAT CANCER RESULTED IN UNBLINDING. SUBJECT COULD CONTINUE SAFETY FOLLOW UP AT PHYSICIAN'S DISCRETION WHICH WAS REMOVED ON 11/25/20.		No/ 2020-08-23 (28)	Adverse Event/ AE#1
US3122038	2020-07-27	AMENDMENT 1	No/ 2021-02-09 (198)	Protocol Deviation/ SUBJECT TOOK A VACCINE OUTSIDE OF THE STUDY		Yes/ 2020-08-27 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122047	2020-07-27	AMENDMENT 1	ONGOING			No/ 2020-08-23 (28)	Adverse Event/ AE #1 - PARTICIPANT CHOICE.
US3122111	2020-07-29	AMENDMENT 1	No/ 2020-12-21 (146)	Other/ SUBJECT WAS UNBLINDED 21DEC2020 TO SEE IF HE WAS ELIGIBLE FOR PFIZER VACCINE.		Yes/ 2020-08-27 (30)	
US3122134	2020-07-30	AMENDMENT 1	No/ 2020-12-16 (140)	Other/ MEETS CDC REQUIREMENTS TO RECEIVE PFIZER VACCINE UNDER EUA		Yes/ 2020-08-26 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132016	2020-08-14	AMENDMENT 2	No/ 2020-09-18 (36)	Withdrawal of Consent by Participant/ PT HAD ANTIBODY TESTING DONE AND REQUESTED TO WITHDRAWAL CONSENT.		No/ 2020-09-10 (28)	Withdrawal of Consent by Participant/ SUBJECT HAD AN ANTIBODY TEST AND TESTED NEGATIVE.
US3132051	2020-09-15	AMENDMENT 3	No/ 2021-01-19 (127)	Protocol Deviation/ PROTOCOL DEVIATION, RECEIVED EUA VACCINE PFIZER		Yes/ 2020-10-14 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3132094	2020-09-30	AMENDMENT 3	No/ 2020-12-22 (84)	Other/ SUBJECT UNWILLING TO WAIT FOR AMENDMENT APPROVAL TO BE UNBLINDED		Yes/ 2020-10-27 (28)	
US3142162	2020-08-08	AMENDMENT 2	No/ 2020-12-21 (136)	Lost to Follow-Up		Yes/ 2020-09-03 (27)	
US3142165	2020-08-08	AMENDMENT 2	No/ 2020-09-08 (32)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FOR PERSONAL REASONS		No/ 2020-09-04 (28)	Withdrawal of Consent by Participant/ SUBJECT VERBALLY WITHDREW CONSENT PRIOR TO VISIT DAY 29 FOR PERSONAL REASONS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3142231	2020-08-18	AMENDMENT 2	No/ 2021-01-19 (155)	Withdrawal of Consent by Participant/ PATIENT DID NOT WISH TO CONTINUE WITHOUT GUARANTEED VACCINE INCLUDING 6 MONTH BOOSTER		Yes/ 2020-09-16 (30)	
US3142243	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Adverse Event/ LEFT ARMPIT SWELLING AE#3 FATIGUE AE#1 SITE INJECTION PAIN #3
US3152089	2020-08-05	AMENDMENT 1	No/ 2021-02-02 (182)	Lost to Follow-Up		Yes/ 2020-09-08 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152100	2020-08-06	AMENDMENT	1 No/ 2020-10-01 (57)	Lost to Follow-Up		Yes/ 2020-09-09 (35)	
US3152121	2020-08-10	AMENDMENT	2 No/ 2021-02-02 (177)	Lost to Follow-Up		Yes/ 2020-09-08 (30)	
US3152485	2020-10-14	AMENDMENT	4 No/ 2020-12-10 (58)	Lost to Follow-Up		Yes/ 2020-11-18 (36)	
US3162078	2020-08-07	AMENDMENT	1 ONGOING			No/ 2020-09-03 (28)	Due to SARS-CoV-2
US3162143	2020-08-18	AMENDMENT	2 No/ 2021-01-12 (148)	Protocol Deviation/ REQUEST TO BE UNBLIND/ EUA MODERNA VACCINE HAD BEEN TAKEN ON 12JAN2021		Yes/ 2020-09-21 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3162175	2020-08-21	AMENDMENT 2	No/ 2021-03-01 (193)	Other/ SUBJECT MOVED TO FLORIDA		Yes/ 2020-09-15 (26)	
US3162177	2020-08-21	AMENDMENT 2	No/ 2021-01-12 (145)	Other/ REQUEST TO BE UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-09-15 (26)	
US3162221	2020-09-04	AMENDMENT 3	No/ 2021-01-27 (146)	Protocol Deviation/ REQUEST TO UNBLIND/ EUA COVID-19 VACCINE		Yes/ 2020-10-02 (29)	
US3172005	2020-08-07	AMENDMENT 1	No/ 2021-02-01 (179)	Withdrawal of Consent by Participant		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172008	2020-08-07	AMENDMENT	1 No/ 2020-11-05 (91)	Lost to Follow-Up		No/ 2020-09-03 (28)	Other/ MISSED VISIT DAY 29
US3172031	2020-08-11	AMENDMENT	1 No/ 2020-11-30 (112)	Lost to Follow-Up		No/ 2020-09-07 (28)	Other/ MISSED VISIT.
US3172032	2020-08-11	AMENDMENT	1 No/ 2021-03-02 (204)	Withdrawal of Consent by Participant/ WITHDREW CONSENT		Yes/ 2020-09-08 (29)	
US3172036	2020-08-11	AMENDMENT	1 No/ 2021-03-15 (217)	Other/ SUBJECT MOVED OUT OF TOWN INDEFINITELY.		Yes/ 2020-09-08 (29)	
US3172039	2020-08-11	AMENDMENT	1 No/ 2020-11-30 (112)	Lost to Follow-Up		No/ 2020-09-07 (28)	Other/ MISSED VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172065	2020-08-12	AMENDMENT 1	No/ 2020-10-10 (60)	Lost to Follow-Up		No/ 2020-09-08 (28)	Other/ MISSED VISIT.
US3172112	2020-08-14	AMENDMENT 1	ONGOING			No/ 2020-09-10 (28)	Other/ MISSED VISIT.
US3172121	2020-08-14	AMENDMENT 1	No/ 2020-09-10 (28)	Withdrawal of Consent by Participant/ NO LONGER WANTS TO PARTICIPATE		No/ 2020-09-09 (27)	Withdrawal of Consent by Participant/ NO LONGER WANTS TO PARTICIPATE
US3172149	2020-08-17	AMENDMENT 1	ONGOING			No/ 2020-09-13 (28)	Other/ SUBJECT MISSED DAY 29 VISIT.
US3172161	2020-08-17	AMENDMENT 1	ONGOING			No/ 2020-09-13 (28)	Other/ MISSED VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172164	2020-08-18	AMENDMENT 1	ONGOING			No/ 2020-09-14 (28)	Other/ MISSED VISIT.
US3172167	2020-08-18	AMENDMENT 1	No/ 2020-11-30 (105)	Lost to Follow-Up		No/ 2020-09-14 (28)	Other/ MISSED VISIT.
US3172174	2020-08-18	AMENDMENT 1	No/ 2020-09-30 (44)	Withdrawal of Consent by Participant/ DOES NOT WANT TO CONTINUE IN STUDY		No/ 2020-09-14 (28)	Other/ MISSED VISIT.
US3172186	2020-08-18	AMENDMENT 1	No/ 2020-10-20 (64)	Withdrawal of Consent by Participant		Yes/ 2020-09-15 (29)	
US3172212	2020-08-19	AMENDMENT 1	No/ 2021-03-16 (210)	Lost to Follow-Up		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172217	2020-08-19	AMENDMENT 1	No/ 2020-10-24 (67)	Lost to Follow-Up		No/ 2020-09-15 (28)	Other/ MISSED VISIT.
US3172219	2020-08-19	AMENDMENT 1	ONGOING			No/ 2020-09-15 (28)	Other/ MISSED VISIT
US3172225	2020-08-19	AMENDMENT 1	ONGOING			No/ 2020-09-15 (28)	Other/ MISSED VISIT
US3172238	2020-08-20	AMENDMENT 1	ONGOING			No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ DID NOT WANT TO WAIT
US3172246	2020-08-20	AMENDMENT 1	No/ 2020-10-01 (43)	Other/ MOVED OUT OF TOWN		No/ 2020-09-16 (28)	Other/ SUBJECT MOVED OUT OF TOWN

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172249	2020-08-20	AMENDMENT 1	No/ 2020-09-21 (33)	Withdrawal of Consent by Participant		No/ 2020-09-16 (28)	Other/ SKIPPED VISIT
US3172265	2020-08-21	AMENDMENT 1	ONGOING			No/ 2020-09-17 (28)	Adverse Event/ A/E #1.
US3172290	2020-08-24	AMENDMENT 2	No/ 2020-09-10 (18)	Lost to Follow-Up		No/ 2020-09-09 (17)	Other/ MISSED VISIT DAY 29
US3172313	2020-08-25	AMENDMENT 2	ONGOING			No/ 2020-09-21 (28)	Other/ SUBJECT REFUSED 2ND DOSE OF IP DUE TO PERSONAL ISSUES DESPITE ALL EFFORTS FROM THE SITE TO EDUCATE HIM ON IP TREATMENT COMPLIANCE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172348	2020-08-26	AMENDMENT 3	No/ 2021-01-19 (147)	Lost to Follow-Up		Yes/ 2020-09-22 (28)	
US3172360	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Adverse Event/ A/E #1
US3172366	2020-08-27	AMENDMENT 3	No/ 2020-09-25 (30)	Other/ NO LONGER LIVE IN (b) (6)		No/ 2020-09-23 (28)	Other/ MISSED VISIT
US3172461	2020-10-21	AMENDMENT 2	No/ 2020-11-25 (36)	Withdrawal of Consent by Participant/ NO LONGER WANTED TO PARTICIPATE.		No/ 2020-11-17 (28)	Withdrawal of Consent by Participant/ NO LONGER WANTED TO PARTICIPATE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172474	2020-10-22	AMENDMENT 3	No/ 2021-01-27 (98)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO NOT COMPLIANCE WITH PROTOCOL.		Yes/ 2020-11-19 (29)	
US3172477	2020-10-22	AMENDMENT 3	ONGOING			No/ 2020-11-18 (28)	Other/ MISSED VISIT
US3172481	2020-10-22	AMENDMENT 3	ONGOING			No/ 2020-11-18 (28)	Other/ MISSED VISIT
US3172483	2020-10-22	AMENDMENT 3	ONGOING			No/ 2020-11-18 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172492	2020-10-23	AMENDMENT 3	No/ 2021-02-22 (123)	Withdrawal of Consent by Participant/ SUBJECT REFUSED ALL PROCEDURES AND WITHDREW CONSENT, NO REASON STATED AS TO WHY.		Yes/ 2020-11-20 (29)	
US3172499	2020-10-23	AMENDMENT 3	ONGOING			No/ 2020-11-19 (28)	Other/ MISSED VISIT
US3182108	2020-07-31	AMENDMENT 1	No/ 2020-11-24 (117)	Lost to Follow-Up		Yes/ 2020-08-31 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3182244	2020-08-10	AMENDMENT 2	No/ 2021-02-25 (200)	Protocol Deviation/ SUBJECT RECEIVED PFIZER COVID VACCINE		Yes/ 2020-09-09 (31)	
US3192056	2020-08-04	AMENDMENT 1	No/ 2021-01-31 (181)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-01 (29)	
US3192063	2020-08-05	AMENDMENT 1	No/ 2021-02-19 (199)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192114	2020-08-08	AMENDMENT 1	No/ 2021-01-03 (149)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-05 (29)	
US3192148	2020-08-09	AMENDMENT 1	No/ 2020-09-06 (29)	Withdrawal of Consent by Participant/ PT DECIDED NOT TO CONTINUE PARTICIPATION		No/ 2020-09-05 (28)	Other/ PATIENT REFUSED DOSE 2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192173	2020-08-10	AMENDMENT 1	No/ 2021-02-20 (195)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-04 (26)	
US3192243	2020-08-14	AMENDMENT 1	No/ 2021-02-20 (191)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192296	2020-08-16	AMENDMENT 1	No/ 2021-01-21 (159)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-20 (36)	
US3192329	2020-08-17	AMENDMENT 1	No/ 2020-10-14 (53)	Lost to Follow-Up		No/ 2020-09-19 (28)	Lost to Follow-Up
US3192386	2020-08-21	AMENDMENT 2	No/ 2021-02-20 (184)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192401	2020-08-21	AMENDMENT 2	No/ 2021-02-12 (176)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF BECAUSE HE NO LONGER WANTS TO HAVE LABS ASSESSMENTS DONE.		Yes/ 2020-09-18 (29)	
US3192457	2020-08-24	AMENDMENT 2	No/ 2021-02-01 (162)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-22 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192504	2020-08-26	AMENDMENT 3	No/ 2021-02-20 (179)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-19 (25)	
US3192602	2020-08-31	AMENDMENT 3	No/ 2021-02-20 (174)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-30 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192707	2020-09-05	AMENDMENT 3	No/ 2021-02-12 (161)	Withdrawal of Consent by Participant/ PATIENT WITHDREW ICF, IS NON COMPLIANT WITH E-DIARY ENTRIES AND DOESNT WISH TO CONTINUE.		Yes/ 2020-10-03 (29)	
US3192750	2020-10-07	AMENDMENT 4	No/ 2021-01-31 (117)	Protocol Deviation/ PATIENT RECEIVED PFIZER EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-11-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192828	2020-10-15	AMENDMENT 4	No/ 2021-02-20 (129)	Protocol Deviation/ PATIENT RECEIVED MODERNA EUA OUTSIDE OF TRIAL.		Yes/ 2020-11-17 (34)	
US3192906	2020-10-22	AMENDMENT 4	No/ 2021-03-15 (145)	Physician Decision/ PATIENT WAS ET FROM TRIAL AND SITE DUE TO VIOLENT BEHAVIOR TOWARDS STAFF.		Yes/ 2020-11-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202062	2020-08-07	AMENDMENT 1	No/ 2021-03-08 (214)	Other/ SUBJECT CALLED TO REPORT MOVING FURTHER FROM SITE WITH LIMITED TRANSPORTATION AND NO DESIRE TO CONTINUE B/C OF FULL SCHEDULE		Yes/ 2020-09-03 (28)	
US3202106	2020-08-10	AMENDMENT 1	No/ 2020-09-16 (38)	Withdrawal of Consent by Participant/ SUBJECT OPTED OUT OF GETTING SECOND DOSE		No/ 2020-09-06 (28)	Withdrawal of Consent by Participant/ SUBJECT OPTED OUT OF STUDY, DECIDED NOT TO GET SECOND DOSE OF VACCINE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202112	2020-08-10	AMENDMENT 1	No/ 2020-09-29 (51)	Other/ SUBJECT MOVED TO ANOTHER STATE AND IS NOT INTERESTED IN CONTINUED F/UP		No/ 2020-09-06 (28)	Other/ SUBJECT MOVED TO ANOTHER STATE AND IS NOT INTERESTED IN CONTINUED F/UP
US3202173	2020-08-13	AMENDMENT 2	No/ 2020-10-16 (65)	Protocol Deviation/ NONCOMPLIANCE WITH STUDY GUIDELINES (SUBJECT IS NONCOMPLIANT WITH VISIT SCHEDULES OR ACCURATE REPORTING OF HEALTH)		No/ 2020-09-09 (28)	Protocol Deviation/ SUBJECT MISSED DAY 29 VISIT AND WAS OUT OF WINDOW BY THE TIME WE REACHED HER AND WE'RE NOT ABLE TO CONFIRM APPROPRIATENESS FOR CONTINUING DUE TO APPARENT PSYCHIATRIC ISSUES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202176	2020-08-14	AMENDMENT 2	No/ 2020-10-02 (50)	Withdrawal of Consent by Participant/ MULTIPLE STRESSORS IN PERSONAL LIFE --UNABLE TO GET SECOND DOSE AND HAS "TOO MUCH STRESS" TO WORRY ABOUT CONTINUING IN STUDY		No/ 2020-09-10 (28)	Other/ SUBJECT UNABLE TO COMPLETE DAY 29 WITHIN WINDOW
US3202203	2020-08-15	AMENDMENT 2	ONGOING			No/ 2020-09-11 (28)	Other/ SUBJECT WITHDREW FROM DOSING BUT AGREED TO CONTINUE IN STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202232	2020-08-17	AMENDMENT 2	No/ 2020-09-09 (24)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER INTERESTED IN CONTINUING IN STUDY F/UP OR RECEIVING 2ND DOSE		No/ 2020-09-08 (23)	Withdrawal of Consent by Participant/ SUBJECT NON-RESPONSIVE THEN CONTACTED SITE TO SAY NO LONGER INTERESTED IN FURTHER PARTICIPATION
US3202244	2020-08-18	AMENDMENT 2	No/ 2020-10-01 (45)	Other/ SUBJECT'S SPOUSE INFORMED SITE THAT HE IS INCARCERATED AND NOT CONTINUING		No/ 2020-09-14 (28)	Other/ SUBJECT'S SPOUSE INFORMED SITE THAT HE IS INCARCERATED AND NOT CONTINUING

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202257	2020-08-19	AMENDMENT 2	No/ 2020-11-01 (75)	Lost to Follow-Up		No/ 2020-09-15 (28)	Lost to Follow-Up
US3202263	2020-08-19	AMENDMENT 2	No/ 2020-10-19 (62)	Withdrawal of Consent by Participant/ SUBJECT GAVE NO REASON--JUST STATED THAT SHE WAS WITHDRAWING FROM STUDY.		No/ 2020-09-15 (28)	Withdrawal of Consent by Participant/ SUBJECT DID NOT GIVE REASON--SHE RETURNED CALLS BY (b) (6) BUT TOLD RECEPTIONIST TO INFORM ME THAT SHE WAS WITHDRAWING FROM THE STUDY THEN HUNG UP.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202264	2020-08-19	AMENDMENT 2	No/ 2020-12-22 (126)	Protocol Deviation/ RECEIVED NON-STUDY COVID-19 VACCINE PRIOR TO UNBLINDING AND STUDY DISCONTINUATION		Yes/ 2020-09-22 (35)	
US3202290	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Other/ UNCONTROLLED HYPERTENSION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202307	2020-08-24	AMENDMENT 3	No/ 2020-09-22 (30)	Protocol Deviation/ NONCOMPLIANCE WITH STUDY GUIDELINES AND SUBJECT WAS NOT FOLLOWING CONTRACEPTION GUIDELINES		No/ 2020-09-20 (28)	Physician Decision/ SUBJECT WAS NOT FOLLOWING CONTRACEPTION GUIDELINES.
US3202358	2020-08-28	AMENDMENT 3	No/ 2020-11-20 (85)	Lost to Follow-Up		No/ 2020-09-24 (28)	Lost to Follow-Up
US3202375	2020-09-01	AMENDMENT 3	No/ 2021-04-04 (216)	Death	2021-04-04/ Yes/ N	2020-10-05 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3202383	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ SUBJECT TOO FAR OUT OF WINDOW FOR DOSE 2 DUE TO TRAVELLING FOR FUNERAL AND THEN MULTIPLE RESCHEDULED APPOINTMENTS
US3202399	2020-09-04	AMENDMENT 3	No/ 2020-11-18 (76)	Lost to Follow-Up		No/ 2020-10-01 (28)	Other/ SUBJECT NOT ABLE TO DOSE AT DAY 29 AND NEVER RETURNED FOR R/S VISITS
US3212034	2020-08-04	AMENDMENT 1	No/ 2020-11-18 (107)	Lost to Follow-Up		No/ 2020-08-31 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212039	2020-08-04	AMENDMENT 1	No/ 2020-10-27 (85)	Withdrawal of Consent by Participant		No/ 2020-08-31 (28)	Withdrawal of Consent by Participant
US3212067	2020-08-06	AMENDMENT 1	No/ 2021-03-17 (224)	Withdrawal of Consent by Participant/ SUBJECT CONTACTED SITE TO INFORM THAT SHE IS NO LONGER INTERESTED IN CONTINUING WITH THE STUDY DUE TO NOT ABLE TO OBTAIN THE ANTIBODY TEST RESULTS FROM THE SPONSOR/SITE.		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212182	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Pregnancy
US3212398	2020-09-11	AMENDMENT 3	No/ 2020-10-13 (33)	Withdrawal of Consent by Participant/ SUBJECT CALLED TO WITHDRAW CONSENT FROM THE STUDY. HE WAS OFFERED A SAFETY VISIT AND EVERY EFFORT WAS MADE TO KEEP SUBJECT IN THE STUDY, HOWEVER HE DID NOT WISH TO PROCEED ANY FURTHER.		Yes/ 2020-10-08 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222017	2020-08-06	AMENDMENT 1	No/ 2021-02-04 (183)	Death	2021-02-04/ N	Yes/ 2020-09-03 (29)	
US3222045	2020-08-08	AMENDMENT 1	No/ 2021-01-23 (169)	Withdrawal of Consent by Participant/ SUBJECT WAS DROPPED UNABLE TO MAKE APPTS LIVES TOO FAR		Yes/ 2020-09-07 (31)	
US3222061	2020-08-10	AMENDMENT 1	ONGOING			No/ 2020-09-06 (28)	Adverse Event/ AE #1 LEFT BREAST MASS, HER ONCOLOGIST DIDNT WANT HER TO RECEIVE THE SECOND VACCINE AND THE PI KEPT HER ON THE TRIAL.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222085	2020-08-11	AMENDMENT 1	No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ PT WITHDREW CONSENT DUE TO MEDICAL REASONS UNRELATED TO THIS STUDY		No/ 2020-09-06 (27)	Withdrawal of Consent by Participant/ PT STATED THAT HE HAD TO W/D FOR MEDICAL REASONS UNRELATED TO THIS STUDY.
US3222096	2020-08-11	AMENDMENT 1	No/ 2020-09-15 (36)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT ON FAMILY ADVISE.		No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT BASED ON FAMILY ADVISE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222119	2020-08-13	AMENDMENT 1	No/ 2021-02-06 (178)	Physician Decision/ THE SUBJECT HAS BEEN DISMISSED FROM OUR SITE DUE TO ABUSIVE BEHAVIOR TOWARDS SITE STAFF. SEVERAL WARNING HAVE BEEN SENT WITHOUT IMPROVEMENT.		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222146	2020-08-14	AMENDMENT 2	No/ 2021-01-05 (145)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE PRIOR TO BEING UNBLINDED. PI UNBLINDED PATIENT AND SHE RECEIVED MODERNA ACTIVE VACCINE ON THE TRIAL.		Yes/ 2020-09-13 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222167	2020-08-15	AMENDMENT 2	No/ 2020-12-16 (124)	Withdrawal of Consent by Participant/ PT W/C DUE TO SCHEDULING CONFLICTS BETWEEN WORK AND STUDY		Yes/ 2020-09-12 (29)	
US3222205	2020-08-18	AMENDMENT 2	No/ 2020-10-19 (63)	Withdrawal of Consent by Participant/ SUBJECT UNHAPPY ABOUT WAITING FOR PAYMENT TO BE ADDED TO HER CLINCARD.		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222222	2020-08-19	AMENDMENT 2	No/ 2020-12-02 (106)	Lost to Follow-Up		Yes/ 2020-09-14 (27)	
US3222223	2020-08-19	AMENDMENT 2	No/ 2020-12-02 (106)	Lost to Follow-Up		Yes/ 2020-09-14 (27)	
US3222280	2020-08-22	AMENDMENT 2	No/ 2021-01-22 (154)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE		Yes/ 2020-09-19 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222296	2020-08-23	AMENDMENT 2	No/ 2021-02-12 (174)	Withdrawal of Consent by Participant/ SUBJECTS HAS MUCH TO CONTEND WITH HER MEDICAL HISTORY AND DOESNT WANT TO CONTINUE IN THE TRIAL		Yes/ 2020-09-22 (31)	
US3222300	2020-08-23	AMENDMENT 2	No/ 2020-12-16 (116)	Withdrawal of Consent by Participant/ SUBJECT WC ON 16/DEC/2020 FOR AN UNSPECIFIED REASON.		Yes/ 2020-09-25 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222356	2020-08-27	AMENDMENT 3	No/ 2021-01-31 (158)	Protocol Deviation/ RECEIVED VACCINE JAN 7 AT PUBLIX		Yes/ 2020-09-25 (30)	
US3222433	2020-09-01	AMENDMENT 3	No/ 2020-10-01 (31)	Withdrawal of Consent by Participant/ TOO MUCH OF A COMITMENT		No/ 2020-09-28 (28)	Withdrawal of Consent by Participant/ TOOMUCH OF A COMMITMENT
US3222439	2020-09-01	AMENDMENT 3	No/ 2021-01-01 (123)	Lost to Follow-Up		Yes/ 2020-10-01 (31)	
US3222571	2020-09-10	AMENDMENT 3	No/ 2020-12-02 (84)	Lost to Follow-Up		No/ 2020-10-07 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222572	2020-09-10	AMENDMENT 3	No/ 2020-11-12 (64)	Withdrawal of Consent by Participant/ SUBJECT W/D CONSENT DUE TO PERSONAL ISSUES.		Yes/ 2020-10-15 (36)	
US3222583	2020-09-11	AMENDMENT 3	No/ 2020-12-22 (103)	Withdrawal of Consent by Participant/ SUBJECT MISSED V3 AND WE HAVE BEEN UNABLE TO REACH HER TO COME IN FOR APPTS		Yes/ 2020-10-17 (37)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222609	2020-09-16	AMENDMENT 3	No/ 2021-01-24 (131)	Withdrawal of Consent by Participant/ AFTER UNBLINDING, THE PATIENT NO LONGER WANTED TO PARTICIPATE IN THE TRIAL.		Yes/ 2020-11-02 (48)	
US3222627	2020-09-21	AMENDMENT 3	No/ 2020-11-18 (59)	Lost to Follow-Up		Yes/ 2020-10-19 (29)	
US3222633	2020-09-24	AMENDMENT 3	No/ 2020-10-08 (15)	Lost to Follow-Up		No/ 2020-10-07 (14)	Lost to Follow-Up
US3222634	2020-09-24	AMENDMENT 3	No/ 2020-12-08 (76)	Lost to Follow-Up		No/ 2020-10-21 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3222639	2020-09-25	AMENDMENT 3	No/ 2021-03-07 (164)	Withdrawal of Consent by Participant/ PATIENT REFUSED TO SIGN AMENDMENT 6 AND THE EUA ICF.		Yes/ 2020-10-23 (29)	
US3222641	2020-09-26	AMENDMENT 3	No/ 2020-12-09 (75)	Lost to Follow-Up		No/ 2020-10-23 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3232021	2020-08-10	AMENDMENT 1	No/ 2020-09-28 (50)	Other/ PER SPONSOR, SUBJECT WAS NOT ELIGIBLE FOR RE-ENTRY DUE TO HER STOPPING COMMUNICATION VIA NOT COMPLETING SAFETY CALLS OR VISITS SINCE 28SEP2020		No/ 2020-09-06 (28)	Physician Decision/ SUBJECT ATTRIBUTING WORSENING FINGER JOINT PAIN TO IP DESPITE DIAGNOSIS OF OSTEOARTHRITIS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3232033	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Protocol Deviation/ PATIENT WAS SCHEDULED TO RECEIVE DOSE 2 ON 9/15/2020; HOWEVER SITE WAS CLOSED DUE TO HURRICANE SALLY. UNABLE TO RESCHEDULE SUBJECT. V2 OOW, SPONSOR NOTIFIED, GIVEN OK FOR PATIENT TO CONTINUE.
US3242192	2020-08-24	AMENDMENT 2	No/ 2021-01-19 (149)	Other/ SUBJECT MOVED OUT OF STATE		Yes/ 2020-09-23 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242269	2020-09-01	AMENDMENT 3	No/ 2021-01-22 (144)	Other/ MOVED IN WITH SON, TO FAR AWAY TO PARTICIPATE		Yes/ 2020-09-30 (30)	
US3242288	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242370	2020-09-23	AMENDMENT 3	No/ 2020-10-19 (27)	Serious Adverse Event/ SAE #1 WORSENING OF SCHIZOAFFECTIVE DISORDER, SUBJECT IS UNSTABLE AND PI NOT WILLING TO UPSET SUBJECT OR PUT STAFF AT RISK		No/ 2020-10-18 (26)	Serious Adverse Event/ SAE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252192	2020-08-15	AMENDMENT 2	No/ 2021-01-21 (160)	Withdrawal of Consent by Participant/ PATIENT PREVIOUSLY RECEIVED MRNA. HE HAS WITHDRAWN CONSENT.		Yes/ 2020-09-12 (29)	
US3252322	2020-08-24	AMENDMENT 3	No/ 2021-03-12 (201)	Protocol Deviation/ POST EUA UNBLINDING- RECEIVED MODERNA DOSE.		Yes/ 2020-09-21 (29)	
US3252332	2020-08-25	AMENDMENT 2	No/ 2020-10-23 (60)	Lost to Follow-Up		No/ 2020-09-21 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252349	2020-08-26	AMENDMENT 3	No/ 2021-03-22 (209)	Withdrawal of Consent by Participant/ PATIENT RECONSENTED WITH EUA ADDENDUM AND AFTER DISCUSSING FURTHER REGARDING FUTURE VISITS, PATIENT DECIDED TO WITHDRAW FROM THE STUDY. HE DOES NOT LIKE GETTING BLOOD DRAWN AND HAS CHOSEN TO WITHDRAW.		Yes/ 2020-09-25 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252356	2020-08-28	AMENDMENT 3	No/ 2020-09-21 (25)	Other/ PATIENT HAS BEEN INCARCERATED		No/ 2020-09-20 (24)	Other/ PATIENT IS INCARCERATED

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252409	2020-09-02	AMENDMENT 3	No/ 2020-10-08 (37)	Withdrawal of Consent by Participant/ ATTEMPTED TO CONTACT PATIENT ON 9/29/2020, 9/30/2020, 9/31/2020, 10/1/2020, 10/2/2020, 10/3/2020, 10/5/2020, 10/6/2020, AND 10/7/2020 WITH NO ANSWER. ATTEMPTED TO CONTACT HIS SAFETY CONTACT HOWEVER SH		No/ 2020-09-29 (28)	Other/ PATIENT CANCELLED THE VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252411	2020-09-02	AMENDMENT 3	No/ 2020-10-08 (37)	Withdrawal of Consent by Participant/ UNABLE TO CONTACT PATIENT TO RESCHEDULE HER. ATTEMPTED TO CONTACT HER SAFETY CONTACT HOWEVER SHE DOES NOT ANSWER EITHER. PATIENT ANSWERED ON 10/8/2020 AND INFORMED SITE TO DISCONTINUE		No/ 2020-09-29 (28)	Other/ PATIENT CANCELLED THE VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252471	2020-09-12	AMENDMENT 3	No/ 2021-01-13 (124)	Protocol Deviation/ PATIENT RECEIVED MODERNA VACCINE OUT OF STUDY		Yes/ 2020-10-10 (29)	
US3252489	2020-09-16	AMENDMENT 3	ONGOING			No/ 2020-10-13 (28)	Other/ PATIENT WAS CALLED TO CONFIRM APPOINTMENT, SHE STATED SHE WILL BE OUT OF THE COUNTRY FOR A FEW MORE MONTHS AND WILL NOT BE ABLE TO MAKE IT.
US3252527	2020-09-22	AMENDMENT 3	ONGOING			No/ 2020-10-19 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252563	2020-09-25	AMENDMENT 3	ONGOING			No/ 2020-10-22 (28)	Other/ SUBJECT DISCONTINUED TREATMENT DUE TO SIDE AFFECTS.
US3252572	2020-09-28	AMENDMENT 3	No/ 2020-10-30 (33)	Lost to Follow-Up		No/ 2020-10-25 (28)	Lost to Follow-Up
US3252582	2020-09-30	AMENDMENT 3	No/ 2020-10-26 (27)	Other/ PATIENT STATED THAT HE IS OUT OF TOWN AND WILL NOT BE BACK UNTIL THE END OF NOVEMBER.		No/ 2020-10-25 (26)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252649	2020-10-10	AMENDMENT 3	No/ 2020-12-17 (69)	Protocol Deviation/ POST EUA- PATIENT GOT UNBLINDED AND RECEIVED MODERNA BUT THEY GOT PFIZER VACCINE OUTSIDE OF THE STUDY.		Yes/ 2020-11-07 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3252671	2020-10-15	AMENDMENT 3	No/ 2021-03-12 (149)	Protocol Deviation/ POST EUA UNBLINDING- PATIENT GOT MODERNA VACCINE OUTSIDE OF THE STUDY AND DID NOT CALL US TO GET UNBLINDED.		Yes/ 2020-11-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262004	2020-07-27	AMENDMENT 1	No/ 2020-09-28 (64)	Other/ (b) (6)		No/ 2020-08-23 (28)	Other/ (b) (6)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262034	2020-07-29	AMENDMENT 1	No/ 2020-09-28 (62)	Other/ SUBJECT IS UNABLE TO KEEP HER SAFETY APPOINTMENTS RECENTLY MOVED TO OTHER CITY		Yes/ 2020-08-27 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262035	2020-07-29	AMENDMENT 1	No/ 2020-08-26 (29)	Physician Decision/ PATIENT WAS HARASSING AND THREATENING THE SITE WHEN WE TOLD HER THE CREDIT CARD PAYMENT WOULD BE GIVEN AS SOON AS THE CARDS CAME IN. PATIENT CALLED DAILY AND THREATENED STAFF, PI AS WOULD NOT WAIT.		No/ 2020-08-25 (28)	Physician Decision/ SPOKE TO STUDY TEAM ABOUT STAFF SAFETY CONCERNS OVER THIS PATIENT, AND AGREED TO DISCONTINUE DUE TO THREATENING AND HARASSING BEHAVIOR. DID NOT WANT TO RISK OUR SAFETY OVER THIS UNBALANCED PATIENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262046	2020-07-30	AMENDMENT 1	No/ 2020-08-24 (26)	Other/ MOVED OUT OF AREA		No/ 2020-08-23 (25)	Other/ MOVED OUT OF AREA

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262074	2020-08-03	AMENDMENT 1	No/ 2020-11-10 (100)	Physician Decision/ DUE TO NUMEROUS ABUSIVE CALLS WHERE PT YELLS, ASK FOR REIMBURSEMENT NOT BASED ON THE PROTOCOL JUST BECAUSE HE WANTS. WE ARE DISCONTINUING THE PT HE IS NOT SAFE TO DEAL WITH AS WE DONT KNOW HOW HIS ABU		Yes/ 2020-09-01 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262113	2020-08-06	AMENDMENT 1	No/ 2021-03-09 (216)	Other/ SUBJECT CONTACTED SITE STATING HE WANTED TO BE UNBLINDED DUE TO NOT BEING ABLE TO MAKE IT TO OL VISIT CURRENTLY OVERSEAS AND NOT ABLE TO MAKE IT BEFORE THE DATELINE SUBJECT REQUESTED TO BE UNBLINDED		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262179	2020-08-12	AMENDMENT 2	No/ 2021-01-06 (148)	Other/ PATIENT ASKED TO BE UNBLINDED, AND MOVED TO ANOTHER STATE, SO NOT ABLE TO CONTINUE STUDY PROCEDURES AS PER PROTOCOL AMENDMENT 6 SINCE CAN'T COMPLETE ANY OFFICE VISITS.		Yes/ 2020-09-11 (31)	
US3262189	2020-08-15	AMENDMENT 2	No/ 2020-10-02 (49)	Lost to Follow-Up		Yes/ 2020-09-21 (38)	
US3262204	2020-08-18	AMENDMENT 2	No/ 2020-08-27 (10)	Lost to Follow-Up		No/ 2020-08-26 (9)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262254	2020-08-31	AMENDMENT 2	No/ 2020-12-21 (113)	Physician Decision/ THIS PATIENT HAS BEEN ABUSIVE LONG ENOUGH AND WE NO LONGER WANT TO TAKE HIS ABUSE. HE SAID (b) (6) AND MYSELF HUNG UP ON HIM AND WERE RUDE, AND THAT DIDNÂ€™T HAPPEN. I TOLD HIM THAT WE WERE ON THE		Yes/ 2020-09-28 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262267	2020-09-08	AMENDMENT 2	No/ 2021-03-04 (178)	Other/ SUBJECT REQUESTED TO UNBLINDED AS HE HAD MOVED TO ANOTHER STATE WAS GIVEN THE OPTION TO TRANSFER TO OTHER SITE PER SUBJECT STATED HE JUST NEEDED TO BE UNBLINDED AS HE NEEDS PROOF OF VACCINE FOR EMPLOY		Yes/ 2020-10-08 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3262270	2020-10-06	AMENDMENT 4	No/ 2021-01-14 (101)	Protocol Deviation/ SUBJECT STATED SHE HAD RECEIVED VACCINE WITH EMPLOYER		Yes/ 2020-11-06 (32)	
US3262273	2020-10-08	AMENDMENT 4	No/ 2020-10-22 (15)	Lost to Follow-Up		No/ 2020-10-21 (14)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272013	2020-07-30	AMENDMENT 1	No/ 2021-02-15 (201)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE THROUGH WORK AND ALSO PREVIOUSLY STATED SHE NO LONGER WANTED TO CONTINUE IN THE STUDY.		No/ 2020-08-26 (28)	Other/ SUBJECT MET EXCLUSION CRITERIA.
US3272096	2020-08-10	AMENDMENT 2	No/ 2021-03-03 (206)	Lost to Follow-Up		Yes/ 2020-09-09 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272103	2020-08-11	AMENDMENT 2	No/ 2020-12-10 (122)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WANTS TO PARTICIPATE IN STUDY		Yes/ 2020-09-10 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272128	2020-08-13	AMENDMENT 2	No/ 2020-12-29 (139)	Other/ SUBJECT NO LONGER IN STUDY DUE TO EPIP SENT PRIOR TO AMENDMENT 6 AS SUBJECT WAS PLANNING TO GET EUA VACCINE AND WANTED TO KNOW WHAT THEY RECEIVED PRIOR TO RECEIVING EUA VACCINE.		Yes/ 2020-09-10 (29)	
US3272133	2020-08-13	AMENDMENT 1	No/ 2021-03-03 (203)	Lost to Follow-Up		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272170	2020-08-17	AMENDMENT 2	No/ 2021-03-17 (213)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AND RECEIVED EUA VACCINE THROUGH WORK SUBJECT WAS UNBLINDED OVER THE PHONE AFTER EPIP WAS SENT		Yes/ 2020-09-14 (29)	
US3272294	2020-08-22	AMENDMENT 2	No/ 2020-12-14 (115)	Lost to Follow-Up		Yes/ 2020-09-22 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3282008	2020-08-05	AMENDMENT 1	No/ 2020-12-10 (128)	Other/ PT IS MOVING TO ANOTHER COUNTRY AND DOES NOT WISH TO CONTINUE PARTICIPATION.		Yes/ 2020-08-31 (27)	
US3292007	2020-08-04	AMENDMENT 1	No/ 2021-01-15 (165)	Protocol Deviation/ UNBLINDED FOR SAFETY WITH SPONSOR APPROVAL. PATIENT RECEIVED MODERNA VACCINE. DROPPED FROM TRIAL AS PER SPONSOR		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292023	2020-08-04	AMENDMENT	1 No/ 2021-01-23 (173)	Death	2021-01-23/ N	Yes/ 2020-09-01 (29)	
US3292069	2020-08-08	AMENDMENT	1 No/ 2021-02-03 (180)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-05 (29)	
US3292101	2020-08-08	AMENDMENT	1 No/ 2021-02-03 (180)	Withdrawal of Consent by Participant		Yes/ 2020-09-03 (27)	
US3292119	2020-08-11	AMENDMENT	2 No/ 2021-03-12 (214)	Physician Decision/ PI DISCRETION TO WITHDRAW SUBJECT		Yes/ 2020-09-11 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292185	2020-08-15	AMENDMENT 2	No/ 2020-12-22 (130)	Protocol Deviation/ SUBJECT RECEIVED COMIRNATY BEFORE NOTIFYING SITE.		Yes/ 2020-09-11 (28)	
US3292225	2020-08-18	AMENDMENT 2	No/ 2020-11-10 (85)	Withdrawal of Consent by Participant/ WD CONSENT AFTER DISCUSSION WITH PI		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ PATIENT W/D CONSENT AFTER DISCUSSION WITH PI.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292241	2020-08-20	AMENDMENT 2	No/ 2020-12-31 (134)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINATION OUTSIDE OF STUDY		No/ 2020-09-16 (28)	Adverse Event/ A TEMPERATURE OF 99.8 CONSTANT HEADACHES AND FATIGUE, SWOLLEN LYMPHNODES, SWELLING AND PAIN AROUND THE LEFT EYE (AE#1, AE#2, AE#3, AE#4)
US3292252	2020-08-20	AMENDMENT 2	No/ 2020-09-28 (40)	Withdrawal of Consent by Participant/ PT VERBALLY W/D CONSENT. HAD SAFETY CONCERNS.		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ PT VERBALLY W/D CONSENT. HAD SAFETY CONCERNS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292310	2020-08-25	AMENDMENT 3	ONGOING			No/ 2020-09-21 (28)	Adverse Event/ TINGLING IN HANDS AE#1
US3292392	2020-09-15	AMENDMENT 3	No/ 2020-10-01 (17)	Lost to Follow-Up		No/ 2020-09-30 (16)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3292406	2020-09-22	AMENDMENT 3	No/ 2021-01-28 (129)	Withdrawal of Consent by Participant/ PATIENT REFUSED TO COMPLETE END OF STUDY PROCEDURES AND WISHED TO WITHDRAW. DID NOT WANT TO COMPLETE ANY OTHER PROCEDURES FOR THE STUDY.		Yes/ 2020-10-20 (29)	
US3302059	2020-08-05	AMENDMENT 1	No/ 2020-12-21 (139)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT		Yes/ 2020-08-31 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302116	2020-08-10	AMENDMENT 1	No/ 2021-01-11 (155)	Protocol Deviation/ SUBJECT RECEIVED THE VACCINE THROUGH HIS EMPLOYER AND CALLED SITE TO WITHDRAW FROM STUDY.		Yes/ 2020-09-08 (30)	
US3302120	2020-08-10	AMENDMENT 1	No/ 2020-10-23 (75)	Lost to Follow-Up		Yes/ 2020-09-08 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302123	2020-08-10	AMENDMENT 1	No/ 2020-09-04 (26)	Withdrawal of Consent by Participant/ SUBJECT WISHED TO WITHDRAW DUE TO HIS PCP GUIDANCE		No/ 2020-09-03 (25)	Withdrawal of Consent by Participant/ SUBJECT FOLLOWED HIS PCP ORDERS TO DISCONTINUE FROM TRIAL
US3302188	2020-08-13	AMENDMENT 2	No/ 2021-03-19 (219)	Other/ SUBJECT IS MOVING OUT OF STATE AND NO LONGER ABLE TO ATTEND ANY IN OFFICE VISITS.		Yes/ 2020-09-10 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302203	2020-08-14	AMENDMENT 2	No/ 2020-09-21 (39)	Withdrawal of Consent by Participant/ SUBJECT STATES HE IS NO LONGER ABLE TO PARTICIPATE IN TRIAL.		No/ 2020-09-10 (28)	Withdrawal of Consent by Participant/ SUBJECT STATES HE IS NO LONGER ABLE TO PARTICIPATE IN TRIAL.
US3302261	2020-08-18	AMENDMENT 2	No/ 2020-09-22 (36)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER ABLE TO TAKE PART IN TRIAL DUE TO HAVING TO CARE FOR HIS MOTHER		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER ABLE TO TAKE PART IN TRIAL DUE TO HAVING TO CARE FOR HIS MOTHER

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302263	2020-08-18	AMENDMENT 2	No/ 2020-11-02 (77)	Withdrawal of Consent by Participant/ SUBJECT DECISION DUE TO PERSONAL CONFLICTS		Yes/ 2020-09-15 (29)	
US3302345	2020-08-24	AMENDMENT 3	No/ 2021-02-02 (163)	Pregnancy		Yes/ 2020-09-21 (29)	
US3302377	2020-08-26	AMENDMENT 3	No/ 2020-11-04 (71)	Withdrawal of Consent by Participant/ SUBJECT DECIDED TO DROP DUE TO WORK SCHEDULE CONFLICT		Yes/ 2020-09-24 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302386	2020-08-26	AMENDMENT 3	No/ 2020-09-21 (27)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER INTERESTED DUE TO PERSONAL REASONS		No/ 2020-09-20 (26)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER INTERESTED DUE TO PERSONAL REASONS
US3302387	2020-08-26	AMENDMENT 3	No/ 2020-09-21 (27)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER INTERESTED DUE TO PERSONAL REASONS		No/ 2020-09-20 (26)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER INTERESTED DUE TO PERSONAL REASONS.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302394	2020-08-27	AMENDMENT 3	No/ 2021-02-02 (160)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT AFTER OPEN LABEL VISIT 0.		Yes/ 2020-09-24 (29)	
US3302441	2020-08-28	AMENDMENT 3	No/ 2020-09-28 (32)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO CONTINUE DUE TO WORK SCHEDULE		No/ 2020-09-24 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW DUE TO WORK SCHEDULE
US3302465	2020-09-29	AMENDMENT 3	No/ 2021-01-29 (123)	Death	2021-01-29/ UNK	Yes/ 2020-10-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312006	2020-08-10	AMENDMENT 1	No/ 2021-03-09 (212)	Death	2021-03-09/ Y	Yes/ 2020-09-07 (29)	
US3312033	2020-08-11	AMENDMENT 2	No/ 2021-03-17 (219)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-07 (28)	
US3312063	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Adverse Event/ AE # 4 AND # 5
US3312116	2020-08-17	AMENDMENT 2	No/ 2020-10-15 (60)	Other/ SUBJECT MOVED OUT OF STATE AND DOES NOT WISH TO CONTINUE FURTHER STUDY PROCEDURES OR VISITS		No/ 2020-09-13 (28)	Other/ SUBJECT MOVED OUT OF STATE AND DOES NOT WISH TO CONTINUE FURTHER STUDY PROCEDURES OR VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312191	2020-08-20	AMENDMENT 2	No/ 2020-10-02 (44)	Other/ SUBJECT MOVED OUT OF STATE. SUBJECT DECLINED OPTION TO CONTINUE SAFETY PHONE CALLS, AND DECLINED REMAINING IN STUDY.		Yes/ 2020-09-17 (29)	
US3312197	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Adverse Event/ AE#2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312246	2020-08-24	AMENDMENT 2	No/ 2020-11-06 (75)	Withdrawal of Consent by Participant/ SUBJECT STATES THE WEEKLY EDIARY'S HAVE BECOME TOO MUCH FOR HIM TO KEEP UP WITH, THEY WERE CAUSING TOO MUCH INTERFERENCE WITH PERSONAL LIFE.		Yes/ 2020-09-21 (29)	
US3312338	2020-08-27	AMENDMENT 3	No/ 2020-09-18 (23)	Lost to Follow-Up		No/ 2020-09-17 (22)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312537	2020-09-08	AMENDMENT 3	No/ 2020-09-29 (22)	Lost to Follow-Up		No/ 2020-09-28 (21)	Lost to Follow-Up
US3312562	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Physician Decision/ WARM ANTIBODIES
US3312574	2020-09-09	AMENDMENT 3	No/ 2021-02-02 (147)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WISH TO CONTINUE IN TRIAL. SUBJECT DID NOT GIVE A SPECIFIC REASON.		Yes/ 2020-10-07 (29)	
US3312637	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322015	2020-08-17	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Other/ SKIPPED V2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322026	2020-08-18	AMENDMENT 2	No/ 2020-10-28 (72)	Withdrawal of Consent by Participant/ SUBJECT DID NOT SHOW TO HIS VISIT 3 APPOINTMENT ON 2 OCCASIONS. SITE REACHED OUT TO SUBJECT ONE MORE TIME TO RE-SCHEDULE HIS APPOINTMENT AND SUBJECT EXPRESSED HE WITHDREW CONSENT.		Yes/ 2020-09-15 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322030	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Other/ SKIPPED V2
US3322121	2020-08-27	AMENDMENT 3	No/ 2020-10-05 (40)	Withdrawal of Consent by Participant/ PATIENT WAS NO LONGER INTERESTED IN PARTICIPATING.		No/ 2020-09-23 (28)	Withdrawal of Consent by Participant/ PATIENT WAS NO LONGER INTERESTED IN PARTICIPATING.
US3322174	2020-09-01	AMENDMENT 3	No/ 2020-09-10 (10)	Withdrawal of Consent by Participant/ PATIENT WAS NO LONGER INTERESTED IN PARTICIPATING IN THE STUDY.		No/ 2020-09-09 (9)	Withdrawal of Consent by Participant/ PATIENT WAS NO LONGER INTERESTED IN PARTICIPATING IN THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322223	2020-09-04	AMENDMENT 3	No/ 2021-03-22 (200)	Withdrawal of Consent by Participant/ SUBJECT WAS CONTACTED TO REMIND THEM ABOUT THE SCHEDULED VISIT 4 APPOINTMENT. SUBJECT STATED THAT HE DOES NOT WISH TO CONTINUE IN THE STUDY AND WOULD LIKE TO WITHDRAW CONSENT		Yes/ 2020-10-06 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322291	2020-09-09	AMENDMENT 3	No/ 2020-11-23 (76)	Protocol Deviation/ NONCOMPLIANCE		No/ 2020-10-06 (28)	Other/ SUBJECT WILL SKIP DAY 29 AND PER PI DISCRETION SUBJECT DISCONTINUED DUE TO NON-COMPLIANCE
US3322387	2020-09-21	AMENDMENT 3	No/ 2021-02-12 (136)	Lost to Follow-Up		Yes/ 2020-11-12 (44)	
US3322404	2020-10-01	AMENDMENT 3	No/ 2020-12-08 (69)	Withdrawal of Consent by Participant/ SUBJECT IS NO LONGER INTERESTED IN PARTICIPATING		No/ 2020-10-28 (28)	Withdrawal of Consent by Participant/ SUBJECT IS NO LONGER INTERESTED IN PARTICIPATING

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322417	2020-10-06	AMENDMENT 4	No/ 2020-12-29 (85)	Withdrawal of Consent by Participant/ SUBJECT WAS SCHEDULED FOR THE DAY 57 VISIT 3 ON 01 DEC 2020. ON 29 DEC 2020, SITE REACHED OUT TO SUBJECT AND SUBJECT EXPRESSED HE IS NO LONGER INTERESTED TO CONTINUE HIS PARTICIPATION IN THE STUDY.		Yes/ 2020-11-04 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3332089	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-14 (28)	Due to SARS-CoV-2
US3342017	2020-08-11	AMENDMENT 2	No/ 2021-01-26 (169)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINE OUTSIDE STUDY ON 30DEC2020 AND 20JAN2021 (PFIZER PRODUCT)		Yes/ 2020-09-08 (29)	
US3342018	2020-08-11	AMENDMENT 2	No/ 2020-10-08 (57)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT VIA PHONE ON 08OCT2020		No/ 2020-09-09 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT VIA PHONE ON 08OCT2020

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342044	2020-08-13	AMENDMENT 2	No/ 2020-10-27 (76)	Lost to Follow-Up		Yes/ 2020-09-17 (36)	
US3342050	2020-08-13	AMENDMENT 2	No/ 2021-03-25 (225)	Withdrawal of Consent by Participant/ PI SPOKE TO PT WHO REPORTS HER PROFESSIONAL LIFE IS TOO BUSY TO BE ABLE TO KEEP UP WITH F/U APPTS AND CALLS. WITHDREW CONSENT		Yes/ 2020-09-16 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342102	2020-08-18	AMENDMENT 2	No/ 2021-03-12 (207)	Other/ SUBJECT CALLED SITE ON 12MAR2021 TO WITHDRAW CONSENT FROM THE STUDY. SUBJECT INFORMED SITE THAT HE HAD MOVED OUT OF THE AREA AND WAS UNWILLING TO ATTEND FUTURE VISITS.		Yes/ 2020-09-22 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342119	2020-08-19	AMENDMENT 2	No/ 2020-09-21 (34)	Withdrawal of Consent by Participant/ SUBJECT CAME IN FOR SCHEDULED VISIT OF VACCINATION 2 ON 21SEP2020 AND VERBALIZED SHE WOULD LIKE TO WITHDRAW AND WITHDRAW CONSENT		No/ 2020-09-15 (28)	Withdrawal of Consent by Participant/ SUBJECT CAME IN FOR SCHEDULED VISIT OF VACCINATION 2 ON 21SEP2020 AND VERBALIZED SHE WOULD LIKE TO WITHDRAW AND WITHDRAW CONSENT
US3342139	2020-08-21	AMENDMENT 2	No/ 2020-10-14 (55)	Lost to Follow-Up		Yes/ 2020-09-23 (34)	
US3342167	2020-09-01	AMENDMENT 3	No/ 2020-11-17 (78)	Lost to Follow-Up		No/ 2020-09-28 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342193	2020-09-04	AMENDMENT 3	No/ 2020-12-15 (103)	Withdrawal of Consent by Participant/ SUBJECT IS OUT OF TOWN UNTIL SEP2021, CHOSE TO WITHDRAW FROM STUDY		No/ 2020-10-01 (28)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO WITHDRAW
US3342205	2020-09-08	AMENDMENT 3	No/ 2020-11-06 (60)	Withdrawal of Consent by Participant/ SUBJECT CALLED SITE AND EXPRESSED THAT HE WOULD LIKE TO WITHDRAW FROM STUDY		No/ 2020-10-05 (28)	Withdrawal of Consent by Participant/ SUBJECT CALLED SITE AND EXPRESSED THAT HE WOULD LIKE TO WITHDRAW FROM STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342239	2020-09-10	AMENDMENT 3	No/ 2020-11-11 (63)	Lost to Follow-Up		No/ 2020-10-07 (28)	Adverse Event/ AE #1
US3342272	2020-09-18	AMENDMENT 3	No/ 2020-10-13 (26)	Physician Decision/ PI CHOSE TO WITHDRAW SUBJECT FROM STUDY		No/ 2020-10-12 (25)	Physician Decision/ PI CHOSE TO WITHDRAW SUBJECT FROM STUDY
US3342286	2020-09-26	AMENDMENT 3	ONGOING			No/ 2020-10-23 (28)	Adverse Event/ AE #1
US3342299	2020-09-30	AMENDMENT 3	No/ 2020-09-30 (1)	Lost to Follow-Up		No	Discontinuation from Study
US3342342	2020-10-06	AMENDMENT 4	No/ 2020-11-03 (22)	Lost to Follow-Up		No/ 2020-11-02 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3342356	2020-10-12	AMENDMENT 4	No/ 2021-01-21 (102)	Protocol Deviation/ RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-11-06 (26)	
US3352001	2020-08-04	AMENDMENT 1	No/ 2020-12-28 (147)	Withdrawal of Consent by Participant/ SUBJECT IS NO LONGER WILLING TO COMPLY WITH STUDY PROCEDURES.		Yes/ 2020-09-01 (29)	
US3352017	2020-08-04	AMENDMENT 1	No/ 2020-11-05 (94)	Lost to Follow-Up		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352089	2020-08-13	AMENDMENT 2	No/ 2021-03-18 (218)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT SITE IS TOO FAR AND IS UNABLE TO MAKE IT IN TO ANY VISITS.		Yes/ 2020-09-10 (29)	
US3352101	2020-08-18	AMENDMENT 2	No/ 2020-09-14 (28)	Physician Decision/ SUBJECT NON COMPLIANCE, AS PER PI DECISION SUBJECT WAS WITHDRAWN FROM THE STUDY.		No/ 2020-09-13 (27)	Physician Decision/ SUBJECT NON COMPLIANT AND WITHDRAWN FROM STUDY PER PI DECISION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352104	2020-08-18	AMENDMENT	2 No/ 2021-01-12 (148)	Lost to Follow-Up		Yes/ 2020-09-17 (31)	
US3352107	2020-08-18	AMENDMENT	2 No/ 2021-01-28 (164)	Lost to Follow-Up		Yes/ 2020-09-17 (31)	
US3352122	2020-08-18	AMENDMENT	2 No/ 2020-11-12 (87)	Lost to Follow-Up		Yes/ 2020-09-17 (31)	
US3352155	2020-08-20	AMENDMENT	2 No/ 2020-09-13 (25)	Lost to Follow-Up		No/ 2020-09-12 (24)	Lost to Follow-Up
US3352163	2020-08-20	AMENDMENT	2 No/ 2020-12-22 (125)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE IN STUDY.		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE WITH STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352255	2020-08-25	AMENDMENT 3	No/ 2020-12-13 (111)	Lost to Follow-Up		Yes/ 2020-09-24 (31)	
US3352358	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Other/ SUBJECT DID NOT FEEL COMFORTABLE RECEIVING SECOND VACCINATION.
US3352412	2020-09-24	AMENDMENT 3	No/ 2020-10-16 (23)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE IN TRIAL DUE TO NEW WORK SCHEDULE.		No/ 2020-10-15 (22)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE IN TRIAL DUE TO NEW WORK SCHEDULE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352439	2020-09-29	AMENDMENT 3	No/ 2020-11-28 (61)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO DO ANY EDIARY ENTRIES AND STATED THAT HE IS VERY BUSY AND DOES NOT HAVE ANY TIME TO BE WASTING ON THIS TRIAL.		Yes/ 2020-11-03 (36)	
US3352460	2020-09-29	AMENDMENT 3	No/ 2020-12-24 (87)	Lost to Follow-Up		Yes/ 2020-11-03 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352472	2020-09-29	AMENDMENT 3	No/ 2021-02-23 (148)	Withdrawal of Consent by Participant/ UNABLE TO CONTINUE IN TRIAL DUE TO WORK.		Yes/ 2020-11-03 (36)	
US3352498	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-02 (28)	Other/ SUBJECT REFUSED TO RECIEVE SECOND DOSE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352502	2020-10-06	AMENDMENT 3	No/ 2020-12-11 (67)	Withdrawal of Consent by Participant/ UNABLE TO COMPLY WITH STUDY VISITS DUE TO WORK SCHEDULE AND BEING OUT OF TOWN		Yes/ 2020-11-03 (29)	
US3352506	2020-10-06	AMENDMENT 3	No/ 2021-03-26 (172)	Lost to Follow-Up		No/ 2020-11-02 (28)	Other/ UNABLE TO REACH SUBJECT. POSSIBLE LOST TO FOLLOW-UP. CERTIFIED LETTER HAS BEEN SENT. PENDING RESPONSE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352514	2020-10-08	AMENDMENT 3	No/ 2021-02-09 (125)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT HE IS UNABLE TO CONTINUE IN TRIAL AS IT IS VERY DIFFICULT FOR HIM TO COME INTO THE SITE.		No/ 2020-11-04 (28)	Withdrawal of Consent by Participant/ SUBJECT IS UNABLE TO CONTINUE IN TRIAL.
US3352522	2020-10-08	AMENDMENT 4	No/ 2021-01-29 (114)	Lost to Follow-Up		Yes/ 2020-11-12 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352525	2020-10-08	AMENDMENT 4	No/ 2020-11-06 (30)	Withdrawal of Consent by Participant/ THE SUBJECT STATES SHE STARTED A NEW JOB AND WON'T BE ABLE TO CONTINUE WITH THE STUDY.		No/ 2020-11-04 (28)	Withdrawal of Consent by Participant/ THE SUBJECT STATES SHE STARTED A NEW JOB AND WON'T BE ABLE TO CONTINUE WITH THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352529	2020-10-08	AMENDMENT 3	No/ 2021-01-29 (114)	Withdrawal of Consent by Participant/ SUBJECT WAS UPSET BECAUSE HE DID NOT RECEIVE STIPEND FOR WEEKLY EDIARIES THAT WERE NOT COMPLETED.		Yes/ 2020-11-05 (29)	
US3352543	2020-10-15	AMENDMENT 4	No/ 2021-03-11 (148)	Other/ SUBJECT MOVED TO KENTUCKY		No/ 2020-11-11 (28)	Withdrawal of Consent by Participant/ SUBJECT MOVED TO KENTUCKY .
US3352569	2020-10-15	AMENDMENT 4	No/ 2020-11-07 (24)	Lost to Follow-Up		No/ 2020-11-06 (23)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352594	2020-10-22	AMENDMENT 4	No/ 2021-02-12 (114)	Withdrawal of Consent by Participant/ SUBJECT STATED THAT SHE IN LONGER AVAILABLE TO CONTINUE IN TRIAL DUE TO WORK.		No/ 2020-11-18 (28)	Other/ SUBJECT HAD A GRADE 3 REACTION TO THE 1ST VACCINE, THEREFORE, SUBJECT WILL NOT BE RECEIVING THE SECOND VACCINE.
US3362023	2020-08-03	AMENDMENT 1	ONGOING			No/ 2020-08-30 (28)	Adverse Event/ AE # 1
US3362112	2020-08-11	AMENDMENT 2	No/ 2021-02-09 (183)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA VACCINE		Yes/ 2020-09-09 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362124	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3362215	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT FOR SECOND INJECTION. PATIENT REFUSED SECOND INJECTION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362243	2020-08-24	AMENDMENT 2	No/ 2020-10-30 (68)	Withdrawal of Consent by Participant/ SUBJECT STATED SHE NO LONGER WISHED TO PARTICIPATE AS SHE WAS NO LONGER ABLE TO COMPLY WITH AN "INCLUSION/EXCLUSION CRITERIA" BUT SHE WOULD NOT ELABORATE.		Yes/ 2020-09-23 (31)	
US3362244	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Adverse Event/ AE # 2, AE # 3, AND AE # 5

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362289	2020-09-26	AMENDMENT 3	No/ 2020-11-13 (49)	Withdrawal of Consent by Participant/ PATIENT CONTACTED SITE ON 13NOV2020 TO WITHDRAW HIS PARTICIPATION IN STUDY DUE TO INABILITY TO COMPLY WITH STUDY SCHEDULE AND VISITS.		No/ 2020-10-23 (28)	Withdrawal of Consent by Participant/ PATIENT CONTACTED SITE ON 13NOV2020 TO WITHDRAW HIS PARTICIPATION IN STUDY DUE TO INABILITY TO COMPLY WITH STUDY SCHEDULE AND VISITS.
US3372034	2020-08-05	AMENDMENT 1	No/ 2021-01-15 (164)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372108	2020-08-13	AMENDMENT 2	No/ 2021-01-07 (148)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE		Yes/ 2020-09-10 (29)	
US3372112	2020-08-13	AMENDMENT 1	No/ 2021-01-21 (162)	Withdrawal of Consent by Participant/ SUBJECT WAS OFFERED A VACCINE ELSEWHERE, WAS UNBLINDED 21JAN2021 AND WITHDREW FROM STUDY		Yes/ 2020-09-14 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372123	2020-08-14	AMENDMENT 2	No/ 2020-11-04 (83)	Withdrawal of Consent by Participant/ SUBJECT HAS DEVELOPED CHRONIC KIDNEY DISEASE AND NO LONGER FEELS THEY CAN CONTINUE		Yes/ 2020-09-14 (32)	
US3372157	2020-08-18	AMENDMENT 2	No/ 2021-02-10 (177)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WISH TO TRAVEL		Yes/ 2020-09-17 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3372306	2020-09-01	AMENDMENT 3	No/ 2020-09-30 (30)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT		Yes/ 2020-09-30 (30)	
US3372330	2020-09-03	AMENDMENT 3	No/ 2021-03-23 (202)	Lost to Follow-Up		Yes/ 2020-10-06 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382029	2020-08-14	AMENDMENT 2	No/ 2021-01-27 (167)	Protocol Deviation/ RECEIVED MANDATORY PFIZER VACCINE AT WORK. MODERNA HAD NOT DECIDED ABOUT UNBLINDING AT THAT TIME. FINAL WORD TO D/C SUBJECTS WHO RECEIVED ANY COVID VACCINE OUTSIDE THE CLINIC CAME AROUND LATE JANUARY.		Yes/ 2020-09-11 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382040	2020-08-17	AMENDMENT 2	No/ 2021-01-24 (161)	Protocol Deviation/ SUBJECT IS A HEALTHCARE PROVIDER AND RECEIVED PFIZER COVID-19 VACCINE PROVIDED BY THE HOSPITAL SHE WORK AT AS MODERNA HAD NOT DECIDED TO UNBLIND AT THAT TIME.		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382132	2020-08-27	AMENDMENT 3	No/ 2021-01-08 (135)	Protocol Deviation/ SUBJECT IS A HEALTHCARE PROVIDER. SHE RECEIVED PFIZER VACCINATION FROM THE HOSPITAL SHE WORKED BECAUSE MODERNA HAD NOT DECIDED TO UNBLIND AT THAT TIME AND COVID-19 VACCINATION WAS MANDATORY FOR HER.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382167	2020-09-02	AMENDMENT 3	No/ 2021-01-27 (148)	Protocol Deviation/ SUBJECT ASKED TO BE DISCONTINUED EXPRESSING THAT THE PI AT A STUDY SHE'S BEEN INVOLVED IN, CONCURRENTLY, ADVISED HER TO. SUBJECT HADN'T DISCLOSED INFORMATION ABOUT THE OTHER STUDY AT SCREENING.		Yes/ 2020-10-07 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382209	2020-09-04	AMENDMENT 3	No/ 2021-01-08 (127)	Protocol Deviation/ OBTAINED MANDATORY COVID-19 VACCINE (MANDATORY) AT WORKPLACE AS MODERNA HAD NOT DECIDED TO UNBLIND THE SUBJECT AT THAT TIME.		Yes/ 2020-10-06 (33)	
US3382243	2020-09-10	AMENDMENT 3	No/ 2021-01-26 (139)	Lost to Follow-Up		Yes/ 2020-10-19 (40)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382271	2020-09-12	AMENDMENT 3	No/ 2021-01-08 (119)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WANT TO HAVE ANY MORE BLOOD DRAWS OR NASAL SWABS.		Yes/ 2020-10-14 (33)	
US3382283	2020-09-16	AMENDMENT 3	No/ 2020-12-04 (80)	Withdrawal of Consent by Participant/ SUBJECT CONCERNED WITH LONG TERM SIDE EFFECTS OF VACCINE		Yes/ 2020-11-06 (52)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382284	2020-09-16	AMENDMENT 3	No/ 2020-11-20 (66)	Serious Adverse Event/ AE#2 (SAE) SUBJECT WITHDREW CONSENT		No/ 2020-10-13 (28)	Serious Adverse Event/ AE #2
US3392092	2020-08-27	AMENDMENT 3	No/ 2021-02-19 (177)	Other/ RELOCATION: SUBJECT IS OUT OF THE COUNTRY AND IS UNABLE TO FOLLOW-UP FOR FUTURE VISITS		Yes/ 2020-09-21 (26)	
US3392149	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Serious Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392186	2020-09-09	AMENDMENT 3	No/ 2020-09-30 (22)	Lost to Follow-Up		No/ 2020-09-29 (21)	Lost to Follow-Up
US3392207	2020-09-10	AMENDMENT 3	No/ 2020-11-16 (68)	Lost to Follow-Up		Yes/ 2020-10-21 (42)	
US3392218	2020-09-10	AMENDMENT 3	No/ 2020-10-14 (35)	Other/ SUBJECT INCARCERATED WITH NO PLANS OF RELEASE.		No/ 2020-10-07 (28)	Physician Decision/ SUBJECT INCARCERATED WITH NO PLANS OF RELEASE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3392278	2020-09-14	AMENDMENT 3	No/ 2020-11-11 (59)	Withdrawal of Consent by Participant/ PATIENT DECISION TO QUIT. (DATA CORRECT)		No/ 2020-10-11 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED "HE IS NOT COMFORTABLE RETURNING TO THE STUDY" AFTER SYNCOPES DURING VISIT 02 MONTH 1 VISIT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402081	2020-07-29	AMENDMENT 1	No/ 2020-09-04 (38)	Other/ SUBJECT WAS BEING PLACED IN AN INPATIENT PSYCHIATRIC FACILITY BY DAUGHTER AND COULD NO LONGER DO WHAT WAS BEING ASKED OF HER IN THE STUDY.		Yes/ 2020-08-26 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402113	2020-07-30	AMENDMENT 1	No/ 2021-02-02 (188)	Other/ SUBJECT MOVED AND WANTED TO GET ON WITH OTHER SITE HOWEVER DIDN'T WANT TO WAIT FOR THE PROCESS TO TRANSE. GOT SHOT ELSE WHERE.		Yes/ 2020-08-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402189	2020-08-02	AMENDMENT 1	No/ 2021-01-21 (173)	Other/ THREE ATTEMPTS MADE CERTIFIED LETTER SENT ON 13NOV2020/12JAN2 021 SUBJECT CALLED SITE WANTED TO BE UNBLINDED VACCINE OUTSIDE THE STUDY. UNSUCCESSF AT RETAIN SUBJECT UNBLINDED ADVISED OF THE VACCINATION		Yes/ 2020-09-04 (34)	
US3402224	2020-08-04	AMENDMENT 1	No/ 2021-01-25 (175)	Lost to Follow-Up		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402232	2020-08-05	AMENDMENT 1	No/ 2021-03-26 (234)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO COMPLY WITH CONVALESCENT PERIOD REQUIREMENTS .		Yes/ 2020-09-02 (29)	
US3402265	2020-08-06	AMENDMENT 1	ONGOING			No/ 2020-09-02 (28)	Physician Decision/ REACTION TO VACCINATION 1
US3402297	2020-08-08	AMENDMENT 2	No/ 2021-01-22 (168)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE THROUGH EMPLOYER.		Yes/ 2020-09-08 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402298	2020-08-08	AMENDMENT 2	No/ 2020-12-22 (137)	Other/ SUBJECT WAS NOT WILLING TO WAIT UNTIL AMENDMENT 6 CAME OUT FOR UNBLINDING		Yes/ 2020-09-08 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402361	2020-08-15	AMENDMENT 2	No/ 2020-09-05 (22)	Withdrawal of Consent by Participant/ SUBJECT CALLED THE OFFICE TO SAY THEY MOVED OUT OF STATE AND NO LONGER WISHED TO PARTICIPATE IN THE STUDY AT THAT TIME SUBJECT WITHDREW CONSENT.		No/ 2020-09-04 (21)	Withdrawal of Consent by Participant/ SUBJECT MOVED OUT OF STATE
US3402443	2020-09-09	AMENDMENT 2	No/ 2020-10-02 (24)	Lost to Follow-Up		No/ 2020-10-01 (23)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402477	2020-10-23	AMENDMENT 4	No/ 2021-01-11 (81)	Other/ SUBJECT DEPLOYED TO TEXAS		Yes/ 2020-11-20 (29)	
US3412017	2020-07-29	AMENDMENT 1	No/ 2021-03-03 (218)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER VACCINE		Yes/ 2020-08-26 (29)	
US3412101	2020-08-03	AMENDMENT 1	No/ 2020-09-25 (54)	Lost to Follow-Up		No/ 2020-08-30 (28)	Lost to Follow-Up
US3412126	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Adverse Event/ AE#3
US3412129	2020-08-05	AMENDMENT 1	ONGOING			No/ 2020-09-01 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3412151	2020-08-06	AMENDMENT 1	No/ 2021-04-02 (240)	Death	2021-04-02/ N	Yes/ 2020-09-03 (29)	
US3412172	2020-08-07	AMENDMENT 1	No/ 2020-10-26 (81)	Lost to Follow-Up		No/ 2020-09-03 (28)	Lost to Follow-Up
US3412317	2020-08-25	AMENDMENT 3	No/ 2021-02-24 (184)	Withdrawal of Consent by Participant/ SUBJECT EXPRESSED THAT HE WANTED TO WITHDRAW CONSENT DUE TO LIVING IN INDIA A WHICH IS OVER (b) (6) HOURS AWAY FROM THE SITE.		Yes/ 2020-09-21 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3422244	2020-09-09	AMENDMENT 3	No/ 2021-01-03 (117)	Death	2021-01-03/ Y	Yes/ 2020-10-07 (29)	
US3422249	2020-09-09	AMENDMENT 3	No/ 2021-03-22 (195)	Other/ PARTICIPANT MOVING OUT OF THE COUNTRY DUE TO FAMILY EMERGENCY		Yes/ 2020-10-07 (29)	
US3432054	2020-08-07	AMENDMENT 1	ONGOING			No/ 2020-09-03 (28)	Other/ SUBJECT OUT OF TOWN FOR SEVERAL MONTHS
US3432261	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Other/ UNABLE TO BRING PARTICIPANT IN DURING WINDOW.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432267	2020-08-24	AMENDMENT 2	No/ 2020-11-20 (89)	Other/ UNBLINDING PRE EUA		Yes/ 2020-09-22 (30)	
US3432334	2020-08-28	AMENDMENT 3	No/ 2020-12-29 (124)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE STUDY		No/ 2020-09-24 (28)	Due to SARS-CoV-2
US3432408	2020-09-02	AMENDMENT 3	No/ 2021-01-06 (127)	Other/ PARTICIPANT WITHDREW FROM STUDY UPON UNBLINDING VISIT COMPLETED. PARTICIPANT HAS MOVED OUT OF THE COUNTRY.		Yes/ 2020-09-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3432531	2020-09-19	AMENDMENT 3	No/ 2020-11-16 (59)	Withdrawal of Consent by Participant/ PT DID NOT WANT TO BE PART OF THE STUDY ANYMORE AND WITHDREW FROM THE STUDY.		Yes/ 2020-10-16 (28)	
US3442018	2020-08-14	AMENDMENT 2	No/ 2020-11-21 (100)	Lost to Follow-Up		No/ 2020-09-10 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442059	2020-08-21	AMENDMENT 2	No/ 2021-01-25 (158)	Protocol Deviation/ SUBJECT WITHDREW CONSENT DUE TO RECEIVING EUA COVID VACCINE PRIOR TO UNBLINDING		Yes/ 2020-09-18 (29)	
US3442087	2020-08-25	AMENDMENT 3	ONGOING			No/ 2020-09-21 (28)	Withdrawal of Consent by Participant/ SUBJECT DID NOT LIKE SOLICITED REACTIONS CAUSED BY THE VACCINE AND "DOES NOT TRUST" THE 2ND DOSE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442146	2020-09-14	AMENDMENT 3	No/ 2021-03-25 (193)	Withdrawal of Consent by Participant/ PHONE CALL FROM SUBJECT, STATES HE WOULD LIKE TO WITHDRAWN CONSENT.		Yes/ 2020-10-09 (26)	
US3442165	2020-09-15	AMENDMENT 3	ONGOING			No/ 2020-10-12 (28)	Physician Decision/ GIVEN THE REACTION POST FIRST VACCINATION PI SUGGESTS SUBJECT NOT RECEIVE SECOND DOSE OF MRNA-1273

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3442248	2020-10-22	AMENDMENT 4	No/ 2020-12-30 (70)	Protocol Deviation/ EXCLUSION #4. SUBJECT RECEIVED COVID VACCINE THROUGH EMPLOYER WHILE IN STUDY. SUBJECT DROPPED FROM STUDY.		Yes/ 2020-11-16 (26)	
US3452056	2020-07-31	AMENDMENT 1	No/ 2021-03-08 (221)	Withdrawal of Consent by Participant/ DUE TO PERSONAL REASONS AND TIME		Yes/ 2020-08-31 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452061	2020-07-31	AMENDMENT 1	No/ 2021-03-24 (237)	Other/ SUBJECT MOVING AND WILL NO LONGER BE ABLE TO COME TO SITE FOR F/U.		Yes/ 2020-09-04 (36)	
US3452105	2020-08-01	AMENDMENT 1	No/ 2020-09-29 (60)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO WITHDRAW DUE TO HECTIC SCHEDULE		Yes/ 2020-08-29 (29)	
US3452151	2020-08-03	AMENDMENT 1	No/ 2021-01-26 (177)	Withdrawal of Consent by Participant/ GIVEN VACCINE THROUGH WORK		Yes/ 2020-08-31 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452170	2020-08-04	AMENDMENT 1	No/ 2020-12-23 (142)	Withdrawal of Consent by Participant		Yes/ 2020-08-31 (28)	
US3452196	2020-08-04	AMENDMENT 1	No/ 2021-02-09 (190)	Withdrawal of Consent by Participant/ JECT LIVES (b) (6) HOURS AWAY AND HAS BECOME UNABLE TO TRAVEL TO COMPLETE STUDY VISITS.		Yes/ 2020-09-01 (29)	
US3452218	2020-08-05	AMENDMENT 1	No/ 2020-12-30 (148)	Withdrawal of Consent by Participant/ WITHDREW ICF TO RECEIVE VACCINE FROM EMPLOYER		Yes/ 2020-09-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452222	2020-08-05	AMENDMENT 1	No/ 2021-01-06 (155)	Withdrawal of Consent by Participant/ W/D DUE TO ANOTHER VACCINE AVAILABLE		Yes/ 2020-09-01 (28)	
US3452259	2020-08-05	AMENDMENT 1	No/ 2021-03-09 (217)	Other/ SUBJECT IS OUT OF STATE LONG TERM DUE TO FAMILY EMERGENCY		Yes/ 2020-09-04 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452274	2020-08-06	AMENDMENT 1	No/ 2021-01-06 (154)	Withdrawal of Consent by Participant/ SUBJECT CHOSE TO WITHDRAW CONSENT DUE TO WORK SCHEDULE		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452334	2020-08-24	AMENDMENT 2	No/ 2020-09-23 (31)	Withdrawal of Consent by Participant/ SUBJECT WAS CONTACTED TO FOLLOW UP ON DAY 29 DEHYDRATION, AT THIS TIME SUBJECT INFORMED SITE THAT WANTED TO WITHDRAW CONSENT.		No/ 2020-09-20 (28)	Physician Decision/ SUBJECT VERY DEHYDRATED
US3452363	2020-09-15	AMENDMENT 3	No/ 2020-09-25 (11)	Withdrawal of Consent by Participant/ SUBJECT ASKED TO BE W/D FROM STUDY		No/ 2020-09-24 (10)	Withdrawal of Consent by Participant/ SUBJECT ASKED TO BE WITHDRAWN FORM STUDY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452377	2020-09-22	AMENDMENT 3	No/ 2020-11-17 (57)	Lost to Follow-Up		No/ 2020-10-19 (28)	Lost to Follow-Up
US3452378	2020-09-22	AMENDMENT 3	No/ 2020-11-17 (57)	Lost to Follow-Up		No/ 2020-10-19 (28)	Lost to Follow-Up
US3452381	2020-09-22	AMENDMENT 3	No/ 2020-10-22 (31)	Withdrawal of Consent by Participant		No/ 2020-10-19 (28)	Withdrawal of Consent by Participant
US3452383	2020-09-22	AMENDMENT 3	No/ 2021-03-19 (179)	Withdrawal of Consent by Participant/ UNABLE TO PARTICIPATE		Yes/ 2020-10-19 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452395	2020-09-23	AMENDMENT 3	No/ 2020-10-21 (29)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE.		No/ 2020-10-20 (28)	Withdrawal of Consent by Participant/ DUE TO WORK SCHEDULE.
US3452397	2020-09-24	AMENDMENT 3	No/ 2020-09-30 (7)	Withdrawal of Consent by Participant/ PT. WDC DUE TO WORK		No/ 2020-09-29 (6)	Withdrawal of Consent by Participant/ PT WDC DUE TO WORK
US3452398	2020-09-24	AMENDMENT 3	No/ 2021-01-26 (125)	Withdrawal of Consent by Participant/ NO LONGER WILLING TO MAKE VISITS		Yes/ 2020-10-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452414	2020-09-30	AMENDMENT 3	No/ 2020-11-30 (47)	Other/ SUBJECT WITHDREW CONSENT DUE TO MOVING FROM OKLAHOMA FOR WORK.		Yes/ 2020-11-10 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462016	2020-08-04	AMENDMENT 1	No/ 2021-03-18 (227)	Withdrawal of Consent by Participant/ SUBJECT WAS CONTACTED MULTIPLE TIMES TO SCHEDULE VISIT 209 LVM'S NO CONTACT BACK THEIR FOR SUBJECT IS BEING WITHDRAWN FROM STUDY PER PI.		Yes/ 2020-09-08 (36)	
US3462066	2020-08-06	AMENDMENT 1	No/ 2020-11-24 (111)	Withdrawal of Consent by Participant/ MOVED		Yes/ 2020-09-03 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462071	2020-08-07	AMENDMENT 1	No/ 2020-09-02 (27)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO PERSONAL REASONS.		No/ 2020-09-01 (26)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DUE TO PERSONAL PROBLEMS.
US3462110	2020-08-11	AMENDMENT 2	No/ 2020-08-17 (7)	Withdrawal of Consent by Participant/ PATIENT WANTED TO WITHDRAW CONSENT FROM THE STUDY		No/ 2020-08-16 (6)	Withdrawal of Consent by Participant/ PATIENT WANTED TO WITHDRAW CONSENT FROM THE STUDY.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462133	2020-08-12	AMENDMENT 2	No/ 2020-09-14 (34)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT DUE TO UNSTABLE HEALTH.		No/ 2020-09-08 (28)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT DUE TO UNSTABLE HEALTH.
US3462206	2020-08-17	AMENDMENT 2	No/ 2021-03-24 (220)	Withdrawal of Consent by Participant/ WITHDRAW OF CONSENT AS PATIENT DOES NOT WANT TO COMPLETE ANY OTHER STUDY PROCEDURES		Yes/ 2020-09-14 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462261	2020-08-20	AMENDMENT 2	No/ 2021-03-05 (198)	Withdrawal of Consent by Participant/ PATIENT WITHDREW CONSENT		Yes/ 2020-09-15 (27)	
US3462270	2020-08-20	AMENDMENT 2	No/ 2021-02-05 (170)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE. FIRST DOSE ON 12 JAN 2021 AND SECOND DOSE ON 2 FEB 2021		Yes/ 2020-09-18 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3462343	2020-08-26	AMENDMENT 2	No/ 2021-01-25 (153)	Protocol Deviation/ SUBJECT WAS UNBLINDED AND WITHDREW CONSENT TO GET THE EUA VACCINE.		Yes/ 2020-09-22 (28)	
US3472001	2020-08-31	AMENDMENT 3	No/ 2020-11-27 (89)	Death	2020-11-27/ UNK	Yes/ 2020-10-01 (32)	
US3472091	2020-10-05	AMENDMENT 3	No/ 2020-12-07 (64)	Withdrawal of Consent by Participant/ PARTICIPANT REPORTS HE NEEDS TO WORK AND THE VISITS TAKE TOO LONG.		No/ 2020-11-01 (28)	Withdrawal of Consent by Participant/ PARTICIPANT REPORTS HE NEEDS TO WORK AND THE VISITS TAKE TOO LONG.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472125	2020-10-21	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Lost to Follow-Up
US3482064	2020-08-17	AMENDMENT 1	ONGOING			No/ 2020-09-13 (28)	Adverse Event/ AE#1
US3482284	2020-10-09	AMENDMENT 4	ONGOING			No/ 2020-11-12 (28)	Serious Adverse Event/ #1 #2 #3 #4 #5 #6
US3492023	2020-08-28	AMENDMENT 2	No/ 2021-03-11 (196)	Protocol Deviation/ RECEIVED PFIZER VACCINE UNDER EUA		Yes/ 2020-09-25 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492087	2020-09-08	AMENDMENT 2	No/ 2020-10-06 (29)	Withdrawal of Consent by Participant/ SUBJECT WENT AND HAD AN ANTIBODY TEST AND FELT THAT HE WASN'T ON ACTIVE AND WANTED TO TRY ANOTHER STUDY.		No/ 2020-10-05 (28)	Withdrawal of Consent by Participant/ SUBJECT HAD AB TEST THAT WAS NEGATIVE AND WANTED TO DROP OUT AND ATTEMPT ANOTHER STUDY
US3492095	2020-09-08	AMENDMENT 2	No/ 2021-01-08 (123)	Protocol Deviation/ PARTICIPANT GOT PFIZER VACCINATION PRIOR TO UNBLINDING		Yes/ 2020-10-06 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3492109	2020-09-09	AMENDMENT 2	No/ 2021-01-14 (128)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER WILLING TO PARTICIPATE IN STUDY. DECLINED TO GIVE CONCRETE REASON.		Yes/ 2020-10-09 (31)	
US3492155	2020-09-15	AMENDMENT 3	No/ 2020-11-17 (64)	Withdrawal of Consent by Participant/ ADVANCED AGE, DIFFICULTY AMBULATING, DIFFICULTY FINDING PARKING NEAR CLINIC		Yes/ 2020-10-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502066	2020-08-31	AMENDMENT 3	No/ 2020-10-30 (61)	Withdrawal of Consent by Participant/ SHE CANNOT COMMIT BECAUSE SHE HAS TO TAKE CARE OF HER SICK FATHER.		Yes/ 2020-09-29 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502135	2020-09-10	AMENDMENT 3	No/ 2020-10-29 (50)	Withdrawal of Consent by Participant/ HE LIVES TOO FAR AWAY AND DOES NOT THINK HE COULD COMMIT TO STUDY VISITS, ESPECIALLY SINCE HE DID NOT (AND CANNOT) RECEIVE THE SECOND DOSE.		No/ 2020-10-07 (28)	Other/ PT DID NOT COME IN FOR HIS VISIT 2.
US3502180	2020-09-25	AMENDMENT 3	ONGOING			No/ 2020-10-22 (28)	Other/ PT COULD NOT STAY FOR OBSERVATION PERIOD AND COULD NOT RETURN TO CLINIC IN WINDOW.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3502218	2020-10-23	AMENDMENT 4	No/ 2020-11-27 (36)	Lost to Follow-Up		No/ 2020-11-19 (28)	Lost to Follow-Up
US3512042	2020-08-12	AMENDMENT 2	No/ 2020-09-01 (21)	Death	2020-09-01/ UNK	No/ 2020-09-01 (21)	Death
US3512149	2020-08-26	AMENDMENT 3	No/ 2021-02-23 (182)	Protocol Deviation/ RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY PRIOR TO UNBLINDING.		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512237	2020-09-05	AMENDMENT 3	No/ 2020-10-07 (33)	Withdrawal of Consent by Participant/ SUBJECT STATED HE IS NO LONGER INTERESTED IN THE STUDY AND DOES NOT WANT TO RECEIVE THE SECOND DOSE. HE STATES HE DOES NOT WANT TO COMPLETE ANYMORE VISITS OR BE CALLED FOR ANY PHONE VISITS.		No/ 2020-10-02 (28)	Withdrawal of Consent by Participant/ SUBJECT STATED HE IS NO LONGER INTERESTED IN THE STUDY AND DOES NOT WANT TO RECEIVE THE SECOND DOSE. HE STATES HE DOES NOT WANT TO COMPLETE ANYMORE VISITS OR BE CALLED FOR ANY PHONE VISITS.
US3512287	2020-09-30	AMENDMENT 3	No/ 2020-10-22 (23)	Lost to Follow-Up		No/ 2020-10-21 (22)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512288	2020-10-01	AMENDMENT 3	No/ 2021-03-26 (177)	Protocol Deviation/ SUBJECT RECEIVED COVID-19 VACCINATION OUTSIDE OF STUDY.		Yes/ 2020-10-29 (29)	
US3512312	2020-10-23	AMENDMENT 4	ONGOING			No/ 2020-11-19 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522182	2020-08-18	AMENDMENT 1	No/ 2020-09-18 (32)	Withdrawal of Consent by Participant/ PARTICIPANT CALLED US ON 18 SEP 2020 ASKING TO WITHDRAW IN PREPARATION FOR AN FDA APPROVED VACCINE		Yes/ 2020-09-11 (25)	
US3522266	2020-08-21	AMENDMENT 2	No/ 2020-12-21 (123)	Other/ WITHDREW TO RECEIVE EUA APPROVED COVID-19 VACCINE		Yes/ 2020-09-15 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522351	2020-08-25	AMENDMENT 2	No/ 2020-09-11 (18)	Other/ PARTICIPANT MOVED AND WITHDREW AS THEY COULD NOT MAKE THE COMMITMENT.		No/ 2020-09-10 (17)	Other/ PARTICIPANT MOVED AND WITHDREW AS THEY COULD NOT MAKE THE COMMITMENT.
US3522537	2020-09-02	AMENDMENT 3	No/ 2021-03-02 (182)	Protocol Deviation/ PARTICIPANT DID NOT DISCLOSE TAKING ANOTHER EUA APPROVED VACCINE. WAS UNBLINDED WHEN THIS WAS DISCOVERED AND WITHDRAWN.		Yes/ 2020-10-01 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522664	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Adverse Event/ AE#1
US3522665	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Other/ PARTICIPANT DOES NOT CONSENT TO THE SECOND DOSE, BUT DOES TO ALL FUTURE VISITS

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532032	2020-08-14	AMENDMENT 2	No/ 2021-01-13 (153)	Withdrawal of Consent by Participant/ DUE TO LIMITED KIT F'S BEING AVAILABLE AT SITE HAD TO CALL SUBJECT TO RESCHEDULE. AFTER SPEAKING THROUGH OPTIONS, SUBJECT WANTED TO BE UNBLINDED FOR EUA. PI INFORMED, SUBJECT UNBLINDED AND WITHDREW		Yes/ 2020-09-15 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3532202	2020-09-01	AMENDMENT 3	No/ 2020-12-28 (119)	Protocol Deviation/ SUBJECT RECEIVED EUA PRIOR TO UNBLINDING		Yes/ 2020-09-29 (29)	
US3532279	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542048	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Physician Decision/ PARTICIPANT WAS VERY DIFFICULT TO SCHEDULE VISIT 2 AND RE-SCHEDULED MULTIPLE TIMES. GIVEN DELAY IN SCHEDULING THIS VISIT BECAME EXTREMELY OUT OF WINDOW AND THEREFORE A DECISION WAS MADE TO D/C DOSING.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3542247	2020-09-17	AMENDMENT 3	No/ 2021-03-16 (181)	Protocol Deviation/ PARTICIPANT RECEIVED A DOSE OF MRNA-1273 OUTSIDE OF THE STUDY VIA EUA.		Yes/ 2020-10-16 (30)	
US3542289	2020-09-24	AMENDMENT 3	No/ 2020-10-29 (36)	Lost to Follow-Up		No/ 2020-10-21 (28)	Lost to Follow-Up
US3542293	2020-09-24	AMENDMENT 3	No/ 2021-01-19 (118)	Lost to Follow-Up		Yes/ 2020-10-19 (26)	
US3542332	2020-10-09	AMENDMENT 4	ONGOING			No/ 2020-11-05 (28)	Serious Adverse Event/ SAE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552024	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Other/ SUBJECT CONSENTS FOR FOLLOW-UP, BUT NOT FOR SECOND VACCINATION.
US3552035	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Adverse Event/ AE #1
US3552189	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Physician Decision/ SUBJECT IS POOR HISTORIAN FOR RECORDING REACTOGENICITY; DOES NOT MAKE OBJECTIVE MEASURES. PI DISCRETION TO NOT VACCINATE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552326	2020-09-04	AMENDMENT 3	No/ 2020-10-05 (32)	Withdrawal of Consent by Participant/ SUBJECT WOULD LIKE TO WITHDRAW DUE TO CHANGES IN WORK SCHEDULE AND SCHOOL SCHEDULE.		No/ 2020-10-01 (28)	Withdrawal of Consent by Participant/ SUBJECT WOULD LIKE TO WITHDRAW DUE TO CHANGES IN WORK SCHEDULE AND SCHOOL SCHEDULE.
US3552371	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552450	2020-09-17	AMENDMENT 3	No/ 2021-02-05 (142)	Protocol Deviation/ SUBJECT RECEIVED EUA VACCINE ON 1/14; DID NOT NOTIFY SITE UNTIL 2/5		Yes/ 2020-10-12 (26)	
US3552497	2020-09-26	AMENDMENT 3	ONGOING			No/ 2020-10-23 (28)	Adverse Event/ AE #1
US3552499	2020-09-26	AMENDMENT 3	ONGOING			No/ 2020-10-23 (28)	Physician Decision/ SUBJECT BEING WORKED UP FOR HEADACHE (PART OF MEDICAL HISTORY)

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3552528	2020-10-13	AMENDMENT 4	No/ 2021-02-26 (137)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO RELIABLY COME IN FOR VISITS DUE TO NEW A JOB THAT REQUIRES LONG TERM TRAVEL		Yes/ 2020-11-10 (29)	
US3562003	2020-08-04	AMENDMENT 1	No/ 2020-08-10 (7)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO CONTINUE WITH STUDY DUE TO PERSONAL REASON AND WITHDREW CONSENT		No/ 2020-08-09 (6)	Withdrawal of Consent by Participant/ DOES NOT WANT TO CONTINUE WITH STUDY DUE TO PERSONAL REASON

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562011	2020-08-06	AMENDMENT 1	No/ 2020-11-03 (90)	Withdrawal of Consent by Participant/ PT WAS NOT ABLE TO COMPLIANCE WITH STUDY PROCEDURE AND NEVER RETURN FOR VISIT 3 !		Yes/ 2020-09-03 (29)	
US3562017	2020-08-07	AMENDMENT 1	No/ 2020-10-02 (57)	Withdrawal of Consent by Participant/ DURING VISIT 3 PATIENT CHANGED HER MIND AND SHE WITHDREW CONSENT !		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562051	2020-08-17	AMENDMENT 2	No/ 2020-10-12 (57)	Withdrawal of Consent by Participant/ PT DOES NOT WANT TO CONTINUE WITH STUDY . SHE STATES HER PCP ADVICE HER TO WITHDREW		Yes/ 2020-09-14 (29)	
US3562061	2020-08-20	AMENDMENT 2	No/ 2021-01-15 (149)	Protocol Deviation/ PT RECEIVED PFIZER VACCINE ON 1/13/2021 AS HE DID NOT DEVELOP ANTIBODIES AFTER MODERNA VACCINE		Yes/ 2020-09-21 (33)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3562157	2020-09-11	AMENDMENT 3	No/ 2020-12-02 (83)	Serious Adverse Event/ SAE # 2		Yes/ 2020-10-14 (34)	
US3562209	2020-10-02	AMENDMENT 4	No/ 2021-03-26 (176)	Lost to Follow-Up		Yes/ 2020-11-02 (32)	
US3562230	2020-10-15	AMENDMENT 4	No/ 2020-11-20 (37)	Withdrawal of Consent by Participant/ DOE NOT WANT TO CONTINUE WITH STUDY DUE TO RECENT HOSPITALIZED		No/ 2020-11-11 (28)	Serious Adverse Event/ AE # 2
US3572008	2020-08-18	AMENDMENT 2	No/ 2020-09-08 (22)	Lost to Follow-Up		No/ 2020-09-07 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572020	2020-08-19	AMENDMENT 2	No/ 2021-03-01 (195)	Withdrawal of Consent by Participant/ SUBJECT WOULD LIKE TO WITHDRAW FROM STUDY. HIS EMPLOYMENT REQUIRES HIM TO WORK LONG HOURS AND HE FEARS HE WILL NOT BE ABLE TO MAKE APPOINTMENTS ON TIME.		Yes/ 2020-09-24 (37)	
US3572031	2020-08-19	AMENDMENT 2	No/ 2021-03-04 (198)	Lost to Follow-Up		Yes/ 2020-09-21 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572066	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Other/ SUBJECT WAS AT SITE FOR D29 BUT LEFT DUE TO WAIT TIME. SUBJECT WAS EDUCATED BY PI ON IMPORTANCE OF VISITS.
US3572068	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Other/ NON-RESPONSIVE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572109	2020-08-27	AMENDMENT 2	No/ 2020-09-09 (14)	Withdrawal of Consent by Participant/ AS PER LAST COMMUNICATION WITH THE SUBJECT WITH SAFETY NURSE ON 09 SEP. 2020, SUBJECT DOES NOT WANT ANY MORE CONTACT		No/ 2020-09-08 (13)	Withdrawal of Consent by Participant/ AS PER LAST COMMUNICATION WITH THE SUBJECT WITH SAFETY NURSE ON 09 SEP. 2020, SUBJECT DOES NOT WANT ANY MORE CONTACT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572161	2020-09-01	AMENDMENT 3	No/ 2021-02-02 (155)	Protocol Deviation/ SUBJECT WOULD LIKE TO WITHDRAW FROM STUDY. SUBJECT ALSO GOT VACCINE OUTSIDE OF THE STUDY. PI AWARE AND AGREES OF SUBJECT WITHDRAW.		No/ 2020-09-28 (28)	Other/ SUBJECT WOULD LIKE TO WITHDRAW FROM STUDY. SUBJECT ALSO GOT VACCINE OUTSIDE OF THE STUDY. PI AWARE AND AGREES OF SUBJECT WITHDRAW.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572225	2020-09-08	AMENDMENT 3	No/ 2021-02-11 (157)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		Yes/ 2020-10-05 (28)	
US3572232	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ SUBJECT MISSED VISIT 2 DAY 29 (DOSE 2) UNDER PART A OF THE STUDY
US3572251	2020-09-10	AMENDMENT 3	No/ 2021-04-03 (206)	Death	2021-04-03/ Y	Yes/ 2020-10-06 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572326	2020-09-18	AMENDMENT 3	ONGOING			No/ 2020-10-25 (28)	Lost to Follow-Up
US3572355	2020-09-29	AMENDMENT 3	No/ 2020-11-02 (35)	Withdrawal of Consent by Participant/ PATIENT WAS NOT ABLE TO GET THE SECOND DOSE PER MODERNA BECAUSE PATIENT WAS FROM MEXICO. HENCE PATIENT DECIDED TO WITHDRAW		No/ 2020-10-26 (28)	Withdrawal of Consent by Participant/ PATIENT WAS NOT ABLE TO GET THE SECOND DOSE PER MODERNA BECAUSE PATIENT WAS FROM MEXICO. HENCE PATIENT DECIDED TO WITHDRAW

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572368	2020-10-06	AMENDMENT 3	No/ 2020-11-03 (29)	Withdrawal of Consent by Participant/ PATIENT WAS NOT ABLE TO (b) (6) (b) (6)		No/ 2020-11-02 (28)	Withdrawal of Consent by Participant/ PATIENT WAS NOT ABLE TO (b) (6) (b) (6)
US3572372	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-02 (28)	Other/ PER MODERNA PATIENT IS NOT ELIGIBLE TO GET DOSED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572390	2020-10-12	AMENDMENT 4	No/ 2021-01-06 (87)	Protocol Deviation/ SUBJECT WITHDRAWN FROM STUDY BECAUSE SHE RECEIVED THE VACCINE OUTSIDE OF STUDY. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN FROM STUDY.		Yes/ 2020-11-12 (32)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582056	2020-08-27	AMENDMENT 3	No/ 2021-01-12 (139)	Protocol Deviation/ PARTICIPANT RECEIVED NON-STUDY EUA COVID-19 VACCINE		Yes/ 2020-09-24 (29)	
US3582148	2020-09-16	AMENDMENT 3	No/ 2020-10-23 (38)	Lost to Follow-Up		No/ 2020-10-13 (28)	Other/ PARTICIPANT UNABLE TO COMPLETE VISIT WITHIN WINDOW DUE TO BEING OUT OF TOWN DURING THAT TIME. PARTICIPANT AGREED TO CONTINUE IN STUDY. DOSE DISCONTINUATION DATE BASED ON DOSE 2 TARGET DATE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3582178	2020-10-07	AMENDMENT 4	No/ 2020-12-14 (69)	Withdrawal of Consent by Participant/ PARTICIPANT NO LONGER WISHES TO CONTINUE		No/ 2020-11-03 (28)	Other/ PARTICIPANT UNABLE TO COMPLETE VISIT 2 WITHIN WINDOW DUE TO INDECISION ABOUT WHETHER TO CONTINUE IN STUDY. REQUESTED TIME TO THINK ABOUT IT. STILL PENDING. DATE BASED ON DOSE 2 TARGET DATE.
US3592019	2020-08-05	AMENDMENT 1	No/ 2020-09-30 (57)	Lost to Follow-Up		No/ 2020-09-01 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592032	2020-08-06	AMENDMENT 1	No/ 2020-10-05 (61)	Withdrawal of Consent by Participant/ SUBJECT CITES BUSY SCHEDULE AS REASON FOR WITHDRAWAL.		No/ 2020-09-02 (28)	Withdrawal of Consent by Participant/ SUBJECT CITES BUSY SCHEDULE FOR REASON TO DISCONTINUE.
US3592065	2020-08-08	AMENDMENT 1	No/ 2021-01-13 (159)	Other/ SUBJECT MOVING OUT OF STATE		Yes/ 2020-09-05 (29)	
US3592073	2020-08-08	AMENDMENT 1	No/ 2020-09-18 (42)	Lost to Follow-Up		No/ 2020-09-04 (28)	Lost to Follow-Up
US3592120	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Other/ SUBJECT TAKING PROHIBITED MEDICATION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3592152	2020-08-13	AMENDMENT 2	No/ 2020-11-25 (105)	Lost to Follow-Up		Yes/ 2020-09-10 (29)	
US3592160	2020-08-14	AMENDMENT 2	No/ 2020-09-28 (46)	Lost to Follow-Up		Yes/ 2020-09-11 (29)	
US3592247	2020-08-29	AMENDMENT 3	No/ 2021-01-19 (144)	Protocol Deviation/ RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-26 (29)	
US3602067	2020-09-21	AMENDMENT 3	No/ 2021-01-06 (108)	Lost to Follow-Up		No/ 2020-10-18 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3602148	2020-10-15	AMENDMENT 4	No/ 2021-01-05 (83)	Withdrawal of Consent by Participant/ REQUEST TO UNBLIND BY THE SUBJECT AND MEETS THE EUA FOR COVID-19 VACCINE NOW AND IS ABLE TO GET IT AT WORKPLACE.		Yes/ 2020-11-12 (29)	
US3622010	2020-08-11	AMENDMENT 1	No/ 2021-01-20 (163)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUT OF STUDY.		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622169	2020-09-09	AMENDMENT 3	No/ 2021-01-21 (135)	Death	2021-01-21/ UNK	Yes/ 2020-10-07 (29)	
US3622180	2020-09-12	AMENDMENT 3	No/ 2020-10-27 (46)	Withdrawal of Consent by Participant/ WITHDREW CONSENT		Yes/ 2020-10-13 (32)	
US3622217	2020-09-22	AMENDMENT 3	No/ 2020-10-08 (17)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT AS SHE HAS "TOO MUCH GOING ON"		No/ 2020-10-07 (16)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT AS SHE HAS "TOO MUCH GOING ON"

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622221	2020-09-23	AMENDMENT 3	No/ 2021-03-09 (168)	Withdrawal of Consent by Participant/ PARTICIPANT WITHDREW CONSENT.		Yes/ 2020-10-20 (28)	
US3632135	2020-10-15	AMENDMENT 4	No/ 2020-10-20 (6)	Withdrawal of Consent by Participant/ PARTICIPANT ASKED TO WITHDRAW FROM THE STUDY BECAUSE HE FELT OVERWHELMED.		No/ 2020-10-19 (5)	Withdrawal of Consent by Participant/ PARTICIPANT ASKED TO WITHDRAW FROM THE STUDY BECAUSE HE FELT "OVERWHELMED" WITH THE STUDY PROCEDURES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642017	2020-08-26	AMENDMENT 3	No/ 2021-01-08 (136)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642092	2020-09-03	AMENDMENT 3	No/ 2021-03-09 (188)	Withdrawal of Consent by Participant/ PATIENT CHOSE TO WITHDRAWAL CONSENT TO FOCUS ON HIS TIME ON UPCOMING APPOINTMENTS AND TREATMENTS FOR NEW LUNG CANCER DIAGNOSIS.		Yes/ 2020-10-01 (29)	
US3642215	2020-09-15	AMENDMENT 3	No/ 2021-03-04 (171)	Protocol Deviation/ PATIENT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA.		Yes/ 2020-10-13 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642268	2020-09-21	AMENDMENT 3	ONGOING			No/ 2020-10-18 (28)	Adverse Event/ AE # 1
US3642284	2020-09-28	AMENDMENT 3	No/ 2021-01-23 (118)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-30 (33)	
US3642296	2020-10-02	AMENDMENT 3	No/ 2020-12-26 (86)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-10-30 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3642327	2020-10-16	AMENDMENT 3	No/ 2020-12-29 (75)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE OUTSIDE OF STUDY THROUGH EUA		Yes/ 2020-11-20 (36)	
US3652038	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-22 (28)	Adverse Event/ AE #2
US3662029	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Other/ MET EXCLUSION CRITERIA 12, PRIOR TO ENROLLMENT.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672020	2020-08-07	AMENDMENT 1	No/ 2021-02-22 (200)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE		Yes/ 2020-09-11 (36)	
US3672092	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Adverse Event/ AE#1, AE #2
US3672110	2020-08-14	AMENDMENT 2	No/ 2021-01-13 (153)	Protocol Deviation/ REQUEST TO UNBLIND		Yes/ 2020-09-11 (29)	
US3672163	2020-08-18	AMENDMENT 2	No/ 2021-03-01 (196)	Adverse Event/ AE#2 & AE#3		No/ 2020-09-14 (28)	Adverse Event/ AE#2, AE# 3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672209	2020-08-19	AMENDMENT 2	No/ 2021-01-18 (153)	Protocol Deviation/ PT WAS UNBLINDED.		Yes/ 2020-09-17 (30)	
US3672210	2020-08-19	AMENDMENT 2	No/ 2021-03-05 (199)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE THROUGH WORK		Yes/ 2020-09-17 (30)	
US3672240	2020-08-20	AMENDMENT 2	No/ 2021-02-22 (187)	Lost to Follow-Up		Yes/ 2020-09-21 (33)	
US3672251	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Adverse Event/ AE#1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672298	2020-08-25	AMENDMENT 2	No/ 2021-01-21 (150)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER COVID VACCINE		Yes/ 2020-09-28 (35)	
US3672336	2020-08-26	AMENDMENT 2	No/ 2021-01-24 (152)	Protocol Deviation/ RECEIVED PFIZER COVID-19 VACCINES		Yes/ 2020-09-24 (30)	
US3672346	2020-08-27	AMENDMENT 3	No/ 2020-10-08 (43)	Lost to Follow-Up		No/ 2020-09-23 (28)	Lost to Follow-Up
US3672363	2020-08-27	AMENDMENT 3	No/ 2020-12-17 (113)	Other/ REQUEST TO UNBLIND		Yes/ 2020-09-23 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672369	2020-08-28	AMENDMENT 3	No/ 2021-03-05 (190)	Protocol Deviation/ PATIENT RECEIVED PFIZER VACCINE THROUGH WORK		Yes/ 2020-09-28 (32)	
US3672377	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Adverse Event/ AE #5,6,7
US3672379	2020-08-28	AMENDMENT 3	No/ 2021-01-22 (148)	Protocol Deviation/ RECEIVED PFIZER COVID VACCINE		Yes/ 2020-09-25 (29)	
US3672392	2020-09-01	AMENDMENT 3	No/ 2020-11-24 (85)	Lost to Follow-Up		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672411	2020-09-04	AMENDMENT 3	No/ 2021-01-25 (144)	Protocol Deviation/ REPORTS GETTING THE PFIZER COVID VACCINE		Yes/ 2020-10-02 (29)	
US3682017	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Other/ PT. MISSING FOR V2 BUT CAME IN A WEEK LATER. WE REQUESTED TWICE WITH EPIP TO BE ABLE TO GIVE SECOND INJECTION BUT WERE TOLD "NO".

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3702010	2020-09-04	AMENDMENT 3	No/ 2021-02-25 (175)	Death	2021-02-25/ UNK	No/ 2020-10-01 (28)	Other/ PARTICIPANT REFUSED SECOND INJECTION DUE TO SIDE EFFECTS. HE CONSENTED TO CONTINUE STUDY VISITS.
US3702046	2020-09-23	AMENDMENT 3	No/ 2021-03-09 (166)	Death	2021-03-09/	Yes/ 2020-10-23 (29)	
US3712034	2020-09-03	AMENDMENT 3	No/ 2021-03-17 (190)	Protocol Deviation/ RECEIVED MODERNA VACCINE PRIOR TO BEING UNBLINDED		Yes/ 2020-10-06 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712062	2020-09-09	AMENDMENT 3	No/ 2021-03-05 (172)	Lost to Follow-Up		Yes/ 2020-10-13 (29)	
US3712165	2020-09-23	AMENDMENT 3	No/ 2021-02-15 (144)	Withdrawal of Consent by Participant/ SUBJECT STATES THAT HE HAS "DONE THERE PART" AND WANTS TO WITHDRAW AFTER BEING UNBLINDED		Yes/ 2020-10-28 (34)	
US3712172	2020-10-01	AMENDMENT 4	No/ 2021-02-15 (131)	Other/ RELOCATION		Yes/ 2020-11-05 (29)	
US3712253	2020-10-16	AMENDMENT 4	No/ 2021-03-05 (134)	Lost to Follow-Up		Yes/ 2020-11-20 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722182	2020-08-11	AMENDMENT 2	No/ 2021-02-26 (200)	Other/ SUBJECT REQUESTED TO DROP OUT OF STUDY DUE TO MOVING OUT OF TOWN		Yes/ 2020-09-09 (30)	
US3722352	2020-08-24	AMENDMENT 2	No/ 2020-10-16 (54)	Lost to Follow-Up		No/ 2020-09-20 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722371	2020-08-24	AMENDMENT 2	No/ 2021-01-11 (141)	Protocol Deviation/ SUBJECT RECEIVED THE OTHER VACCINE WHILE BEING ON COVE STUDY. SUBJECT DEMANDED TO BE UNBLINDED EARLY AND PER PROTOCOL SUBJECT WAS REMOVED.		Yes/ 2020-09-30 (38)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722406	2020-08-28	AMENDMENT 3	No/ 2021-01-04 (130)	Protocol Deviation/ SUBJECT IS A HEALTHCARE PROFESSIONAL AND INFORMED THE SITE THAT HE TOOK THE PFIZER VACCINE. WE UNBLINDED AND HE HAD GOTTEN THE VACCINE. OFF STUDY DUE TO TAKING OTHER VACCINE.		Yes/ 2020-09-30 (34)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3722418	2020-09-12	AMENDMENT 3	ONGOING			No/ 2020-10-09 (28)	Other/ SUBJECT HAD EXCLUSIONARY MEDS AND WAS NOT GIVEN THE 2ND INJECTION. SUBJECT IS STAYING IN THE STUDY FOR SAFETY REASONS.
US3732054	2020-08-12	AMENDMENT 2	No/ 2021-03-22 (223)	Protocol Deviation/ RECEIVED EUA VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732086	2020-08-18	AMENDMENT 2	No/ 2021-03-09 (204)	Protocol Deviation/ RECEIVED MODERNA EUA VACCINE OUTSIDE OF STUDY ON 31DEC2020. INFORMED SITE ON 09MAR2021.		Yes/ 2020-09-15 (29)	
US3732134	2020-08-21	AMENDMENT 2	No/ 2020-10-13 (54)	Lost to Follow-Up		No/ 2020-09-17 (28)	Lost to Follow-Up
US3732162	2020-08-25	AMENDMENT 3	No/ 2021-03-10 (198)	Physician Decision/ SUBJECT INABILITY TO COMPLETE IN-CLINIC VISITS		Yes/ 2020-09-22 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732168	2020-08-25	AMENDMENT 3	No/ 2020-12-18 (116)	Protocol Deviation/ RECEIVED PFIZER EUA COVID-19 VACCINE		Yes/ 2020-09-22 (29)	
US3732192	2020-08-27	AMENDMENT 3	No/ 2021-02-24 (182)	Protocol Deviation/ SUBJECT RECEIVED EUA PFIZER VACCINE ON 11FEB2021		Yes/ 2020-09-25 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732202	2020-08-27	AMENDMENT 3	No/ 2021-01-07 (134)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA FIRST DOSE ON 01JAN2021. RELAYED TO SITE ON 07JAN2021.		Yes/ 2020-09-25 (30)	
US3732272	2020-09-03	AMENDMENT 3	No/ 2020-12-29 (118)	Protocol Deviation/ SUBJECT RECEIVED PFIZER EUA VACCINE ON 28DEC2020. SITE AWARE 29DEC2020.		Yes/ 2020-09-30 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732278	2020-09-04	AMENDMENT 3	No/ 2020-12-16 (104)	Protocol Deviation/ RECEIPT OF OUTSIDE VACCINE		Yes/ 2020-10-06 (33)	
US3732279	2020-09-04	AMENDMENT 3	No/ 2020-11-30 (88)	Physician Decision/ PHYSICIANS DECISION-SECONDARY TO PSYCHOTIC DISORDER		Yes/ 2020-10-02 (29)	
US3732286	2020-09-04	AMENDMENT 3	No/ 2021-03-25 (203)	Lost to Follow-Up		Yes/ 2020-10-07 (34)	
US3732311	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Adverse Event/ AE #2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732338	2020-09-15	AMENDMENT 3	No/ 2021-02-16 (155)	Lost to Follow-Up		Yes/ 2020-10-13 (29)	
US3732363	2020-09-21	AMENDMENT 3	No/ 2021-01-26 (128)	Lost to Follow-Up		Yes/ 2020-10-19 (29)	
US3732364	2020-09-21	AMENDMENT 3	No/ 2021-02-15 (148)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT 15FEB2021 AFTER BEING REMOTELY UNBLINDED (EPIP APPROVED) DUE TO LEAVING THE COUNTRY INDEFINITELY IN THE NEAR FUTURE.		Yes/ 2020-10-20 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3732395	2020-10-15	AMENDMENT 3	No/ 2021-03-25 (162)	Lost to Follow-Up		Yes/ 2020-11-11 (28)	
US3742045	2020-08-22	AMENDMENT 2	No/ 2021-03-20 (211)	Other/ PARTICIPANT MOVED TO VA AND FEELS IT IS TOO FAR TO CONTINUE VISITS.		Yes/ 2020-09-19 (29)	
US3742063	2020-08-24	AMENDMENT 2	No/ 2021-01-20 (150)	Protocol Deviation/ VOLUNTEER RECEIVED THE POST EUA MODERNA VACCINE OUTSIDE OF STUDY BEFORE BEING UNBLINDED		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742097	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Other/ VOLUNTEER DECLINED 2ND VACCINATION. WILL CONTINUE IN STUDY FOR FOLLOW UP.
US3742111	2020-08-27	AMENDMENT 3	No/ 2021-01-13 (140)	Protocol Deviation/ VOLUNTEER RECEIVED A DOSE OF PFIZER COVID VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742168	2020-08-31	AMENDMENT 3	No/ 2021-01-22 (145)	Protocol Deviation/ VOLUNTEER RECEIVED THE POST EUA PFIZER VACCINE OUTSIDE OF STUDY		Yes/ 2020-09-26 (27)	
US3742169	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Serious Adverse Event/ SAE (AE#2)
US3742367	2020-09-14	AMENDMENT 3	No/ 2021-01-08 (117)	Protocol Deviation/ VOLUNTEER RECEIVED POST EUA MRNA-1273 VACCINE OUTSIDE OF STUDY		Yes/ 2020-10-12 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742368	2020-09-14	AMENDMENT 3	No/ 2020-10-22 (32)	Withdrawal of Consent by Participant/ HE NO LONGER WANT TO PARTICIPATE BECAUSE HIS FAMILY DOES NOT WANT HIM TO DO.		No/ 2020-10-18 (28)	Withdrawal of Consent by Participant/ PARTICIPANT STATED FAMILY DOESN'T WANT HIM TO PARTICIPATE
US3742391	2020-09-16	AMENDMENT 3	No/ 2020-11-18 (64)	Protocol Deviation/ SCHEDULING NONCOMPLIANCE		Yes/ 2020-10-13 (28)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742397	2020-09-17	AMENDMENT 3	No/ 2020-10-14 (28)	Withdrawal of Consent by Participant/ PARTICIPANT WANTED CASH NOT GIFT CARD AS PAYMENT.		No/ 2020-10-13 (27)	Withdrawal of Consent by Participant/ PARTICIPANT WANTED CASH, NOT GIFT CARD AS PAYMENT
US3742417	2020-09-18	AMENDMENT 3	No/ 2021-01-12 (117)	Protocol Deviation/ VOLUNTEER RECEIVED POST EUA PFIZER VACCINE OUTSIDE OF STUDY.		Yes/ 2020-10-15 (28)	
US3752004	2020-08-07	AMENDMENT 1	No/ 2021-03-10 (216)	Lost to Follow-Up		Yes/ 2020-09-04 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752020	2020-08-10	AMENDMENT 1	No/ 2021-02-02 (177)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER COVID VACCINE OUTSIDE OF THE STUDY. HE IS BEING WITHDRAWN DUE MODERNA GUIDELINES.		Yes/ 2020-09-08 (30)	
US3752056	2020-08-12	AMENDMENT 2	No/ 2021-03-10 (211)	Lost to Follow-Up		Yes/ 2020-09-11 (31)	
US3752060	2020-08-12	AMENDMENT 2	No/ 2021-03-09 (210)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER COVID-19 VACCINE		Yes/ 2020-09-17 (37)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752118	2020-08-17	AMENDMENT 2	No/ 2021-01-07 (144)	Protocol Deviation/ PATIENT RECEIVED THE MODERNA VACCINE OUTSIDE OF THE STUDY. THIS PATIENT WAS UNBLINDED AND WITHDRAWN PER MODERNA THROUGH AN EPIP THAT WAS SENT.		Yes/ 2020-09-23 (38)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752172	2020-08-20	AMENDMENT 2	No/ 2021-02-24 (189)	Protocol Deviation/ PATIENT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE STUDY SO WAS UNBLINDED AND BEING DROPPED DUE TO MODERNA GUIDELINES.		Yes/ 2020-09-15 (27)	
US3752173	2020-08-20	AMENDMENT 2	No/ 2020-11-01 (74)	Death	2020-11-01/ N	Yes/ 2020-09-18 (30)	
US3752224	2020-08-24	AMENDMENT 2	No/ 2020-09-28 (36)	Lost to Follow-Up		No/ 2020-09-20 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752258	2020-08-26	AMENDMENT 2	No/ 2021-01-04 (132)	Protocol Deviation/ SUBJECT RECEIVED THE PFIZER VACCINE OUTSIDE OF THE MODERNA STUDY VIA HIS WORKPLACE UNDER THE EUA.		Yes/ 2020-09-29 (35)	
US3752364	2020-09-02	AMENDMENT 3	No/ 2021-01-04 (125)	Protocol Deviation/ PATIENT RECEIVED PFIZER COVID-19 VACCINE VIA HIS WORKPLACE UNDER THE EUA OUTSIDE OF THE MODERNA STUDY.		Yes/ 2020-10-02 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3752414	2020-09-04	AMENDMENT 3	No/ 2020-12-18 (106)	Protocol Deviation/ EAU VACCINE RECEIVED		Yes/ 2020-10-05 (32)	
US3752421	2020-09-08	AMENDMENT 3	No/ 2021-03-10 (184)	Lost to Follow-Up		Yes/ 2020-10-06 (29)	
US3762177	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Adverse Event/ INJECTION SITE REACTION AE1, AE2, AE3, AND AE4

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772012	2020-08-05	AMENDMENT 1	No/ 2020-10-13 (70)	Protocol Deviation/ SUBJECT WOULD NOT COMPLY WITH THE PROTOCOL AND WOULD NOT SHOW UP TO APPOINTMENTS		Yes/ 2020-09-08 (35)	
US3772013	2020-08-05	AMENDMENT 1	No/ 2020-10-15 (72)	Protocol Deviation/ SUBJECT WOULD NOT COMPLY WITH PROTOCOL REQUIRED VISITS		Yes/ 2020-09-08 (35)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772077	2020-08-17	AMENDMENT 2	No/ 2021-01-14 (151)	Protocol Deviation/ SUBJECT RECEIVED MODERNA COVID-19 VACCINE OUTSIDE OF STUDY WITHOUT NOTIFYING SITE AND WHEN UNBLINDED IT WAS DISCOVERED THEY ALSO RECEIVED VACCINE IN STUDY		Yes/ 2020-09-11 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772087	2020-08-18	AMENDMENT 2	No/ 2021-03-10 (205)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO WEAR A MASK IN OUR FACILITY WHEN PROVIDED WITH A MASK AND ASKED TO WEAR IT, THE SUBJECT DEMANDED THEIR VACCINATION CARD AND TO BE DROPPED FORM THE STUDY		Yes/ 2020-09-14 (28)	
US3772107	2020-08-20	AMENDMENT 2	No/ 2020-10-20 (62)	Lost to Follow-Up		No/ 2020-09-16 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3772188	2020-08-31	AMENDMENT 3	No/ 2021-01-26 (149)	Other/ RELOCATION		Yes/ 2020-09-28 (29)	
US3772277	2020-09-21	AMENDMENT 3	No/ 2020-12-18 (89)	Lost to Follow-Up		Yes/ 2020-10-26 (36)	
US3782111	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Other/ PARTICIPANT AGREES TO BE FOLLOWED BUT DECLINES SECOND VACCINATION OVER CONCERN OF POTENTIAL ADVERSE REACTION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3782198	2020-10-23	AMENDMENT 4	ONGOING			No/ 2020-11-19 (28)	Physician Decision/ PHYSICIAN DECISION DUE TO RASH OF UNKNOWN ETIOLOGY AND NO MEDICAL EVALUATION AVAILABLE TO PATIENT BY PCP BEFORE WINDOW CLOSED
US3792085	2020-10-02	AMENDMENT 4	No/ 2020-12-17 (77)	Lost to Follow-Up		Yes/ 2020-11-19 (49)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3792091	2020-10-07	AMENDMENT 4	No/ 2020-12-14 (69)	Withdrawal of Consent by Participant/ WITHDRAWAL OF CONSENT OF THE SUBJECT		Yes/ 2020-11-09 (34)	
US3802026	2020-08-24	AMENDMENT 2	No/ 2021-02-19 (180)	Lost to Follow-Up		Yes/ 2020-09-22 (30)	
US3802212	2020-09-10	AMENDMENT 3	No/ 2021-03-03 (175)	Lost to Follow-Up		Yes/ 2020-10-13 (34)	
US3812025	2020-08-04	AMENDMENT 1	No/ 2020-12-17 (136)	Protocol Deviation/ RECEIVED EUA PFIZER VACCINE		Yes/ 2020-09-01 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3812032	2020-08-04	AMENDMENT 1	No/ 2020-12-26 (145)	Protocol Deviation/ SUBJECT RECEIVED EUA/PFIZER VACCINE		Yes/ 2020-08-31 (28)	
US3812128	2020-08-11	AMENDMENT 1	No/ 2020-09-01 (22)	Lost to Follow-Up		No/ 2020-08-31 (21)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822010	2020-08-05	AMENDMENT 1	ONGOING			No/ 2020-09-01 (28)	Other/ THE SUBJECT RECEIVED THE FIRST DOSE OF STUDY VACCINE AND WAS TEMPORARILY LOST TO FOLLOW-UP AFTER THE DAY 22 PHONE CALL. THE SUBJECT RECEIVED THE 2ND DOSE OF STUDY VACCINE ON 30DEC2020.
US3822169	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822293	2020-08-27	AMENDMENT 2	No/ 2021-02-24 (182)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO COME IN FOR THE VISIT AND DECIDED THEY DID NOT WANT TO CONTINUE IN THE STUDY.		No/ 2020-09-23 (28)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO COME IN FOR THE VISIT AND DOES NOT WANT TO CONTINUE IN THE STUDY.
US3822380	2020-09-09	AMENDMENT 3	No/ 2020-11-06 (59)	Lost to Follow-Up		Yes/ 2020-10-05 (27)	
US3822404	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-14 (28)	Other/ PATIENT HAD TO LEAVE THE COUNTRY DUE TO A FAMILY EMERGENCY

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822443	2020-09-28	AMENDMENT 3	No/ 2021-02-11 (137)	Death	2021-02-11/ N	Yes/ 2020-10-27 (30)	
US3832184	2020-08-13	AMENDMENT 2	No/ 2020-10-08 (57)	Lost to Follow-Up		Yes/ 2020-09-10 (29)	
US3832242	2020-08-21	AMENDMENT 2	No/ 2021-03-24 (216)	Withdrawal of Consent by Participant/ SUBJECT STATES SHE NO LONGER WISHES TO PARTICIPATE.		Yes/ 2020-09-18 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3832244	2020-08-21	AMENDMENT 2	No/ 2020-09-25 (36)	Withdrawal of Consent by Participant/ SUBJECT STATED HE IS NOT LONGER ABLE TO PARTICIPATE IN STUDY DUE TO UNEXPECTED INCREASE IN WORKLOAD.		No/ 2020-09-17 (28)	Withdrawal of Consent by Participant/ PERSONAL DECISION
US3832250	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Pregnancy
US3842060	2020-10-21	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852056	2020-08-28	AMENDMENT 3	No/ 2020-10-22 (56)	Withdrawal of Consent by Participant/ SHE HAS CHOSEN TO WITHDRAW FROM THE TRIAL DUE TO THE MIX UP OF DOSES BETWEEN HER AND HER SISTER (2057)		Yes/ 2020-09-25 (29)	
US3852082	2020-09-01	AMENDMENT 3	No/ 2021-02-26 (179)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF THE STUDY. PI NOTIFIED. EPIP SENT.		Yes/ 2020-10-01 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852108	2020-09-04	AMENDMENT 3	No/ 2021-01-14 (133)	Protocol Deviation/ SUBJECT NOTIFIED US THAT SHE RECEIVED THE PFIZER VACCINE WITHOUT UNBLINDING PRIOR. SUBJECT HAS BEEN WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-06 (33)	
US3852194	2020-09-22	AMENDMENT 3	No/ 2020-11-27 (67)	Lost to Follow-Up		Yes/ 2020-10-21 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852200	2020-10-13	AMENDMENT 4	No/ 2020-12-18 (58)	Protocol Deviation/ PATIENT FAILS TO SHOW FOR APPOINTMENTS AND RETURN CALLS. ONLY ONE INJECTION GIVEN FOR VISIT 1.		No/ 2020-11-18 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862003	2020-08-11	AMENDMENT 1	No/ 2021-01-06 (149)	Protocol Deviation/ RECEIVED A 3RD DOSE OF MODERNA VACCINE FROM EMPLOYER AFTER THE 1ST 2 DOSES WERE GIVEN IN PART-A OF THE TRIAL.		Yes/ 2020-09-15 (36)	
US3862100	2020-09-01	AMENDMENT 3	No/ 2021-01-20 (142)	Protocol Deviation/ #4; SUBJECT RECEIVED ON 19JAN2021 EUA COVID19 VACCINE		Yes/ 2020-09-29 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862141	2020-09-08	AMENDMENT 3	No/ 2021-03-09 (183)	Death	2021-03-09/ UNK	Yes/ 2020-10-06 (29)	
US3862175	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Adverse Event/ AE #1 AND #2
US3862203	2020-09-16	AMENDMENT 3	No/ 2020-12-18 (94)	Protocol Deviation/ PD FOR NON STUDY EUA COVID 19 VACCINE		Yes/ 2020-10-15 (30)	
US3862261	2020-09-29	AMENDMENT 3	No/ 2021-02-20 (145)	Lost to Follow-Up		Yes/ 2020-10-27 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862262	2020-09-29	AMENDMENT 3	No/ 2020-12-24 (87)	Protocol Deviation/ EUA COVID 19 VACCINE (PFIZER VACCINE)		No/ 2020-10-26 (28)	Adverse Event/ AE #1
US3862286	2020-10-16	AMENDMENT 4	ONGOING			No/ 2020-11-12 (28)	Adverse Event/ AE# 01
US3872126	2020-08-11	AMENDMENT 1	No/ 2021-02-03 (177)	Other/ SUBJECT MOVED TO CANADA AND VERBALLY WITH DREW CONSENT.		Yes/ 2020-09-08 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872153	2020-08-12	AMENDMENT 1	No/ 2020-09-14 (34)	Protocol Deviation/ SUBJECT WAS NOT COOPERATIVE WHEN TRYING TO RESCHEDULE HIS V2 HE MISSED. SUBJECT SAID HE WAS ON THE EAST COAST AND WAS NOT RETURNING FOR AT LEAST A COUPLE MONTHS. HE WOULD NOT GIVE FURTHER INFORMATION		No/ 2020-09-08 (28)	Physician Decision/ SUBJECT WAS NOT COOPERATIVE WHEN TRYING TO RESCHEDULE HIS V2 HE MISSED. SUBJECT SAID HE WAS ON THE EAST COAST AND WAS NOT RETURNING FOR AT LEAST A COUPLE MONTHS. HE WOULD NOT GIVE FURTHER INFORMATION

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872202	2020-08-14	AMENDMENT 1	ONGOING			No/ 2020-09-10 (28)	Other/ NP SWAB RESULTS NOT BACK FROM LAB.
US3872276	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Protocol Deviation/ V2 OOW TOO FAR
US3872318	2020-08-27	AMENDMENT 2	No/ 2020-09-16 (21)	Death	2020-09-16/ N	No/ 2020-09-16 (21)	Death
US3872319	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872321	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER PI TO SKIP 2 AND MOVE ON TO V3
US3872348	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872351	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3872358	2020-08-29	AMENDMENT 3	ONGOING			No/ 2020-09-25 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872371	2020-08-29	AMENDMENT 3	ONGOING			No/ 2020-09-25 (28)	Protocol Deviation/ SWAB RESULTS WERE NOT BACK AT SITE . V2 TOO FAR OOW
US3872388	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Protocol Deviation/ SUBJECT WAS SCHEDULED FOR V2 BUT BP WAS TOO HIGH TO BE SEEN THAT DAY, RESCHEDULED VISIT. SUBJECT THEN RETURNED FOR R/S V2 AND REPORTED FLU VACCINE, V2 WAS SKIPPED BECAUSE TOO FAR OOW. WILL PROCEED V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation Reason for Study or Completion (Day)	Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872396	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Protocol Deviation/ SUBJECT HAD ELECTIVE SURGERY AND WAS ON ANTIBIOTIC , WHEN DONE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872397	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Protocol Deviation/ DUE TO ELEVATED BP AT PREVIOUS ATTEMPTED V2 PT 'S V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3872417	2020-09-02	AMENDMENT 2	No/ 2021-01-14 (135)	Withdrawal of Consent by Participant/ PERSONAL CHOICE		No/ 2020-09-29 (28)	Protocol Deviation/ SWAB RESULTS NOT BACK FROM LAB, V2 TOO FAR OOW WHEN WAS RECEIVED. PER SPONSOR SKIP V2 AND GO V3.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872423	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ THE V2 WAS TOO FAR OOW PER MM AND EPIPS IT IS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3872425	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ SWAB RESULT WAS NOT BACK FROM LAB AND BY THE TIME IT WAS RECEIVED THE V2 WAS TOO FAR OOW.
US3872429	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Protocol Deviation/ V2 TOO FAR OOW WAS INSTRUCTED TO SKIP V2 AND GO TO V3

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872437	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V2 TOO FAR OOW WAS INSTRUCTED TO SKIP V2 AND GO TO V3. NO SWAB RESULT BACK IN TIME
US3872439	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ THE V2 WAS TOO FAR OOW PER MM IT IS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3872441	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ SUBJECTS V2 NOT DONE DUE TO LACK OF LAB SUPPLIES FROM SPONSOR ON SITE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872443	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V1 SWAB RESULTS NOT BACK BEFORE V2 . WHEN RESULTS RECEIVED AT SITE TOO FAR OOW TO CONDUCT 2,
US3872444	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ SUBJECTS VISIT 2 WAS TOO FAR OOW TO BE DONE PER EPIP.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872445	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V2NOT COMPLETED DUE TO NO LAB KIT A'S ON SITE DUE TO STUDY SHORTAGE. V2 TOO FAR OOW WHEN WAS RECEIVED. PER SPONSOR SKIP V2 AND GO V3.
US3872452	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ SUBJECTS SWAB RESULTS NOT BACK , CXLD V2 AND WAS OVERLOOKED TO RESCHEDULE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872469	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Protocol Deviation/ V2 POSTPONED DUE TO RECEIPT OF FLU VACCINE 10OCT20 AND THEN MOVED OUT OF STATE PRIOR TO RESCHEDULING
US3872479	2020-09-08	AMENDMENT 3	No/ 2021-03-08 (182)	Other/ SUBJECT RECEIVED PFIZER VACCINE OUTSIDE OF STUDY ON 05JAN2021		No/ 2020-10-05 (28)	Protocol Deviation/ SUBJECT WAS A NO CALL NO SHOW FOR SCHEDULED V2 WAS NOT RESCHEDULED IN OVERSITE.
US3872485	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ VISIT 2 WAS TOO FAR OOW TO BE COMPLETED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872489	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Protocol Deviation/ VISIT 2 NOT DONE DUE TO NO LAB KITS AND SPONSOR ADVISING SITE NOT TO CONTINUE AND SKIP V2
US3872496	2020-09-09	AMENDMENT 3	No/ 2020-12-17 (100)	Death	2020-12-17/ UNK	Yes/ 2020-10-09 (31)	
US3872506	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Other/ SUBJECT HAD BACK TO BACK ILLNESS VISITS AFTER V1. SWAB FROM ILLNESS VISIT 1 WAS NEGATIVE

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3882010	2020-09-02	AMENDMENT 3	No/ 2021-02-02 (153)	Withdrawal of Consent by Participant/ SUBJECT OPTED TO BE UN BLINDED AND DISENROLL FROM STUDY.		Yes/ 2020-10-02 (30)	
US3882016	2020-09-03	AMENDMENT 3	No/ 2021-03-04 (182)	Physician Decision/ NON COMPLIANT		Yes/ 2020-10-02 (29)	
US3882049	2020-10-19	AMENDMENT 4	ONGOING			No/ 2020-11-19 (28)	Due to SARS-CoV-2
US3892001	2020-08-21	AMENDMENT 2	No/ 2020-09-21 (29)	Lost to Follow-Up		Yes/ 2020-09-21 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3892033	2020-08-31	AMENDMENT 3	No/ 2021-01-27 (150)	Protocol Deviation/ SUBJECT RECEIVED OUTSIDE EUA VACCINE (PFIZER MRNA LNP-S)		Yes/ 2020-09-28 (29)	
US3902018	2020-09-02	AMENDMENT 3	No/ 2021-02-25 (177)	Withdrawal of Consent by Participant/ SUBJECT ELECTED TO DISCONTINUE STUDY ON EUA CONSENT		Yes/ 2020-09-30 (29)	
US3902030	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Adverse Event/ AE #1

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3902075	2020-09-11	AMENDMENT 3	No/ 2020-12-31 (112)	Lost to Follow-Up		Yes/ 2020-10-16 (36)	
US3902084	2020-09-15	AMENDMENT 3	No/ 2021-02-16 (155)	Lost to Follow-Up		Yes/ 2020-10-13 (29)	
US3912024	2020-08-28	AMENDMENT 3	No/ 2020-11-22 (87)	Death	2020-11-22/ N	Yes/ 2020-09-24 (28)	
US3912061	2020-09-01	AMENDMENT 3	No/ 2020-10-13 (43)	Lost to Follow-Up		Yes/ 2020-09-29 (29)	
US3912114	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Protocol Deviation/ SUBJECT WAS FOUND TO HAVE NOT MET INCLUSION #7
US3912152	2020-09-11	AMENDMENT 3	No/ 2020-11-02 (53)	Lost to Follow-Up		Yes/ 2020-10-09 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3912191	2020-09-18	AMENDMENT 3	No/ 2021-01-18 (123)	Lost to Follow-Up		Yes/ 2020-10-22 (35)	
US3922036	2020-08-26	AMENDMENT 2	No/ 2020-11-30 (97)	Protocol Deviation/ NON-COMPLIANT		No/ 2020-09-22 (28)	Physician Decision/ PHYSICIAN DECISION DUE TO SUBJECT NON-COMPLIANCE.
US3922076	2020-09-02	AMENDMENT 3	No/ 2020-09-14 (13)	Physician Decision/ PI DECISION DUE TO SUBJECT NON-COMPLIANCE		No/ 2020-09-13 (12)	Physician Decision/ PI DECISION DUE TO SUBJECT NON-COMPLIANCE
US3922080	2020-09-03	AMENDMENT 3	No/ 2021-02-25 (176)	Lost to Follow-Up		No/ 2020-09-30 (28)	Adverse Event/ AE #1
US3922137	2020-10-12	AMENDMENT 4	No/ 2020-11-19 (39)	Lost to Follow-Up		No/ 2020-11-08 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932008	2020-08-26	AMENDMENT 2	No/ 2021-02-22 (181)	Protocol Deviation/ SUBJECT VACCINATED OUTSIDE OF CLINIC		Yes/ 2020-09-28 (34)	
US3932086	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Lost to Follow-Up
US3932141	2020-09-16	AMENDMENT 3	No/ 2021-01-05 (112)	Lost to Follow-Up		No/ 2020-10-13 (28)	Protocol Deviation/ SECOND VISIT WAS OUT OF WINDOW AND COULD NOT BE CONDUCTED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932142	2020-09-16	AMENDMENT 3	No/ 2021-02-22 (160)	Withdrawal of Consent by Participant/ SUBJECT EXPRESSED WANTING TO BE UNBLINDED AND WITHDREW FROM STUDY SUBJECT CITED RELIGIOUS REASONS.		Yes/ 2020-10-12 (27)	
US3932163	2020-09-21	AMENDMENT 3	ONGOING			No/ 2020-10-18 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932174	2020-09-23	AMENDMENT 3	No/ 2021-01-25 (125)	Other/ THE PATIENT DECIDED TO WITHDRAW CONSENT. THE PATIENT INFORMED SITE THAT THEY ARE MOVING OUT OF STATE AND NEEDS TO DROP FROM STUDY WITH NO FURTHER PARTICIPATION.		Yes/ 2020-10-19 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932189	2020-09-25	AMENDMENT 3	No/ 2021-03-13 (170)	Protocol Deviation/ SUBJECT RECEIVED OTHER VACCINE OUTSIDE OF STUDY		No/ 2020-10-22 (28)	Protocol Deviation/ PATIENT WAS SCHEDULED FOR V2 BUT WOULD NOT MAKE THE WINDOW DUE TO BEING OUT OF TOWN, V2 DOSE NOT ADMINISTERED.
US3932197	2020-09-26	AMENDMENT 3	No/ 2021-03-13 (169)	Death	2021-03-13/ UNK	Yes/ 2020-10-27 (32)	
US3932207	2020-09-28	AMENDMENT 3	No/ 2020-10-06 (9)	Lost to Follow-Up		No/ 2020-10-05 (8)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3932214	2020-09-30	AMENDMENT 3	No/ 2021-03-16 (168)	Other/ SUBJECT MOVED OUT OF STATE AND NOT WILLING TO TRANSFER.		Yes/ 2020-11-03 (35)	
US3932222	2020-10-03	AMENDMENT 4	ONGOING			No/ 2020-10-30 (28)	Lost to Follow-Up
US3932246	2020-10-13	AMENDMENT 4	No/ 2021-01-02 (82)	Death	2021-01-02/ Y	Yes/ 2020-11-10 (29)	
US3942021	2020-08-28	AMENDMENT 3	No/ 2020-10-08 (42)	Adverse Event/ AE#2		No/ 2020-09-24 (28)	Adverse Event/ AE#2
US3942031	2020-08-29	AMENDMENT 3	No/ 2020-10-23 (56)	Lost to Follow-Up		No/ 2020-09-25 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942037	2020-09-01	AMENDMENT 3	No/ 2020-10-13 (43)	Withdrawal of Consent by Participant/ SUBJECT CALLED FOR DAY 36 TC AND YELLED AT SITE THAT THEY NEVER WISHED TO BE CALLED AGAIN AND THEY ARE WITHDRAWING FROM THE STUDY DUE TO PERSONAL REASONS		Yes/ 2020-10-06 (36)	
US3942070	2020-09-04	AMENDMENT 3	No/ 2021-02-17 (167)	Lost to Follow-Up		Yes/ 2020-10-02 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942121	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-21 (28)	Other/ OOW DUE TO CONVALESCENT PERIOD
US3952019	2020-09-01	AMENDMENT 2	No/ 2020-12-30 (121)	Withdrawal of Consent by Participant/ SUBJECT IS MOVING		Yes/ 2020-10-02 (32)	
US3952032	2020-09-02	AMENDMENT 2	No/ 2020-10-29 (58)	Other/ MOVING OVERSEAS		Yes/ 2020-10-02 (31)	
US3952092	2020-09-15	AMENDMENT 3	No/ 2021-03-11 (178)	Protocol Deviation/ RECEIVED OUTSIDE EUA VACCINE		Yes/ 2020-10-15 (31)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952100	2020-09-17	AMENDMENT 3	No/ 2021-01-15 (121)	Protocol Deviation/ SUBJECT TOOK EMERGENCY USE AUTHORIZATION VACCINE OUTSIDE OF STUDY ON 09 JAN 2021		Yes/ 2020-10-20 (34)	
US3952104	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-14 (28)	Adverse Event/ #1
US3952114	2020-09-18	AMENDMENT 3	ONGOING			No/ 2020-10-15 (28)	Other/ DAY 1 COVID-19 PCR TEST RESULT NOT AVAILABLE FOR PI REVIEW UNTIL DAY 29 VISIT WINDOW HAD EXPIRED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3952150	2020-09-24	AMENDMENT 3	No/ 2020-11-13 (51)	Lost to Follow-Up		No/ 2020-10-21 (28)	Lost to Follow-Up
US3952158	2020-09-28	AMENDMENT 3	ONGOING			No/ 2020-10-25 (28)	Adverse Event/ #1
US3952216	2020-10-09	AMENDMENT 4	ONGOING			No/ 2020-11-05 (28)	Adverse Event/ #2
US3962094	2020-09-09	AMENDMENT 3	No/ 2020-10-15 (37)	Death	2020-10-15/ N	No/ 2020-10-06 (28)	Serious Adverse Event/ SAE #1
US3972010	2020-08-24	AMENDMENT 2	No/ 2021-01-08 (138)	Death	2021-01-08/ UNK	Yes/ 2020-09-21 (29)	
US3972045	2020-08-27	AMENDMENT 3	No/ 2020-12-03 (99)	Death	2020-12-03/ UNK	Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3972097	2020-09-03	AMENDMENT 3	No/ 2021-01-29 (149)	Protocol Deviation/ SUBJECT RECEIVED EUA DOSE FROM OUTSIDE THE STUDY		Yes/ 2020-10-01 (29)	
US3972225	2020-10-12	AMENDMENT 4	ONGOING			No/ 2020-11-08 (28)	Due to SARS-CoV-2
US3982023	2020-08-27	AMENDMENT 3	No/ 2021-01-11 (138)	Protocol Deviation/ UNBLINDED/ RECEIVED EUA PFIZER COVID 19 VACCINE OUTSIDE OF STUDY.		Yes/ 2020-09-24 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982026	2020-08-27	AMENDMENT	3 No/ 2020-11-30 (96)	Lost to Follow-Up		Yes/ 2020-09-24 (29)	
US3982061	2020-08-31	AMENDMENT	3 No/ 2020-12-14 (106)	Lost to Follow-Up		Yes/ 2020-10-02 (33)	
US3982091	2020-09-03	AMENDMENT	3 No/ 2020-11-02 (61)	Lost to Follow-Up		Yes/ 2020-10-05 (33)	
US3982142	2020-09-09	AMENDMENT	3 No/ 2020-09-28 (20)	Lost to Follow-Up		No/ 2020-09-27 (19)	Lost to Follow-Up
US3982157	2020-09-11	AMENDMENT	3 No/ 2020-12-18 (99)	Lost to Follow-Up		Yes/ 2020-10-09 (29)	
US3982158	2020-09-11	AMENDMENT	3 No/ 2020-10-16 (36)	Protocol Deviation/ NON-COMPLIANCE		No/ 2020-10-08 (28)	Physician Decision/ AE WORSENING OF PSEUDOTUMOR CEREBRI

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982213	2020-09-21	AMENDMENT 3	ONGOING			No/ 2020-10-18 (28)	Adverse Event/ AE#2
US3982222	2020-09-22	AMENDMENT 3	No/ 2021-02-24 (156)	Lost to Follow-Up		Yes/ 2020-10-20 (29)	
US3982234	2020-09-24	AMENDMENT 3	No/ 2020-12-14 (82)	Lost to Follow-Up		Yes/ 2020-10-23 (30)	
US3982244	2020-09-28	AMENDMENT 3	ONGOING			No/ 2020-10-25 (28)	Protocol Deviation/ SUBJECT RECEIVED FLU VACCINE ON SAME DAY OF DAY 29 VISIT BEFORE SUBJECT CAME IN TO CLINIC.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Negative; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3992126	2020-10-22	AMENDMENT 4	No/ 2020-12-31 (71)	Protocol Deviation/ SUBJECT RECEIVED PFIZER VACCINE ON 12/21/20		Yes/ 2020-11-17 (27)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002352	2020-10-08	AMENDMENT 4	ONGOING			No/ 2020-11-04 (28)	Due to SARS-CoV-2
US3032211	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Due to SARS-CoV-2
US3032320	2020-08-22	AMENDMENT 2	No/ 2021-01-07 (139)	Protocol Deviation/ SUBJECT RECEIVED VACCINE THROUGH WORK.		No/ 2020-09-18 (28)	Due to SARS-CoV-2
US3042063	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042150	2020-08-12	AMENDMENT 2	No/ 2021-03-17 (218)	Protocol Deviation/ PATIENT REPORTS WILL GET COVID VACCINE THROUGH EMPLOYER		No/ 2020-09-08 (28)	Due to SARS-CoV-2
US3052113	2020-08-06	AMENDMENT 1	No/ 2020-10-06 (62)	Withdrawal of Consent by Participant/ WITHDREW OF CONSENT OF PT		No/ 2020-09-02 (28)	Due to SARS-CoV-2
US3092114	2020-08-11	AMENDMENT 2	No/ 2021-03-08 (210)	Lost to Follow-Up		Yes/ 2020-09-16 (37)	
US3122026	2020-07-27	AMENDMENT 1	ONGOING			No/ 2020-08-23 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3122035	2020-07-27	AMENDMENT 1	ONGOING			No/ 2020-08-23 (28)	Due to SARS-CoV-2
US3142145	2020-08-07	AMENDMENT 2	ONGOING			No/ 2020-09-03 (28)	Due to SARS-CoV-2
US3152462	2020-10-09	AMENDMENT 4	ONGOING			No/ 2020-11-05 (28)	Due to SARS-CoV-2
US3162159	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3172010	2020-08-10	AMENDMENT 1	ONGOING			No/ 2020-09-06 (28)	Other/ SECOND DOSE WAS NOT GIVEN TO SUBJECT DUE TO THE 1ST NASAL SWAB RESULT WAS POSITIVE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172026	2020-08-11	AMENDMENT 1	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3172037	2020-08-11	AMENDMENT 1	No/ 2020-09-15 (36)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW CONSENT DURING THE DAY 29 VISIT.		No/ 2020-09-07 (28)	Withdrawal of Consent by Participant/ SUBJECT REFUSED 2ND DOSE
US3172038	2020-08-11	AMENDMENT 1	ONGOING			No/ 2020-09-07 (28)	Serious Adverse Event/ SAE #2
US3172106	2020-08-14	AMENDMENT 1	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172116	2020-08-14	AMENDMENT 1	No/ 2020-11-02 (81)	Withdrawal of Consent by Participant		Yes/ 2020-09-11 (29)	
US3172126	2020-08-14	AMENDMENT 1	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3172166	2020-08-18	AMENDMENT 1	ONGOING			No/ 2020-09-14 (28)	Due to SARS-CoV-2
US3172180	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Due to SARS-CoV-2
US3172185	2020-08-18	AMENDMENT 1	ONGOING			No/ 2020-09-14 (28)	Serious Adverse Event/ SAE #1
US3172254	2020-08-20	AMENDMENT 2	No/ 2021-02-15 (180)	Withdrawal of Consent by Participant		Yes/ 2020-09-17 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172274	2020-08-21	AMENDMENT 2	No/ 2020-09-30 (41)	Other/ MOVED TO (b) (6) TEXAS		No/ 2020-09-17 (28)	Other/ MOVED TO (b) (6) TEXAS
US3172361	2020-08-27	AMENDMENT 3	No/ 2020-11-04 (70)	Lost to Follow-Up		No/ 2020-09-23 (28)	Other/ MISSED VISIT
US3172367	2020-08-27	AMENDMENT 3	ONGOING			No/ 2020-09-23 (28)	Other/ SUBJECT NP NASAL SWAB FROM SCREENING WAS POSITIVE. THEREFORE SUBJECT WAS NOT ELIGIBLE TO GET THE SECOND VACCINE DOSE.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172440	2020-10-20	AMENDMENT 2	ONGOING			No/ 2020-11-16 (28)	Other/ SUBJECT DID NOT DOSE DUE TO COVID NASAL SWAB POSITIVE RESULTS.
US3172444	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Other/ MISSED VISIT
US3172450	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2
US3172467	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2
US3172493	2020-10-23	AMENDMENT 3	ONGOING			No/ 2020-11-19 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3182279	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3192381	2020-08-20	AMENDMENT 2	No/ 2021-02-06 (171)	Protocol Deviation/ PATIENT RECEIVED EUA VACCINE OUTSIDE OF TRIAL.		Yes/ 2020-09-17 (29)	
US3202081	2020-08-08	AMENDMENT 1	No/ 2020-10-27 (81)	Withdrawal of Consent by Participant/ POSITIVE PCR, PARTICIPANT WITHDRAWAL		No/ 2020-09-04 (28)	Due to SARS-CoV-2
US3212040	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212066	2020-08-06	AMENDMENT 1	ONGOING			No/ 2020-09-02 (28)	Other/ COVID-19 POSITIVE RESULTS
US3212087	2020-08-07	AMENDMENT 1	ONGOING			No/ 2020-09-03 (28)	Due to SARS-CoV-2
US3252285	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2
US3252318	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Due to SARS-CoV-2
US3252519	2020-09-21	AMENDMENT 2	ONGOING			No/ 2020-10-18 (28)	Due to SARS-CoV-2
US3252601	2020-10-02	AMENDMENT 3	ONGOING			No/ 2020-10-29 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3302384	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Due to SARS-CoV-2
US3312020	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3312049	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3312216	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312438	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3312495	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3312583	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3312603	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322011	2020-08-17	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Due to SARS-CoV-2
US3342295	2020-09-29	AMENDMENT 3	No/ 2020-10-23 (25)	Lost to Follow-Up		No/ 2020-10-22 (24)	Lost to Follow-Up
US3352045	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3352141	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3352202	2020-08-22	AMENDMENT 2	No/ 2020-12-22 (123)	Other/ REQUEST TO UNBLIND/EAU COVID-19 VACCINE		Yes/ 2020-09-19 (29)	
US3352220	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352272	2020-08-25	AMENDMENT 3	No/ 2021-01-18 (147)	Lost to Follow-Up		Yes/ 2020-09-22 (29)	
US3352289	2020-08-25	AMENDMENT 3	ONGOING			No/ 2020-09-21 (28)	Due to SARS-CoV-2
US3352292	2020-08-25	AMENDMENT 3	No/ 2020-11-16 (84)	Withdrawal of Consent by Participant/ THE SUBJECT STATED SHE CANNOT CONTINUE PARTICIPATING IN THE STUDY DUE TO THE JOB SCHEDULE. SUBJECT WITHDREW CONSENT		Yes/ 2020-09-19 (26)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352355	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3352363	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3352410	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-21 (28)	Due to SARS-CoV-2
US3352442	2020-09-29	AMENDMENT 3	No/ 2021-03-03 (156)	Protocol Deviation/ SUBJECT WAS ENROLLED IN ANOTHER STUDY AT ANOTHER SITE.		Yes/ 2020-11-03 (36)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352468	2020-09-29	AMENDMENT 3	No/ 2020-11-25 (58)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER ABLE TO PROCEED WITH TRIAL DUE TO WORK SCHEDULE.		No/ 2020-10-26 (28)	Withdrawal of Consent by Participant/ SUBJECT NO LONGER ABLE TO PROCEED WITH TRIAL DUE TO WORK SCHEDULE.
US3352487	2020-09-29	AMENDMENT 3	No/ 2020-12-11 (74)	Protocol Deviation/ THE SUBJECT STATED HE WAS CURRENTLY ADMITTED AT ANOTHER SITE FOR ANOTHER CLINICAL TRIAL.		Yes/ 2020-11-12 (45)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352521	2020-10-08	AMENDMENT 3	No/ 2021-02-02 (118)	Other/ NON-COMPLIANT, SUBJECT IS DETAINED AND RELEASE DATE IS UNKNOWN		Yes/ 2020-11-03 (27)	
US3362019	2020-08-03	AMENDMENT 1	No/ 2021-03-03 (213)	Protocol Deviation/ SUBJECT RECEIVED COVID VACCINE		No/ 2020-08-30 (28)	Due to SARS-CoV-2
US3362180	2020-08-17	AMENDMENT 2	No/ 2020-10-26 (71)	Withdrawal of Consent by Participant/ WORK SCHEDULE CONFLICT		No/ 2020-09-13 (28)	Withdrawal of Consent by Participant/ WORK SCHEDULE CONFLICT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3362183	2020-08-18	AMENDMENT 2	No/ 2020-09-01 (15)	Withdrawal of Consent by Participant/ WITHDRAWAL OF CONSENT DUE TO BASELINE POSITIVE PCR		No/ 2020-08-31 (14)	Withdrawal of Consent by Participant
US3372092	2020-08-11	AMENDMENT 1	ONGOING			No/ 2020-09-15 (28)	Due to SARS-CoV-2
US3382035	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382280	2020-09-15	AMENDMENT 3	No/ 2021-01-26 (134)	Protocol Deviation/ SUBJECT RECEIVED MANDATORY MODERNA VACCINE AT HER WORKPLACE. SUBJECT NOTIFIED CLINIC AFTER SHE RECEIVED TWO DOSES.		Yes/ 2020-10-14 (30)	
US3392008	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Due to SARS-CoV-2
US3392240	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3402446	2020-10-16	AMENDMENT 4	ONGOING			No/ 2020-11-12 (28)	Due to SARS-CoV-2
US3402452	2020-10-21	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2
US3412087	2020-07-31	AMENDMENT 1	ONGOING			No/ 2020-08-27 (28)	Due to SARS-CoV-2
US3442204	2020-09-30	AMENDMENT 3	ONGOING			No/ 2020-10-27 (28)	Due to SARS-CoV-2
US3452295	2020-08-06	AMENDMENT 1	ONGOING			No/ 2020-09-02 (28)	Due to SARS-CoV-2
US3452406	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-22 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3472090	2020-10-02	AMENDMENT 3	ONGOING			No/ 2020-10-29 (28)	Due to SARS-CoV-2
US3482188	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Due to SARS-CoV-2
US3492030	2020-08-31	AMENDMENT 2	ONGOING			No/ 2020-09-27 (28)	Due to SARS-CoV-2
US3492295	2020-10-09	AMENDMENT 3	ONGOING			No/ 2020-11-05 (28)	Due to SARS-CoV-2
US3512063	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3512199	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3522353	2020-08-25	AMENDMENT 2	ONGOING			No/ 2020-09-21 (28)	Due to SARS-CoV-2
US3522637	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Due to SARS-CoV-2
US3552530	2020-10-14	AMENDMENT 4	ONGOING			No/ 2020-11-10 (28)	Due to SARS-CoV-2
US3562079	2020-08-26	AMENDMENT 3	No/ 2021-02-26 (185)	Protocol Deviation/ PT WAS ENROLLED AT 2 DIFFERENT SITE AND DISCONTINUE FROM STUDY PER SPONSOR		Yes/ 2020-09-23 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572042	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3572088	2020-08-25	AMENDMENT 3	No/ 2021-01-05 (134)	Protocol Deviation/ SUBJECT RECEIVED VACCINE OUTSIDE OF STUDY CONFINES. AS PER SPONSOR DIRECTIVE SUBJECT NEEDS TO BE WITHDRAWN.		No/ 2020-09-21 (28)	Other/ PATIENT MISSED THE SECOND DOSING APPOINTMENT, HOWEVER PATIENT WILL CONTINUE PARTICIPATING IN THE STUDY
US3572100	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572113	2020-08-27	AMENDMENT 3	No/ 2021-02-19 (177)	Protocol Deviation/ SUBJECT GOT COVID VACCINE OUTSIDE OF STUDY CONFINES. SUBJECT WAS UNBLINDED AND WAS ON PLACEBO ON PART A OF THE STUDY. SUBJECT IS AWARE THAT SUBJECT IS WITHDRAWN FROM THE STUDY.		Yes/ 2020-09-25 (30)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572215	2020-09-07	AMENDMENT 3	No/ 2021-02-08 (155)	Other/ SUBJECT A TRAVELING NURSE NOT ABLE TO COME IN FOR NEW ICF AND IS BEING OFFERED VACCINE THROUGH EMPLOYER. AS PER SPONSOR (EPIP) DIRECTIVES THEN SUBJECT CAN BE UNBLINDED AND WITHDRAWN FROM THE STUDY.		Yes/ 2020-10-06 (30)	
US3592196	2020-08-16	AMENDMENT 2	ONGOING			No/ 2020-09-12 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3622066	2020-08-24	AMENDMENT 3	No/ 2021-01-11 (123)	Protocol Deviation/ PARTICIPANT RECEIVED COVID-19 VACCINE (EUA) OUT OF STUDY. PLEASE REFER TO CONMED #2.		No/ 2020-10-08 (28)	Adverse Event/ #1
US3622118	2020-08-31	AMENDMENT 2	No/ 2020-12-29 (121)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		Yes/ 2020-09-28 (29)	
US3642257	2020-09-19	AMENDMENT 3	ONGOING			No/ 2020-10-16 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3672343	2020-08-27	AMENDMENT 3	No/ 2020-12-22 (118)	Other/ UNBLINDING OCCURRED AND SUBJECT WILL BE RECEIVING THE PFIZER COVID VACCINE		Yes/ 2020-09-25 (30)	
US3732156	2020-08-25	AMENDMENT 2	No/ 2020-12-28 (123)	Protocol Deviation/ EUA VACCINATION		No/ 2020-09-24 (28)	Adverse Event/ AE #1
US3742044	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Due to SARS-CoV-2
US3792014	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3802190	2020-09-09	AMENDMENT 3	No/ 2020-09-30 (22)	Lost to Follow-Up		No/ 2020-09-29 (21)	Lost to Follow-Up
US3802225	2020-09-11	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Due to SARS-CoV-2
US3812146	2020-08-12	AMENDMENT 1	No/ 2020-09-02 (22)	Lost to Follow-Up		No/ 2020-09-01 (21)	Due to SARS-CoV-2
US3812257	2020-08-25	AMENDMENT 2	ONGOING			No/ 2020-09-21 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822175	2020-08-18	AMENDMENT 2	No/ 2021-01-19 (155)	Withdrawal of Consent by Participant/ PER PATIENT, SINCE HE WOULD NOT BE RECEIVING SECOND DOSE OF VACCINE, HE WANTED TO WITHDRAW FROM THE STUDY.		No/ 2020-09-14 (28)	Withdrawal of Consent by Participant/ PER PATIENT, SINCE HE WOULD NOT BE RECEIVING SECOND DOSE OF VACCINE, HE WANTED TO WITHDRAW FROM THE STUDY.
US3822207	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3852018	2020-08-25	AMENDMENT 3	No/ 2021-01-12 (141)	Other/ SUBJECT CALLED TO BE UNBLINDED. HE IS MOVING OUT OF STATE THIS MONTH AND WILL NOT BE ABLE TO COME TO VISITS. HE STATES HE WILL HAVE OPTION TO GET THE PFIZER VACCINE AT NEW PLACE OF EMPLOYMENT.		No/ 2020-09-21 (28)	Due to SARS-CoV-2
US3862127	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3862272	2020-10-02	AMENDMENT 3	No/ 2021-02-24 (146)	Lost to Follow-Up		No/ 2020-10-29 (28)	Due to SARS-CoV-2
US3872312	2020-08-26	AMENDMENT 2	No/ 2021-02-18 (177)	Withdrawal of Consent by Participant/ SUBJECT WANTED TO DROP OUT.		No/ 2020-09-22 (28)	Due to SARS-CoV-2
US3932080	2020-09-04	AMENDMENT 3	No/ 2020-09-16 (9)	Lost to Follow-Up		No/ 2020-09-15 (8)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942006	2020-08-24	AMENDMENT 2	No/ 2020-09-28 (36)	Withdrawal of Consent by Participant/ SUBJECT WITHDREW FROM STUDY WHILE ONSITE.		No/ 2020-09-20 (28)	Withdrawal of Consent by Participant/ SUBJECT REFUSED TO COMPLETE STUDY PROCEDURES AND DECIDED TO WITHDRAW FROM STUDY
US3952193	2020-10-05	AMENDMENT 4	ONGOING			No/ 2020-11-01 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982068	2020-09-01	AMENDMENT 3	No/ 2021-03-22 (203)	Withdrawal of Consent by Participant/ SUBJECT CAME TO SITE ON 22MAR2021 FOR FIRST OPEN LABEL DOSE. SUBJECT HAD TO LEAVE SITE BEFORE RECEIVING DOSE DUE TO WORK SCHEDULE. SINCE SUBJECT WOULD NOT BE ABLE TO RECEIVE DOSE ON A FUTURE DATE, SUB		No/ 2020-09-28 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982195	2020-09-17	AMENDMENT 3	No/ 2021-02-19 (156)	Withdrawal of Consent by Participant/ INCL. #2: SUBJECT DISCONTINUED FROM STUDY PARTICIPATION DUE TO MOVING OUT OF STATE AND NOT BEING ABLE TO COMPLY WITH STUDY VISITS AND PROCEDURES.		Yes/ 2020-10-20 (34)	
US3982212	2020-09-21	AMENDMENT 3	ONGOING			No/ 2020-10-18 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982273	2020-10-13	AMENDMENT 4	No/ 2020-12-11 (60)	Lost to Follow-Up		Yes/ 2020-11-17 (36)	
US3992066	2020-10-06	AMENDMENT 3	No/ 2021-02-16 (134)	Withdrawal of Consent by Participant/ DIFFICULTY PARTICIPATING DUE TO WORK SCHEDULE AND DISTANCE FROM HOME.		Yes/ 2020-11-18 (44)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3002223	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Due to SARS-CoV-2
US3002357	2020-10-12	AMENDMENT 4	No/ 2021-01-05 (86)	Withdrawal of Consent by Participant/ SUBJECT DOES NOT WANT TO CONTINUE IN STUDY JUST WANTED TO BE UNBLINDED		Yes/ 2020-12-07 (57)	
US3012118	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Due to SARS-CoV-2
US3012352	2020-10-20	AMENDMENT 4	ONGOING			No/ 2020-11-16 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3022012	2020-07-27	AMENDMENT 1	ONGOING			No/ 2020-08-23 (28)	Due to SARS-CoV-2
US3022208	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Serious Adverse Event/ SAE #1
US3032088	2020-08-04	AMENDMENT 1	No/ 2021-01-07 (157)	Protocol Deviation/ PFIZER VACCINE THROUGH WORK.		Yes/ 2020-09-02 (30)	
US3042054	2020-08-03	AMENDMENT 1	ONGOING			No/ 2020-08-30 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3042235	2020-08-18	AMENDMENT 2	No/ 2021-03-17 (212)	Withdrawal of Consent by Participant/ PHASE 2 CROSSOVER, PART C		Yes/ 2020-09-15 (29)	
US3052191	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3052219	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3062235	2020-08-14	AMENDMENT 2	ONGOING			No/ 2020-09-10 (28)	Due to SARS-CoV-2
US3092099	2020-08-10	AMENDMENT 2	ONGOING			No/ 2020-09-06 (28)	Pregnancy

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3152201	2020-08-14	AMENDMENT 2	No/ 2020-09-04 (22)	Lost to Follow-Up		No/ 2020-09-03 (21)	Lost to Follow-Up
US3152492	2020-10-15	AMENDMENT 4	ONGOING			No/ 2020-11-11 (28)	Due to SARS-CoV-2
US3172011	2020-08-10	AMENDMENT 1	No/ 2021-02-18 (193)	Withdrawal of Consent by Participant/ NO LONGER INTERESTED		No/ 2020-09-06 (28)	Due to SARS-CoV-2
US3172014	2020-08-10	AMENDMENT 1	ONGOING			No/ 2020-09-06 (28)	Other/ SUBJECT DID NOT DOSE DUE TO CONTINUING POSITIVE FOR PCR NASAL SWAB.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172085	2020-08-13	AMENDMENT 1	ONGOING			No/ 2020-09-09 (28)	Other/ COVID POSITIVE ON DAY 1. SUBJECT DID NOT RECEIVE 2ND DOSE.
US3172091	2020-08-13	AMENDMENT 1	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3172204	2020-08-19	AMENDMENT 1	No/ 2020-11-03 (77)	Withdrawal of Consent by Participant/ DID NOT WANT TO CONTINUE IN STUDY		Yes/ 2020-09-16 (29)	

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172223	2020-08-19	AMENDMENT 1	No/ 2021-03-02 (196)	Withdrawal of Consent by Participant/ SUBJECT WAS CONTACTED FOR EDIARIES AND EXPRESSED CONCERNS FOR HEALTHY AND ASKED TO BE REMOVED FROM STUDY.		Yes/ 2020-09-16 (29)	
US3172233	2020-08-20	AMENDMENT 1	No/ 2020-10-19 (61)	Lost to Follow-Up		No/ 2020-09-16 (28)	Other/ MISSED VISIT
US3172261	2020-08-21	AMENDMENT 1	ONGOING			No/ 2020-09-17 (28)	Other/ MISSED VISIT

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172268	2020-08-21	AMENDMENT 1	ONGOING			No/ 2020-09-17 (28)	Lost to Follow-Up
US3172298	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Due to SARS-CoV-2
US3172301	2020-08-24	AMENDMENT 2	No/ 2021-02-22 (183)	Withdrawal of Consent by Participant/ WITHDRAWAL OF CONSENT BY PARTICIPANT, NO LONGER WANTED TO CONTINUE IN STUDY.		No/ 2020-09-20 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172314	2020-08-25	AMENDMENT 3	No/ 2020-09-28 (35)	Withdrawal of Consent by Participant/ WITHDREW CONSENT		No/ 2020-09-21 (28)	Other/ SUBJECT DID NOT COME TO THE VISIT.
US3172330	2020-08-25	AMENDMENT 3	No/ 2021-03-24 (212)	Withdrawal of Consent by Participant/ SUBJECT WOULD NO LONGER LIKE TO PARTICIPATE IN STUDY		Yes/ 2020-09-21 (28)	
US3172382	2020-10-16	AMENDMENT 3	ONGOING			No/ 2020-11-12 (28)	Due to SARS-CoV-2
US3172443	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3172464	2020-10-21	AMENDMENT 2	ONGOING			No/ 2020-11-17 (28)	Due to SARS-CoV-2
US3172466	2020-10-21	AMENDMENT 2	No/ 2021-01-14 (86)	Lost to Follow-Up		No/ 2020-11-17 (28)	Other/ SUBJECT DID NOT RECEIVE VACCINE DUE TO POSITIVE NASAL SWAB RESULTS FROM BASELINE.
US3182107	2020-07-31	AMENDMENT 1	ONGOING			No/ 2020-08-27 (28)	Due to SARS-CoV-2
US3182280	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3192300	2020-08-16	AMENDMENT 1	ONGOING			No/ 2020-09-16 (28)	Other/ PATIENT HAD POSITIVE PCR SWAB.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3192462	2020-08-24	AMENDMENT 2	ONGOING			No/ 2020-09-20 (28)	Due to SARS-CoV-2
US3192889	2020-10-21	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Other/ ASYMPTOMATIC POSITIVE PCR SWAB
US3202277	2020-08-20	AMENDMENT 2	No/ 2020-10-12 (54)	Withdrawal of Consent by Participant/ SUBJ WITHDREW CONSENT		No/ 2020-09-16 (28)	Withdrawal of Consent by Participant/ SUBJ WITHDREW CONSENT
US3212005	2020-08-03	AMENDMENT 1	ONGOING			No/ 2020-08-30 (28)	Due to SARS-CoV-2
US3212016	2020-08-03	AMENDMENT 1	ONGOING			No/ 2020-08-30 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3212358	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Due to SARS-CoV-2
US3222631	2020-09-24	AMENDMENT 3	No/ 2021-02-19 (149)	Protocol Deviation/ PATIENT REFUSES TO COMPLY WITH STUDY PROCEDURES AND WON'T COME IN FOR D 57 CLINIC VISIT AND NOT COMPLIANT WITH E-DIARIES.		Yes/ 2020-10-22 (29)	
US3242082	2020-08-13	AMENDMENT 2	ONGOING			No/ 2020-09-09 (28)	Due to SARS-CoV-2
US3242119	2020-08-17	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3242224	2020-08-26	AMENDMENT 3	ONGOING			No/ 2020-09-22 (28)	Due to SARS-CoV-2
US3252075	2020-08-07	AMENDMENT 1	ONGOING			No/ 2020-09-03 (28)	Due to SARS-CoV-2
US3252609	2020-10-02	AMENDMENT 2	ONGOING			No/ 2020-10-29 (28)	Due to SARS-CoV-2
US3262062	2020-07-31	AMENDMENT 1	ONGOING			No/ 2020-08-27 (28)	Due to SARS-CoV-2
US3262219	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3272074	2020-08-07	AMENDMENT 1	No/ 2020-10-12 (67)	Lost to Follow-Up		No/ 2020-09-03 (28)	Adverse Event/ POSITIVE COVID19

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3272180	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Due to SARS-CoV-2
US3272241	2020-08-21	AMENDMENT 2	No/ 2020-09-24 (35)	Lost to Follow-Up		No/ 2020-09-17 (28)	Lost to Follow-Up
US3272260	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Due to SARS-CoV-2
US3292412	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-21 (28)	Due to SARS-CoV-2
US3312409	2020-08-31	AMENDMENT 3	ONGOING			No/ 2020-09-27 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3312571	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION
US3312584	2020-09-09	AMENDMENT 3	ONGOING			No/ 2020-10-06 (28)	Other/ KNOWN HISTORY OF SARS-COV-2 INFECTION.
US3322048	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3322364	2020-09-17	AMENDMENT 3	No/ 2020-10-09 (23)	Withdrawal of Consent by Participant/ PATIENT VERBALLY REQUESTED TO WITHDRAW FROM THE STUDY DURING SAFETY CALL DAY 22		No/ 2020-10-08 (22)	Withdrawal of Consent by Participant/ PATIENT VERBALLY REQUESTED TO WITHDRAW FROM THE STUDY DURING SAFETY CALL DAY 22
US3342198	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-01 (28)	Due to SARS-CoV-2
US3342296	2020-09-29	AMENDMENT 3	No/ 2020-10-27 (29)	Lost to Follow-Up		No/ 2020-10-26 (28)	Lost to Follow-Up
US3342326	2020-10-02	AMENDMENT 3	ONGOING			No/ 2020-11-08 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352055	2020-08-11	AMENDMENT 2	ONGOING			No/ 2020-09-07 (28)	Due to SARS-CoV-2
US3352143	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3352150	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3352151	2020-08-20	AMENDMENT 2	ONGOING			No/ 2020-09-16 (28)	Due to SARS-CoV-2
US3352169	2020-08-20	AMENDMENT 2	No/ 2020-11-24 (97)	Lost to Follow-Up		Yes/ 2020-09-29 (41)	
US3352199	2020-08-22	AMENDMENT 2	ONGOING			No/ 2020-09-18 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352244	2020-08-25	AMENDMENT 3	No/ 2020-09-15 (22)	Lost to Follow-Up		No/ 2020-09-14 (21)	Lost to Follow-Up
US3352331	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3352443	2020-09-29	AMENDMENT 3	No/ 2020-11-16 (49)	Other/ THE SUBJECT STATED HE MOVED TO (b) (6) AND WILL NO LONGER BE ABLE TO PARTICIPATE IN THE STUDY.		No/ 2020-10-26 (28)	Other/ THE SUBJECT STATED HE MOVED TO (b) (6) AND WILL NO LONGER BE ABLE TO PARTICIPATE IN THE STUDY.
US3352474	2020-09-29	AMENDMENT 3	No/ 2020-10-24 (26)	Lost to Follow-Up		No/ 2020-10-23 (25)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352491	2020-10-06	AMENDMENT 3	ONGOING			No/ 2020-11-02 (28)	Protocol Deviation/ SUBJECT DID NOT COMPLETE DAY 29 VISIT.
US3352512	2020-10-08	AMENDMENT 4	No/ 2020-12-30 (84)	Lost to Follow-Up		No/ 2020-11-04 (28)	Due to SARS-CoV-2
US3352549	2020-10-15	AMENDMENT 4	No/ 2021-01-15 (93)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO CONTINUE OR COMPLY DUE TO NO TRANSPORTATION.		No/ 2020-11-11 (28)	Withdrawal of Consent by Participant/ SUBJECT UNABLE TO COMPLY OR CONTINUE DUE TO NO TRANSPORTATION.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3352593	2020-10-22	AMENDMENT 4	No/ 2020-11-12 (22)	Lost to Follow-Up		No/ 2020-11-11 (21)	Other/ UNABLE TO REACH SUBJECT. POSSIBLE LOST TO FOLLOW-UP. CERTIFIED LETTER TO BE SENT. PENDING RESPONSE.
US3352596	2020-10-22	AMENDMENT 4	No/ 2021-03-26 (156)	Lost to Follow-Up		No/ 2020-11-18 (28)	Other/ SUBJECT HAS BEEN OUT OF TOWN.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3382010	2020-08-10	AMENDMENT 2	No/ 2021-01-25 (169)	Protocol Deviation/ SUBJECT RECEIVED AN MRNA VACCINE FROM OUTSIDE THE RESEARCH CLINIC. WE GOT A FINAL WORD VIA OUR MONITOR THAT SUCH PARTICIPANTS CAN NO LONGER BE IN THE STUDY.		No/ 2020-09-06 (28)	Due to SARS-CoV-2
US3432187	2020-08-18	AMENDMENT 2	ONGOING			No/ 2020-09-14 (28)	Due to SARS-CoV-2
US3442211	2020-10-05	AMENDMENT 3	ONGOING			No/ 2020-11-01 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3452200	2020-08-04	AMENDMENT 1	ONGOING			No/ 2020-08-31 (28)	Due to SARS-CoV-2
US3452401	2020-09-24	AMENDMENT 3	No/ 2020-11-17 (55)	Lost to Follow-Up		No/ 2020-10-21 (28)	Lost to Follow-Up
US3492237	2020-09-22	AMENDMENT 3	ONGOING			No/ 2020-10-19 (28)	Due to SARS-CoV-2
US3502203	2020-10-13	AMENDMENT 4	ONGOING			No/ 2020-11-09 (28)	Other/ PT TESTED POSITIVE FOR COVID-19 (ASYMPTOMATIC) AT BASELINE. PT RECEIVED HIS SECOND DOSE AT OL- DAY 1 19JAN2021

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3512297	2020-10-15	AMENDMENT 4	No/ 2021-02-16 (125)	Lost to Follow-Up		No/ 2020-11-11 (28)	Due to SARS-CoV-2
US3522157	2020-08-17	AMENDMENT 1	ONGOING			No/ 2020-09-13 (28)	Due to SARS-CoV-2
US3522426	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Due to SARS-CoV-2
US3572129	2020-08-28	AMENDMENT 3	ONGOING			No/ 2020-09-24 (28)	Other/ MISSED THEIR VISIT 2 DAY 29 VISIT (DOSE 2) UNDER PART A OF THE STUDY
US3572158	2020-09-01	AMENDMENT 3	ONGOING			No/ 2020-09-28 (28)	Other/ PATIENT MISSED APPOINTMENT AND IS NOW OUT OF WINDOW

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3572307	2020-09-16	AMENDMENT 3	No/ 2020-10-07 (22)	Withdrawal of Consent by Participant/ CALLED PATIENT REGARDING MISSING APPOINTMENTS. PATIENT WISHES TO WITHDRAW FROM THE STUDY DUE TO INTERFERENCE WITH SCHOOL EXAMS		No/ 2020-10-06 (21)	Withdrawal of Consent by Participant/ CALLED PATIENT REGARDING MISSING APPOINTMENTS. PATIENT WISHES TO WITHDRAW FROM THE STUDY DUE TO INTERFERENCE WITH SCHOOL EXAMS
US3572404	2020-10-16	AMENDMENT 4	ONGOING			No/ 2020-11-12 (28)	Other/ PER MODERNA PATIENT IS NOT ELIGIBLE TO GET DOSED.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3652030	2020-09-16	AMENDMENT 3	ONGOING			No/ 2020-10-26 (28)	Due to SARS-CoV-2
US3652060	2020-10-19	AMENDMENT 4	ONGOING			No/ 2020-11-17 (28)	Other/ PARTICIPANT UNABLE TO COME INTO CLINIC.
US3672077	2020-08-12	AMENDMENT 2	ONGOING			No/ 2020-09-08 (28)	Due to SARS-CoV-2
US3672261	2020-08-21	AMENDMENT 2	ONGOING			No/ 2020-09-17 (28)	Due to SARS-CoV-2
US3712041	2020-09-04	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3712171	2020-09-24	AMENDMENT 3	ONGOING			No/ 2020-10-22 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3712209	2020-10-14	AMENDMENT 4	No/ 2021-03-08 (145)	Withdrawal of Consent by Participant/ SUBJECT REFUSING TO COME IN AND BE UNBLINDED		No/ 2020-11-11 (28)	Due to SARS-CoV-2
US3732262	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Adverse Event/ SYMPTOMATIC COVID-19 AE #1
US3742401	2020-09-17	AMENDMENT 3	ONGOING			No/ 2020-10-18 (28)	Other/ PARTICIPANT REFUSED FOR SECOND VACCINATION BUT WILL CONTINUE OTHER STUDY PROCEDURES.

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3742416	2020-09-18	AMENDMENT 3	No/ 2021-01-12 (117)	Other/ REQUEST TO UNBLIND / EUA COVID-19 VACCINE		No/ 2020-10-15 (28)	Due to SARS-CoV-2
US3802162	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Due to SARS-CoV-2
US3802254	2020-09-15	AMENDMENT 3	ONGOING			No/ 2020-10-12 (28)	Due to SARS-CoV-2
US3812267	2020-08-26	AMENDMENT 2	ONGOING			No/ 2020-09-22 (28)	Due to SARS-CoV-2
US3812293	2020-08-28	AMENDMENT 2	ONGOING			No/ 2020-09-24 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3822149	2020-08-17	AMENDMENT 2	ONGOING			No/ 2020-09-13 (28)	Other/ PATIENT TESTED POSITIVE AT VISIT 1 AND DISCONTINUED PROTOCOL TREATMENT. PATIENT CONTINUING ON STUDY FOLLOW UP.
US3832216	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Due to SARS-CoV-2
US3832225	2020-08-19	AMENDMENT 2	ONGOING			No/ 2020-09-15 (28)	Due to SARS-CoV-2
US3862147	2020-09-08	AMENDMENT 3	ONGOING			No/ 2020-10-05 (28)	Due to SARS-CoV-2
US3862218	2020-09-18	AMENDMENT 3	ONGOING			No/ 2020-10-15 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872313	2020-08-26	AMENDMENT 2	No/ 2020-10-27 (63)	Withdrawal of Consent by Participant/ SUBJECT WAS NOT HAPPY ABOUT NOT RECEIVING VACCINE 2.		No/ 2020-09-22 (28)	Protocol Deviation/ SWAB RESULT NOT BACK AND THEY CAME BACK THE V2 WAS TOO FAR OOW PER MM AND WAS RECOMMENDED TO PI TO SKIP 2 AND MOVE ON TO V3
US3872416	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Due to SARS-CoV-2

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3872453	2020-09-03	AMENDMENT 3	ONGOING			No/ 2020-09-30 (28)	Protocol Deviation/ V2 WAS TOO FAR OOW , TRIED TO SCHEDULE SUBJECT 2 TIMES AND HE COULD NOT MAKE IT IN FOR EITHER VISIT FOR V2. WILL MOVE ON TO V3
US3872501	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-07 (28)	Due to SARS-CoV-2
US3912235	2020-10-08	AMENDMENT 4	No/ 2021-02-09 (125)	Lost to Follow-Up		Yes/ 2020-11-09 (33)	
US3932186	2020-09-24	AMENDMENT 3	No/ 2020-10-08 (15)	Lost to Follow-Up		No/ 2020-10-07 (14)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3942051	2020-09-02	AMENDMENT 3	ONGOING			No/ 2020-09-29 (28)	Due to SARS-CoV-2
US3942066	2020-09-04	AMENDMENT 3	No/ 2020-12-02 (90)	Lost to Follow-Up		No/ 2020-10-01 (28)	Lost to Follow-Up
US3942091	2020-09-10	AMENDMENT 3	ONGOING			No/ 2020-10-08 (28)	Due to SARS-CoV-2
US3972184	2020-09-16	AMENDMENT 3	No/ 2020-12-11 (87)	Lost to Follow-Up		Yes/ 2020-10-19 (34)	
US3972224	2020-10-12	AMENDMENT 4	ONGOING			No/ 2020-11-08 (28)	Due to SARS-CoV-2
US3982123	2020-09-07	AMENDMENT 3	No/ 2020-10-02 (26)	Lost to Follow-Up		No/ 2020-10-01 (25)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31

Listing 16.2.1.1

Subject Disposition for Subjects Who Discontinued from Participation in the Study or Discontinued from Study Vaccine Randomization Set

Baseline SARS-CoV-2 Status: Positive; Treatment Group: mRNA-1273

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation or Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation or Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US3982190	2020-09-17	AMENDMENT 3	No/ 2020-10-06 (18)	Lost to Follow-Up		No/ 2020-10-05 (17)	Lost to Follow-Up

* indicates re-screen subjects.

For subjects who did not receive any injection, day is defined as study day from randomization date; for subjects who received at least one injection, day is defined as study day from first injection date.

Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\116020101.sas 23JUN2021 16:31